

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05970 A2

(51) International Patent Classification⁷: C12N 15/12,
C07K 14/47, G01N 33/53, C12Q 1/68, A61K 38/17,
C07K 16/18, A01K 67/027

(21) International Application Number: PCT/US00/19698

(22) International Filing Date: 19 July 2000 (19.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/144,595 19 July 1999 (19.07.1999) US
60/150,460 23 August 1999 (23.08.1999) US
60/159,849 15 October 1999 (15.10.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 60/144,595 (CIP)
Filed on 19 July 1999 (19.07.1999)
US 60/150,460 (CIP)
Filed on 23 August 1999 (23.08.1999)
US 60/159,849 (CIP)
Filed on 15 October 1999 (15.10.1999)

(71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass

Drive, Santa Clara, CA 95054 (US). AU-YOUNG, Janice [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Avenue, #3, Sunnyvale, CA 94086 (US). YANG, Junming [CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US).

(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/05970 A2

(54) Title: GTP-BINDING ASSOCIATED PROTEINS

(57) Abstract: The invention provides human GTP-binding associated proteins (GBAP) and polynucleotides which identify and encode GBAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of GBAP.

GTP-BINDING ASSOCIATED PROTEINS

TECHNICAL FIELD

5 This invention relates to nucleic acid and amino acid sequences of GTP-binding associated proteins and to the use of these sequences in the diagnosis, treatment, and prevention of immune system, reproductive, nervous system, and cell signaling disorders, and cell proliferative disorders including cancer.

10 BACKGROUND OF THE INVENTION

Guanine nucleotide binding proteins (GTP-binding proteins) are present in all eukaryotic cells and function in processes including metabolism, cellular growth, differentiation, signal transduction, cytoskeletal organization, and intracellular vesicle transport and secretion. In higher organisms they are involved in signaling that regulates such processes as the immune response (Aussel, C. et al. (1988) J. Immunol. 140:215-220), apoptosis, differentiation, and cell proliferation including oncogenesis (Dhanasekaran, N. et al. (1998) Oncogene 17:1383-1394).

The superfamily of GTP-binding proteins can be subdivided into groups such as translational factors, heterotrimeric GTP-binding proteins involved in transmembrane signaling processes (also called G-proteins), proto-oncogene Ras proteins, other low molecular weight GTP-binding proteins including the products of rab, rap, rho, rac, smg21, smg25, YPT, SEC4, and ARF genes, and tubulins (Kazi, Y. et al. (1991) Annu. Rev. Biochem. 60:349-400).

GTP-binding proteins are involved in protein biosynthesis and include initiation factor 2 (IF-2), elongation factor 2 (EF-Tu), and elongation factor G (EF-G), observed in prokaryotes; and initiation factor 2 (eIF-2), elongation factor 1 α (EF-1 α), elongation factor 2 (EF-2), and release factor 3 (eRF3) observed in eukaryotes (Kazi, supra). IF-2 promotes the GTP-dependent binding of the tRNA to the small subunit of the ribosome, the step that initiates protein translation. Elongation factors promote the binding of tRNA and GTP and the displacement of GDP after hydrolysis as protein biosynthesis proceeds. eRF3 participates in the recognition of stop codons and the release of nascent proteins from ribosomes.

30 Heterotrimeric GTP-binding proteins are composed of 3 subunits (α , β and γ) which, in the resting state, associate as a trimer at the inner face of the plasma membrane. Heterotrimeric G-proteins may be classified based on the sequence similarity of α subunits into the Gs, Gi, Gq and G12 subgroups. In the resting state, the α subunit binds guanosine diphosphate (GDP), and stimulation of the G-protein by an activated receptor leads to exchange of GDP for guanosine triphosphate (GTP).
35 This exchange results in the separation of the α from the β and γ subunits, which remain tightly

associated as a dimer. Both the α subunit and β - γ dimer are then able to interact with effectors, either individually or in a cooperative manner. The intrinsic GTPase activity of the α subunit hydrolyzes the bound GTP to GDP. This returns the α subunit to its inactive conformation and allows it to reassociate with the β - γ complex, thus restoring the system to its resting state (Kaziro, *supra*). Some α subunits show tissue-specific expression indicating a specialized signaling role (Dhanasekaran, *supra*).

The α -s class of G-protein subunits is sensitive to ADP-ribosylation by pertussis toxin which uncouples the receptor:G-protein interaction. This uncoupling blocks signal transduction to receptors that decrease cAMP levels. cAMP levels regulate ion channels and activate phospholipases. The inhibitory α -I class is also susceptible to modification by pertussis toxin, which prevents α -I from lowering cAMP levels. Two novel classes of α subunits refractory to pertussis toxin modification are α -q, which activates phospholipase C, and α -12, which has sequence homology with the *Drosophila* gene *concertina* and may contribute to the regulation of embryonic development (Simon, M.I. (1991) Science 252:802-808).

The mammalian G-protein β and γ subunits, each about 340 amino acids long, share more than 80% homology. The β subunit (also called β -transducin) contains seven repeating units, each about 43 amino acids long. This WD-repeat, or G-beta repeat motif, is found in a variety of proteins with regulatory function such as Sec13, a yeast WD repeat protein involved in vesicular traffic; coronin-2, a mammalian WD repeat protein involved in regulation of the actin cytoskeleton; and Bop1, a mammalian WD repeat protein involved in growth suppression (Garcia-Higuera, I. et al. (1998) J. Biol. Chem. 273:9041-9049; Okumura, M. et al. (1998) DNA Cell Biol. 17:779-787; Pestov, D.G. et al. (1998) Oncogene 17:3187-3197). The activity of the β and γ subunits may be regulated by other proteins such as calmodulin, phosducin, or the neural protein GAP 43 (Clapham, D.E. and E.J. Neer (1993) Nature 365:403-406). The β subunit sequences are highly conserved among species, suggesting that they perform a fundamentally important role in the organization and function of G-protein linked systems (Van der Voorn, L. and H.L. Ploegh (1992) FEBS Lett. 307:131-134).

Mutations and variant expression of β -transducin proteins are linked with various disorders. Mutations in LIS1, a subunit of the human platelet activating factor acetylhydrolase, cause Miller-Dieker lissencephaly. RACK1 binds activated protein kinase C, and RbAp48 binds retinoblastoma protein. CstF is required for polyadenylation of mammalian pre-mRNA *in vitro* and associates with subunits of cleavage-stimulating factor. Defects in the regulation of β -catenin contribute to the neoplastic transformation of human cells. The WD40 repeats of the human F-box protein β TrCP mediate binding to β -catenin, thus regulating the targeted degradation of β -catenin by ubiquitin ligase (Neer, E.J. et al. (1994) Nature 371:297-300; Hart, M. et al. (1999) Curr. Biol. 9:207-210).

The γ subunit sequences are more variable than those of the β subunits. They are often post-translationally modified by isoprenylation and carboxyl-methylation of a cysteine residue four amino

acids from the C-terminus. These modifications appear to be necessary for the interaction of the β - γ dimer with the membrane and with other GTP-binding proteins. The β - γ dimer has been shown to modulate the activity of adenylyl cyclase isoforms, phospholipase C, and some ion channels. It is involved in receptor phosphorylation via specific kinases and has been implicated in the p21ras-
5 dependent activation of the MAP kinase cascade and the recognition of specific receptors by GTP-binding proteins (Clapham and Neer, supra).

G-proteins interact with a variety of effectors including adenylyl cyclase (Clapham and Neer, supra). The signaling pathway mediated by cAMP is mitogenic in hormone-dependent endocrine tissues such as adrenal cortex, thyroid, ovary, pituitary, and testes. Cancers in these tissues have been related
10 to a mutationally activated form of a $G\alpha$, known as the gsp (Gs protein) oncogene (Dhanasekaran, supra). Another effector is phosducin, a retinal phosphoprotein, which forms a specific complex with retinal G-protein β and γ subunits and modulates the ability of the β - γ dimer to interact with retinal α subunits (Clapham and Neer, supra). Additional G-protein effectors include RIN1 (Ras interaction/interference), which acts as an effector of H-Ras and interferes with the Ras signal
15 transduction pathway; Rabin3, which associates with the Ras-like GTPase Rab3A; and Rhotekin, a protein that binds with, and inhibits, Rho GTPase activity (Han, L. and J. Colicelli (1995) Mol. Cell Biol. 15:1318-1323; Brondyk, W.H. et al. (1995) Mol. Cell Biol. 15:1137-1143; and Reid, T. et al. (1996) J. Biol. Chem. 27:13556-13560).

The low molecular weight GTP-binding proteins regulate cell growth, cell cycle control, protein
20 secretion, and intracellular vesicle interaction. These GTP-binding proteins respond to extracellular signals from receptors and activating proteins by transducing mitogenic signals (Tavitian, A. (1995) C. R. Seances Soc. Biol. Fil. 189:7-12). Low molecular weight GTP-binding proteins consist of single polypeptides of 21-30kD which, like the α subunit of heterotrimeric GTP-binding proteins, are able to bind to and hydrolyze GTP, thus cycling from an inactive to an active state. The intrinsic rate of GTP
25 hydrolysis of these GTP-binding proteins is typically very slow, but it can be stimulated by several orders of magnitude by GTPase-activating proteins (GAPs), such as β 2-chimaerin (Geyer, M. and Wittinghofer, A. (1997) Curr. Opin. Struct. Biol. 7:786-792; Caloca, M. J. et al. (1997) J. Biol. Chem. 272:26488-26496).

Low molecular weight GTP-binding proteins play critical roles in cellular protein trafficking
30 events, such as the translocation of proteins and soluble complexes from the cytosol to the membrane through an exchange of GDP for GTP (Kistakis, N.T. (1998) BioEssays 20:495-504). In vesicle transport, the interaction between vesicle- and target- specific identifiers (v-SNAREs and tSNAREs) docks the vesicle to the acceptor membrane. The budding process is regulated by GTPases such as the closely related ADP ribosylation factors (ARFs) and SAR proteins, while GTPases such as Rab allow
35 assembly of SNARE complexes and may play a role in removal of defective complexes (Rothman, J.E.

and F.T. Wieland (1996) Science 272:227-234). The rab proteins control the translocation of vesicles to and from membranes for protein localization, protein processing, and secretion. The rho GTP-binding proteins control signal transduction pathways that link growth factor receptors to actin polymerization which is necessary for normal cellular growth and division. The ran GTP-binding proteins are located in the nucleus of cells and have a key role in nuclear protein import, the control of DNA synthesis, and cell-cycle progression (Hall, A. (1990) Science 249:635-640; Scheffzek, K. et al. (1995) Nature 374:378-381).

The Ras proteins Ras1, Ras2 and G_α stimulate adenylyl cyclase (Kaziro, supra) which affects a broad array of cellular processes including determination of whether cells continue to grow or become terminally differentiated. Stimulation of cell surface receptors activates Ras which, in turn, activates cytoplasmic kinases. These kinases translocate to the nucleus and activate key transcription factors that control gene expression and protein synthesis (Barbacid, M. (1987) Annu. Rev. Biochem. 56:779-827; Treisman, R. (1994) Curr. Opin. Genet. Dev. 4:96-101). Mutant Ras-family proteins which bind but cannot hydrolyze GTP are permanently activated and are thus rendered oncogenic (Drivas, G.T. et al. (1990) Mol. Cell. Biol. 10:1793-1798).

Ras-like proteins have also been implicated in tumor suppression. For example, NOEY2, a novel gene encoding a Ras-like protein, is expressed in normal ovarian and breast epithelial cells. However, NOEY2 expression is reduced or abrogated in ovarian and breast carcinomas, suggesting a role for the NOEY2 gene product in tumor suppression (Yu, Y. et al. (1999) Proc. Natl. Acad. Sci. USA 96:214-219).

Irregularities in GTP-binding protein signaling cascades may result in abnormal activation of leukocytes and lymphocytes, leading to the tissue damage and destruction seen in many inflammatory and autoimmune diseases such as rheumatoid arthritis, biliary cirrhosis, hemolytic anemia, lupus erythematosus, and thyroiditis. Abnormal cell proliferation, including cyclic AMP-mediated stimulation of brain, thyroid, adrenal, and gonadal tissue proliferation is regulated by G proteins. Mutations in G_α subunits have been found in growth-hormone-secreting pituitary somatotroph tumors, hyperfunctioning thyroid adenomas, and ovarian and adrenal neoplasms (Meij, J.T.A. (1996) Mol. Cell. Biochem. 157:31-38; Aussel, supra).

The discovery of new GTP-binding associated proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of immune system, reproductive, nervous system, and cell signaling disorders, and cell proliferative disorders including cancer.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, GTP-binding associated proteins, referred to

collectively as "GBAP" and individually as "GBAP-1," "GBAP-2," "GBAP-3," "GBAP-4," "GBAP-5," "GBAP-6," "GBAP-7," "GBAP-8," "GBAP-9," "GBAP-10," "GBAP-11," "GBAP-12," "GBAP-13," "GBAP-14," "GBAP-15," "GBAP-16," "GBAP-17," "GBAP-18," "GBAP-19," "GBAP-20," "GBAP-21," "GBAP-22," "GBAP-23," "GBAP-24," "GBAP-25," "GBAP-26," "GBAP-27,"

5 "GBAP-28," "GBAP-29," "GBAP-30," "GBAP-31," "GBAP-32," "GBAP-33," "GBAP-34," "GBAP-35," "GBAP-36," "GBAP-37," "GBAP-38," "GBAP-39," "GBAP-40," "GBAP-41," "GBAP-42," "GBAP-43," "GBAP-44," "GBAP-45," "GBAP-46," "GBAP-47," "GBAP-48," "GBAP-49," "GBAP-50," "GBAP-51," "GBAP-52," "GBAP-53," "GBAP-54," "GBAP-55," "GBAP-56," "GBAP-57," "GBAP-58," "GBAP-59," "GBAP-60," "GBAP-61," "GBAP-62,"

10 "GBAP-63," "GBAP-64," "GBAP-65," and "GBAP-66." In one aspect, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence

15 selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-66.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least

20 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. In one alternative, the polynucleotide encodes a polypeptide selected

25 from the group consisting of SEQ ID NO:1-66. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:67-132.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group

30 consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. In one alternative, the invention provides a cell transformed with the

35 recombinant polynucleotide. In another alternative, the invention provides a transgenic organism

comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66.

The invention further provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or

fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said
5 target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e)
10 an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide
15 comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected
20 from the group consisting of SEQ ID NO:1-66, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional GBAP, comprising administering to a patient in need of such treatment the composition.

25 The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence
30 selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the
35 invention provides a method of treating a disease or condition associated with decreased expression of

functional GBAP, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional GBAP, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-66. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a

change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a
 5 sequence selected from the group consisting of SEQ ID NO:67-132, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound;
 10 b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, ii) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, iii) a
 15 polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, ii) a naturally occurring polynucleotide sequence having at least
 20 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:67-132, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of the above polynucleotide sequence; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated
 25 biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

30 Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding GBAP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods, algorithms, and searchable databases used for analysis of GBAP.

35 Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression

patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding GBAP were isolated.

5 Table 5 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood
10 that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an,"
15 and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings
20 as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in
25 connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"GBAP" refers to the amino acid sequences of substantially purified GBAP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and
30 human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of GBAP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GBAP either by directly interacting with GBAP or by acting on components of the biological pathway in which GBAP participates.

35 An "allelic variant" is an alternative form of the gene encoding GBAP. Allelic variants may

result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.

- 5 Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

“Altered” nucleic acid sequences encoding GBAP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as GBAP or a polypeptide with at least one functional characteristic of GBAP. Included within this definition are

10 polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GBAP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GBAP. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GBAP. Deliberate

15 amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of GBAP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may

20 include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms “amino acid” and “amino acid sequence” refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic

25 molecules. Where “amino acid sequence” is recited to refer to a sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

“Amplification” relates to the production of additional copies of a nucleic acid sequence.

Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known

30 in the art.

The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity of GBAP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GBAP either by directly interacting with GBAP or by acting on components of the biological pathway in which GBAP

35 participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind GBAP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used
5 to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that
10 makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

15 The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having
20 modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the
25 designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic GBAP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific
30 antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a
35 given amino acid sequence" refer broadly to any composition containing the given polynucleotide or

amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding GBAP or fragments of GBAP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be
 5 deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (PE Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from
 10 one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least
 15 interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
20	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
25	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
30	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
35	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
	Val	Ile, Leu, Thr

40 Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the

side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical
5 modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

10 A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

A "fragment" is a unique portion of GBAP or the polynucleotide encoding GBAP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a
15 fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected
20 from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:67-132 comprises a region of unique polynucleotide sequence that
25 specifically identifies SEQ ID NO:67-132, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:67-132 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:67-132 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:67-132 and the region of SEQ ID NO:67-132 to which the fragment corresponds are routinely
30 determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-66 is encoded by a fragment of SEQ ID NO:67-132. A fragment of SEQ ID NO:1-66 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-66. For example, a fragment of SEQ ID NO:1-66 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-66.
35 The precise length of a fragment of SEQ ID NO:1-66 and the region of SEQ ID NO:1-66 to which the

fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full-length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full-length" polynucleotide sequence encodes a "full-length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

5 *Expect: 10*

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over
10 the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

15 Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to
20 the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

25 Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with
30 polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (Apr-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

35 *Matrix: BLOSUM62*

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

5 *Filter: on*

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150
10 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for
15 chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a
20 complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e.,
25 binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v)
30 SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the
35 target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions

for nucleic acid hybridization are well known and can be found in Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of GBAP which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of GBAP which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of GBAP. For example, modulation

may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of GBAP.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an GBAP may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of GBAP.

"Probe" refers to nucleic acid sequences encoding GBAP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for

example Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al., 1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs
5 can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to
10 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences
15 and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from
20 their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and
25 polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

30 A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have
35 been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a

recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is
5 expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

10 "Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear
15 sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding GBAP, or fragments thereof, or GBAP itself, may comprise a bodily fluid; an extract
20 from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure
25 of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are
30 removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

35 "Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters,

chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular cell type
5 or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type
10 of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

15 A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with
20 a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants, and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection,
25 transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the
30 nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant
35 identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides

due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule.

Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

15 THE INVENTION

The invention is based on the discovery of new human GTP-binding associated proteins (GBAP), the polynucleotides encoding GBAP, and the use of these compositions for the diagnosis, treatment, or prevention of immune system, reproductive, nervous system, and cell signaling disorders, and cell proliferative disorders including cancer.

20 Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding GBAP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each GBAP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries.

25 Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. In some cases, GenBank sequence identifiers are also shown in column 5. The Incyte clones and GenBank cDNA sequences, where indicated, in column 5 were used to assemble the consensus nucleotide sequence of each GBAP and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: 30 column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical methods and in some cases, searchable databases to which the analytical methods were applied. The methods of 35 column 7 were used to characterize each polypeptide through sequence homology and protein motifs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding GBAP. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:67-132 and to distinguish between SEQ ID NO:67-132 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express GBAP as a fraction of total tissues expressing GBAP. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing GBAP as a fraction of total tissues expressing GBAP. Column 5 lists the vectors used to subclone each cDNA library. Of particular note is the expression of SEQ ID NO:84 in lung tissues, and the tissue-specific expression of SEQ ID NO:132. Over 90% of tissues expressing SEQ ID NO:132 are derived from the nervous system, particularly the brain.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding GBAP were isolated. Column 1 references the nucleotide SEQ ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

SEQ ID NO:70 maps to chromosome 7 within the interval from 111.6 to 123.4 centiMorgans. This interval contains a gene that is down regulated in adenoma. SEQ ID NO:74 maps to chromosome 11 within the interval from 104.8 to 123.5 centiMorgans. This interval contains a gene associated with the cerebellar degenerative disorder, ataxia telangiectasia. SEQ ID NO:75 maps to chromosome 17 within the interval from 62.9 to 65.0 centiMorgans. SEQ ID NO:77 maps to chromosome 3 within the interval from 12.9 to 16.5 centiMorgans. SEQ ID NO:80 maps to chromosome 9 within the interval from 42.0 to 57.3 centiMorgans. SEQ ID NO:86 maps to chromosome 1 within the interval from 159.6 to 164.1 centiMorgans. SEQ ID NO:87 maps to chromosome 11 within the interval from 147.2 to 151.6. SEQ ID NO:90 maps to chromosome 1 within the interval from 219.2 to 223.0 centiMorgans. This interval contains a gene encoding a RAB interacting protein. SEQ ID NO:92 and SEQ ID NO:106 both map to chromosome 1 within the interval from 48.8 to 81.6 centiMorgans. This interval also contains genes associated with familial hypercholesterolemia, glucose transport defect, infantile hypophosphatasia, infantile neuronal ceroid lipofuscinosis, Kostmann disease, multiple epiphyseal dysplasia, porphyria cutanea tarda, and T-cell acute lymphocytic leukemia 1. SEQ ID NO:93 maps to chromosome 12 within the interval from 76.5 to 87.6 centiMorgans. This interval also contains genes associated with mucopolysaccharidosis type IIID, pseudovitamin D deficiency rickets, and renal amyloidosis. SEQ ID NO:94 and SEQ ID NO:109 both map to chromosome 1 within the interval from 143.1 to 146.6 centiMorgans, to chromosome 14 within the interval from 46.8 to 50.9 centiMorgans, to chromosome 16 within the interval from 88.1 to 90.2 centiMorgans, and to chromosome 19 within the

interval from 58.7 to 97.5 centiMorgans. The interval on chromosome 14 from 46.8 to 50.9 centiMorgans also contains a gene associated with dopa-responsive dystonia. The interval on chromosome 19 from 58.7 to 97.5 centiMorgans also contains genes associated with colorectal cancer, DNA ligase I deficiency, glutaricaciduria IIB, myotonic dystrophy, renal amyloidosis, T-cell acute lymphoblastic leukemia, and xeroderma pigmentosum D. SEQ ID NO:97 maps to chromosome 2 within the interval from 236.2 to 269.5 centiMorgans. This interval also contains genes associated with Crigler-Najjar syndrome, familial hypercholesterolemia, Oguchi disease, and primary hyperoxaluria. SEQ ID NO:101 maps to chromosome 2 within the interval from 225.6 to 233.1 centiMorgans, to chromosome 6 within the interval from 132.7 to 144.4 centiMorgans, and to chromosome 11 within the interval from 117.9 to 120.8 centiMorgans. The interval on chromosome 2 from 225.6 to 233.1 centiMorgans also contains a gene associated with Waardenburg syndrome 1. The interval on chromosome 6 from 132.7 to 144.4 centiMorgans also contains genes associated with familial disseminated atypical mycobacterial infection and rhizomelic chondrodysplasia punctata. The interval on chromosome 11 from 117.9 to 120.8 centiMorgans also contains a gene associated with acute intermittent porphyria. SEQ ID NO:111 maps to chromosome 19 within the interval from 35.5 to 49.4 centiMorgans, to chromosome 1 within the interval from the p-terminus to 16.4 centiMorgans, and to chromosome 11 within the interval from 147.2 centiMorgans to the q-terminus. SEQ ID NO:112 maps to chromosome 19 within the interval from 41.7 to 49.4 centiMorgans. SEQ ID NO:113 maps to chromosome 9 within the interval from 136.2 to 163.0 centiMorgans. SEQ ID NO:115 maps to chromosome 14 within the interval from 95.5 to 103.7 centiMorgans and to the X chromosome (23) within the interval from the p-terminus to 55.5 centiMorgans. SEQ ID NO:117 maps to chromosome 13 at 46.9 centiMorgans. SEQ ID NO:118 maps to chromosome 1 within the interval from 16.4 to 22.9 centiMorgans. SEQ ID NO:121 maps to chromosome 12 within the interval from 116.6 to 118.9 centiMorgans. SEQ ID NO:128 maps to chromosome 1 within the interval from the p-terminus to 16.4 centiMorgans.

The invention also encompasses GBAP variants. A preferred GBAP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the GBAP amino acid sequence, and which contains at least one functional or structural characteristic of GBAP.

The invention also encompasses polynucleotides which encode GBAP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:67-132, which encodes GBAP. The polynucleotide sequences of SEQ ID NO:67-132, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding GBAP. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GBAP. A particular aspect of the invention encompasses a variant of a polynucleotide
5 sequence comprising a sequence selected from the group consisting of SEQ ID NO:67-132 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:67-132. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of GBAP.

10 It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GBAP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in
15 accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring GBAP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode GBAP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring GBAP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GBAP or its
20 derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GBAP and its derivatives without altering the encoded amino acid sequences include the production of
25 RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode GBAP and GBAP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems
30 using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GBAP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:67-132 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and
35 S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol.

152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of
5 DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (PE Biosystems, Foster City CA), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV),
10 PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (PE Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (PE Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in
15 Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding GBAP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed,
20 restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids
25 Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences
30 are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences,
35 Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a

GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include
5 sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary
10 sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, PE Biosystems), and the entire
15 process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GBAP may be cloned in recombinant DNA molecules that direct expression of GBAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of
20 the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express GBAP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GBAP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA
25 shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such
30 as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of GBAP, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene
35 variants is produced using PCR-mediated recombination of gene fragments. The library is then

subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

10 In another embodiment, sequences encoding GBAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) *Nucleic Acids Symp. Ser. 7*:215-223; and Horn, T. et al. (1980) *Nucleic Acids Symp. Ser. 7*:225-232.) Alternatively, GBAP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g.,
15 Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) *Science* 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (PE Biosystems). Additionally, the amino acid sequence of GBAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a
20 sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

25 In order to express a biologically active GBAP, the nucleotide sequences encoding GBAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences
30 encoding GBAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GBAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding GBAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be
35 needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous

translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.*

5 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GBAP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory
 10 Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding GBAP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with
 15 yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509; Bitter, G.A. et al. (1987) *Methods Enzymol.* 153:516-544;
 20 Scorer, C.A. et al. (1994) *Bio/Technology* 12:181-184; Engelhard, E.K. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3224-3227; Sandig, V. et al. (1996) *Hum. Gene Ther.* 7:1937-1945; Takamatsu, N. (1987) *EMBO J.* 6:307-311; Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp.
 25 191-196; Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659; and Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids; may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) *Cancer Gen. Ther.* 5(6):350-356; Yu, M. et al., (1993) *Proc. Natl. Acad. Sci.*
 30 *USA* 90(13):6340-6344; Buller, R.M. et al. (1985) *Nature* 317(6040):813-815; McGregor, D.P. et al. (1994) *Mol. Immunol.* 31(3):219-226; and Verma, I.M. and N. Somia (1997) *Nature* 389:239-242.)
 The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding GBAP. For example, routine cloning,
 35 subcloning, and propagation of polynucleotide sequences encoding GBAP can be achieved using a

multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPO1 plasmid (Life Technologies). Ligation of sequences encoding GBAP into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of GBAP are needed, e.g. for the production of antibodies, vectors which direct high level expression of GBAP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of GBAP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, supra; and Scorer, supra.)

Plant systems may also be used for expression of GBAP. Transcription of sequences encoding GBAP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, supra; Broglie, supra; and Winter, supra.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GBAP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses GBAP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of GBAP in cell lines is preferred. For example, sequences encoding GBAP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *ap^r* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding GBAP is inserted within a marker gene sequence, transformed cells containing sequences encoding GBAP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GBAP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding GBAP and that express GBAP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based

technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of GBAP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence
5 activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GBAP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New
10 York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GBAP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the
15 sequences encoding GBAP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US
20 Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding GBAP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein
25 produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GBAP may be designed to contain signal sequences which direct secretion of GBAP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the
30 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities
35 (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture

Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GBAP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric GBAP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of GBAP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the GBAP encoding sequence and the heterologous protein sequence, so that GBAP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled GBAP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

GBAP of the present invention or fragments thereof may be used to screen for compounds that specifically bind to GBAP. At least one and up to a plurality of test compounds may be screened for specific binding to GBAP. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of GBAP, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which GBAP binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express GBAP, either as a secreted

protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing GBAP or cell membrane fractions which contain GBAP are then contacted with a test compound and binding, stimulation, or inhibition of activity of either GBAP or the compound is analyzed.

5 An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with GBAP, either in solution or affixed to a solid support, and detecting the binding of GBAP to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a
10 labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

GBAP of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of GBAP. Such compounds may include agonists, antagonists, or partial or
15 inverse agonists. In one embodiment, an assay is performed under conditions permissive for GBAP activity, wherein GBAP is combined with at least one test compound, and the activity of GBAP in the presence of a test compound is compared with the activity of GBAP in the absence of the test compound. A change in the activity of GBAP in the presence of the test compound is indicative of a compound that modulates the activity of GBAP. Alternatively, a test compound is combined with an
20 in vitro or cell-free system comprising GBAP under conditions suitable for GBAP activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of GBAP may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding GBAP or their mammalian homologs may
25 be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of
30 interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids
35 Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred

to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding GBAP may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding GBAP can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding GBAP is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress GBAP, e.g., by secreting GBAP in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of GBAP and GTP-binding associated proteins. In addition, the expression of GBAP is closely associated with reproductive tissues, inflammation and the immune response, trauma, cell proliferation, and cancer. Therefore, GBAP appears to play a role in immune system, reproductive, nervous system, and cell signaling disorders, and cell proliferative disorders including cancer. In the treatment of disorders associated with increased GBAP expression or activity, it is desirable to decrease the expression or activity of GBAP. In the treatment of disorders associated with decreased GBAP expression or activity, it is desirable to increase the expression or activity of GBAP.

Therefore, in one embodiment, GBAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GBAP. Examples of such disorders include, but are not limited to, an immune system disorder such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable

bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis,

5 systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma; a reproductive disorder such as a disorder of prolactin production, infertility, including tubal disease, ovulatory defects, and endometriosis, a disruption of the estrous cycle, a disruption of

10 the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, an endometrial or ovarian tumor, a uterine fibroid, autoimmune disorders, an ectopic pregnancy, and teratogenesis, cancer of the breast, fibrocystic breast disease, and galactorrhea, a disruption of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; a nervous

15 system disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural

20 abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central

25 nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, akathisia, amnesia, catatonia, diabetic neuropathy,

30 tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; a cell signaling disorder including endocrine disorders such as disorders of the hypothalamus and pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma; disorders associated with

35 hyperpituitarism including acromegaly, gigantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma; disorders associated with

hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection; disorders associated with hyperparathyroidism including Conn disease (chronic hypercalcemia); pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications; disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal
5 cortex, hypertension associated with alkalosis; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbations of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and
10 germinal cell aplasia, hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5 α -reductase, and gynecomastia; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including
15 adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

In another embodiment, a vector capable of expressing GBAP or a fragment or derivative
20 thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GBAP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified GBAP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GBAP including, but not limited
25 to, those provided above.

In still another embodiment, an agonist which modulates the activity of GBAP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GBAP including, but not limited to, those listed above.

In a further embodiment, an antagonist of GBAP may be administered to a subject to treat or
30 prevent a disorder associated with increased expression or activity of GBAP. Examples of such disorders include, but are not limited to, those immune system, reproductive, nervous system, and cell signaling disorders, and cell proliferative disorders including cancer, described above. In one aspect, an antibody which specifically binds GBAP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express
35 GBAP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding GBAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GBAP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of GBAP may be produced using methods which are generally known in the art. In particular, purified GBAP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GBAP. Antibodies to GBAP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with GBAP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GBAP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of GBAP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to GBAP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and

Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce GBAP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for GBAP may also be generated. For example, such fragments include, but are not limited to, $F(ab')_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GBAP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GBAP epitopes is generally used, but a competitive binding assay may also be employed (Pound, *supra*).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for GBAP. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of GBAP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple GBAP epitopes, represents the average affinity, or avidity, of the antibodies for GBAP. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular GBAP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from

about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the GBAP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of GBAP, preferably in active form, from the antibody (Catty, D. (1988)

- 5 Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg
10 specific antibody/ml, is generally employed in procedures requiring precipitation of GBAP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al., supra.)

In another embodiment of the invention, the polynucleotides encoding GBAP, or any fragment
15 or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding GBAP. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GBAP.
20 (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g.,
25 Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other
30 systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding GBAP may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency
35 (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked

inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and Somia, N. (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in GBAP expression or regulation causes disease, the expression of GBAP from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in GBAP are treated by constructing mammalian expression vectors encoding GBAP and introducing these vectors by mechanical means into GBAP-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of GBAP include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). GBAP may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V.

and H.M. Blau, *supra*), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding GBAP from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver
5 polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

10 In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to GBAP expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding GBAP under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences
15 required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) *Proc. Natl. Acad. Sci. USA* 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al.
20 (1987) *J. Virol.* 61:1647-1650; Bender, M.A. et al. (1987) *J. Virol.* 61:1639-1646; Adam, M.A. and A.D. Miller (1988) *J. Virol.* 62:3802-3806; Dull, T. et al. (1998) *J. Virol.* 72:8463-8471; Zufferey, R. et al. (1998) *J. Virol.* 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference.
25 Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) *J. Virol.* 71:7020-7029; Bauer, G. et al. (1997) *Blood* 89:2259-2267; Bonyhadi, M.L. (1997) *J. Virol.* 71:4707-4716; Ranga, U. et al. (1998) *Proc. Natl. Acad. Sci. USA* 95:1201-1206; Su, L. (1997) *Blood* 89:2283-2290).

30 In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding GBAP to cells which have one or more genetic abnormalities with respect to the expression of GBAP. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas
35 (Csete, M.E. et al. (1995) *Transplantation* 27:263-268). Potentially useful adenoviral vectors are

described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) *Annu. Rev. Nutr.* 19:511-544; and Verma, I.M. and N. Somia (1997) *Nature* 18:389:239-242, both incorporated by reference herein.

5 In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding GBAP to target cells which have one or more genetic abnormalities with respect to the expression of GBAP. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing GBAP to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with
10 ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) *Exp. Eye Res.* 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV
15 d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) *J. Virol.* 73:519-532 and Xu, H. et al. (1994) *Dev. Biol.* 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus
20 sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to
25 deliver polynucleotides encoding GBAP to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotech.* 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the
30 overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for GBAP into the alphavirus genome in place of the capsid-coding region results in the production of a large number of GBAP-coding RNAs and the synthesis of high levels of GBAP in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in
35 hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic

replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of GBAP into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GBAP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding GBAP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be
5 extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding GBAP. Compounds
10 which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of
15 polynucleotide expression. Thus, in the treatment of disorders associated with increased GBAP expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding GBAP may be therapeutically useful, and in the treatment of disorders associated with decreased GBAP expression or activity, a compound which specifically promotes expression of the polynucleotide encoding GBAP may be therapeutically useful.

20 At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound
25 based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding GBAP is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an *in vitro* cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding GBAP are assayed
30 by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding GBAP. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide
35 exposed to a test compound indicates that the test compound is effective in altering the expression of

the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

10 Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat.

15 Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such pharmaceutical compositions may consist of GBAP, antibodies to GBAP, and mimetics, agonists, antagonists, or

20 inhibitors of GBAP.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

30 Pharmaceutical compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of

35 the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g.,

Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The
5 determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of pharmaceutical compositions may be prepared for direct intracellular delivery of macromolecules comprising GBAP or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, GBAP or a fragment thereof may be joined to a short
10 cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys,
15 or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example GBAP or fragments thereof, antibodies of GBAP, and agonists, antagonists or inhibitors of GBAP, which
20 ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Pharmaceutical compositions which
25 exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

30 The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy.
35 Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or

biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art.

- 5 Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

- In another embodiment, antibodies which specifically bind GBAP may be used for the diagnosis
10 of disorders characterized by expression of GBAP, or in assays to monitor patients being treated with GBAP or agonists, antagonists, or inhibitors of GBAP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for GBAP include methods which utilize the antibody and a label to detect GBAP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be
15 labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

- A variety of protocols for measuring GBAP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of GBAP expression. Normal or standard values for GBAP expression are established by combining body fluids or cell extracts taken
20 from normal mammalian subjects, for example, human subjects, with antibody to GBAP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of GBAP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

- 25 In another embodiment of the invention, the polynucleotides encoding GBAP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of GBAP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of
30 GBAP, and to monitor regulation of GBAP levels during therapeutic intervention.

- In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GBAP or closely related molecules may be used to identify nucleic acid sequences which encode GBAP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a
35 conserved motif, and the stringency of the hybridization or amplification will determine whether the

probe identifies only naturally occurring sequences encoding GBAP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the GBAP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:67-132 or from genomic sequences including promoters, enhancers, and introns of the GBAP gene.

Means for producing specific hybridization probes for DNAs encoding GBAP include the cloning of polynucleotide sequences encoding GBAP or GBAP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding GBAP may be used for the diagnosis of disorders associated with expression of GBAP. Examples of such disorders include, but are not limited to, an immune system disorder such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma; a reproductive disorder such as a disorder of prolactin production, infertility, including tubal disease, ovulatory defects, and endometriosis, a disruption of the estrous cycle, a disruption of the menstrual cycle, polycystic ovary syndrome, ovarian hyperstimulation syndrome, an endometrial or ovarian tumor, a uterine fibroid, autoimmune disorders, an ectopic pregnancy, and teratogenesis, cancer of the breast, fibrocystic breast disease, and galactorrhea, a disruption of spermatogenesis, abnormal sperm physiology, cancer of the testis, cancer of the prostate, benign

prostatic hyperplasia, prostatitis, Peyronie's disease, impotence, carcinoma of the male breast, and gynecomastia; a nervous system disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron

5 disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases

10 of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic,

15 endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; a cell signaling disorder including endocrine disorders such as disorders of the hypothalamus and pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with

20 pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma; disorders associated with hyperpituitarism including acromegaly, giantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma; disorders associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection;

25 disorders associated with hyperparathyroidism including Conn disease (chronic hypercalcemia); pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications; disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbations of the

30 menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5 α -reductase, and gynecomastia; and a

35 cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal

hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, 5 penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. The polynucleotide sequences encoding GBAP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered GBAP expression. Such qualitative or quantitative methods are well known in the art.

10 In a particular aspect, the nucleotide sequences encoding GBAP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding GBAP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard 15 value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding GBAP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

20 In order to provide a basis for the diagnosis of a disorder associated with expression of GBAP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GBAP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with 25 values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, 30 hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or 35 overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development

of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

- 5 Additional diagnostic uses for oligonucleotides designed from the sequences encoding GBAP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding GBAP, or a fragment of a polynucleotide complementary to the polynucleotide encoding GBAP, and will be employed under optimized conditions for identification of a specific gene or condition.
- 10 Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

- In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding GBAP may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease
- 15 in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding GBAP are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary
- 20 and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual
- 25 overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

- 30 Methods which may also be used to quantify the expression of GBAP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of
- 35 interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid

quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described in Seilhamer, J.J. et al., "Comparative Gene Transcript Analysis," U.S. Patent No. 5,840,484, incorporated herein by reference. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, antibodies specific for GBAP, or GBAP or fragments thereof may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity

(Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, *supra*). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently

positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry.

- 5 The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for GBAP to quantify the levels of GBAP expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) *Anal. Biochem.* 270:103-111; Mendoz, L.G. et al. (1999) *Biotechniques* 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

- 15 Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) *Electrophoresis* 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

- 35 Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g.,

Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding GBAP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, e.g., Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding GBAP on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may

also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, GBAP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between GBAP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with GBAP, or fragments thereof, and washed. Bound GBAP is then detected by methods well known in the art. Purified GBAP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GBAP specifically compete with a test compound for binding GBAP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GBAP.

In additional embodiments, the nucleotide sequences which encode GBAP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, in particular U.S. Ser. No. 60/144,595, U.S. Ser. No. 60/150,460, and U.S. Ser. No. 60/159,849, are hereby expressly incorporated by reference.

EXAMPLES

I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic

solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA
5 purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

10 In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic
15 oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g.,
20 PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), pcDNA2.1 plasmid (Invitrogen, Carlsbad CA), or pINCY plasmid (Incyte Genomics, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

25 Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid
30 purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-
35 well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using

PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows.

- 5 Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (PE Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI
- 10 PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (PE Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA
- 15 sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VI.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions,

20 references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between

25 two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

30 The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programing, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation

35 using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full

length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the
 5 GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and
 10 amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:67-132. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

IV. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene
 15 and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is
 20 much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum} \{ \text{length}(\text{Seq. 1}), \text{length}(\text{Seq. 2}) \}}$$

25

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by
 30 assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter
 35 of the two sequences being compared. A product score of 70 is produced either by 100% identity and

70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding GBAP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories.

Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Chromosomal Mapping of GBAP Encoding Polynucleotides

The cDNA sequences which were used to assemble SEQ ID NO:67-132 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:67-132 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 5). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO., to that map location.

The genetic map locations of SEQ ID NO:70, 74, 75, 77, 80, 86, 87, 90, 92, 93, 94, 97, 101, 106, 109, 111, 112, 113, 115, 117, 118, 121, and 128 are described in The Invention as ranges, or intervals, of human chromosomes. More than one map location is reported for SEQ ID NO:94, 101, 109, 111, and 115, indicating that previously mapped sequences having similarity, but not complete identity, to SEQ ID NO:94, 101, 109, 111, and 115 were assembled into their respective clusters. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters.

VI. Extension of GBAP Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:67-132 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this

fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at 5 temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR 10 was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and β -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 15 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN 20 quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis 25 on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose 30 gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x 35 carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems).

10 In like manner, the polynucleotide sequences of SEQ ID NO:67-132 are used to obtain 5' regulatory sequences using the procedure above, along with oligonucleotides designed for such extension, and an appropriate genomic library.

VII. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:67-132 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

25 The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

VIII. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, *supra*), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), *supra*). Suggested

substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) *Science* 270:467-470; Shalon, D. et al. (1996) *Genome Res.* 6:639-645; Marshall, A. and J. Hodgson (1998) *Nat. Biotechnol.* 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/μl RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by *in vitro* transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μl 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μ l of sample mixture consisting of 0.2 μ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide

containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. 5 Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, 10 although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples 15 from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital 20 (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping 25 emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

30 IX. Complementary Polynucleotides

Sequences complementary to the GBAP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GBAP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 35 4.06 software (National Biosciences) and the coding sequence of GBAP. To inhibit transcription, a

complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GBAP-encoding transcript.

X. Expression of GBAP

5 Expression and purification of GBAP is achieved using bacterial or virus-based expression systems. For expression of GBAP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory
10 element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express GBAP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of GBAP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is
15 replaced with cDNA encoding GBAP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et
20 al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, GBAP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton
25 enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from GBAP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-
30 His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified GBAP obtained by these methods can be used directly in the assays shown in Examples XI and XV.

XI. Demonstration of GBAP Activity

35 GTP-binding activity of GBAP is determined in an assay that measures the binding of GBAP

to α - 32 P-labeled GTP. Purified GBAP is first blotted onto filters and rinsed in a suitable buffer. The filters are then incubated in buffer containing radiolabeled α - 32 P-GTP. The filters are washed in buffer to remove unbound GTP and counted in a radioisotope counter. Non-specific binding is determined in an assay that contains a 100-fold excess of unlabeled GTP. The amount of specific binding is

5 proportional to the activity of GBAP.

GTPase activity of GBAP is determined in an assay that measures the conversion of α - 32 P-GTP to α - 32 P-GDP. GBAP is incubated with α - 32 P-GTP in buffer for an appropriate period of time, and the reaction is terminated by heating or acid precipitation followed by centrifugation. An aliquot of the supernatant is subjected to polyacrylamide gel electrophoresis (PAGE) to separate GDP and GTP
10 together with unlabeled standards. The GDP spot is cut out and counted in a radioisotope counter. The amount of radioactivity recovered in GDP is proportional to GTPase activity of GBAP.

XII. Functional Assays

GBAP function is assessed by expressing the sequences encoding GBAP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression
15 vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT plasmid (Life Technologies) and pCR3.1 plasmid (Invitrogen), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a
20 marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the
25 apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in
30 expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of GBAP on gene expression can be assessed using highly purified populations of
35 cells transfected with sequences encoding GBAP and either CD64 or CD64-GFP. CD64 and CD64-

GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression
5 of mRNA encoding GBAP and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIII. Production of GBAP Specific Antibodies

GBAP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to
10 immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the GBAP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well
15 described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (PE Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH
20 complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-GBAP activity by, for example, binding the peptide or GBAP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XIV. Purification of Naturally Occurring GBAP Using Specific Antibodies

Naturally occurring or recombinant GBAP is substantially purified by immunoaffinity
25 chromatography using antibodies specific for GBAP. An immunoaffinity column is constructed by covalently coupling anti-GBAP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing GBAP are passed over the immunoaffinity column, and the column is washed
30 under conditions that allow the preferential absorbance of GBAP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GBAP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GBAP is collected.

XV. Identification of Molecules Which Interact with GBAP

35 GBAP, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent.

(See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GBAP, washed, and any wells with labeled GBAP complex are assayed. Data obtained using different concentrations of GBAP are used to calculate values for the number, affinity, and association of GBAP with the
5 candidate molecules.

Alternatively, molecules interacting with GBAP are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989, Nature 340:245-246), or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

GBAP may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT)
10 which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

Various modifications and variations of the described methods and systems of the invention will
15 be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following
20 claims.

Table 1

Protein SEQ ID No:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	67	1405545	LATRTUT02	1405545F6 (LATRTUT02), 1405545H1 (LATRTUT02), 2926327F7 (TLYMNOT04), 2926327T6 (TLYMNOT04)
2	68	1451265	PENITUT01	700515X14 (SYNORAT03), 758541H1 (BRAITUT02), 1348685F6 (PROSNOT11), 1451265H1 (PENITUT01), 187277F6 (LEUKNOT02)
3	69	1556311	BLADTUT04	1556311H1 (BLADTUT04), 3221281T6 (COLNNON03), 3350311F6 (BRAITUT24), SBFA02256F1, SBFA01440F1, SBFA01098F1, SBFA04741F1
4	70	1901373	BLADTUT06	758057H1 (BRAITUT02), 1255886H1 (MENITUT03), 1887731X12C1 (BLADTUT07), 1901373H1 (BLADTUT06), 2866863H1 (KIDNNOT20), 3090943H1 (BRSTNOT19), 3215237H1 (TESTNOT07), 3719233H1 (PENCNOT10), 4319601H1 (BRADDIT02)
5	71	2367767	ADRENOT07	1331124F1 (PANCNOT07), 2367767H1 (ADRENOT07), 2367779F6 (ADRENOT07), 2782232F6 (BRSTNOT13), 3079286H2 (BRAIUNT01), 3584043T6 (293TF4T01), 4994696H1 (LIVRTUT11)
6	72	3090433	BRSTNOT19	312565H1 (LUNGNOT02), 841829R6 (PROSTUT05), 1340809H1 (COLNTUT03), 1842057H1 (COLNNOT07), 2693513F6 (LUNGNOT23), 3090433H1 (BRSTNOT19), 4895874H1 (LIVRTUT12)
7	73	3800591	SPLNNOT12	554715F1 (SCORNOT01), 882035X23 (THYRNUT02), 3042234F7 (BRSTNOT16), 3630695H1 (COLNNOT38), 3800591H1 (SPLNNOT12), 4975447H1 (HELATXT03)
8	74	5308471	MONOTXT02	790680R1 (PROSTUT03), 870507R1 (LUNGAST01), 948177R1 (PANCNOT05), 1682469T7 (PROSNOT15), 2897215H1 (KIDNTUT14), 5308471H1 (MONOTXT02)
9	75	5324322	FIBPFEN06	1001977R1 (BRSTNOT03), 1312045F1 (COLNFET02), 1334040F2 (COLNNOT13), 1488082F6 (UCMCL5T01), 1570077F1 (UTRSNOT05), 1929845H1 (COLNTUT03), 2306061H1 (NGANNOT01), 3127730F7 (LUNGUTUT12), 3494367H1 (ADRETUT07), 3578924H1 (293TF3T01), 4619513H1 (ENDVNOT01), 4932823H1 (BRSTTUT20), 5324322H1 (FIBPFEN06)
10	76	067184	HUVESTB01	067184H1 (HUVESTB01), 067184R1 (HUVESTB01), 067184X12 (HUVESTB01), 067184X23C1 (HUVESTB01), 067184X29C1 (HUVESTB01), 968551H1 (BRSTNOT05), 2611874T6 (LUNGUTUT10)
11	77	722896	SYNOOAT01	722896H1 (SYNOOAT01), 722896X19C1 (SYNOOAT01), 1433775T1 (BEPINON01), 1477633T6 (CORPNOT02), 2676923F6 (KIDNNOT19), 3230945H1 (COTRNUT01), 3389989H1 (LUNGUTUT17)
12	78	1571739	UTRSNOT05	1571739H1 (UTRSNOT05), 1571739X12R1 (UTRSNOT05), 2799982H1 (PENCNOT01), 4059114F6 (BRAINT021)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
13	79	1739479	HIPONON01	511157H1 (MPHGNOT03), 511157T6 (MPHGNOT03), 1739479H1 (HIPONON01), 2092446T6 (PANCNOT04), 3880948F6 (SPLNNOT11)
14	80	1999147	BRSTTUT03	1339243T6 (COLNTUT03), 1999147H1 (BRSTTUT03), 2094940X11F1 (BRAITUT02), 2670959T6 (ESOGTUT02), 3297709H1 (TLYJINT01), 3396927H1 (UTRSNOT16), SCBA00828V1, SCBA00615V1, SCBA04422V1, SCBA04646V1, SCBA01715V1, 5544151H1 (TESTNOC01)
15	81	2182085	SININOT01	767764R6 (LUNGNOT04), 1655010F6 (PROSTUT08), 1701703T6 (BLADTUT05), 1871360F6 (SKINBIT01), 2081835F6 (UTRSNOT08), 2411644H1 (BSTMNON02)
16	82	2216640	SINTFET03	489759H1 (HNT2AGT01), 2057454T6 (BEPINOT01), 2097739H1 (BRAITUT02), 2216640H1 (SINTFET03), 2325135H1 (OVARNOT02), 2361273R6 (LUNGFET05), 2667958H1 (ESOGTUT02), 3462348H1 (293TF2T01), 3478754H1 (OVARNOT11), 4163069F6 (BRSTNOT32).
17	83	2417361	HNT3AZT01	1394742F1 (THYRNOT03), 2417361F6 (HNT3AZT01), 2417361H1 (HNT3AZT01)
18	84	2454384	ENDANOT01	2454384H1 (ENDANOT01), 2454384T6 (ENDANOT01), 2589653T6 (LUNGNOT22), 2643348F6 (LUNGUTUT08), 27233048H1 (LUNGUTUT10), 3130367H1 (LUNGUTUT12)
19	85	2610262	LUNGUTUT08	1226946R6 (COLNNOT01), 1226946T6 (COLNNOT01), 2610262F6 (LUNGUTUT08), 2610262H1 (LUNGUTUT08)
20	86	2700075	OVARUTUT10	604199R1 (BRSTTUT01), 1225126R1 (COLNTUT02), 1923323R6 (BRSTTUT01), 2301778R6 (BRSTNOT05), 2506882F6 (CONUTUT01), 2700075F6 (OVARUTUT10), 2700075H1 (OVARUTUT10), 2744960F6 (LUNGUTUT11), 2833994F6 (TLYMNOT03), 2915413H1 (THYMFET03), 3647274H1 (ENDINOT01)
21	87	2786701	BRSTNOT13	754370R1 (BRAITUT02), 1426163R6 (BEPINON01), 1850667F6 (LUNGFET03), 1923562R6 (BRSTTUT01), 2215161F6 (SINTFET03), 2215161T6 (SINTFET03), 2498589H1 (ADRETUT05), 2991672F6 (KIDNFET02), 3028991H1 (HEARFET02), 3729514H1 (SMCCNON03), 5065467H1 (ARTFDT01)
22	88	3068538	UTRSNOR01	908465R2 (COLNNOT09), 957130R6 (KIDNNOT05), 1301520F6 (BRSTNOT07), 1580628H1 (DUODNOT01), 2631247F6 (COLNTUT15), 3068538H1 (UTRSNOR01), 3532286T6 (KIDNNOT25)
23	89	5159072	BRSTTWT02	412241R1 (BRSTNOT01), 660435H1 (BRAINOT03), 881160H1 (THYRNOT02), 1304119F6 (PLACNOT02), 1324073F1 (LPARNOT02), 2520427H1 (BRAITUT21), 5159072H1 (BRSTTWT02)

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
24	90	5519057	LIVRDIR01	066809H1 (HUVSTB01), 3279230H1 (STOMFET02), 5370305F6 (BRAINOT22), 5508943F6 (BRADDIR01), 5508943R6 (BRADDIR01), 5519057H1 (LIVRDIR01)
25	91	035379	HUVENOB01	035379H1 (HUVENOB01), 035379X11 (HUVENOB01), 035379X12 (HUVENOB01), 035379X13 (HUVENOB01), 035379X11D1 (HUVENOB01), 112161R1 (PITUNOT01), 1922877R6 (BRSTTUT01), 2133108F6 (ENDCNOT01), 3107232H1 (BRSTTUT15), 4798135H1 (LIVRTUT09), SCHA01519V1, g1802757
26	92	275354	TESTNOT03	275354H1 (TESTNOT03), 275354X1 (TESTNOT03), 1663122T6 (BRSTNOT09), 2104284R6 (BRAITUT02), 2738788T6 (OVARNOT09), 3584082T6 (293TF4T01), SCGA07807V1
27	93	311658	LUNGNOT02	207452X12 (SPLNNOT02), 238306X85F1 (SINTNOT02), 264489H1 (HNT2AGT01), 311658H1 (LUNGNOT02), 1292829F6 (PGANNOT03), 1298271F1 (BRSTNOT07), 1488285H1 (UCMCISUT01), 2555757H1 (THYMNOT03), 2665984F6 (ADRENOT08), 2665984T6 (ADRENOT08), 3079209H1 (BRAIUNT01)
28	94	1251632	LUNGFET03	1251632H1 (LUNGFET03), 1251632X11 (LUNGFET03), 1251632X13 (LUNGFET03), 1316814T1 (BLADTUT02), 1384212F1 (BRAITUT08), 1711274F6 (PROSNOT16), 3128230H1 (LUNGUTUT12), 4819602H1 (PROSTUT17), SZZZ00620R1
29	95	1331955	PANCNOT07	1363667X12 (LUNGNOT12), 1363667X13 (LUNGNOT12), SBBA01489F1, SBBA01528F1
30	96	1412614	BRAINOT12	1412614F6 (BRAINOT12), 1412614H1 (BRAINOT12), 2278130H1 (PROSNON01), 2278130T6 (PROSNON01), 5105388T6 (PROSTUS19)
31	97	1750781	LIVRTUT01	452712T6 (TYMNNOT02), 483862R6 (HNT2RAT01), 77729R6 (COLNNOT05), 1394724F1 (THYRNOT03), 1652134F6 (PROSTUT08), 1750781F6 (LIVRTUT01), 1750781H1 (LIVRTUT01), 1750781X305F1 (LIVRTUT01), 1750781X307D2 (LIVRTUT01), 3221477H1 (COLNNON03), SCHA02984V1, SXAA02156D1, SXAA00802D1
32	98	1821658	GBLATUT01	909674H1 (STOMNOT02), 1579095F1 (DUODNOT01), 1821658H1 (GBLATUT01), 1821658T6 (GBLATUT01), 2508922F6 (CONUTUT01), 2584263H1 (BRAITUT22), 5571821H1 (TYMNNOT08)
33	99	1872574	LEUKNOT02	305990F1 (HEARNOT01), 908252R2 (COLNNOT09), 1872574H1 (LEUKNOT02), 2051868F6 (LIVRFET02), 2285632R6 (BRAINON01), 3181732F6 (TYJNNOT01), 3285854F6 (HEAONOT05), 3332012H1 (BRAIFET01), SBWA02751V1, SBWA02849V1, SBWA04744V1, SBWA00180V1

Table 1 (cont.)

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
34	100	2590967	LUNGNOT22	1340471F6 (COLNTUT03), 2590967F6 (LUNGNOT22), 2590967H1 (LUNGNOT22), 2771160F6 (COLANOT02), 3150287R6 (ADREN004)
35	101	2824491	ADRETUT06	1381834X14 (BRAITUT08), 1381834X16 (BRAITUT08), 1381834X17 (BRAITUT08), 1381834X31 (BRAITUT08), 1972345F6 (UCMCL5T01), 2824491H1 (ADRETUT06), 3413970H1 (PTHYNOT04)
36	102	2825460	ADRETUT06	870873R6 (LUNGAST01), 1440326F1 (THYRN0T03), 2825460H1 (ADRETUT06), 2825460T6 (ADRETUT06), 4154518H1 (MUSLTWT01), 5068209H1 (PANCNOT23), SBLA03097F1
37	103	2871116	THYRN0T10	357664R6 (PROSN0T01), 1419595F1 (KIDN0T09), 1419595T1 (KIDN0T09), 1577877F6 (LN0DNOT03), 1577877T1 (LN0DNOT03), 2767635H1 (COLANOT02), 2871116F6 (THYRN0T10), 2871116H1 (THYRN0T10), 4650546H1 (PROSTUT20), SBHA03160F1, SBHA02613F1, SBHA02703F1
38	104	2942212	CONNTUT05	1270807H1 (TESTTUT02), 1270807X301D1 (TESTTUT02), 1270807X309D2 (TESTTUT02), 2942212H2 (CONNTUT05), g1924758
39	105	3685151	HEAANOT01	860843R1 (BRAITUT03), 1932207F6 (COLN0T16), 1932207T6 (COLN0T16), 2210580F6 (SINTFET03), 3043060H1 (HEAANOT01), 3685151H1 (HEAANOT01), 4960825H1 (TLYMNOT05)
40	106	4881515	UTRMTWT01	925415R1 (BRAINOT04), 1337450F6 (COLN0T13), 1961288R6 (BRSTNOT04), 3581069H1 (293TF3T01), 3583842T6 (293TF4T01), 4881515H1 (UTRMTWT01), 5488514H1 (DRGTN004), g1156606
41	107	5324681	FIBPPEN06	2455960T6 (ENDANOT01), 2458281F6 (ENDANOT01), 3834084F6 (PANCNOT17), 4046332H1 (LUNGNOT35), 5324681H1 (FIBPPEN06), g1733388, g1522074
42	108	5387651	BRAINOT19	810934T1 (LUNGNOT04), 822997R1 (KERANOT02), 1282647F1 (COLN0T16), 1282647T1 (COLN0T16), 1571430T6 (UTRSN0T05), 2208839F6 (SINTFET03), 2844787H1 (DRGLN0T01), 2908748H1 (THYMN0T05), 5387651H1 (BRAINOT19)
43	109	5595679	COLCDIT03	044292R6 (TBLYN0T01), 826501R1 (PROSN0T06), 1251632X12 (LUNGFET03), 1303934F1 (PLACN0T02), 1316814F1 (BLADTUT02), 1339567T1 (COLNTUT03), 2806159H1 (BLADTUT08), 2837021H1 (TLYMNOT03), 3037493H1 (BRSTNOT16), 3119883H1 (LUNGNOT13), 3395946H1 (LUNGNOT28), 3748742H1 (UTRSN0T18)
44	110	5782457	BRAXNOT03	532593R6 (BRAINOT03), 532593T6 (BRAINOT03), 5782457H1 (BRAXNOT03)

Table 1 (cont.)

Protein SEQ ID No:	Nucleotide SEQ ID No:	Clone ID	Library	Fragments
45	111	760677	BRAITUT02	745006X13 (BRAITUT01), 760677H1 (BRAITUT02), 760677X19 (BRAITUT02), 763135X12 (BRAITUT02), 946075H1 (RATRN0202), 953938H1 (SCORNON01)
46	112	1348567	PROSN0T11	1348567H1 (PROSN0T11), 1505075F6 (BRAITUT07), 1620627F6 (BRAITUT13), 2069105F6 (ISLTN0T01), 2417901F6 (HNT3AZT01), 2494683H1 (ADRETUT05), 3320166H1 (PROSBPT03)
47	113	1751354	LIVRTUT01	029909F1 (SPLNFET01), 029909R1 (SPLNFET01), 512371H1 (MPHGN0T03), 1439362F6 (PANCN0T08), 1751354F6 (LIVRTUT01), 1751354H1 (LIVRTUT01), 1900168F6 (BLADTUT06)
48	114	1976780	PANCTUT02	001347H1 (U937N0T01), 1755035X307D2 (LIVRTUT01), 1976780H1 (PANCTUT02), 2798389H1 (NPOLN0T01), 4050076H1 (SINTN0T18), 4228943H1 (BRAMDIT01), 4291877H1 (BRABDIR01), 5514957H1 (BRABDIR01), SCHAO4173V1, SCHAO2986V1, SCHAO1162V1, SCIA02096V1
49	115	2048234	LIVRFET02	1553355F6 (BLADTUT04), 1929455F6 (COLNNTUT03), 2048234H1 (LIVRFET02), 2699864T6 (OVRTUT10)
50	116	2111754	BRAITUT03	1335055F6 (COLNNT013), 2105233R6 (BRAITUT03), 2111754H1 (BRAITUT03), 2111754R6 (BRAITUT03), 3706377H1 (PENCN0T07)
51	117	2123286	BRSTN0T07	411359F1 (BRSTN0T01), 411359R1 (BRSTN0T01), 708105R6 (SYNORAT04), 1322780F6 (BLADN0T04), 2123286H1 (BRSTN0T07), 2719651F6 (LUNGUTUT10), 2880143F6 (UTRSTUT05), 3206153F6 (PENCN0T03), 3210501F6 (BLADN0T08), 3346625F6 (BRAITUT24), 3489118H1 (EPIGN0T01), 3605764H1 (LUNGNOT30), 4242993H1 (SYNWDIT01), 5089472H1 (UTRSTMR01)
52	118	2477507	SMCAN0T01	488096H1 (HNT2AGT01), 1672690F6 (BLADN0T05), 1802830F6 (COLNNT027), 1818538H1 (PROSN0T20), 2171841H1 (ENDCN0T03), 2477507H1 (SMCAN0T01), 3434030F6 (PENCN0T05)
53	119	2759119	THP1AZS08	496782H1 (HNT2N0T01), 1251166H1 (LUNGFET03), 1289067F1 (BRAIN0T11), 1295658T6 (PGANN0T03), 1510901F1 (LUNGNOT14), 1531583F1 (SPLNNT04), 1533488F1 (SPLNNT04), 1817447H1 (PROSN0T20), 2154846F6 (BRAIN0T09), 2468875H1 (THYRN0T08), 2498852F6 (ADRETUT05), 2506652F6 (CONUTUT01), 2630812F6 (COLNNTUT15), 2759119H1 (THP1AZS08), 2991227H1 (KIDNFET02), 3036646F6 (PENCN0T02), 3213032H1 (BLADN0T08)
54	120	2823818	ADRETUT06	618671R6 (PGANN0T01), 2823818H1 (ADRETUT06), 2950988F6 (KIDNFET01), q1679455

Table 1 (cont.)

Protein SEQ ID No:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
55	121	2859730	SININOT03	103901X6 (BMARNOT02), 510695H1 (MPHGNOT03), 1452088H1 (PENITUT01), 1527095F6 (UCMCL5T01), 2285371H1 (BRAINON01), 2843029H1 (DRGLNOT01), 2859730H1 (SININOT03)
56	122	2861155	SININOT03	875215T1 (LUNCAST01), 999673H1 (KIDNTUT01), 1425091R6 (BEPINON01), 2861155F6 (SININOT03), 2861155H1 (SININOT03), 2901915F6 (DRGCNOT01), 3621947H2 (ENDANOT03)
57	123	3002667	TYMNOT06	227882F1 (PANCNOT01), 227882R1 (PANCNOT01), 260725H1 (HNT2RAT01), 1432542R1 (BEPINON01), 2474761F6 (SMCANOT01), 3002667H1 (TYMNOT06), 3188977H1 (THYMNON04), 3461163H1 (293TFIT01), 4860339F6 (PROSTUT09)
58	124	3043734	HEAANOT01	3043734H1 (HEAANOT01), 3043734T6 (HEAANOT01), 3209823H1 (BLADNOT08), 5277071H1 (MUSLNOT01)
59	125	3294893	TYLJINT01	389234H1 (THYMNOT02), 1242886H1 (LUNGNOT03), 1539958T1 (SINTTUT01), 1870567H1 (SKINBIT01), 2069284F6 (ISLTNOT01), 2280217R6 (PROSNON01), 2353465T6 (LUNGNOT20), 2798990F6 (NPOLNOT01), 3180440H1 (TYLJNOT01), 3294893H1 (TYLJINT01), 3816962H1 (TONSNOT03), 5039889H2 (COLHTUT01), 5118831H1 (SMCBUNT01)
60	126	3349052	BRAITUT24	731775H1 (LUNGNOT03), 1449575H1 (PLACNOT02), 1899442F6 (BLADTUT06), 1967162T6 (BRSTNOT04), 2630025F6 (COLNTUT15), 2717821H1 (THYRNOT09), 3180478T6 (TYLJNOT01), 3349052H1 (BRAITUT24), 4523961F6 (HNT2TXT01), 5565623H1 (TYMNOT08), 6141909H1 (BMARTXT03)
61	127	3357264	PROSTUT16	2378150F6 (ISLTNOT01), 2378150X304B1 (ISLTNOT01), 2378150X304D1 (ISLTNOT01), 2807493F6 (BLADTUT08), 2881251F6 (UTRSTUT05), 3357264F6 (PROSTUT16), 3357264H1 (PROSTUT16), 3593272H1 (293TF5T01), 4163652T6 (BRSTNOT32), 4821588F6 (PROSTUT17), 4872125H1 (COLDNOT01)
62	128	3576329	BRONNOT01	1444072F6 (THYRNOT03), 1649584T6 (PROSTUT09), 1720770X15C1 (BLADNOT06), 1720770X16C1 (BLADNOT06), 2204612F6 (SPLNFET02), 3576329H1 (BRONNOT01), SAFC01083F1
63	129	3805550	BLADTUT03	1416364F6 (BRAINOT12), 1553473H1 (BLADTUT04), 3232384H1 (COLNUCT03), 3287257H1 (HEAONOT05), 3539473H1 (SEMVNOT04), 3805550H1 (BLADTUT03)

Table 1 (cont.)

Protein SEQ ID No:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
64	130	4546403	COLXTDT01	1687704F6 (PROSTUT10), 1962744R6 (BRSTNOT04), 2674742F6 (KIDNNOT19), 4546403H1 (COLXTDT01), 4632828T6 (GBLADIT02)
65	131	4767318	BRATNOT02	134566R1 (BARNOT02), 549352R1 (BEPINOT01), 1819757T6 (GBLATUT01), 2863295H1 (KIDNNOT20), 4767318H1 (BRATNOT02), SBLA03778F1, g3737930
66	132	4834527	BRAWNOT01	859906X38C1 (BRAITUT03), 1231225H1 (BRAITUT01), 1393681T6 (THYRNOT03), 1416996F6 (BRAINOT12), 2422475H1 (SCORNON02), 3999137R6 (HNT2AZS07), 4834527F6 (BRAWNOT01), 4834527H1 (BRAWNOT01), 5691642H1 (BRAUNOT02)

Table 2

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
1	269	S59 T71 T146 T211 T73 S127 T133 S216	N12	GTP-binding protein: D79-M234, Y80-C239 ATP/GTP binding site (P-loop): G102-S109	GTP-binding protein; Cgpa [Caulobacter crescentus] g3820578	BLAST-Genbank BLAST-DOMO MOTIFS
2	428	S59 S188 S200 S284 S367 S381 T399 T29 T193 T288 T354 S419		Beta transducin family, G-beta repeats: T269-L315, F261-D293 L280-V294, V185-V199 Signal peptide: M1-A35		ProfileScan MOTIFS BLIMPS-PRINTS HMMER-PFAM SPScan
3	562	S151 S152 T443 T444 S33 S104 S126 S127 S135 S216 S239 T350 T383 S450 T481 S146 T223 S287 S356 T434 T470 Y501	N125 N354 N445		Ras inhibitor [Homo sapiens] g190895	BLAST-Genbank
4	229	T108 S153 S9 S160 S215 T219 T142 S180	N111 N140 N198	ATP/GTP-binding site: G28-S35 Ras family: K23-T219 Ras transforming protein: V22-M43, A63-S85, P124-A137, L156-A178, D102-S145, K150-S180	Small GTP binding protein [Saccharomyces cerevisiae] g1171484	BLAST-Genbank MOTIFS HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-DOMO
5	360	T108 S360 S115 T217 T264 S295 S296 S35 S52 S160 S174 T206 T249	N149 N287 N327 N351	WD domain, G-beta repeats: M1-T64, M27-K41, F274-K306	Similar to WD domain, G-beta repeat protein [C. elegans] g3880929	BLAST-Genbank HMMER-PFAM ProfileScan BLIMPS-PRINTS
6	460	T18 T107 T123 S149 S199 S280 S336 S369 S71 T106 S387 Y302 Y400	N270 N350	Signal peptide: M1-A57	Rabin3 [Rattus norvegicus] g624225	BLAST-Genbank SPScan

Table 2 (cont.)

SEQ ID No:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
7	239	S234 S25 T47 T52 S98 T190 T206 S236 S223	N188	Phosducin: L20-I179, S25-I179, E30-D239	Phosducin-like protein [Homo sapiens] g4104075	BLAST-Genbank BLAST-PRODOM BLAST-DMO
8	334	T225 T235 S260 T4 S45 S63 S133 S162 S193 T279 T308		ATP/GTP-binding site (P-loop): G150-S157 GTP1/OBG family: L75-D89, I146-Q166 G-protein, alpha subunit: I79-L87	GTP-binding protein homolog [L. braziliensis] g2570231	BLAST-Genbank MOTIFS BLIMPS-BLOCKS BLIMPS-PRINTS
9	341	S91 T122 S185 T199 T228 S65 T85 S323		Signal peptide: M1-A61 WD domain, G-beta repeats: L164-D196, C173-P217, V183-L197, S185-W195	Putative WD-40 repeat protein [Arabidopsis thaliana] g4191773	SPScan BLAST-Genbank MOTIFS ProfileScan HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS
10	513	T29 T72 T109 S124 S136 S215 T341 T481 T501 S65 T245 T330 S338 T372 T386 S437 S451 T473 Y228 Y254	N242 N417	Beta-transducin family, G-beta repeats: F345-N377, K210-N242, E303-G335, S366-W376, N353-V400, L229-F243, I364-M378	Similar to WD domain G-beta repeats protein [C. elegans] g3875246	BLAST-Genbank MOTIFS HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS ProfileScan
11	186	T61 S80 S107 S163 S31 T66 S183	N64 N148	ARF-family: N6-S186, P51-S90, M95-L149 GTP-binding, SAR1 protein: F78-K103, I123-I144 ATP/GTP binding site (P-loop): G27-T34	Similar to ADP- ribosylation factor [C. elegans] g3881189	BLAST-Genbank HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
12	204	S184 S203 S34 S152 T14 T20 T25 T62 S86		Ras family: K5-M189 Ras transforming protein: M1-E150, V4-T25, V113-L126 ATP/GTP binding site (P-loop): G10-S17	Ras-like protein, rit [Mus musculus] g1656005	BLAST-Genbank HMMER-PFAM BLIMPS-PRINTS BLAST-DOMO MOTIFS
13	100	S31 S46 T52 T61 S84 S4 S26 S27 T86		Beta-transducin, WD repeats: L81-M95, V70-S100, M1-S100	Similar to beta-transducin [C. elegans] g3875373; Alzheimer's disease protein [Homo sapiens] GeneSeq W21578	BLAST-Genbank MOTIFS BLIMPS-BLOCKS ProfileScan BLIMPS-PRINTS BLAST-PRODOM
14	795	T569 S776 S54 S188 S201 T248 T249 T298 S306 S368 T422 S466 T561 S586 S625 S678 T731 S777 S13 T42 S120 T134 T174 S213 S254 T266 S391 S415 S588 S620 S694 T742	N52 N421 N559 N585 N708	WD domain, G-beta repeats: L108-L139, L147-K179, T168-W178, Y227-K259, L126-N140, M166-A180	Phospholipase A2-activating protein [Rattus Norvegicus] g1017706	BLAST-Genbank BLAST-PRODOM BLAST-DOMO HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS
15	393	S48 S61 T143 T334 T148 T200 S208 T212 T245 S266 S325	N182 N197	WD domain, G-beta repeats: L121-A153, L357-R389, P322-F369, L140-S154	Putative WD-repeat protein [Arabidopsis thaliana] g4263521	BLAST-Genbank HMMER-PFAM ProfileScan BLIMPS-PRINTS
16	485	S31 S108 S222 S321 S346 S357 T84 T125 T137 T151 T187 S227 T268 S395 T403 S409 T437 Y92 Y261		Beta-transducin, WD repeats: L129-L143, V219-T233, S262-W272, V387-G401, L429-V443, L452-G468	Notchless protein [Xenopus laevis] g3687833	BLAST-Genbank MOTIFS HMMER-PFAM ProfileScan BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-DOMO BLAST-PRODOM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
17	199	T32 T91 S177 T56 S153 S186 Y149		ATP/GTP-binding site (P-loop): G15-T22 Transforming protein, p21: L9-H30, T32-K48, I50-S72, Q115-L128, Y149-A171 Ras protein: K5-E151	Rab7 [Mus musculus] g1050551	BLAST-Genbank MOTIFS BLIMPS-PRINTS BLAST-PRODROM BLAST-DOMO
18	163	T18 T46 S120 S5 T151 T83 S125	N81 N159		Rhotekin [Mus musculus] g1293145	BLAST-Genbank
19	290	S56 S84 T234 S41 T91 T132 T234 T11 T47 T80 T194	N89 N188	Beta-transducin, WD-repeats: S41-W51, F195-D227, L238-M270, L214-I228, L257-M271, T203-S249	Similar to beta-transducin; [C. elegans] g3875373; Alzheimer's disease protein [Homo sapiens] GeneSeq W21578	BLAST-Genbank MOTIFS HMMER-PFAM BLIMPS-BLOCKS ProfileScan BLIMPS-PRINTS BLAST-PRODROM
20	705	T277 T364 S393 S448 S479 S483 T554 T568 S586 S239 S250 T374 S379 T398 S485 T528	N274	Beta-transducin, WD-repeats: L390-L404, L370-D403, L413-R445	Similar to WD domain G-beta repeat prot. [C. elegans] g3880340; 70kD tumor-specific antigen [R. norvegicus] g2505957	BLAST-Genbank HMMER-PFAM BLAST-PRODROM BLAST-DOMO BLIMPS-BLOCKS BLIMPS-PRINTS MOTIFS
21	454	T426 S451 S28 S51 T81 T89 T166 S214 T241 S264 T305 S343 S185 T193 S421	N58	ATP/GTP-binding site (P-loop): G73-S80 Cell division control protein: V47-P240	Similar to Drosophila melanogaster septin (sep2) [Homo sapiens] g1503988	BLAST-Genbank BLAST-PRODROM BLAST-DOMO MOTIFS
22	433	S169 T239 T292 S309 S382 S129 S297 Y60 Y101 Y315	N338	Protein GTPase activating protein: L8-S169 PH domain: Y138-Q355, Q191-I351, P210-E375	RhoGAP protein [Homo sapiens] g312212	BLAST-Genbank BLAST-PRODROM BLAST-DOMO

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
23	406	T83 S143 S303 T75 T115 T126 T211 S216 T289 T315 Y247	N184 N401 N402		Rab 9 effector, p40 [Homo sapiens] g2217970	BLAST-GenBank
24	229	S7 S127 T50 S178		ATP/GTP-binding site (P-loop): G40-T47 Ras family: K35-L217 Transforming protein, p21: F34-A55, R57-R73, V75-K97, N139-L152	Rab GTPase, Rab33B [Mus musculus] g2516239	BLAST-GenBank MOTIFS HMMER-PFAM BLIMPS-PRINTS BLAST-DOMO
25	670	T28 T45 S69 S3 S108 T277 S406 S6 T52 T82 S91 S102 S126 S609 S158 S197 T213 S217 T281 S323 S416 T419 T428 T474 S496 T540 S624 T664	N343	G-beta WD repeat domain: F386-D424, L411-T425, Y429-D465, L469-D504, L510-D545, L549-D585, K589-S629, M633-T669 Beta-transducin Trp-Asp repeats signature: C401-I447	Beta transducin- like protein [Podospira anserina] g607003	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS ProfilesScan
26	445	T17 T48 T126 T160 T293 T364 T97 T132 S201 S217 S305 T322 S357 S434 Y339	N46 N95 N355	G-beta WD repeat domain: L62-N95, V82-L96, F124-M138, F297-V311 Beta-transducin Trp-Asp repeats signature: S316-A356 SOF1 protein, WD repeat: D129-V277, F309-V444	Beta-transducin [Schizosaccharomyces pombe] g3393019	BLAST-GenBank BLAST-DOMO BLAST-PRODOM BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS
27	236	S24 S60 S86 T181 S117 S140		GYP7, GTPase activating protein: M1-I155	GTPase activating protein [Yarrowia lipolytica] g2370595	BLAST-GenBank BLAST-PRODOM MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
28	498	S97 T158 S247 S281 S425 S468 S494 T84 S176 T355 T474 Y239		G-beta WD repeat domain: L188-Q220, L446-G479, M466-P480 Beta-transducin Trp-Asp repeats signature: F200-A245	Similarity to guanine nucleotide binding protein [Caenorhabditis elegans] g3878300	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMME-PFAM MOTIFS ProfileScan
29	334	S63 S104 S148 S189 T208 S276 S50 T110 S118 T124 S152 T160 T237 T326	N265	G-beta WD repeat domain: L41-G73, I83-D115, L102-V116, L125-D157, L167-D199, I210-D242 Beta-transducin Trp-Asp repeats signature: S49-A308 Signal peptide: M1-A47	Similar to guanine nucleotide binding protein [Caenorhabditis elegans] g3874290	BLAST-GenBank BLAST-PRODOM BLIMPS-BLOCKS BLIMPS-PRINTS HMME-PFAM MOTIFS ProfileScan SPScan
30	292	S102 T145 S188 S52 T89 S204 S222 S283	N209	Protein with WD repeat: P7-W129 Signal peptide: M1-S68	F-box protein FBX16 [Mus musculus] g6456114	BLAST-PRODOM BLAST-GenBank MOTIFS SPScan
31	588	T184 T76 T137 S139 T161 T174 T183 S285 T351 T375 S432 T473 S488 S213 T265 S389 S394 T412 T546	N159	G-beta WD repeat domain: A293-E331, C337-T375, Y379-D417, I404-L418, E460-D497, T506-S543, G547-A586 Beta-transducin Trp-Asp repeats signature: A308-E354, L393-Q441	TipD (sequence similarity to Beta-transducin family) [Dictyostelium discoideum] g2407788	BLAST-GenBank BLAST-PRODOM BLIMPS-BLOCKS BLIMPS-PRINTS HMME-PFAM MOTIFS ProfileScan
32	326	T50 T84 S98 S142 T261 T65 T148 T178 T189 T221	N187	G-beta WD repeat domain: L120-N153, I140-L154		BLIMPS-BLOCKS BLIMPS-PRINTS HMME-PFAM MOTIFS
33	453	T157 T218 T248 S320 S347 S412 S7 T236 S290 T396 T406 Y63	N59 N225	G-beta WD repeat domain: D180-E211, A198-V212		BLIMPS-BLOCKS BLIMPS-PRINTS HMME-PFAM MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
34	161	T137 T18 T102 Y96		DMR-N9 protein: K93-S148	DMR-N9 (homology to WD repeat sequences) [Mus musculus] g817954	BLAST-GenBank BLAST-PRODOM MOTIFS
35	684	T173 S25 S43 S74 S83 S127 S152 S154 S182 T316 T331 T341 S372 T535 T606 S623 T138 T151 S168 S238 S299 T336 T422 S476 T506 T530 T628 T647	N526 N621	ATP/GTP-binding site motif A (P-loop): G267 Elongation factor 1 alpha protein (GTP-binding) domain: D485-E684 Elongation factor Tu domain: K258-D658, N262-K273, M343-G374, R664-G677 GTP-binding elongation factors signature: A249-E420, N262-T275, K294-P346, T341-F351, T357-V368, L401-Q410, P443-I682 RAS transforming protein: K258-V439	eRFS (related to eukaryotic release factor 3) [Mus musculus] g4566435	BLAST-GenBank BLAST-DOMO BLAST-PRODOM BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS ProfileScan
36	366	S342 T52 S71 T102 T119 T224 T324 T66 S195 S271 T353 Y225	N32	G-beta WD repeat domain: V146-L160, L284-I298 Signal Peptide: M1-T56		BLIMPS-PRINTS MOTIFS SPScan
37	339	S152 S183 T107 T115		Beta-transducin Trp-Asp repeats signature: N101-L162 Trp-Asp repeats-containing protein: R54-A172 Transmembrane domain: A300-I323	Hypothetical trp-asp repeats containing protein [Schizosaccharomyces pombe] g3850059	BLAST-GenBank BLAST-DOMO BLAST-PRODOM HMMER MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
38	213	T29 T134 S153 T181 S200 T92 T129 S207		ATP/GTP-binding site motif A (P-loop): G15 GTP-binding protein signature (Arf1, Ran): W5-E179 Ras family signature: R10-C213 Transforming protein p21: F9-E30, R32-R48, E51-S73, Y114-L127, Y149-I171 Signal peptide: M1-V19	Rab-related GTP-binding protein [Homo sapiens] g1491714	BLAST-GenBank BLAST-DOMO BLAST-PRODOM BLIMPS-PRINTS HMMER-PFAM MOTIFS SPScan
39	393	S209 T363 S60 S99 S119 S135 T144 T147 S174 S210 T350 S359 S370 T371		G-beta WD repeat domain: G33-D69, K73-D110, L97-A111, W114-N152, L236-K276, I263-L277 Signal peptide: M1-T43	Similar to beta-transducin [Caenorhabditis elegans] g860695	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS SPScan
40	399	S86 T191 S219 S224 S254 S275 S308 S59 S72 T96 S373 S385 T394	N88 N106 N321 N322	ATP/GTP-binding site motif A (P-loop): G68 G-protein alpha subunit: R63-Q78 GTP-binding protein GTR1: A57-D294 Ras transforming protein: K61-L203	Gtr2 homolog, novel small GTPase subfamily [Schizosaccharomyces pombe] g3560242	BLAST-GenBank BLAST-DOMO BLAST-PRODOM BLIMPS-PRINTS MOTIFS
41	412	T106 S337 S391 S29 S30 S41 S130 S154 S207 S231 S326 S82 S97 T212 S220	N367	G-beta WD repeat domain: C184-E217, L204-Y218 Signal peptide: M1-G18	Putative transcriptional regulation protein, trp-asp repeat containing [Schizosaccharomyces pombe] g3766375	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMMER-PFAM MOTIFS SPScan

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
42	163	S15 S17 S71 T114 Y49			Arf-like 2 binding protein BART1 [Homo sapiens] g4426962	BLAST-GenBank MOTIFS
43	514	S113 T174 S263 S297 S441 S484 S510 T100 S192 T371 T490 Y255		G-beta WD repeat domain: L204-Q236, L462-G495, M482-P496 Beta-transducin Trp-Asp repeats signature: F216-A261	Similarity to guanine nucleotide binding protein [Caenorhabditis elegans] g3878300	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMME-PFAM MOTIFS ProfileScan
44	67	T30 S15 Y18		G-protein gamma subunit: E2-L67, M9-R24, K10-P57, D45-G62 Prenyl group binding site (CAAX box): V64	G gamma protein [Mus musculus] g7259257	BLAST-GenBank BLIMPS-BLOCKS BLIMPS-PRINTS HMME-PFAM MOTIFS
45	315	T148 S162 S209 S244 S252 S45 T48 S132 S140 S158 T214 S244	N79	WD40 domains/G-beta repeats: Q15-N53, G57-N95, G99-D137, P143-D179, G223-D263 WD/G-beta profiles: L71-Q116, T114-V161 WD/G-beta repeat signature: V250-L264	Contains similarity to G beta repeats (PROSITE:PS00670) of the beta- transducin family [Caenorhabditis elegans] g1086900	BLAST-GenBank MOTIFS ProfileScan HMME-PFAM
46	504	T268 T99 T193 S323 S324 T409 T493 T91 T98 T133 T185 T234 T259 T264 T287 T337 S415 S498	N37 N295	WD40 domains/G-beta repeats: A211-D250, E254-S292, A296-A331, G338-D378, R382-D420 WD/G-beta profiles: T396-I442, T268-A316, C355-F400 WD/G-beta signatures: L407-L421, V279-V293 WD repeat protein-like region: I4-A226	Similar to S. cerevisiae PRP19 protein; similar to G-beta repeat region of guanine nucleotide binding protein [Caenorhabditis elegans] g727450	BLAST-GenBank BLAST-PRODOM MOTIFS BLIMPS-PRINTS ProfileScan HMME-PFAM

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
47	522	S84 S315 S510 T20 S50 S57 S74 S116 S122 S128 S161 S185 T274 T300 S339 S345 S357 S367 T373 S459 T474 S136 S143 T174 S200 T300 S315 S356 S385 S420 T492	N226 N355		SAPK (stress activated protein kinase) interacting protein (similar to ras inhibitor) [Gallus gallus] g4929812	BLAST-GenBank MOTIFS
48	316	T109 S27 S86 S188 S7 S8 S82 T96 T105	N29 N136 N186	Pleckstrin homology (PH) domains: S3-N45, I59-Q301 RhoGAP domain: P140-N291 GTPase protein-like region: G125-L307	Beta2-chimaerin [Homo sapiens] g457230	BLAST-GenBank BLAST-PRODOM BLAST-DOMO HMMER-PFAM MOTIFS BLIMPS-PRINTS BLIMPS-PRODOM
49	387	S97 S199 T249 S342 S369 S382 T54 T182 T381		ATP/GTP-binding site motif (P-loop): G155-S162 GTP1/OBG GTP-binding protein family signatures: V151-A171, K172-I190, V200-G215, G217-D235 GTP-binding protein-like region: F15-P173 RAS transforming protein-like region: L145-L296	GTP-binding protein [Aquifex aeolicus] g2984292	BLAST-GenBank BLAST-PRODOM BLAST-DOMO BLIMPS-BLOCKS BLIMPS-PRINTS MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
50	334	T228 T308 S65 S91 T224 T228 T262 S34 S81 T224 T262 S286 T324	N108 N257 N322	ATP/GTP-binding site motif (P-loop): G149-S156 Ras domain: R144-M334 p21/ras-related transforming protein signatures: Y143-S164, N166-L182, H248-D261, F282-K304 Ras transforming protein-like region: I140-E284	NOEY2 putative tumor suppressor [Homo sapiens] g4100355	BLAST-GenBank BLAST-PRODOM BLAST-DOLO HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS MOTIFS
51	551	T199 S38 T62 S85 T116 S169 S351 T379 S421 S422 S456 S12 S22 S150 T366 S383 T482 Y404 Y449	N133 N148 N179 N293 N296	Regulator of chromosome condensation (RCC1)/ guanine nucleotide dissociation stimulator domains: E117-S169, D170-D222, T223-D274, E275-G292, G328-G339 RCC1 signatures: V157-L167, V262-L272	UVB-resistance protein UVR8 [Arabidopsis thaliana] g5478530	BLAST-GenBank BLAST-PRODOM HMMER-PFAM PROFILES-PRINTS BLIMPS-PRINTS MOTIFS
52	308	S152 T230 S266 S299 S19 S22 S240	N76	WD40 domains/G-beta repeats: Q33-R73, W79-T119, W126-K181, W188-T230, P241-K276, S11-A50 Sec13 related/WD repeat protein-like region: R73-I177 WD/G-beta profile: G11-A50	Sec13-related protein [Arabidopsis thaliana] g3150415	BLAST-GenBank HMMER-PFAM PROFILES-PRINTS BLIMPS-PRINTS BLAST-PRODOM MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
53	949	S206 S514 T22 S216 T226 S273 T315 S663 T745 T908 T155 S232 S258 T350 S359 S472 S609 S776 S837 S913 Y682 Y862	N114	WD40 domains/G-beta repeats: V199-K237, V248-S284, G287-H326 Drosophila lethal(2) giant larvae tumor suppressor protein signature: K221-P244, A353-E377		HMME-PFAM BLIMPS-PRINTS MOTIFS
54	227	S11 T113 S173 T155 S173	N38	ATP/GTP-binding site motif (P-loop): G37-T44 Ras family domain: K32-C227 p21/ras-related transforming protein signatures: F31-D52, S54-K70, V72-T94, D134-M147, F169-I191 Ras transforming protein-like region: P27-T172	GTP-binding protein [Bos taurus] g162764	BLAST-GenBank HMME-PFAM BLIMPS-PRINTS BLAST-DOMO BLAST-PRODOM MOTIFS
55	474	T430 S98 S118 S309 S450 S463 T66 S130 T141 S241 S289 S309 S389 S450	N179 N185	WD40 domains/G-beta repeats: D70-Q109, T120-N159, E164-D202 G-beta repeat signature: L146-V160 WD repeat/coronin protein-like region: I208-Q467	Coronin-2 [Mus musculus] g4895039	BLAST-GenBank HMME-PFAM BLAST-PRODOM BLAST-DOMO MOTIFS
56	547	S16 T77 S85 S90 S112 S114 T132 S160 T166 T225 S248 S438 S491 S526 S125 S267 T299 T305 S504	N101 N110 N147 N297	WD40 domains/G-beta repeats: G159-N197, C312-A353, G357-D396 WD40/G-beta signatures: V245-A259, L428-T442	Guanine nucleotide-binding protein beta 5 [Mesocricetus auratus] g1001939	BLAST-GenBank HMME-PFAM BLIMPS-PRINTS MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
57	686	T331 S431 T637 S34 S169 S554 S28 S124 S192 S273 S341 T366 S426 S449 S470 S15 T2 S3 T24	N26 N44 N271 N424 N628	G-beta profile: S106-S152	Beta-transducin-like protein [Podospora anserina] g607003	BLAST-GenBank PROFILER-SCAN HMMER-PFAM
58	93				HP protein (RhoGAP ortholog) [Homo sapiens] g2559002	BLAST-GenBank MOTIFS
59	521	S63 S223 T64 T117 S147 S159 S195 S200 T214 S271 S401 S448 T49 S110 S195 T235 T280 T439	N71 N108 N381	Amino acyl tRNA ligase motif: P173-T183	GTPase activating protein [Schizosaccharomyces pombe] g3150248	BLAST-GenBank MOTIFS
60	751	T287 S543 T61 S275 S345 T430 T474 T565 T676 S705 S726 T727 S57 T63 T70 T287 S345 T389 T432 S458 T479 T518 T538	N344 N640	GTP binding elongation factor Tu family domain: E44-T530 Elongation factor G C-terminus domain: L556-T727 GTP binding elongation factor signatures: N48-T61, Q97-A105, N117-F127, R133-V144, F169-R178	Elongation factor G [Rattus norvegicus] g310102	BLAST-GenBank HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS ProfileScan BLAST-PRODOM BLAST-DOMO MOTIFS
61	666	T492 S615 S619 T35 S142 T177 T212 S224 S270 T353 S403 T456 T471 T500 T550 S560 S572 T378 S403 S496 T509 T608 T611 T625	N75 N582		Rho target rhophilin [Mus musculus] g1176422	BLAST-GenBank MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
62	746	S22 T98 S571 T46 S53 S61 S66 S70 S71 T97 S14 S126 S127 T165 T184 T190 S249 S279 S323 S430 S519 S680 S736 S115 T190 T237 S349 S436 T444 S567 S598 S601 T613 S652 T741		WD40 domains/G-beta repeats: T403-E441, R570-H606, Q610-D648, T653-H691, L704-T746, C418-A461 G-beta repeat signature: L428-V442 Trp-Asp repeat protein-like region: S22-L407	Bop1 growth control protein [Mus musculus] g1679772	BLAST-GenBank BLAST-PRODOM BLAST-DOMO MOTIFS BLIMPS-PRINTS ProfileScan HMMER-PFAM
63	212	S105 S142 S148 S162 S167 S44 T56 T101 S162 S190	N131	ATP/GTP-binding site motif (p-loop): G25-T32 Ras family domain: K20-C212 ADP-ribosylation factor family domain: P6-R183 p21/ras-related transforming protein signatures: F19-T40, A42-K58, L60-T82, S122-L135, A158-L180 Ras transforming protein-like region: Y15-I155	Rab19 [Mus musculus] g2598565	BLAST-GenBank HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-DOMO BLAST-PRODOM MOTIFS

Table 2 (cont.)

SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Motifs, and Domains	Homologous Sequences	Analytical Methods & Databases
64	307	T275 S276 T15 S25 T99 S164 S201 S6 S270 T293	N196 N291	WD40 domains/G-beta repeats: M1-I49, L60-D98, E102-Q140 Sterile alpha motif (SAM): E161-R225 WD/G-beta signatures: L36-V50, L127-F141 G-beta profile: L74-P122	Hypothetical trp-asp repeats protein [C. elegans] SwissProt Q93847	BLAST-SwissProt HMMER-PFAM BLIMPS-PRINTS ProfileScan MOTIFS
65	378	S137 T167 T193 S202 S237 S276 S290 S310 S362 S82 T150 T158 T199 S362 T368		WD40 domains/G-beta repeats: H72-L110, L116-D155, L241-D279 G-beta profiles: S137-C175, S87-C133, I255-S312	WD repeat protein [Schizosaccharomyces pombe] g5701965	BLAST-GenBank HMMER-PFAM ProfileScan MOTIFS
66	466	S6 T24 S69 T209 S246 S357 T450 S181 S236 S242 T322 T407 T450	N448	RasGEF domain: V197-E397 Guanine nucleotide releasing protein-like region: P201-S432	Putative guanine-nucleotide releasing factor [Drosophila affinis] g2981229	BLAST-GenBank HMMER-PFAM BLAST-PRODOM BLAST-DOMO

Table 3

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
67	434-478	Cardiovascular (0.238) Reproductive (0.238) Hematopoietic/Immune (0.190)	Cancer (0.429) Inflammation/Trauma (0.524) Cell Proliferation (0.095)	pINCY
68	380-424 551-595	Nervous (0.185) Reproductive (0.167) Gastrointestinal (0.148)	Cancer (0.444) Cell Proliferation (0.315) Inflammation/Trauma (0.278)	pINCY
69	433-477	Reproductive (0.429) Nervous (0.142) Hematopoietic/Immune (0.142)	Cancer (0.714) Inflammation/Trauma (0.142)	pINCY
70	684-728	Reproductive (0.333) Nervous (0.178) Cardiovascular (0.111)	Cancer (0.467) Cell Proliferation (0.244) Inflammation/Trauma (0.267)	pINCY
71	219-263	Hematopoietic/Immune (0.257) Reproductive (0.229) Gastrointestinal (0.143)	Cell Proliferation (0.400) Inflammation/Trauma (0.429) Cancer (0.314)	pINCY
72	865-912	Gastrointestinal (0.286) Reproductive (0.286) Cardiovascular (0.238)	Cancer (0.667) Cell Proliferation (0.143) Inflammation/Trauma (0.238)	pINCY
73	900-944	Reproductive (0.229) Hematopoietic/Immune (0.157) Nervous (0.157)	Cancer (0.422) Inflammation/Trauma (0.349) Cell Proliferation (0.205)	pINCY
74	109-153 919-963	Reproductive (0.270) Gastrointestinal (0.162) Cardiovascular (0.135)	Cancer (0.405) Cell Proliferation (0.270) Inflammation/Trauma (0.324)	pINCY
75	1352-1396 1568-1612	Reproductive (0.296) Gastrointestinal (0.167) Nervous (0.167)	Cancer (0.509) Inflammation/Trauma (0.269) Cell Proliferation (0.157)	pINCY
76	541-585 1189-1233	Reproductive (0.238) Cardiovascular (0.190) Gastrointestinal (0.190)	Cancer (0.524) Inflammation/Trauma (0.310) Cell Proliferation (0.143)	PBLUESCRIPT
77	110-154	Reproductive (0.250) Nervous (0.224) Hematopoietic/Immune (0.132) Gastrointestinal (0.132)	Cancer (0.355) Inflammation/Trauma (0.342) Cell Proliferation (0.211)	PSPORT1
78	218-262	Reproductive (0.375) Nervous (0.188) Urologic (0.188)	Cancer (0.562) Inflammation/Trauma (0.250)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
79	380-424	Hematopoietic/Immune (0.227) Nervous (0.227) Reproductive (0.227)	Inflammation/Trauma (0.636) Cancer (0.364)	PSPORT1
80	217-261	Reproductive (0.275) Gastrointestinal (0.196) Nervous (0.196)	Cancer (0.431) Inflammation/Trauma (0.451) Cell Proliferation (0.196)	PSPORT1
81	488-532 812-856	Reproductive (0.301) Nervous (0.151) Gastrointestinal (0.130)	Cancer (0.466) Inflammation/Trauma (0.288) Cell Proliferation (0.151)	pINCY
82	595-639	Reproductive (0.333) Developmental (0.148) Gastrointestinal (0.148)	Cancer (0.444) Cell Proliferation (0.370) Inflammation/Trauma (0.333)	pINCY
83	219-263	Hematopoietic/Immune (0.400) Gastrointestinal (0.200) Cardiovascular (0.100)	Inflammation/Trauma (0.429) Cell Proliferation (0.357) Cancer (0.286)	pINCY
84	164-208	Cardiovascular (0.667) Nervous (0.222) Hematopoietic/Immune (0.111)	Cancer (0.556) Cell Proliferation (0.111)	PBLUESCRIPT
85	487-531 757-801	Reproductive (0.182) Cardiovascular (0.091)	Cancer (0.308) Cell Proliferation (0.231) Inflammation/Trauma (0.154)	pINCY
86	325-369 811-855	Hematopoietic/Immune (0.288) Reproductive (0.197) Cardiovascular (0.136)	Inflammation (0.394) Cancer (0.318) Cell Proliferation (0.212)	pINCY
87	163-207	Reproductive (0.218) Nervous (0.172) Gastrointestinal (0.138)	Cancer (0.448) Cell Proliferation (0.218) Inflammation (0.207)	pINCY
88	362-406 758-802	Reproductive (0.273) Gastrointestinal (0.227) Cardiovascular (0.136) Musculoskeletal (0.136)	Cancer (0.681) Cell Proliferation (0.182) Inflammation/Trauma (0.318)	pINCY
89	272-316	Reproductive (0.229) Gastrointestinal (0.193) Nervous (0.193)	Cancer (0.404) Inflammation (0.220) Cell Proliferation (0.165)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
90	98-142	Nervous (0.400) Cardiovascular (0.200) Developmental (0.200) Gastrointestinal (0.200)	Cell Proliferation (0.400) Inflammation (0.400) Cancer (0.200)	pINCY
91	384-428 2016-2060	Reproductive (0.221) Gastrointestinal (0.156) Hematopoietic/Immune (0.143)	Cancer (0.468) Inflammation/Trauma (0.325) Cell Proliferation (0.273)	PBLUESCRIPT
92	80-124 731-775	Reproductive (0.286) Hematopoietic/Immune (0.143) Nervous (0.143)	Cancer (0.469) Inflammation/Trauma (0.326) Cell Proliferation (0.306)	PBLUESCRIPT
93	437-481 641-685	Reproductive (0.250) Nervous (0.200) Cardiovascular (0.183)	Cancer (0.550) Inflammation/Trauma (0.284) Cell Proliferation (0.150)	PBLUESCRIPT
94	397-441 1036-1080	Reproductive (0.291) Hematopoietic/Immune (0.228) Nervous (0.152)	Inflammation/Trauma (0.468) Cancer (0.392) Cell Proliferation (0.165)	pINCY
95	247-291	Reproductive (0.242) Hematopoietic/Immune (0.121) Nervous (0.121) Urologic (0.121)	Cancer (0.455) Inflammation/Trauma (0.333) Cell Proliferation (0.273)	pINCY
96	453-497 858-902	Nervous (0.600) Reproductive (0.400)	Cancer (0.400) Inflammation/Trauma (0.200) Neurological (0.200)	pINCY
97	224-268 770-814 1211-1255	Gastrointestinal (0.262) Reproductive (0.215) Nervous (0.169)	Cancer (0.462) Inflammation/Trauma (0.339) Cell Proliferation (0.231)	pINCY
98	3-47 1086-1130	Reproductive (0.211) Gastrointestinal (0.211) Hematopoietic/Immune (0.158)	Cancer (0.553) Cell Proliferation (0.368) Inflammation/Trauma (0.342)	pINCY
99	388-432 874-918	Reproductive (0.268) Nervous (0.146) Cardiovascular (0.146)	Cancer (0.390) Inflammation/Trauma (0.390) Cell Proliferation (0.220)	pINCY
100	26-70	Gastrointestinal (0.238) Cardiovascular (0.190) Hematopoietic/Immune (0.143) Nervous (0.143) Endocrine (0.143)	Cancer (0.429) Inflammation/Trauma (0.381) Cell Proliferation (0.190)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
101	226-270 2062-2106	Nervous (0.234) Hematopoietic/Immune (0.170) Reproductive (0.149)	Inflammation/Trauma (0.383) Cancer (0.362) Cell Proliferation (0.213)	pINCY
102	487-531	Reproductive (0.276) Nervous (0.161) Gastrointestinal (0.138) Cardiovascular (0.138)	Cancer (0.494) Cell Proliferation (0.310) Inflammation/Trauma (0.264)	pINCY
103	561-605	Reproductive (0.274) Gastrointestinal (0.194) Cardiovascular (0.129)	Cancer (0.452) Inflammation/Trauma (0.339) Cell Proliferation (0.258)	pINCY
104	287-331 806-850	Gastrointestinal (0.500) Reproductive (0.250) Musculoskeletal (0.250)	Cancer (0.500) Inflammation/Trauma (0.250)	pINCY
105	154-198 505-549 757-801	Gastrointestinal (0.233) Reproductive (0.209) Hematopoietic/Immune (0.163) Nervous (0.163)	Cancer (0.465) Inflammation/Trauma (0.326) Cell Proliferation (0.209)	pINCY
106	174-218 1182-1226	Reproductive (0.185) Hematopoietic/Immune (0.185) Nervous (0.185)	Inflammation/Trauma (0.352) Cell Proliferation (0.333) Cancer (0.315)	pINCY
107	120-164 489-533	Reproductive (0.231) Hematopoietic/Immune (0.231) Nervous (0.154) Cardiovascular (0.154)	Cell Proliferation (0.462) Inflammation/Trauma (0.385) Cancer (0.231)	pINCY
108	64-108 1738-1782	Nervous (0.277) Reproductive (0.255) Cardiovascular (0.160)	Cancer (0.362) Inflammation/Trauma (0.362) Cell Proliferation (0.149)	pINCY
109	415-459 1027-1071 1549-1593	Reproductive (0.274) Hematopoietic/Immune (0.226) Nervous (0.167)	Inflammation/Trauma (0.476) Cancer (0.393) Cell Proliferation (0.179)	pINCY
110	242-286	Reproductive (0.500) Nervous (0.500)	Cancer (1.000)	pINCY
111	488-541 1028-1081	Reproductive (0.270) Nervous (0.191) Gastrointestinal (0.126)	Cancer (0.507) Inflammation/Trauma (0.284) Cell Proliferation (0.172)	PSPORT1

Table 3 (cont.)

Nucleotide SEQ ID NO.:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
112	273-326 867-920 1299-1352	Reproductive (0.312) Nervous (0.281) Gastrointestinal (0.094)	Cancer (0.469) Inflammation/Trauma (0.328) Cell Proliferation (0.172)	pINCY
113	866-1135	Reproductive (0.245) Gastrointestinal (0.136) Nervous (0.136)	Cancer (0.445) Cell Proliferation (0.227) Inflammation/Trauma (0.327)	pINCY
114	155-325 812-1105	Nervous (0.314) Reproductive (0.275) Gastrointestinal (0.098)	Cancer (0.471) Inflammation/Trauma (0.118)	pINCY
115	14-298	Gastrointestinal (0.190) Nervous (0.190) Reproductive (0.190)	Cancer (0.476) Cell Proliferation (0.190) Inflammation/Trauma (0.238)	pINCY
116	41-235	Reproductive (0.400) Nervous (0.267) Musculoskeletal (0.133)	Cancer (0.600) Inflammation/Trauma (0.334) Cell Proliferation (0.067)	PSPORT1
117	379-432 973-1026 1297-1350	Reproductive (0.327) Nervous (0.184) Urologic (0.102)	Cancer (0.531) Cell Proliferation (0.224) Inflammation/Trauma (0.265)	pINCY
118	974-1465	Reproductive (0.231) Nervous (0.190) Gastrointestinal (0.169)	Cancer (0.446) Inflammation/Trauma (0.343) Cell Proliferation (0.226)	pINCY
119	543-1028	Reproductive (0.292) Nervous (0.163) Gastrointestinal (0.139)	Cancer (0.517) Cell Proliferation (0.167) Inflammation/Trauma (0.235)	PSPORT1
120	385-552	Nervous (0.571) Cardiovascular (0.143) Developmental (0.143)	Cancer (0.429) Inflammation/Trauma (0.572) Cell Proliferation (0.143)	pINCY
121	685-864	Nervous (0.300) Hematopoietic/Immune (0.200) Cardiovascular (0.140)	Cancer (0.340) Inflammation/Trauma (0.440) Cell Proliferation (0.200)	pINCY
122	703-1026	Reproductive (0.400) Cardiovascular (0.160) Nervous (0.160)	Cancer (0.680) Cell Proliferation (0.120) Inflammation/Trauma (0.160)	pINCY
123	830-1351	Reproductive (0.200) Cardiovascular (0.154) Hematopoietic/Immune (0.154)	Cancer (0.415) Cell Proliferation (0.277) Inflammation/Trauma (0.354)	pINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragments	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
124	272-325	Cardiovascular (0.250) Gastrointestinal (0.250) Musculoskeletal (0.250)	Inflammation/Trauma (0.750)	pINCY
125	130-972	Reproductive (0.180) Cardiovascular (0.160) Hematopoietic/Immune (0.160)	Cancer (0.440) Inflammation/Trauma (0.340) Cell Proliferation (0.220)	pINCY
126	434-973	Reproductive (0.188) Cardiovascular (0.156) Gastrointestinal (0.156)	Cancer (0.422) Inflammation/Trauma (0.328) Cell Proliferation (0.203)	pINCY
127	489-899	Gastrointestinal (0.333) Reproductive (0.333) Nervous (0.125)	Cancer (0.625) Inflammation/Trauma (0.208) Cell Proliferation (0.042)	pINCY
128	19-1242	Reproductive (0.354) Nervous (0.188) Gastrointestinal (0.146)	Cancer (0.562) Cell Proliferation (0.250) Inflammation/Trauma (0.250)	pINCY
129	217-270 541-594	Reproductive (0.364) Cardiovascular (0.182) Gastrointestinal (0.182)	Cancer (0.636) Inflammation/Trauma (0.364)	pINCY
130	115-864	Gastrointestinal (0.250) Hematopoietic/Immune (0.208) Nervous (0.208)	Cancer (0.500) Inflammation/Trauma (0.292)	pINCY
131	255-308	Reproductive (0.265) Nervous (0.169) Gastrointestinal (0.120)	Cancer (0.482) Cell Proliferation (0.349) Inflammation/Trauma (0.253)	pINCY
132	23-541	Nervous (0.909) Endocrine (0.091)	Cancer (0.636) Cell Proliferation (0.091) Inflammation/Trauma (0.182)	pINCY

Table 4

SEQ ID NO:	Library	Library Comment
67	LATRTUT02	Library was constructed using RNA isolated from a myxoma removed from the left atrium of a 43-year-old Caucasian male during annuloplasty. Pathology indicated atrial myxoma. Patient history included pulmonary insufficiency, acute myocardial infarction, atherosclerotic coronary artery disease, and hyperlipidemia. Family history included benign hypertension, acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
68	PENITUT01	Library was constructed using RNA isolated from tumor tissue removed from the penis of a 64-year-old Caucasian male during penile amputation. Pathology indicated a fungating invasive grade 4 squamous cell carcinoma involving the inner wall of the foreskin and extending onto the glans penis. Patient history included benign neoplasm of the large bowel, atherosclerotic coronary artery disease, angina pectoris, gout, and obesity. Family history included malignant pharyngeal neoplasm, chronic lymphocytic leukemia, and chronic liver disease.
69	BLADTUT04	Library was constructed using RNA isolated from bladder tumor tissue removed from a 60-year-old Caucasian male during a radical cystectomy, prostatectomy, and vasectomy. Pathology indicated grade 3 transitional cell carcinoma in the left bladder wall. Carcinoma in-situ was identified in the dome and trigone. Family history included type I diabetes, a malignant neoplasm of the stomach, atherosclerotic coronary artery disease, and an acute myocardial infarction.
70	BLADTUT06	Library was constructed using RNA isolated from bladder tumor tissue removed from the posterior bladder wall of a 58-year-old Caucasian male during a radical cystectomy, radical prostatectomy, and gastrostomy. Pathology indicated grade 3 transitional cell carcinoma in the left lateral bladder wall. The remaining bladder showed marked cystitis with scattered microscopic foci of transitional cell carcinoma in situ. Patient history included angina and emphysema. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
71	ADRENOT07	Library was constructed using RNA isolated from adrenal tissue removed from a 61-year-old female during a bilateral adrenalectomy. Patient history included an unspecified disorder of the adrenal glands.
72	BRSTNOT19	Library was constructed using RNA isolated from breast tissue removed from a 67-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated residual invasive lobular carcinoma. Patient history included depressive disorder, benign large bowel neoplasm, and hemorrhoids. Family history included cerebrovascular and cardiovascular disease and lung cancer.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
73	SPLNNOT12	Library was constructed using RNA isolated from spleen tissue removed from a 65-year-old female. Pathology indicated the spleen was negative for metastasis. Pathology for the associated tumor tissue indicated well-differentiated neuroendocrine carcinoma (islet cell tumor), nuclear grade 1, forming a dominant mass in the distal pancreas. Multiple smaller tumor nodules were immediately adjacent to the main mass. The liver showed metastatic grade 1 islet cell tumor, forming multiple nodules. Multiple (4) pericholedochal lymph nodes contained metastatic grade 1 islet cell tumor.
74	MONOTXT02	Library was constructed using RNA isolated from treated monocytes from peripheral blood removed from a 42-year-old female. The cells were treated with interleukin-10 (IL-10) and lipopolysaccharide (LPS). IL-10 was added at time 0 at 10 ng/ml, LPS was added at 1 hour at 5 ng/ml. The monocytes were isolated from buffy coat by adherence to plastic. Incubation time was 24 hours.
75	FIBPFEN06	Library was constructed from 1.56 million independent clones from a prostate stromal fibroblast tissue library. Starting RNA was made from fibroblasts of prostate stroma removed from a male fetus, who died after 26 weeks' gestation. The libraries were normalized in two rounds using conditions adapted from Soares et al. (1994) Proc. Natl. Acad. Sci. USA 91:9228 and Bonaldo et al. (1996) Genome Research 6:791, except that a significantly longer (48-hours/round) reannealing hybridization was used.
76	HUVESTB01	Library was constructed using RNA isolated from shear-stressed HUV-EC-C (ATCC CRL 1730) cells. Before RNA isolation, the cells were subjected to a shear stress of 10 dynes/cm.
77	SYNOOAT01	Library was constructed using RNA isolated from the knee synovial membrane tissue of an 82-year-old female with osteoarthritis.
78	UTRSNOT05	Library was constructed using RNA isolated from the uterine tissue of a 45-year-old Caucasian female during a total abdominal hysterectomy and total colectomy. Pathology for the associated tumor tissue indicated multiple leiomyomas of the myometrium and a grade 2 colonic adenocarcinoma of the cecum. Patient history included multiple sclerosis and mitral valve disorder. Family history included type I diabetes, cerebrovascular disease, atherosclerotic coronary artery disease, malignant skin neoplasm, hypertension, and malignant neoplasm of the colon.
79	HIPONON01	Library was constructed from 1.13 million independent clones from a hippocampus library. RNA was isolated from the hippocampus tissue of a 72-year-old Caucasian female who died from an intracranial bleed. Patient history included nose cancer, hypertension, and arthritis. The normalization and hybridization conditions were adapted from Soares et al. (1994) Proc. Natl. Acad. Sci. USA 91:9228.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
80	BRSTTUT03	Library was constructed using RNA isolated from breast tumor tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated multicentric invasive grade 4 lobular carcinoma. The mass was identified in the upper outer quadrant, and three separate nodules were found in the lower outer quadrant of the left breast. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular disease, coronary artery aneurysm, breast cancer, prostate cancer, atherosclerotic coronary artery disease, and type I diabetes.
81	SININOT01	Library was constructed using RNA isolated from ileum tissue obtained from the small intestine of a 4-year-old Caucasian female, who died from a closed head injury. Patient history included jaundice. Previous surgeries included a double hernia repair.
82	SINTFET03	Library was constructed using RNA isolated from small intestine tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation.
83	HNT3AZT01	Library was constructed using RNA isolated from the hNT2 cell line (derived from a human teratocarcinoma that exhibited properties characteristic of a committed neuronal precursor). Cells were treated for three days with 0.35 micromolar 5-aza-2'-deoxycytidine (AZ).
84	ENDANOT01	Library was constructed using RNA isolated from aortic endothelial cell tissue from an explanted heart removed from a male during a heart transplant.
85	LUNGTUT08	Library was constructed using RNA isolated from lung tumor tissue removed from a 63-year-old Caucasian male during a right upper lobectomy with fiberoptic bronchoscopy. Pathology indicated a grade 3 adenocarcinoma. Patient history included atherosclerotic coronary artery disease, an acute myocardial infarction, rectal cancer, an asymptomatic abdominal aortic aneurysm, tobacco abuse, and cardiac dysrhythmia. Family history included congestive heart failure, stomach cancer, and lung cancer, type II diabetes, atherosclerotic coronary artery disease, and an acute myocardial infarction.
86	OVRTUT10	Library was constructed using RNA isolated from ovarian tumor tissue removed from the left ovary of a 58-year-old Caucasian female during a total abdominal hysterectomy, removal of a solitary ovary, and repair of inguinal hernia. Pathology indicated a metastatic grade 3 adenocarcinoma of colonic origin, forming a partially cystic and necrotic tumor mass in the left ovary, and an adenocarcinoma of colonic origin, forming a nodule in the left mesovarium. A single intramural leiomyoma was identified in the myometrium. The cervix showed mild chronic cystic cervicitis. Patient history included benign hypertension, follicular cyst of the ovary, colon cancer, benign colon neoplasm, and osteoarthritis. Family history included emphysema, myocardial infarction, atherosclerotic coronary artery disease, benign hypertension, and hyperlipidemia.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
87	BRSTNOT13	Library was constructed using RNA isolated from breast tissue removed from a 36-year-old Caucasian female during bilateral simple mastectomy. Patient history included a breast neoplasm, depressive disorder, hyperlipidemia, and a chronic stomach ulcer. Family history included cardiovascular and cerebrovascular disease; hyperlipidemia; skin, breast, esophageal, bladder, and bone cancer; and Hodgkin's lymphoma.
88	UTRSNOR01	Library was constructed using RNA isolated from uterine endometrium tissue removed from a 29-year-old Caucasian female during a vaginal hysterectomy and cystocele repair. Pathology indicated the endometrium was secretory, and the cervix showed mild chronic cervicitis with focal squamous metaplasia. Pathology for the associated tumor tissue indicated intramural uterine leiomyoma. Patient history included hypothyroidism, pelvic floor relaxation, and paraplegia. Family history included benign hypertension, type II diabetes, and hyperlipidemia.
89	BRSTTMT02	Library was constructed using RNA isolated from diseased right breast tissue removed from a 46-year-old Caucasian female during a unilateral extended simple mastectomy and open breast biopsy. Pathology indicated mildly proliferative fibrocystic change, including intraductal duct ectasia, papilloma formation, and ductal hyperplasia. Pathology for the associated tumor tissue indicated multifocal ductal carcinoma in situ, both comedo and non-comedo types, nuclear grade 2 with extensive intraductal calcifications. Patient history included deficiency anemia, normal delivery, chronic sinusitis, extrinsic asthma, and kidney infection. Family history included type II diabetes, benign hypertension, cerebrovascular disease, skin cancer, and hyperlipidemia.
90	LIVRDIR01	Library was constructed using RNA isolated from diseased liver tissue removed from a 63-year-old Caucasian female during a liver transplant. Patient history included primary biliary cirrhosis. Serology was positive for anti-mitochondrial antibody.
91	HUVENOB01	Library was constructed using RNA isolated from HUV-EC-C (ATCC CRL 1730) cells.
92	TESTNOT03	Library was constructed using RNA isolated from testicular tissue removed from a 37-year-old Caucasian male, who died from liver disease. Patient history included cirrhosis, jaundice, and liver failure.
93	LUNGNOT02	Library was constructed using RNA isolated from the lung tissue of a 47-year-old Caucasian male, who died of a subarachnoid hemorrhage.
94	LUNGFET03	Library was constructed using RNA isolated from lung tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation.
95	PANCNOT07	Library was constructed using RNA isolated from the pancreatic tissue of a Caucasian male fetus, who died at 23 weeks' gestation.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
96	BRAINOT12	Library was constructed using RNA isolated from brain tissue removed from the right frontal lobe of a 5-year-old Caucasian male during a hemispherectomy. Pathology indicated extensive polymicrogyria and mild to moderate gliosis (predominantly subpial and subcortical), which are consistent with chronic seizure disorder. Family history included a cervical neoplasm.
97	LIVRTUT01	Library was constructed using RNA isolated from liver tumor tissue removed from a 51-year-old Caucasian female during a hepatic lobectomy. Pathology indicated metastatic grade 3 adenocarcinoma consistent with colon cancer. Family history included a malignant neoplasm of the liver.
98	GBLATUT01	Library was constructed using RNA isolated from gall bladder tumor tissue removed from a 78-year-old Caucasian female during a cholecystectomy. Pathology indicated invasive grade 2 squamous cell carcinoma, forming a mass in the gall bladder. Patient history included diverticulitis of the colon, palpitations, benign hypertension, and hyperlipidemia. Family history included a cholecystectomy, atherosclerotic coronary artery disease, hyperlipidemia, and benign hypertension.
99	LEUKNOT02	Library was constructed using RNA isolated from white blood cells of a 45-year-old female with blood type O+. The donor tested positive for cytomegalovirus (CMV).
100	LUNGNOT22	Library was constructed using RNA isolated from lung tissue removed from a 58-year-old Caucasian female. The tissue sample used to construct this library was found to have tumor contaminant upon microscopic examination. Pathology for the associated tumor tissue indicated a caseating granuloma. Family history included congestive heart failure, breast cancer, secondary bone cancer, acute myocardial infarction and atherosclerotic coronary artery disease.
101	ADRETUT06	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland.
102	ADRETUT06	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland.
103	THYRNOT10	Library was constructed using RNA isolated from diseased left thyroid tissue removed from a 30-year-old Caucasian female during a unilateral thyroid lobectomy and parathyroid reimplantation. Pathology indicated lymphocytic thyroiditis.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
104	CONNTUT05	Library was constructed using RNA isolated from tumorous skull soft tissue removed from a 34-year-old Caucasian female during skull lesion excision. Pathology indicated grade 3 ependymoma forming an implant in the dermis and subcutis associated with dense fibrosis. Patient history included seizures, bone cancer, and brain cancer. Surgeries included cranioplasty and cerebral meninges lesion excision, and treatment included whole brain radiation. Family history included anxiety and depression.
105	HEAANOT01	Library was constructed using RNA isolated from right coronary and right circumflex coronary artery tissue removed from the explanted heart of a 46-year-old Caucasian male during a heart transplantation. Patient history included myocardial infarction from total occlusion of the left anterior descending coronary artery, atherosclerotic coronary artery disease, hyperlipidemia, myocardial ischemia, dilated cardiomyopathy, left ventricular dysfunction, and tobacco abuse. Family history included atherosclerotic coronary artery disease.
106	UTRMTMT01	Library was constructed using RNA isolated from myometrial tissue removed from a 45-year-old Caucasian female during vaginal hysterectomy and bilateral salpingo-oophorectomy. Pathology indicated the myometrium was negative for tumor. Pathology for the associated tumor tissue indicated multiple (23) subserosal, intramural, and submucosal leiomyomata. The endometrium was in proliferative phase. The right ovary contained an old corpus luteum. The cervix, left ovary, and right and left fallopian tubes were unremarkable. The patient presented with stress incontinence. Patient history included extrinsic asthma without status asthmaticus and normal delivery. Patient medications included Motrin, iron sulfate, Premarin, prednisone, Tylenol #3, and Colace. Family history included cerebrovascular disease, depression, and atherosclerotic coronary artery disease.
107	FIBPFEN06	This normalized library was constructed from 1.56 million independent clones from a prostate stromal fibroblast library. RNA was isolated from a male fetus, who died after 26 weeks' gestation. The normalization and hybridization conditions were adapted from Soares et al. (1994) Proc. Natl. Acad. Sci. USA 91:9228.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
108	BRAINOT19	Library was constructed using RNA isolated from diseased brain tissue removed from the left frontal lobe of a 27-year-old Caucasian male during a brain lobectomy. Pathology indicated a focal deep white matter lesion, characterized by marked gliosis, calcifications, and hemosiderin-laden macrophages, consistent with a remote perinatal injury. This tissue also showed mild to moderate generalized gliosis, predominantly subpial and subcortical, consistent with chronic seizure disorder. The left temporal lobe, including the mesial temporal structures, showed focal, marked pyramidal cell loss and gliosis in hippocampal sector CA1, consistent with mesial temporal sclerosis. GFAP was positive for astrocytes. Patient presented with intractable epilepsy, focal epilepsy, hemiplegia, and an unspecified brain injury. Patient history included cerebral palsy, abnormality of gait, and depressive disorder. Family history included brain cancer.
109	COLCDIT03	Library was constructed using RNA isolated from diseased colon polyp tissue removed from the cecum of a 67-year-old female. Pathology indicated a benign cecum polyp. Pathology for the associated tumor tissue indicated invasive grade 3 adenocarcinoma that arose in tubulovillous adenoma forming a fungating mass in the cecum.
110	BRAXNOT03	Library was constructed using RNA isolated from sensory-motor cortex tissue removed from the brain of a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomeningeal fibrosis and multiple microinfarctions of the cerebral neocortex. The cerebral hemisphere revealed moderate fibrosis of the leptomeninges with focal calcifications. There was evidence of shrunken and slightly eosinophilic pyramidal neurons throughout the cerebral hemispheres. There were also multiple small microscopic areas of cavitation with surrounding gliosis, scattered throughout the cerebral cortex. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly and an enlarged spleen and liver. Patient medications included simethicone, Lasix, Digoxin, Colace, Zantac, Captopril, and Vasotec.
111	BRAITUT02	Library was constructed using RNA isolated from brain tumor tissue removed from the frontal lobe of a 58-year-old Caucasian male during excision of a cerebral meningeal lesion. Pathology indicated a grade 2 metastatic hypernephroma. Patient history included a grade 2 renal cell carcinoma, insomnia, and chronic airway obstruction. Family history included a malignant neoplasm of the kidney.
112	PROSNOT11	Library was constructed using RNA isolated from the prostate tissue of a 28-year-old Caucasian male, who died from a self-inflicted gunshot wound.
113	LIVRUT01	Library was constructed using RNA isolated from liver tumor tissue removed from a 51-year-old Caucasian female during a hepatic lobectomy. Pathology indicated metastatic grade 3 adenocarcinoma consistent with colon cancer. Family history included a malignant neoplasm of the liver.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
114	PANCTUT02	Library was constructed using RNA isolated from pancreatic tumor tissue removed from a 45-year-old Caucasian female during radical pancreaticoduodenectomy. Pathology indicated a grade 4 anaplastic carcinoma. Family history included benign hypertension, hyperlipidemia and atherosclerotic coronary artery disease.
115	LIVRFET02	Library was constructed using RNA isolated from liver tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation. Family history included seven days of erythromycin treatment for bronchitis in the mother during the first trimester.
116	BRAITUT03	Library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 17-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a grade 4 fibrillary giant and small-cell astrocytoma. Family history included benign hypertension and cerebrovascular disease.
117	BRSTNOT07	Library was constructed using RNA isolated from diseased breast tissue removed from a 43-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated mildly proliferative fibrocystic changes with epithelial hyperplasia, papillomatosis, and duct ectasia. Pathology for the associated tumor tissue indicated invasive grade 4, nuclear grade 3 mammary adenocarcinoma with extensive comedo necrosis. Family history included epilepsy, cardiovascular disease, and type II diabetes.
118	SMCANOT01	Library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male during a heart transplant.
119	THP1AZS08	Library was constructed using 5.76 million clones from a 5-aza-2'-deoxycytidine (AZ) treated THP-1 promonocyte cell line library. Starting RNA was made from THP-1 promonocyte cells treated for three days with 0.8 micromolar AZ. The hybridization probe for subtraction was derived from a similarly constructed library, made from 1 microgram of polyA RNA isolated from untreated THP-1 cells. 5.76 million clones from the AZ-treated THP-1 cell library were then subjected to two rounds of subtractive hybridization with 5 million clones from the untreated THP-1 cell library. Subtractive hybridization conditions were based on the methodologies of Swaroop et al. (1991) Nucleic Acids Res. 19:1954, and Bonaldo et al. (1996) Genome Research 6:791. THP-1 (ATCC TIB 202) is a human promonocyte line derived from peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171).
120	ADRETUT06	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 57-year-old Caucasian female during a unilateral right adrenalectomy. Pathology indicated pheochromocytoma, forming a nodular mass completely replacing the medulla of the adrenal gland.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
121	SININOT03	Library was constructed using RNA isolated from ileum tissue obtained from an 8-year-old Caucasian female, who died from head trauma. Serology was positive for cytomegalovirus (CMV).
122	SININOT03	Library was constructed using RNA isolated from ileum tissue obtained from an 8-year-old Caucasian female, who died from head trauma. Serology was positive for cytomegalovirus (CMV).
123	TLYMNOT06	Library was constructed using RNA isolated from activated Th2 cells. These cells were differentiated from umbilical cord CD4 T cells with IL-4 in the presence of anti-IL-12 antibodies and B7-transfected COS cells, and then activated for six hours with anti-CD3 and anti-CD28 antibodies.
124	HEAANOT01	Library was constructed using RNA isolated from right coronary and right circumflex coronary artery tissue removed from the explanted heart of a 46-year-old Caucasian male during a heart transplantation. Patient history included myocardial infarction from total occlusion of the left anterior descending coronary artery, atherosclerotic coronary artery disease, hyperlipidemia, myocardial ischemia, dilated cardiomyopathy, left ventricular dysfunction, and tobacco abuse. Previous surgeries included cardiac catheterization. Family history included atherosclerotic coronary artery disease.
125	TLYJINT01	Library was constructed using RNA isolated from a Jurkat cell line derived from the T cells of a male. The cells were treated for 18 hours with 50 ng/ml phorbol ester (PMA) and 1 micromolar calcium ionophore. Patient history included acute T-cell leukemia.
126	BRAITUT24	Library was constructed using RNA isolated from right frontal brain tumor tissue removed from a 50-year-old Caucasian male during a cerebral meninges lesion excision. Pathology indicated meningioma. Family history included colon cancer and cerebrovascular disease.
127	PROSTUT16	Library was constructed using RNA isolated from prostate tumor tissue removed from a 55-year-old Caucasian male. Pathology indicated adenocarcinoma, Gleason grade 5+4. Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Patient history included calculus of the kidney. Family history included lung cancer and breast cancer.
128	BRONNOT01	Library was constructed using RNA isolated from bronchial tissue removed from a 15-year-old Caucasian male.

Table 4 (cont.)

SEQ ID NO:	Library	Library Comment
129	BLADTUT03	Library was constructed using RNA isolated from bladder tumor tissue removed from a 58-year-old Caucasian male during a radical cystectomy, radical prostatectomy, regional lymph node excision, and urinary diversion to bowel. Pathology indicated invasive grade 3 transitional cell carcinoma. Patient history included a benign colon neoplasm. Family history included cerebrovascular disease and atherosclerotic coronary artery disease.
130	COLXTDT01	Library was constructed using RNA isolated from colon tissue removed from the appendix of a 37-year-old Black female during myomectomy, dilation and curettage, right fimbrial region biopsy, and incidental appendectomy. Pathology indicated an unremarkable appendix. Pathology for the associated tumor tissue indicated multiple (12) uterine leiomyomata. Patient history included premenopausal menorrhagia and sarcoidosis of the lung. Family history included acute myocardial infarction and atherosclerotic coronary artery disease.
131	BRATNOT02	Library was constructed using RNA isolated from superior temporal cortex tissue removed from the brain of a 35-year-old Caucasian male. No neuropathology was found. Patient history included dilated cardiomyopathy, congestive heart failure, and an enlarged spleen and liver.
132	BRAWNOT01	Library was constructed using RNA isolated from dentate nucleus tissue removed from the brain of a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomeningeal fibrosis and multiple microinfarctions of the cerebral neocortex. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly, and an enlarged spleen and liver.

Table 5 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score = 1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score = 120 or greater; Match length = 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score = 3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, 10 SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, 15 SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66,

b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, 20 SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, 25 SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66,

c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID 30 NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID 35 NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID

NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66, and

d) an immunogenic fragment of an amino acid sequence selected from the group consisting
5 of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID
10 NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and SEQ
15 ID NO:66.

2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID
20 NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID
25 NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66.

3. An isolated polynucleotide encoding a polypeptide of claim 1.

30

4. An isolated polynucleotide encoding a polypeptide of claim 2.

5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID
35 NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID

NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:132.

- 10 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
7. A cell transformed with a recombinant polynucleotide of claim 6.
- 15 8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
9. A method for producing a polypeptide of claim 1, the method comprising:
- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide
- 20 comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
- b) recovering the polypeptide so expressed.
10. An isolated antibody which specifically binds to a polypeptide of claim 1.
- 25 11. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:
- a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106,
- 35 SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:119,

SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:132,

b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a
 5 polynucleotide sequence selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ
 10 ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID
 15 NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:132,

c) a polynucleotide sequence complementary to a),

d) a polynucleotide sequence complementary to b), and

e) an RNA equivalent of a)-d).

20

12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

13. A method for detecting a target polynucleotide in a sample, said target polynucleotide
 25 having a sequence of a polynucleotide of claim 11, the method comprising:

a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
 30 b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

15. A method for detecting a target polynucleotide in a sample, said target polynucleotide
 35 having a sequence of a polynucleotide of claim 11, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

5

16. A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

17. A composition of claim 16, wherein the polypeptide comprises an amino acid sequence
10 selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID
NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID
NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID
NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID
NO:88, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:95, SEQ ID
15 NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:102, SEQ ID
NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:109,
SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID
NO:115, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121,
SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID
20 NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, and SEQ ID
NO:132.

18. A method for treating a disease or condition associated with decreased expression of
functional GBAP, comprising administering to a patient in need of such treatment the pharmaceutical
25 composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of
claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- 30 b) detecting agonist activity in the sample.

20. A composition comprising an agonist compound identified by a method of claim 19 and
a pharmaceutically acceptable excipient.

35 21. A method for treating a disease or condition associated with decreased expression of
functional GBAP, comprising administering to a patient in need of such treatment a pharmaceutical

composition of claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- 5 a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
 b) detecting antagonist activity in the sample.

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

10

24. A method for treating a disease or condition associated with overexpression of functional GBAP, comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 23.

15 25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
 b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a
20 compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions
25 permissive for the activity of the polypeptide of claim 1,
 b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
 c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change
30 in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method
35 comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, and

b) detecting altered expression of the target polynucleotide.

28. A method for assessing toxicity of a test compound, said method comprising:

a) treating a biological sample containing nucleic acids with the test compound;

5 b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;

10 c) quantifying the amount of hybridization complex; and

 d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

SEQUENCE LISTING

<110> INCYTE GENOMICS, INC.

YUE, Henry

TANG, Y. Tom

BANDMAN, Olga

HILLMAN, Jennifer L.

LAL, Preeti

AU-YOUNG, Janice

REDDY, Roopa

YANG, Junming

BAUGHN, Mariah R.

LU, Dyung Aina M.

AZIMZAI, Yalda

PATTERSON, Chandra

<120> GTP-BINDING ASSOCIATED PROTEINS

<130> PF-0714 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/144,595; 60/150,460; 60/159,849

<151> 1999-07-19; 1999-08-23; 1999-10-15

<160> 132

<170> PERL Program

<210> 1

<211> 269

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1405545CD1

<400> 1

Met	Pro	Ala	Val	Leu	Glu	Arg	Leu	Ser	Arg	Tyr	Asn	Ser	Thr	Ser
1				5					10					15
Gln	Ala	Phe	Ala	Glu	Val	Leu	Arg	Leu	Pro	Lys	Gln	Gln	Leu	Arg
				20					25					30
Lys	Leu	Leu	Tyr	Pro	Leu	Gln	Glu	Val	Glu	Arg	Phe	Leu	Ala	Pro
				35					40					45
Tyr	Gly	Arg	Gln	Asp	Leu	His	Leu	Arg	Ile	Phe	Asp	Pro	Ser	Pro
				50					55					60
Glu	Asp	Ile	Ala	Arg	Ala	Asp	Asn	Ile	Phe	Thr	Ala	Thr	Glu	Arg
				65					70					75
Asn	Arg	Ile	Asp	Tyr	Val	Ser	Ser	Ala	Val	Arg	Ile	Asp	His	Ala
				80					85					90
Pro	Asp	Leu	Pro	Arg	Pro	Glu	Val	Cys	Phe	Ile	Gly	Arg	Ser	Asn
				95					100					105
Val	Gly	Lys	Ser	Ser	Leu	Ile	Lys	Ala	Leu	Phe	Ser	Leu	Ala	Pro
				110					115					120
Glu	Val	Glu	Val	Arg	Val	Ser	Lys	Lys	Pro	Gly	His	Thr	Lys	Lys
				125					130					135
Met	Asn	Phe	Phe	Lys	Val	Gly	Lys	His	Phe	Thr	Val	Val	Asp	Met
				140					145					150
Pro	Gly	Tyr	Gly	Phe	Arg	Ala	Pro	Glu	Asp	Phe	Val	Asp	Met	Val
				155					160					165
Glu	Thr	Tyr	Leu	Lys	Glu	Arg	Arg	Asn	Leu	Lys	Arg	Thr	Phe	Leu

Leu Val Asp Ser	170	Val Val Gly Ile Gln	175	Lys Thr Asp Asn Ile	180
	185		190		195
Ile Glu Met Cys	200	Glu Glu Phe Ala Leu	205	Pro Tyr Val Ile Val	210
	215		220		225
Thr Lys Ile Asp	230	Lys Ser Ser Lys Gly	235	His Leu Leu Lys Gln	240
	245		250		255
Leu Gln Ile Gln	260	Lys Phe Val Asn Met	265	Lys Thr Gln Gly Cys	
Pro Gln Leu Phe		Pro Val Ser Ala Val		Thr Phe Ser Gly Ile	
Leu Leu Arg Cys		Phe Ile Ala Ser Val		Thr Gly Ser Leu Asp	

<210> 2

<211> 428

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1451265CD1

<400> 2

Met Glu Val Ala Val	1	Cys Thr Asp Ser	5	Ala Ala Pro Met Trp	10	Ser	15
	5		10		15		
Cys Ile Val Trp	20	Glu Leu His Ser Gly	25	Ala Asn Leu Leu Thr	30	Tyr	35
	35		40		45		
Arg Gly Gly Gln	50	Ala Gly Pro Arg Gly	55	Leu Ala Leu Leu Asn	60	Gly	65
	65		70		75		
Glu Tyr Leu Leu	80	Ala Ala Gln Leu Gly	85	Lys Asn Tyr Ile Ser	90	Ala	95
	95		100		105		
Trp Glu Leu Gln	110	Arg Lys Asp Gln Leu	115	Gln Gln Lys Ile Met	120	Cys	125
	125		130		135		
Pro Gly Pro Val	140	Thr Cys Leu Thr Ala	145	Ser Pro Asn Gly Leu	150	Tyr	155
	155		160		165		
Val Leu Ala Gly	170	Val Ala Glu Ser Ile	175	His Leu Trp Glu Val	180	Ser	185
	185		190		195		
Thr Gly Asn Leu	200	Leu Val Ile Leu Ser	205	Arg His Tyr Gln Asp	210	Val	215
	215		220		225		
Ser Cys Leu Gln	230	Phe Thr Gly Asp Ser	235	Ser His Phe Ile Ser	240	Gly	245
	245		250		255		
Gly Lys Asp Cys	260	Leu Val Leu Val Trp	265	Ser Leu Cys Ser Val	270	Leu	275
	275		280		285		
Gln Ala Asp Pro	290	Ser Arg Ile Pro Ala	295	Pro Arg His Val Trp	300	Ser	305
	305		310		315		
His His Thr Leu	320	Pro Ile Thr Asp Leu	325	His Cys Gly Phe Gly	330	Gly	335
	335		340		345		
Pro Leu Ala Arg	350	Val Ala Thr Ser Ser	355	Leu Asp Gln Thr Val	360	Lys	365
	365		370		375		
Leu Trp Glu Val	380	Ser Ser Gly Glu Leu	385	Leu Leu Ser Val Leu	390	Phe	395
	395		400		405		
Asp Val Ser Ile	410	Met Ala Val Thr Met	415	Asp Leu Ala Glu His	420	His	425
	425		430		435		
Met Phe Cys Gly	440	Gly Ser Glu Gly Ser	445	Ile Phe Gln Val Asp	450	Leu	455
	455		460		465		
Phe Thr Trp Pro	470	Gly Gln Arg Glu Arg	475	Ser Phe His Pro Glu	480	Gln	485
	485		490		495		
Asp Ala Gly Lys	500	Val Phe Lys Gly His	505	Arg Asn Gln Val Thr	510	Cys	515
	515		520		525		
Leu Ser Val Ser	530	Thr Asp Gly Ser Val	535	Leu Leu Ser Gly Ser	540	His	545
	545		550		555		
Asp Glu Thr Val	560	Arg Leu Trp Asp Val	565	Gln Ser Lys Gln Cys	570	Ile	575
	575		580		585		

```

Arg Thr Val Ala Leu Lys Gly Pro Val Thr Asn Ala Ala Ile Leu
      305                      310                      315
Leu Ala Pro Val Ser Met Leu Ser Ser Asp Phe Arg Pro Ser Leu
      320                      325                      330
Pro Leu Pro His Phe Asn Lys His Leu Leu Gly Ala Glu His Gly
      335                      340                      345
Asp Glu Pro Arg His Gly Gly Leu Thr Leu Arg Leu Gly Leu His
      350                      355                      360
Gln Gln Gly Ser Glu Pro Ser Tyr Leu Asp Arg Thr Glu Gln Leu
      365                      370                      375
Gln Ala Val Leu Cys Ser Thr Met Glu Lys Ser Val Leu Gly Gly
      380                      385                      390
Gln Asp Gln Leu Arg Val Arg Val Thr Glu Leu Glu Asp Glu Val
      395                      400                      405
Arg Asn Leu Arg Lys Ile Asn Arg Asp Leu Phe Asp Phe Ser Thr
      410                      415                      420
Arg Phe Ile Thr Arg Pro Ala Lys
      425

```

<210> 3

<211> 562

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1556311CD1

<400> 3

```

Met Pro Glu Thr Val Asn His Asn Lys His Gly Asn Val Ala Leu
  1                      5                      10                      15
Pro Gly Thr Lys Pro Thr Pro Ile Pro Pro Pro Arg Leu Lys Lys
      20                      25                      30
Gln Ala Ser Phe Leu Glu Ala Glu Gly Gly Ala Lys Thr Leu Ser
      35                      40                      45
Gly Gly Arg Pro Gly Ala Gly Pro Glu Leu Glu Leu Gly Thr Ala
      50                      55                      60
Gly Ser Pro Gly Gly Ala Pro Pro Glu Ala Ala Pro Gly Asp Cys
      65                      70                      75
Thr Arg Ala Pro Pro Pro Ser Ser Glu Ser Arg Pro Pro Cys His
      80                      85                      90
Gly Gly Arg Gln Arg Leu Ser Asp Met Ser Ile Ser Thr Ser Ser
      95                      100                     105
Ser Asp Ser Leu Glu Phe Asp Arg Ser Met Pro Leu Phe Gly Tyr
      110                     115                     120
Glu Ala Asp Thr Asn Ser Ser Leu Glu Asp Tyr Glu Gly Glu Ser
      125                     130                     135
Asp Gln Glu Thr Met Ala Pro Pro Ile Lys Ser Lys Lys Lys Arg
      140                     145                     150
Ser Ser Ser Phe Val Leu Pro Lys Leu Val Lys Ser Gln Leu Gln
      155                     160                     165
Lys Val Ser Gly Val Phe Ser Ser Phe Met Thr Pro Glu Lys Arg
      170                     175                     180
Met Val Arg Arg Ile Ala Glu Leu Ser Arg Asp Lys Cys Thr Tyr
      185                     190                     195
Phe Gly Cys Leu Val Gln Asp Tyr Val Ser Phe Leu Gln Glu Asn
      200                     205                     210
Lys Glu Cys His Val Ser Ser Thr Asp Met Leu Gln Thr Ile Arg
      215                     220                     225
Gln Phe Met Thr Gln Val Lys Asn Tyr Leu Ser Gln Ser Ser Glu
      230                     235                     240
Leu Asp Pro Pro Ile Glu Ser Leu Ile Pro Glu Asp Gln Ile Asp
      245                     250                     255
Val Val Leu Glu Lys Ala Met His Lys Cys Ile Leu Lys Pro Leu

```

	260		265		270
Lys Gly His Val	Glu Ala Met Leu Lys	Asp Phe His Met Ala	Asp		
	275		280		285
Gly Ser Trp Lys	Gln Leu Lys Glu Asn	Leu Gln Leu Val Arg	Gln		
	290		295		300
Arg Asn Pro Gln	Glu Leu Gly Val Phe	Ala Pro Thr Pro Asp	Phe		
	305		310		315
Val Asp Val Glu	Lys Ile Lys Val Lys	Phe Met Thr Met Gln	Lys		
	320		325		330
Met Tyr Ser Pro	Glu Lys Lys Val Met	Leu Leu Leu Arg Val	Cys		
	335		340		345
Lys Leu Ile Tyr	Thr Val Met Glu Asn	Asn Ser Gly Arg Met	Tyr		
	350		355		360
Gly Ala Asp Asp	Phe Leu Pro Val Leu	Thr Tyr Val Ile Ala	Gln		
	365		370		375
Cys Asp Met Leu	Glu Leu Asp Thr Glu	Ile Glu Tyr Met Met	Glu		
	380		385		390
Leu Leu Asp Pro	Ser Leu Leu His Gly	Glu Gly Gly Tyr Tyr	Leu		
	395		400		405
Thr Ser Ala Tyr	Gly Ala Leu Ser Leu	Ile Lys Asn Phe Gln	Glu		
	410		415		420
Glu Gln Ala Ala	Arg Leu Leu Ser Ser	Glu Thr Arg Asp Thr	Leu		
	425		430		435
Arg Gln Trp His	Lys Arg Arg Thr Thr	Asn Arg Thr Ile Pro	Ser		
	440		445		450
Val Asp Asp Phe	Gln Asn Tyr Leu Arg	Val Ala Phe Gln Glu	Val		
	455		460		465
Asn Ser Gly Cys	Thr Gly Lys Thr Leu	Leu Val Arg Pro Tyr	Ile		
	470		475		480
Thr Thr Glu Asp	Val Cys Gln Ile Cys	Ala Glu Lys Phe Lys	Val		
	485		490		495
Gly Asp Pro Glu	Glu Tyr Ser Leu Phe	Leu Phe Val Asp Glu	Thr		
	500		505		510
Trp Gln Gln Leu	Ala Glu Asp Thr Tyr	Pro Gln Lys Ile Lys	Ala		
	515		520		525
Glu Leu His Ser	Arg Pro Gln Pro His	Ile Phe His Phe Val	Tyr		
	530		535		540
Lys Arg Ile Lys	Asn Asp Pro Tyr Gly	Ile Ile Phe Gln Asn	Gly		
	545		550		555
Glu Glu Asp Leu	Thr Thr Ser				
	560				

<210> 4

<211> 229

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1901373CD1

<400> 4

Met Ala Glu Asp	Lys Thr Lys Pro Ser	Glu Leu Asp Gln Gly	Lys
1	5	10	15
Tyr Asp Ala Asp	Asn Val Lys Ile	Ile Cys Leu Gly Asp	Ser
	20	25	30
Ala Val Gly Lys	Ser Lys Leu Met Glu	Arg Phe Leu Met Asp	Gly
	35	40	45
Phe Gln Pro Gln	Gln Leu Ser Thr Tyr	Ala Leu Thr Leu Tyr	Lys
	50	55	60
His Thr Ala Thr	Val Asp Gly Arg Thr	Ile Leu Val Asp Phe	Trp
	65	70	75
Asp Thr Ala Gly	Gln Glu Arg Phe Gln	Ser Met His Ala Ser	Tyr
	80	85	90

```

Tyr His Lys Ala His Ala Cys Ile Met Val Phe Asp Val Gln Arg
      95      100      105
Lys Val Thr Tyr Arg Asn Leu Ser Thr Trp Tyr Thr Glu Leu Arg
      110      115      120
Glu Phe Arg Pro Glu Ile Pro Cys Ile Val Val Ala Asn Lys Ile
      125      130      135
Asp Ala Asp Ile Asn Val Thr Gln Lys Ser Phe Asn Phe Ala Lys
      140      145      150
Lys Phe Ser Leu Pro Leu Tyr Phe Val Ser Ala Ala Asp Gly Thr
      155      160      165
Asn Val Val Lys Leu Phe Asn Asp Ala Ile Arg Leu Ala Val Ser
      170      175      180
Tyr Lys Gln Asn Ser Gln Asp Phe Met Asp Glu Ile Phe Gln Glu
      185      190      195
Leu Glu Asn Phe Ser Leu Glu Gln Glu Glu Glu Asp Val Pro Asp
      200      205      210
Gln Glu Gln Ser Ser Ser Ile Glu Thr Pro Ser Glu Glu Val Ala
      215      220      225
Ser Pro His Ser

```

<210> 5

<211> 360

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2367767CD1

<400> 5

```

Met Phe Val Ala Arg Ser Ile Ala Ala Asp His Lys Asp Leu Ile
  1      5      10      15
His Asp Val Ser Phe Asp Phe His Gly Arg Arg Met Ala Thr Cys
      20      25      30
Ser Ser Asp Gln Ser Val Lys Val Trp Asp Lys Ser Glu Ser Gly
      35      40      45
Asp Trp His Cys Thr Ala Ser Trp Lys Thr His Ser Gly Ser Val
      50      55      60
Trp Arg Val Thr Trp Ala His Pro Glu Phe Gly Gln Val Leu Ala
      65      70      75
Ser Cys Ser Phe Asp Arg Thr Ala Ala Val Trp Glu Glu Ile Val
      80      85      90
Gly Glu Ser Asn Asp Lys Leu Arg Gly Gln Ser His Trp Val Lys
      95      100      105
Arg Thr Thr Leu Val Asp Ser Arg Thr Ser Val Thr Asp Val Lys
      110      115      120
Phe Ala Pro Lys His Met Gly Leu Met Leu Ala Thr Cys Ser Ala
      125      130      135
Asp Gly Ile Val Arg Ile Tyr Glu Ala Pro Asp Val Met Asn Leu
      140      145      150
Ser Gln Trp Ser Leu Gln His Glu Ile Ser Cys Lys Leu Ser Cys
      155      160      165
Ser Cys Ile Ser Trp Asn Pro Ser Ser Ser Arg Ala His Ser Pro
      170      175      180
Met Ile Ala Val Gly Ser Asp Asp Ser Ser Pro Asn Ala Met Ala
      185      190      195
Lys Val Gln Ile Phe Glu Tyr Asn Glu Asn Thr Arg Lys Tyr Ala
      200      205      210
Lys Ala Glu Thr Leu Met Thr Val Thr Asp Pro Val His Asp Ile
      215      220      225
Ala Phe Ala Pro Asn Leu Gly Arg Ser Phe His Ile Leu Ala Ile
      230      235      240
Ala Thr Lys Asp Val Arg Ile Phe Thr Leu Lys Pro Val Arg Lys

```

	245		250		255
Glu Leu Thr Ser	Ser Gly Gly Pro Thr	Lys Phe Glu Ile His	Ile		
	260		265		270
Val Ala Gln Phe	Asp Asn His Asn Ser	Gln Val Trp Arg Val	Ser		
	275		280		285
Trp Asn Ile Thr	Gly Thr Val Leu Ala	Ser Ser Gly Asp Asp	Gly		
	290		295		300
Cys Val Arg Leu	Trp Lys Ala Asn Tyr	Met Asp Asn Trp Lys	Cys		
	305		310		315
Thr Gly Ile Leu	Lys Gly Asn Gly Ser	Pro Val Asn Gly Ser	Ser		
	320		325		330
Gln Gln Gly Thr	Ser Asn Pro Ser Leu	Gly Ser Asn Ile Pro	Ser		
	335		340		345
Leu Gln Asn Ser	Leu Asn Gly Ser Ser	Ala Gly Arg Lys His	Ser		
	350		355		360

<210> 6

<211> 460

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3090433CD1

<400> 6

Met Ala Asn Asp	Pro Leu Glu Gly Phe	His Glu Val Asn Leu	Ala
1	5	10	15
Ser Pro Thr Ser	Pro Asp Leu Leu Gly	Val Tyr Glu Ser Gly	Thr
	20	25	30
Gln Glu Gln Thr	Thr Ser Pro Ser Val	Ile Tyr Arg Pro His	Pro
	35	40	45
Ser Ala Leu Ser	Ser Val Pro Ile Gln	Ala Asn Ala Leu Asp	Val
	50	55	60
Ser Glu Leu Pro	Thr Gln Pro Val Tyr	Ser Ser Pro Arg Arg	Leu
	65	70	75
Asn Cys Ala Glu	Ile Ser Ser Ile Ser	Phe His Val Thr Asp	Pro
	80	85	90
Ala Pro Cys Ser	Thr Ser Gly Val Thr	Ala Gly Leu Thr Lys	Leu
	95	100	105
Thr Thr Arg Lys	Asp Asn Tyr Asn Ala	Glu Arg Glu Phe Leu	Gln
	110	115	120
Gly Ala Thr Ile	Thr Glu Ala Cys Asp	Gly Ser Asp Asp Ile	Phe
	125	130	135
Gly Leu Ser Thr	Asp Ser Leu Ser Arg	Leu Arg Ser Pro Ser	Val
	140	145	150
Leu Glu Val Arg	Glu Lys Gly Tyr Glu	Arg Leu Lys Glu Glu	Leu
	155	160	165
Ala Lys Ala Gln	Arg Glu Leu Lys Leu	Lys Asp Glu Glu Cys	Glu
	170	175	180
Arg Leu Ser Lys	Val Arg Asp Gln Leu	Gly Gln Glu Leu Glu	Glu
	185	190	195
Leu Thr Ala Ser	Leu Phe Glu Glu Ala	His Lys Met Val Arg	Glu
	200	205	210
Ala Asn Ile Lys	Gln Ala Thr Ala Glu	Lys Gln Leu Lys Glu	Ala
	215	220	225
Gln Gly Lys Ile	Asp Val Leu Gln Ala	Glu Val Ala Ala Leu	Lys
	230	235	240
Thr Leu Val Leu	Ser Ser Ser Pro Thr	Ser Pro Thr Gln Glu	Pro
	245	250	255
Leu Pro Gly Gly	Lys Thr Pro Phe Lys	Lys Gly His Thr Arg	Asn
	260	265	270
Lys Ser Thr Ser	Ser Ala Met Ser Gly	Ser His Gln Asp Leu	Ser


```

275      280      285
Val Ile Gln Pro Ile Val Lys Asp Cys Lys Glu Ala Asp Leu Ser
290      295      300
Leu Tyr Asn Glu Phe Arg Leu Trp Lys Asp Glu Pro Thr Met Asp
305      310      315
Arg Thr Cys Pro Phe Leu Asp Lys Ile Tyr Gln Glu Asp Ile Phe
320      325      330
Pro Cys Leu Thr Phe Ser Lys Ser Glu Leu Ala Ser Ala Val Leu
335      340      345
Glu Ala Val Glu Asn Asn Thr Leu Ser Ile Glu Pro Val Gly Leu
350      355      360
Gln Pro Ile Arg Phe Val Lys Ala Ser Ala Val Glu Cys Gly Gly
365      370      375
Pro Lys Lys Cys Ala Leu Thr Gly Gln Ser Lys Ser Cys Lys His
380      385      390
Arg Ile Lys Leu Gly Asp Ser Ser Asn Tyr Tyr Tyr Ile Ser Pro
395      400      405
Phe Cys Arg Tyr Arg Ile Thr Ser Val Cys Asn Phe Phe Thr Tyr
410      415      420
Ile Arg Tyr Ile Gln Gln Gly Leu Val Lys Gln Gln Asp Val Asp
425      430      435
Gln Met Phe Trp Glu Val Met Gln Leu Arg Lys Glu Met Ser Leu
440      445      450
Ala Lys Leu Gly Tyr Phe Lys Glu Glu Leu
455      460
<210> 7
<211> 239
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3800591CD1

<400> 7
Met Gln Asp Pro Asn Ala Asp Thr Glu Trp Asn Asp Ile Leu Arg
1      5      10      15
Lys Lys Gly Ile Leu Pro Pro Lys Glu Ser Leu Lys Glu Leu Glu
20      25      30
Glu Glu Ala Glu Glu Glu Gln Arg Ile Leu Gln Gln Ser Val Val
35      40      45
Lys Thr Tyr Glu Asp Met Thr Leu Glu Glu Leu Glu Asp His Glu
50      55      60
Asp Glu Phe Asn Glu Glu Asp Glu Arg Ala Ile Glu Met Tyr Arg
65      70      75
Arg Arg Arg Leu Ala Glu Trp Lys Ala Thr Lys Leu Lys Asn Lys
80      85      90
Phe Gly Glu Val Leu Glu Ile Ser Gly Lys Asp Tyr Val Gln Glu
95      100      105
Val Thr Lys Ala Gly Glu Gly Leu Trp Val Ile Leu His Leu Tyr
110      115      120
Lys Gln Gly Ile Pro Leu Cys Ala Leu Ile Asn Gln His Leu Ser
125      130      135
Gly Leu Ala Arg Lys Phe Pro Asp Val Lys Phe Ile Lys Ala Ile
140      145      150
Ser Thr Thr Cys Ile Pro Asn Tyr Pro Asp Arg Asn Leu Pro Thr
155      160      165
Ile Phe Val Tyr Leu Glu Gly Asp Ile Lys Ala Gln Phe Ile Gly
170      175      180
Pro Leu Val Phe Gly Gly Met Asn Leu Thr Arg Asp Glu Leu Glu
185      190      195
Trp Lys Leu Ser Glu Ser Gly Ala Ile Met Thr Asp Leu Glu Glu
200      205      210

```

Asn	Pro	Lys	Lys	Pro	Ile	Glu	Asp	Val	Leu	Leu	Ser	Ser	Val	Arg
				215					220					225
Arg	Ser	Val	Leu	Met	Lys	Arg	Asp	Ser	Asp	Ser	Glu	Gly	Asp	
				230					235					

<210> 8

<211> 334

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5308471CD1

<400> 8

Met	Arg	Leu	Thr	Pro	Arg	Ala	Leu	Cys	Ser	Ala	Ala	Gln	Ala	Ala
1				5					10					15
Trp	Arg	Glu	Asn	Phe	Pro	Leu	Cys	Gly	Arg	Asp	Val	Ala	Arg	Trp
				20					25					30
Phe	Pro	Gly	His	Met	Ala	Lys	Gly	Leu	Lys	Lys	Met	Gln	Ser	Ser
				35					40					45
Leu	Lys	Leu	Val	Asp	Cys	Ile	Ile	Glu	Val	His	Asp	Ala	Arg	Ile
				50					55					60
Pro	Leu	Ser	Gly	Arg	Asn	Pro	Leu	Phe	Gln	Glu	Thr	Leu	Gly	Leu
				65					70					75
Lys	Pro	His	Leu	Leu	Val	Leu	Asn	Lys	Met	Asp	Leu	Ala	Asp	Leu
				80					85					90
Thr	Glu	Gln	Gln	Lys	Ile	Met	Gln	His	Leu	Glu	Gly	Glu	Gly	Leu
				95					100					105
Lys	Asn	Val	Ile	Phe	Thr	Asn	Cys	Val	Lys	Asp	Glu	Asn	Val	Lys
				110					115					120
Gln	Ile	Ile	Pro	Met	Val	Thr	Glu	Leu	Ile	Gly	Arg	Ser	His	Arg
				125					130					135
Tyr	His	Arg	Lys	Glu	Asn	Leu	Glu	Tyr	Cys	Ile	Met	Val	Ile	Gly
				140					145					150
Val	Pro	Asn	Val	Gly	Lys	Ser	Ser	Leu	Ile	Asn	Ser	Leu	Arg	Arg
				155					160					165
Gln	His	Leu	Arg	Lys	Gly	Lys	Ala	Thr	Arg	Val	Gly	Gly	Glu	Pro
				170					175					180
Gly	Ile	Thr	Arg	Ala	Val	Met	Ser	Lys	Ile	Gln	Val	Ser	Glu	Arg
				185					190					195
Pro	Leu	Met	Phe	Leu	Leu	Asp	Thr	Pro	Gly	Val	Leu	Ala	Pro	Arg
				200					205					210
Ile	Glu	Ser	Val	Glu	Thr	Gly	Leu	Lys	Leu	Ala	Leu	Cys	Gly	Thr
				215					220					225
Val	Leu	Asp	His	Leu	Val	Gly	Glu	Glu	Thr	Met	Ala	Asp	Tyr	Leu
				230					235					240
Leu	Tyr	Thr	Leu	Asn	Lys	His	Gln	Arg	Phe	Gly	Tyr	Val	Gln	His
				245					250					255
Tyr	Gly	Leu	Gly	Ser	Ala	Cys	Asp	Asn	Val	Glu	Arg	Val	Leu	Lys
				260					265					270
Ser	Val	Ala	Val	Lys	Leu	Gly	Lys	Thr	Gln	Lys	Val	Lys	Val	Leu
				275					280					285
Thr	Gly	Thr	Gly	Asn	Val	Asn	Val	Ile	Gln	Pro	Asn	Tyr	Pro	Ala
				290					295					300
Ala	Ala	Arg	Asp	Phe	Leu	Gln	Thr	Phe	Arg	Arg	Gly	Leu	Leu	Gly
				305					310					315
Ser	Val	Met	Leu	Asp	Leu	Asp	Val	Leu	Arg	Gly	His	Pro	Pro	Ala
				320					325					330
Glu	Thr	Leu	Pro											

<210> 9

<211> 341

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5324322CD1

<400> 9

```

Met Glu Arg Ala Val Pro Leu Ala Val Pro Leu Gly Gln Thr Glu
 1          5          10          15
Val Phe Gln Ala Leu Gln Arg Leu His Met Thr Ile Phe Ser Gln
 20          25          30
Ser Val Ser Pro Cys Gly Lys Phe Leu Ala Ala Gly Asn Asn Tyr
 35          40          45
Gly Gln Ile Ala Ile Phe Ser Leu Ser Ser Ala Leu Ser Ser Glu
 50          55          60
Ala Lys Glu Glu Ser Lys Lys Pro Val Val Thr Phe Gln Ala His
 65          70          75
Asp Gly Pro Val Tyr Ser Met Val Ser Thr Asp Arg His Leu Leu
 80          85          90
Ser Ala Gly Asp Gly Glu Val Lys Ala Trp Leu Trp Ala Glu Met
 95          100          105
Leu Lys Lys Gly Cys Lys Glu Leu Trp Arg Arg Gln Pro Pro Tyr
 110          115          120
Arg Thr Ser Leu Glu Val Pro Glu Ile Asn Ala Leu Leu Leu Val
 125          130          135
Pro Lys Glu Asn Ser Leu Ile Leu Ala Gly Gly Asp Cys Gln Leu
 140          145          150
His Thr Met Asp Leu Glu Thr Gly Thr Phe Thr Arg Val Leu Arg
 155          160          165
Gly His Thr Asp Tyr Ile His Cys Leu Ala Leu Arg Glu Arg Ser
 170          175          180
Pro Glu Val Leu Ser Gly Gly Glu Asp Gly Ala Val Arg Leu Trp
 185          190          195
Asp Leu Arg Thr Ala Lys Glu Val Gln Thr Ile Glu Val Tyr Lys
 200          205          210
His Glu Glu Cys Ser Arg Pro His Asn Gly Arg Trp Ile Gly Cys
 215          220          225
Leu Ala Thr Asp Ser Asp Trp Met Val Cys Gly Gly Gly Pro Ala
 230          235          240
Leu Thr Leu Trp His Leu Arg Ser Ser Thr Pro Thr Thr Ile Phe
 245          250          255
Pro Ile Arg Ala Pro Gln Lys His Val Thr Phe Tyr Gln Asp Leu
 260          265          270
Ile Leu Ser Ala Gly Gln Gly Arg Cys Val Asn Gln Trp Gln Leu
 275          280          285
Ser Gly Glu Leu Lys Ala Gln Val Pro Gly Ser Ser Pro Gly Leu
 290          295          300
Leu Ser Leu Ser Leu Asn Gln Gln Pro Ala Ala Pro Glu Cys Lys
 305          310          315
Val Leu Thr Ala Ala Gly Asn Ser Cys Arg Val Asp Val Phe Thr
 320          325          330
Asn Leu Gly Tyr Arg Ala Phe Ser Leu Ser Phe
 335          340

```

<210> 10

<211> 513

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 067184CD1

<400> 10

Met	Ser	Ile	Glu	Ile	Glu	Ser	Ser	Asp	Val	Ile	Arg	Leu	Ile	Met
1				5					10					15
Gln	Tyr	Leu	Lys	Glu	Asn	Ser	Leu	His	Arg	Ala	Leu	Ala	Thr	Leu
				20					25					30
Gln	Glu	Glu	Thr	Thr	Val	Ser	Leu	Asn	Thr	Val	Asp	Ser	Ile	Glu
				35					40					45
Ser	Phe	Val	Ala	Asp	Ile	Asn	Ser	Gly	His	Trp	Asp	Thr	Val	Leu
				50					55					60
Gln	Ala	Ile	Gln	Ser	Leu	Lys	Leu	Pro	Asp	Lys	Thr	Leu	Ile	Asp
				65					70					75
Leu	Tyr	Glu	Gln	Val	Val	Leu	Glu	Leu	Ile	Glu	Leu	Arg	Glu	Leu
				80					85					90
Gly	Ala	Ala	Arg	Ser	Leu	Leu	Arg	Gln	Thr	Asp	Pro	Met	Ile	Met
				95					100					105
Leu	Lys	Gln	Thr	Gln	Pro	Glu	Arg	Tyr	Ile	His	Leu	Glu	Asn	Leu
				110					115					120
Leu	Ala	Arg	Ser	Tyr	Phe	Asp	Pro	Arg	Glu	Ala	Tyr	Pro	Asp	Gly
				125					130					135
Ser	Ser	Lys	Glu	Lys	Arg	Arg	Ala	Ala	Ile	Ala	Gln	Ala	Leu	Ala
				140					145					150
Gly	Glu	Val	Ser	Val	Val	Pro	Pro	Ser	Arg	Leu	Met	Ala	Leu	Leu
				155					160					165
Gly	Gln	Ala	Leu	Lys	Trp	Gln	Gln	His	Gln	Gly	Leu	Leu	Pro	Pro
				170					175					180
Gly	Met	Thr	Ile	Asp	Leu	Phe	Arg	Gly	Lys	Ala	Ala	Val	Lys	Asp
				185					190					195
Val	Glu	Glu	Glu	Lys	Phe	Pro	Thr	Gln	Leu	Ser	Arg	His	Ile	Lys
				200					205					210
Phe	Gly	Gln	Lys	Ser	His	Val	Glu	Cys	Ala	Arg	Phe	Ser	Pro	Asp
				215					220					225
Gly	Gln	Tyr	Leu	Val	Thr	Gly	Ser	Val	Asp	Gly	Phe	Ile	Glu	Val
				230					235					240
Trp	Asn	Phe	Thr	Thr	Gly	Lys	Ile	Arg	Lys	Asp	Leu	Lys	Tyr	Gln
				245					250					255
Ala	Gln	Asp	Asn	Phe	Met	Met	Met	Asp	Asp	Ala	Val	Leu	Cys	Met
				260					265					270
Cys	Phe	Ser	Arg	Asp	Thr	Glu	Met	Leu	Ala	Thr	Gly	Ala	Gln	Asp
				275					280					285
Gly	Lys	Ile	Lys	Val	Trp	Lys	Ile	Gln	Ser	Gly	Gln	Cys	Leu	Arg
				290					295					300
Arg	Phe	Glu	Arg	Ala	His	Ser	Lys	Gly	Val	Thr	Cys	Leu	Ser	Phe
				305					310					315
Ser	Lys	Asp	Ser	Ser	Gln	Ile	Leu	Ser	Ala	Ser	Phe	Asp	Gln	Thr
				320					325					330
Ile	Arg	Ile	His	Gly	Leu	Lys	Ser	Gly	Lys	Thr	Leu	Lys	Glu	Phe
				335					340					345
Arg	Gly	His	Ser	Ser	Phe	Val	Asn	Glu	Ala	Thr	Phe	Thr	Gln	Asp
				350					355					360
Gly	His	Tyr	Ile	Ile	Ser	Ala	Ser	Ser	Asp	Gly	Thr	Val	Lys	Ile
				365					370					375
Trp	Asn	Met	Lys	Thr	Thr	Glu	Cys	Ser	Asn	Thr	Phe	Lys	Ser	Leu
				380					385					390
Gly	Ser	Thr	Ala	Gly	Thr	Asp	Ile	Thr	Val	Asn	Ser	Val	Ile	Leu
				395					400					405
Leu	Pro	Lys	Asn	Pro	Glu	His	Phe	Val	Val	Cys	Asn	Arg	Ser	Asn
				410					415					420
Thr	Val	Val	Ile	Met	Asn	Met	Gln	Gly	Gln	Ile	Val	Arg	Ser	Phe
				425					430					435
Ser	Ser	Gly	Lys	Arg	Glu	Gly	Gly	Asp	Phe	Val	Cys	Cys	Ala	Leu
				440					445					450
Ser	Pro	Arg	Gly	Glu	Trp	Ile	Tyr	Cys	Val	Gly	Glu	Asp	Phe	Val
				455					460					465
Leu	Tyr	Cys	Phe	Ser	Thr	Val	Thr	Gly	Lys	Leu	Glu	Arg	Thr	Leu

	470		475		480
Thr Val His Glu Lys Asp Val Ile Gly	Ile Ala His His Pro His				
	485		490		495
Gln Asn Leu Ile Ala Thr Tyr Ser Glu Asp Gly Leu Leu Lys Leu					
	500		505		510

Trp Lys Pro

<210> 11

<211> 186

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 722896CD1

<400> 11

Met Ile Ala Leu Phe Asn Lys Leu Leu Asp Trp Phe Lys Ala Leu		
1 5 10 15		
Phe Trp Lys Glu Glu Met Glu Leu Thr Leu Val Gly Leu Gln Tyr		
20 25 30		
Ser Gly Lys Thr Phe Val Asn Val Ile Ala Ser Gly Gln Phe		
35 40 45		
Asn Glu Asp Met Ile Pro Thr Val Gly Phe Asn Met Arg Lys Ile		
50 55 60		
Thr Lys Gly Asn Val Thr Ile Lys Leu Trp Asp Ile Gly Gly Gln		
65 70 75		
Pro Arg Phe Arg Ser Met Trp Glu Arg Tyr Cys Arg Gly Val Ser		
80 85 90		
Ala Ile Val Tyr Met Val Asp Ala Ala Asp Gln Glu Lys Ile Glu		
95 100 105		
Ala Ser Lys Asn Glu Leu His Asn Leu Leu Asp Lys Pro Gln Leu		
110 115 120		
Gln Gly Ile Pro Val Leu Val Leu Gly Asn Lys Arg Asp Leu Pro		
125 130 135		
Gly Ala Leu Asp Glu Lys Glu Leu Ile Glu Lys Met Asn Leu Ser		
140 145 150		
Ala Ile Gln Asp Arg Glu Ile Cys Cys Tyr Ser Ile Ser Cys Lys		
155 160 165		
Glu Lys Asp Asn Ile Asp Ile Thr Leu Gln Trp Leu Ile Gln His		
170 175 180		
Ser Lys Ser Arg Arg Ser		
185		

<210> 12

<211> 204

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1571739CD1

<400> 12

Met Asn Asp Val Lys Leu Ala Val Leu Gly Gly Glu Gly Thr Gly		
1 5 10 15		
Lys Ser Ala Leu Thr Val Arg Phe Leu Thr Lys Arg Phe Ile Gly		
20 25 30		
Glu Tyr Ala Ser Asn Phe Glu Ser Ile Tyr Lys Lys His Leu Cys		
35 40 45		
Leu Glu Arg Lys Gln Leu Asn Leu Glu Ile Tyr Asp Pro Cys Ser		
50 55 60		
Gln Thr Gln Lys Ala Lys Phe Ser Leu Thr Ser Glu Leu His Trp		
65 70 75		

Ala	Asp	Gly	Phe	Val	Ile	Val	Tyr	Asp	Ile	Ser	Asp	Arg	Ser	Ser	
				80					85					90	
Phe	Ala	Phe	Ala	Lys	Ala	Leu	Ile	Tyr	Arg	Ile	Arg	Glu	Pro	Gln	
				95					100					105	
Thr	Ser	His	Cys	Lys	Arg	Ala	Val	Glu	Ser	Ala	Val	Phe	Leu	Val	
				110					115					120	
Gly	Asn	Lys	Arg	Asp	Leu	Cys	His	Val	Arg	Glu	Val	Gly	Trp	Glu	
				125					130					135	
Glu	Gly	Gln	Lys	Leu	Ala	Leu	Glu	Asn	Arg	Cys	Gln	Phe	Cys	Glu	
				140					145					150	
Leu	Ser	Ala	Ala	Glu	Gln	Ser	Leu	Glu	Val	Glu	Met	Met	Phe	Ile	
				155					160					165	
Arg	Ile	Ile	Lys	Asp	Ile	Leu	Ile	Asn	Phe	Lys	Leu	Lys	Glu	Lys	
				170					175					180	
Arg	Arg	Pro	Ser	Gly	Ser	Lys	Ser	Met	Ala	Lys	Leu	Ile	Asn	Asn	
				185					190					195	
Val	Phe	Gly	Lys	Arg	Arg	Lys	Ser	Val							
				200											

<210> 13

<211> 100

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1739479CD1

<400> 13

Met	Trp	Asp	Ser	Lys	Lys	Ile	Gly	Leu	Arg	Gln	His	His	Cys	Arg	
1				5					10					15	
Lys	Cys	Gly	Lys	Ala	Val	Cys	Gly	Lys	Cys	Ser	Ser	Lys	Arg	Ser	
				20					25					30	
Ser	Ile	Pro	Leu	Met	Gly	Phe	Glu	Phe	Glu	Val	Arg	Val	Cys	Asp	
				35					40					45	
Ser	Cys	His	Glu	Ala	Ile	Thr	Asp	Glu	Glu	Arg	Ala	Pro	Thr	Ala	
				50					55					60	
Thr	Phe	His	Asp	Ser	Lys	His	Asn	Ile	Val	His	Val	His	Phe	Asp	
				65					70					75	
Ala	Thr	Arg	Gly	Trp	Leu	Leu	Thr	Ser	Gly	Thr	Asp	Lys	Val	Ile	
				80					85					90	
Lys	Leu	Trp	Asp	Met	Thr	Pro	Val	Val	Ser						
				95					100						

<210> 14

<211> 795

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1999147CD1

<400> 14

Met	Thr	Ser	Gly	Ala	Thr	Arg	Tyr	Arg	Leu	Ser	Cys	Ser	Leu	Arg	
1				5					10					15	
Gly	His	Glu	Leu	Asp	Val	Arg	Gly	Leu	Val	Cys	Cys	Ala	Tyr	Pro	
				20					25					30	
Pro	Gly	Ala	Phe	Val	Ser	Val	Ser	Arg	Asp	Arg	Thr	Thr	Arg	Leu	
				35					40					45	
Trp	Ala	Pro	Asp	Ser	Pro	Asn	Arg	Ser	Phe	Thr	Glu	Met	His	Cys	
				50					55					60	
Met	Ser	Gly	His	Ser	Asn	Phe	Val	Ser	Cys	Val	Cys	Ile	Ile	Pro	
				65					70					75	
Ser	Ser	Asp	Ile	Tyr	Pro	His	Gly	Leu	Ile	Ala	Thr	Gly	Gly	Asn	

	80		85		90
Asp His Asn Ile Cys Ile Phe Ser Leu Asp Ser Pro Met Pro Leu					
	95		100		105
Tyr Ile Leu Lys Gly His Lys Asn Thr Val Cys Ser Leu Ser Ser					
	110		115		120
Gly Lys Phe Gly Thr Leu Leu Ser Gly Ser Trp Asp Thr Thr Ala					
	125		130		135
Lys Val Trp Leu Asn Asp Lys Cys Met Met Thr Leu Gln Gly His					
	140		145		150
Thr Ala Ala Val Trp Ala Val Lys Ile Leu Pro Glu Gln Gly Leu					
	155		160		165
Met Leu Thr Gly Ser Ala Asp Lys Thr Val Lys Leu Trp Lys Ala					
	170		175		180
Gly Arg Cys Glu Arg Thr Phe Ser Gly His Glu Asp Cys Val Arg					
	185		190		195
Gly Leu Ala Ile Leu Ser Glu Thr Glu Phe Leu Ser Cys Ala Asn					
	200		205		210
Asp Ala Ser Ile Arg Arg Trp Gln Ile Thr Gly Glu Cys Leu Glu					
	215		220		225
Val Tyr Tyr Gly His Thr Asn Tyr Ile Tyr Ser Ile Ser Val Phe					
	230		235		240
Pro Asn Cys Arg Asp Phe Val Thr Thr Ala Glu Asp Arg Ser Leu					
	245		250		255
Arg Ile Trp Lys His Gly Glu Cys Ala Gln Thr Ile Arg Leu Pro					
	260		265		270
Ala Gln Ser Ile Trp Cys Cys Cys Val Leu Asp Asn Gly Asp Ile					
	275		280		285
Val Val Gly Ala Ser Asp Gly Ile Ile Arg Val Phe Thr Glu Ser					
	290		295		300
Glu Asp Arg Thr Ala Ser Ala Glu Glu Ile Lys Ala Phe Glu Lys					
	305		310		315
Glu Leu Ser His Ala Thr Ile Asp Ser Lys Thr Gly Asp Leu Gly					
	320		325		330
Asp Ile Asn Ala Glu Gln Leu Pro Gly Arg Glu His Leu Asn Glu					
	335		340		345
Pro Gly Thr Arg Glu Gly Gln Thr Arg Leu Ile Arg Asp Gly Glu					
	350		355		360
Lys Val Glu Ala Tyr Gln Trp Ser Val Ser Glu Gly Arg Trp Ile					
	365		370		375
Lys Ile Gly Asp Val Val Gly Ser Ser Gly Ala Asn Gln Gln Thr					
	380		385		390
Ser Gly Lys Val Leu Tyr Glu Gly Lys Glu Phe Asp Tyr Val Phe					
	395		400		405
Ser Ile Asp Val Asn Glu Gly Gly Pro Ser Tyr Lys Leu Pro Tyr					
	410		415		420
Asn Thr Ser Asp Asp Pro Trp Leu Thr Ala Tyr Asn Phe Leu Gln					
	425		430		435
Lys Asn Asp Leu Asn Pro Met Phe Leu Asp Gln Val Ala Lys Phe					
	440		445		450
Ile Ile Asp Asn Thr Lys Gly Gln Met Leu Gly Leu Gly Asn Pro					
	455		460		465
Ser Phe Ser Asp Pro Phe Thr Gly Gly Gly Arg Tyr Val Pro Gly					
	470		475		480
Ser Ser Gly Ser Ser Asn Thr Leu Pro Thr Ala Asp Pro Phe Thr					
	485		490		495
Gly Ala Gly Arg Tyr Val Pro Gly Ser Ala Ser Met Gly Thr Thr					
	500		505		510
Met Ala Gly Val Asp Pro Phe Thr Gly Asn Ser Ala Tyr Arg Ser					
	515		520		525
Ala Ala Ser Lys Thr Met Asn Ile Tyr Phe Pro Lys Lys Glu Ala					
	530		535		540
Val Thr Phe Asp Gln Ala Asn Pro Thr Gln Ile Leu Gly Lys Leu					
	545		550		555

Lys	Glu	Leu	Asn	Gly	Thr	Ala	Pro	Glu	Glu	Lys	Lys	Leu	Thr	Glu
				560					565					570
Asp	Asp	Leu	Ile	Leu	Leu	Glu	Lys	Ile	Leu	Ser	Leu	Ile	Cys	Asn
				575					580					585
Ser	Ser	Ser	Glu	Lys	Pro	Thr	Val	Gln	Gln	Leu	Gln	Ile	Leu	Trp
				590					595					600
Lys	Ala	Ile	Asn	Cys	Pro	Glu	Asp	Ile	Val	Phe	Pro	Ala	Leu	Asp
				605					610					615
Ile	Leu	Arg	Leu	Ser	Ile	Lys	His	Pro	Ser	Val	Asn	Glu	Asn	Phe
				620					625					630
Cys	Asn	Glu	Lys	Glu	Gly	Ala	Gln	Phe	Ser	Ser	His	Leu	Ile	Asn
				635					640					645
Leu	Leu	Asn	Pro	Lys	Gly	Lys	Pro	Ala	Asn	Gln	Leu	Leu	Ala	Leu
				650					655					660
Arg	Thr	Phe	Cys	Asn	Cys	Phe	Val	Gly	Gln	Ala	Gly	Gln	Lys	Leu
				665					670					675
Met	Met	Ser	Gln	Arg	Glu	Ser	Leu	Met	Ser	His	Ala	Ile	Glu	Leu
				680					685					690
Lys	Ser	Gly	Ser	Asn	Lys	Asn	Ile	His	Ile	Ala	Leu	Ala	Thr	Leu
				695					700					705
Ala	Leu	Asn	Tyr	Ser	Val	Cys	Phe	His	Lys	Asp	His	Asn	Ile	Glu
				710					715					720
Gly	Lys	Ala	Gln	Cys	Leu	Ser	Leu	Ile	Ser	Thr	Ile	Leu	Glu	Val
				725					730					735
Val	Gln	Asp	Leu	Glu	Ala	Thr	Phe	Arg	Leu	Leu	Val	Ala	Leu	Gly
				740					745					750
Thr	Leu	Ile	Ser	Asp	Asp	Ser	Asn	Ala	Val	Gln	Leu	Ala	Lys	Ser
				755					760					765
Leu	Gly	Val	Asp	Ser	Gln	Ile	Lys	Lys	Tyr	Ser	Ser	Val	Ser	Glu
				770					775					780
Pro	Ala	Lys	Val	Ser	Glu	Cys	Cys	Arg	Phe	Ile	Leu	Asn	Leu	Leu
				785					790					795

<210> 15

<211> 393

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2182085CD1

<400> 15

Met	Glu	Asp	Phe	Glu	Asp	Asp	Pro	Arg	Ala	Leu	Gly	Ala	Arg	Gly
1				5					10					15
His	Arg	Arg	Ser	Val	Ser	Arg	Gly	Ser	Tyr	Gln	Leu	Gln	Ala	Gln
				20					25					30
Met	Asn	Arg	Ala	Val	Tyr	Glu	Asp	Arg	Pro	Pro	Gly	Ser	Val	Val
				35					40					45
Pro	Thr	Ser	Ala	Ala	Glu	Ala	Ser	Arg	Ala	Met	Ala	Gly	Asp	Thr
				50					55					60
Ser	Leu	Ser	Glu	Asn	Tyr	Ala	Phe	Ala	Gly	Met	Tyr	His	Val	Phe
				65					70					75
Asp	Gln	His	Val	Asp	Glu	Ala	Val	Pro	Arg	Val	Arg	Phe	Ala	Asn
				80					85					90
Asp	Asp	Arg	His	Arg	Leu	Ala	Cys	Cys	Ser	Leu	Asp	Gly	Ser	Ile
				95					100					105
Ser	Leu	Cys	Gln	Leu	Val	Pro	Ala	Pro	Pro	Thr	Val	Leu	Arg	Val
				110					115					120
Leu	Arg	Gly	His	Thr	Arg	Gly	Val	Ser	Asp	Phe	Ala	Trp	Ser	Leu
				125					130					135
Ser	Asn	Asp	Ile	Leu	Val	Ser	Thr	Ser	Leu	Asp	Ala	Thr	Met	Arg
				140					145					150

Ile	Trp	Ala	Ser	Glu	Asp	Gly	Arg	Cys	Ile	Arg	Glu	Ile	Pro	Asp	
				155					160					165	
Pro	Asp	Ser	Ala	Glu	Leu	Leu	Cys	Cys	Thr	Phe	Gln	Pro	Val	Asn	
				170					175					180	
Asn	Asn	Leu	Thr	Val	Val	Gly	Asn	Ala	Lys	His	Asn	Val	His	Val	
				185					190					195	
Met	Asn	Ile	Ser	Thr	Gly	Lys	Lys	Val	Lys	Gly	Gly	Ser	Ser	Lys	
				200					205					210	
Leu	Thr	Gly	Arg	Val	Leu	Ala	Leu	Ser	Phe	Asp	Ala	Pro	Gly	Arg	
				215					220					225	
Leu	Leu	Trp	Ala	Gly	Asp	Asp	Arg	Gly	Ser	Val	Phe	Ser	Phe	Leu	
				230					235					240	
Phe	Asp	Met	Ala	Thr	Gly	Lys	Leu	Thr	Lys	Ala	Lys	Arg	Leu	Val	
				245					250					255	
Val	His	Glu	Gly	Ser	Pro	Val	Thr	Ser	Ile	Ser	Ala	Arg	Ser	Trp	
				260					265					270	
Val	Ser	Arg	Glu	Ala	Arg	Asp	Pro	Ser	Leu	Leu	Ile	Asn	Ala	Cys	
				275					280					285	
Leu	Asn	Lys	Leu	Leu	Leu	Tyr	Arg	Val	Val	Asp	Asn	Glu	Gly	Thr	
				290					295					300	
Leu	Gln	Leu	Lys	Arg	Ser	Phe	Pro	Ile	Glu	Gln	Ser	Ser	His	Pro	
				305					310					315	
Val	Arg	Ser	Ile	Phe	Cys	Pro	Leu	Met	Ser	Phe	Arg	Gln	Gly	Ala	
				320					325					330	
Cys	Val	Val	Thr	Gly	Ser	Glu	Asp	Met	Cys	Val	His	Phe	Phe	Asp	
				335					340					345	
Val	Glu	Arg	Ala	Ala	Lys	Ala	Ala	Val	Asn	Lys	Leu	Gln	Gly	His	
				350					355					360	
Ser	Ala	Pro	Val	Leu	Asp	Val	Ser	Phe	Asn	Cys	Asp	Glu	Ser	Leu	
				365					370					375	
Leu	Ala	Ser	Ser	Asp	Ala	Ser	Gly	Met	Val	Ile	Val	Trp	Arg	Arg	
				380					385					390	

Glu Gln Lys

<210> 16

<211> 485

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2216640CD1

<400> 16

Met	Ala	Ala	Ala	Val	Ala	Asp	Glu	Ala	Val	Ala	Arg	Asp	Val	Gln	
1				5					10					15	
Arg	Leu	Leu	Val	Gln	Phe	Gln	Asp	Glu	Gly	Gly	Gln	Leu	Leu	Gly	
				20					25					30	
Ser	Pro	Phe	Asp	Val	Pro	Val	Asp	Ile	Thr	Pro	Asp	Arg	Leu	Gln	
				35					40					45	
Leu	Val	Cys	Asn	Ala	Leu	Leu	Ala	Gln	Glu	Asp	Pro	Leu	Pro	Leu	
				50					55					60	
Ala	Phe	Phe	Val	His	Asp	Ala	Glu	Ile	Val	Ser	Ser	Leu	Gly	Lys	
				65					70					75	
Thr	Leu	Glu	Ser	Gln	Ala	Val	Glu	Thr	Glu	Lys	Val	Leu	Asp	Ile	
				80					85					90	
Ile	Tyr	Gln	Pro	Gln	Ala	Ile	Phe	Arg	Val	Arg	Ala	Val	Thr	Arg	
				95					100					105	
Cys	Thr	Ser	Ser	Leu	Glu	Gly	His	Ser	Glu	Ala	Val	Ile	Ser	Val	
				110					115					120	
Ala	Phe	Ser	Pro	Thr	Gly	Lys	Tyr	Leu	Ala	Ser	Gly	Ser	Gly	Asp	
				125					130					135	
Thr	Thr	Val	Arg	Phe	Trp	Asp	Leu	Ser	Thr	Glu	Thr	Pro	His	Phe	

				140					145					150
Thr	Cys	Lys	Gly	His	Arg	His	Trp	Val	Leu	Ser	Ile	Ser	Trp	Ser
				155					160					165
Pro	Asp	Gly	Lys	Lys	Leu	Ala	Ser	Gly	Cys	Lys	Asn	Gly	Gln	Ile
				170					175					180
Leu	Leu	Trp	Asp	Pro	Ser	Thr	Gly	Lys	Gln	Val	Gly	Arg	Thr	Leu
				185					190					195
Ala	Gly	His	Ser	Lys	Trp	Ile	Thr	Gly	Leu	Ser	Trp	Glu	Pro	Leu
				200					205					210
His	Ala	Asn	Pro	Glu	Cys	Arg	Tyr	Val	Ala	Ser	Ser	Ser	Lys	Asp
				215					220					225
Gly	Ser	Val	Arg	Ile	Trp	Asp	Thr	Thr	Ala	Gly	Arg	Cys	Glu	Arg
				230					235					240
Ile	Leu	Thr	Gly	His	Thr	Gln	Ser	Val	Thr	Cys	Leu	Arg	Trp	Gly
				245					250					255
Gly	Asp	Gly	Leu	Leu	Tyr	Ser	Ala	Ser	Gln	Asp	Arg	Thr	Ile	Lys
				260					265					270
Val	Trp	Arg	Ala	His	Asp	Gly	Val	Leu	Cys	Arg	Thr	Leu	Gln	Gly
				275					280					285
His	Gly	His	Trp	Val	Asn	Thr	Met	Ala	Leu	Ser	Thr	Asp	Tyr	Ala
				290					295					300
Leu	Arg	Thr	Gly	Ala	Phe	Glu	Pro	Ala	Glu	Ala	Ser	Val	Asn	Pro
				305					310					315
Gln	Asp	Leu	Gln	Gly	Ser	Leu	Gln	Glu	Leu	Lys	Glu	Arg	Ala	Leu
				320					325					330
Ser	Arg	Tyr	Asn	Leu	Val	Arg	Gly	Gln	Gly	Pro	Glu	Arg	Leu	Val
				335					340					345
Ser	Gly	Ser	Asp	Asp	Phe	Thr	Leu	Phe	Leu	Trp	Ser	Pro	Ala	Glu
				350					355					360
Asp	Lys	Lys	Pro	Leu	Thr	Arg	Met	Thr	Gly	His	Gln	Ala	Leu	Ile
				365					370					375
Asn	Gln	Val	Leu	Phe	Ser	Pro	Asp	Ser	Arg	Ile	Val	Ala	Ser	Ala
				380					385					390
Ser	Phe	Asp	Lys	Ser	Ile	Lys	Leu	Trp	Asp	Gly	Arg	Thr	Gly	Lys
				395					400					405
Tyr	Leu	Ala	Ser	Leu	Arg	Gly	His	Val	Ala	Ala	Val	Tyr	Gln	Ile
				410					415					420
Ala	Trp	Ser	Ala	Asp	Ser	Arg	Leu	Leu	Val	Ser	Gly	Ser	Ser	Asp
				425					430					435
Ser	Thr	Leu	Lys	Val	Trp	Asp	Val	Lys	Ala	Gln	Lys	Leu	Ala	Met
				440					445					450
Asp	Leu	Pro	Gly	His	Ala	Asp	Glu	Val	Tyr	Ala	Val	Asp	Trp	Ser
				455					460					465
Pro	Asp	Gly	Gln	Arg	Val	Ala	Ser	Gly	Gly	Lys	Asp	Lys	Cys	Leu
				470					475					480
Arg	Ile	Trp	Arg	Arg										
				485										

<210> 17

<211> 199

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2417361CD1

<400> 17

Met	Asn	Pro	Arg	Lys	Lys	Val	Asp	Leu	Lys	Leu	Ile	Ile	Val	Gly
1				5					10					15
Ala	Ile	Gly	Val	Gly	Lys	Thr	Ser	Leu	Leu	His	Gln	Tyr	Val	His
				20					25					30
Lys	Thr	Phe	Tyr	Glu	Glu	Tyr	Gln	Thr	Thr	Leu	Gly	Ala	Ser	Ile
				35					40					45

```

Leu Ser Lys Ile Ile Ile Leu Gly Asp Thr Thr Leu Lys Leu Gln
      50      55      60
Ile Trp Asp Thr Gly Gly Gln Glu Arg Phe Arg Ser Met Val Ser
      65      70      75
Thr Phe Tyr Lys Gly Ser Asp Gly Cys Ile Leu Ala Phe Asp Val
      80      85      90
Thr Asp Leu Glu Ser Phe Glu Ala Leu Asp Ile Trp Arg Gly Asp
      95     100     105
Val Leu Ala Lys Ile Val Pro Met Glu Gln Ser Tyr Pro Met Val
     110     115     120
Leu Leu Gly Asn Lys Ile Asp Leu Ala Asp Arg Lys Val Pro Gln
     125     130     135
Glu Val Ala Gln Gly Trp Cys Arg Glu Lys Asp Ile Pro Tyr Phe
     140     145     150
Glu Val Ser Ala Lys Asn Asp Ile Asn Val Val Gln Ala Phe Glu
     155     160     165
Met Leu Ala Ser Arg Ala Leu Ser Arg Tyr Gln Ser Ile Leu Glu
     170     175     180
Asn His Leu Thr Glu Ser Ile Lys Leu Ser Pro Asp Gln Ser Arg
     185     190     195
Ser Arg Cys Cys

```

<210> 18
 <211> 163
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2454384CD1

```

<400> 18
Met Glu Gly Pro Ser Leu Arg Gly Pro Ala Leu Arg Leu Ala Gly
  1      5      10      15
Leu Pro Thr Gln Gln Asp Cys Asn Ile Gln Glu Lys Ile Asp Leu
      20      25      30
Glu Ile Arg Met Arg Glu Gly Ile Trp Lys Leu Leu Ser Leu Ser
      35      40      45
Thr Gln Lys Asp Gln Val Leu His Ala Val Lys Asn Leu Met Val
      50      55      60
Cys Asn Ala Arg Leu Met Ala Tyr Thr Ser Glu Leu Gln Lys Leu
      65      70      75
Glu Glu Gln Ile Ala Asn Gln Thr Gly Arg Cys Asp Val Lys Phe
      80      85      90
Glu Ser Lys Glu Arg Thr Ala Cys Lys Gly Lys Ile Ala Ile Ser
      95     100     105
Asp Ile Arg Ile Pro Leu Met Trp Lys Asp Ser Asp His Phe Ser
     110     115     120
Asn Lys Glu Arg Ser Arg Arg Tyr Ala Ile Phe Cys Leu Phe Lys
     125     130     135
Met Gly Ala Asn Val Phe Asp Thr Asp Val Val Asn Val Asp Lys
     140     145     150
Thr Ile Thr Asp Ile Cys Phe Glu Asn Val Thr Ile Leu
     155     160

```

<210> 19
 <211> 290
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2610262CD1

<400> 19

```

Met Ala Ala Glu Ile Gln Pro Lys Pro Leu Thr Arg Lys Pro Ile
 1          5          10          15
Leu Leu Gln Arg Met Glu Gly Ser Gln Glu Val Val Asn Met Ala
 20          25          30
Val Ile Val Pro Lys Glu Glu Gly Val Ile Ser Val Ser Glu Asp
 35          40          45
Arg Thr Val Arg Val Trp Leu Lys Arg Asp Ser Gly Gln Tyr Trp
 50          55          60
Pro Ser Val Tyr His Ala Met Pro Ser Pro Cys Ser Cys Met Ser
 65          70          75
Phe Asn Pro Glu Thr Arg Arg Leu Ser Ile Gly Leu Asp Asn Gly
 80          85          90
Thr Ile Ser Glu Phe Ile Leu Ser Glu Asp Tyr Asn Lys Met Thr
 95          100         105
Pro Val Lys Asn Tyr Gln Ala His Gln Ser Arg Val Thr Met Ile
 110         115         120
Leu Phe Val Leu Glu Leu Glu Trp Val Leu Ser Thr Gly Gln Asp
 125         130         135
Lys Gln Phe Ala Trp His Cys Ser Glu Ser Gly Gln Arg Leu Gly
 140         145         150
Gly Tyr Arg Thr Ser Ala Val Ala Ser Gly Leu Gln Phe Asp Val
 155         160         165
Glu Thr Arg His Val Phe Ile Gly Asp His Ser Gly Gln Val Thr
 170         175         180
Ile Leu Lys Leu Glu Gln Glu Asn Cys Thr Leu Val Thr Thr Phe
 185         190         195
Arg Gly His Thr Gly Val Thr Ala Leu Cys Trp Asp Pro Val
 200         205         210
Gln Arg Val Leu Phe Ser Gly Ser Ser Asp His Ser Val Ile Met
 215         220         225
Trp Asp Ile Gly Gly Arg Lys Gly Thr Ala Ile Glu Leu Gln Gly
 230         235         240
His Asn Asp Arg Val Gln Ala Leu Ser Tyr Ala Gln His Thr Arg
 245         250         255
Gln Leu Ile Ser Cys Gly Gly Asp Gly Gly Ile Val Val Trp Asn
 260         265         270
Met Asp Val Glu Arg Gln Glu Pro Leu Trp Ser Cys Phe Val Val
 275         280         285
Met Ile Ser Ala Val
 290

```

<210> 20

<211> 705

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2700075CD1

<400> 20

```

Met Gly Thr Trp Glu His Leu Val Ser Thr Gly Phe Asn Gln Met
 1          5          10          15
Arg Glu Arg Glu Val Lys Leu Trp Asp Thr Arg Phe Phe Ser Ser
 20          25          30
Ala Leu Ala Ser Leu Thr Leu Asp Thr Ser Leu Gly Cys Leu Val
 35          40          45
Pro Leu Leu Asp Pro Asp Ser Gly Leu Leu Val Leu Ala Gly Lys
 50          55          60
Gly Glu Arg Gln Leu Tyr Cys Tyr Glu Val Val Pro Gln Gln Pro
 65          70          75
Ala Leu Ser Pro Val Thr Gln Cys Val Leu Glu Ser Val Leu Arg
 80          85          90

```

Gly	Ala	Ala	Leu	Val	Pro	Arg	Gln	Ala	Leu	Ala	Val	Met	Ser	Cys
			95						100					105
Glu	Val	Leu	Arg	Val	Leu	Gln	Leu	Ser	Asp	Thr	Ala	Ile	Val	Pro
			110						115					120
Ile	Gly	Tyr	His	Val	Pro	Arg	Lys	Ala	Val	Glu	Phe	His	Glu	Asp
			125						130					135
Leu	Phe	Pro	Asp	Thr	Ala	Gly	Cys	Val	Pro	Ala	Thr	Asp	Pro	His
			140						145					150
Ser	Trp	Trp	Ala	Gly	Asp	Asn	Gln	Gln	Val	Gln	Lys	Val	Ser	Leu
			155						160					165
Asn	Pro	Ala	Cys	Arg	Pro	His	Pro	Ser	Phe	Thr	Ser	Cys	Leu	Val
			170						175					180
Pro	Pro	Ala	Glu	Pro	Leu	Pro	Asp	Thr	Ala	Gln	Pro	Ala	Val	Met
			185						190					195
Glu	Thr	Pro	Val	Gly	Asp	Ala	Asp	Ala	Ser	Glu	Gly	Phe	Ser	Ser
			200						205					210
Pro	Pro	Ser	Ser	Leu	Thr	Ser	Pro	Ser	Thr	Pro	Ser	Ser	Leu	Gly
			215						220					225
Pro	Ser	Leu	Ser	Ser	Thr	Ser	Gly	Ile	Gly	Thr	Ser	Pro	Ser	Leu
			230						235					240
Arg	Ser	Leu	Gln	Ser	Leu	Leu	Gly	Pro	Ser	Ser	Lys	Phe	Arg	His
			245						250					255
Ala	Gln	Gly	Thr	Val	Leu	His	Arg	Asp	Ser	His	Ile	Thr	Asn	Leu
			260						265					270
Lys	Gly	Leu	Asn	Leu	Thr	Thr	Pro	Gly	Glu	Ser	Asp	Gly	Phe	Cys
			275						280					285
Ala	Asn	Lys	Leu	Arg	Val	Ala	Val	Pro	Leu	Leu	Ser	Ser	Gly	Gly
			290						295					300
Gln	Val	Ala	Val	Leu	Glu	Leu	Arg	Lys	Pro	Gly	Arg	Leu	Pro	Asp
			305						310					315
Thr	Ala	Leu	Pro	Thr	Leu	Gln	Asn	Gly	Ala	Ala	Val	Thr	Asp	Leu
			320						325					330
Ala	Trp	Asp	Pro	Phe	Asp	Pro	His	Arg	Leu	Ala	Val	Ala	Gly	Glu
			335						340					345
Asp	Ala	Arg	Ile	Arg	Leu	Trp	Arg	Val	Pro	Ala	Glu	Gly	Leu	Glu
			350						355					360
Glu	Val	Leu	Thr	Thr	Pro	Glu	Thr	Val	Leu	Thr	Gly	His	Thr	Glu
			365						370					375
Lys	Ile	Cys	Ser	Leu	Arg	Phe	His	Pro	Leu	Ala	Ala	Asn	Val	Leu
			380						385					390
Ala	Ser	Ser	Ser	Tyr	Asp	Leu	Thr	Val	Arg	Ile	Trp	Asp	Leu	Gln
			395						400					405
Ala	Gly	Ala	Asp	Arg	Leu	Lys	Leu	Gln	Gly	His	Gln	Asp	Gln	Ile
			410						415					420
Phe	Ser	Leu	Ala	Trp	Ser	Pro	Asp	Gly	Gln	Gln	Leu	Ala	Thr	Val
			425						430					435
Cys	Lys	Asp	Gly	Arg	Val	Arg	Val	Tyr	Arg	Pro	Arg	Ser	Gly	Pro
			440						445					450
Glu	Pro	Leu	Gln	Glu	Gly	Pro	Gly	Pro	Lys	Gly	Gly	Arg	Gly	Ala
			455						460					465
Arg	Ile	Val	Trp	Val	Cys	Asp	Gly	Arg	Cys	Leu	Leu	Val	Ser	Gly
			470						475					480
Phe	Asp	Ser	Gln	Ser	Glu	Arg	Gln	Leu	Leu	Leu	Tyr	Glu	Ala	Glu
			485						490					495
Ala	Leu	Ala	Gly	Gly	Pro	Leu	Ala	Val	Leu	Gly	Leu	Asp	Val	Ala
			500						505					510
Pro	Ser	Thr	Leu	Leu	Pro	Ser	Tyr	Asp	Pro	Asp	Thr	Gly	Leu	Val
			515						520					525
Leu	Leu	Thr	Gly	Lys	Gly	Asp	Thr	Arg	Val	Phe	Leu	Tyr	Glu	Leu
			530						535					540
Leu	Pro	Glu	Ser	Pro	Phe	Phe	Leu	Glu	Cys	Asn	Ser	Phe	Thr	Ser
			545						550					555
Pro	Asp	Pro	His	Lys	Gly	Leu	Val	Leu	Leu	Pro	Lys	Thr	Glu	Cys

560	565	570
Asp Val Arg Glu Val Glu Leu Met Arg Cys Leu Arg Leu Arg Gln		
575	580	585
Ser Ser Leu Glu Pro Val Ala Phe Arg Leu Pro Arg Val Arg Lys		
590	595	600
Glu Phe Phe Gln Asp Asp Val Phe Pro Asp Thr Ala Val Ile Trp		
605	610	615
Glu Pro Val Leu Ser Ala Glu Ala Trp Leu Gln Gly Ala Asn Gly		
620	625	630
Gln Pro Trp Leu Leu Ser Leu Gln Pro Pro Asp Met Ser Pro Val		
635	640	645
Ser Gln Ala Pro Arg Glu Ala Pro Ala Arg Arg Ala Pro Ser Ser		
650	655	660
Ala Gln Tyr Leu Glu Glu Lys Ser Asp Gln Gln Lys Lys Glu Glu		
665	670	675
Leu Leu Asn Ala Met Val Ala Lys Leu Gly Asn Arg Glu Asp Pro		
680	685	690
Leu Pro Gln Asp Ser Phe Glu Gly Val Asp Glu Asp Glu Trp Asp		
695	700	705

<210> 21

<211> 454

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2786701CD1

<400> 21

Met Ala Ser Ser Glu Val Ala Arg His Leu Leu Phe Gln Ser His		
1 5 10 15		
Met Ala Thr Lys Thr Cys Met Ser Ser Gln Gly Ser Asp Asp		
20 25 30		
Glu Gln Ile Lys Arg Glu Asn Ile Arg Ser Leu Thr Met Ser Gly		
35 40 45		
His Val Gly Phe Glu Ser Leu Pro Asp Gln Leu Val Asn Arg Ser		
50 55 60		
Ile Gln Gln Gly Phe Cys Phe Asn Ile Leu Cys Val Gly Glu Thr		
65 70 75		
Gly Ile Gly Lys Ser Thr Leu Ile Asp Thr Leu Phe Asn Thr Asn		
80 85 90		
Phe Glu Asp Tyr Glu Ser Ser His Phe Cys Pro Asn Val Lys Leu		
95 100 105		
Lys Ala Gln Thr Tyr Glu Leu Gln Glu Ser Asn Val Gln Leu Lys		
110 115 120		
Leu Thr Ile Val Asn Thr Val Gly Phe Gly Asp Gln Ile Asn Lys		
125 130 135		
Glu Glu Ser Tyr Gln Pro Ile Val Asp Tyr Ile Asp Ala Gln Phe		
140 145 150		
Glu Ala Tyr Leu Gln Glu Glu Leu Lys Ile Lys Arg Ser Leu Phe		
155 160 165		
Thr Tyr His Asp Ser Arg Ile His Val Cys Leu Tyr Phe Ile Ser		
170 175 180		
Pro Thr Gly His Ser Leu Lys Thr Leu Asp Leu Leu Thr Met Lys		
185 190 195		
Asn Leu Asp Ser Lys Val Asn Ile Ile Pro Val Ile Ala Lys Ala		
200 205 210		
Asp Thr Val Ser Lys Thr Glu Leu Gln Lys Phe Lys Ile Lys Leu		
215 220 225		
Met Ser Glu Leu Val Ser Asn Gly Val Gln Ile Tyr Gln Phe Pro		
230 235 240		
Thr Asp Asp Asp Thr Ile Ala Lys Val Asn Ala Ala Met Asn Gly		

	245		250		255
Gln Leu Pro Phe	Ala Val Val Gly Ser	Met Asp Glu Val Lys	Val		
	260		265		270
Gly Asn Lys Met	Val Lys Ala Arg Gln	Tyr Pro Trp Gly Val	Val		
	275		280		285
Gln Val Glu Asn	Glu Asn His Cys Asp	Phe Val Lys Leu Arg	Glu		
	290		295		300
Met Leu Ile Cys	Thr Asn Met Glu Asp	Leu Arg Glu Gln Thr	His		
	305		310		315
Thr Arg His Tyr	Glu Leu Tyr Arg Arg	Cys Lys Leu Glu Glu	Met		
	320		325		330
Gly Phe Thr Asp	Val Gly Pro Glu Asn	Lys Pro Val Ser Val	Gln		
	335		340		345
Glu Thr Tyr Glu	Ala Lys Arg His Glu	Phe His Gly Glu Arg	Gln		
	350		355		360
Arg Lys Glu Glu	Glu Met Lys Gln Met	Phe Val Gln Arg Val	Lys		
	365		370		375
Glu Lys Glu Ala	Ile Leu Lys Glu Ala	Glu Arg Glu Leu Gln	Ala		
	380		385		390
Lys Phe Glu His	Leu Lys Arg Leu His	Gln Glu Glu Arg Met	Lys		
	395		400		405
Leu Glu Glu Lys	Arg Arg Leu Leu Glu	Glu Glu Ile Ile Ala	Phe		
	410		415		420
Ser Lys Lys Lys	Ala Thr Ser Glu Ile	Phe His Ser Gln Ser	Phe		
	425		430		435
Leu Ala Thr Gly	Ser Asn Leu Arg Lys	Asp Lys Asp Arg Lys	Asn		
	440		445		450
Ser Asn Phe Leu					

<210> 22

<211> 433

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3068538CD1

<400> 22

Met Ala Gly Gln Asp	Pro Ala Leu Ser Thr	Ser His Pro Phe Tyr	
1	5	10	15
Asp Val Ala Arg His	Gly Ile Leu Gln Val	Ala Gly Asp Asp Arg	
	20	25	30
Phe Gly Arg Arg Val	Thr Phe Ser Cys	Cys Arg Met Pro Pro	
	35	40	45
Ser His Glu Leu Asp	His Gln Arg Leu Leu	Glu Tyr Leu Lys Tyr	
	50	55	60
Thr Leu Asp Gln Tyr	Val Glu Asn Asp Tyr	Thr Ile Val Tyr Phe	
	65	70	75
His Tyr Gly Leu Asn	Ser Arg Asn Lys Pro	Ser Leu Gly Trp Leu	
	80	85	90
Gln Ser Ala Tyr Lys	Glu Phe Asp Arg Lys	Tyr Lys Lys Asn Leu	
	95	100	105
Lys Ala Leu Tyr Val	Val His Pro Thr Ser	Phe Ile Lys Val Leu	
	110	115	120
Trp Asn Ile Leu Lys	Pro Leu Ile Ser His	Lys Phe Gly Lys Lys	
	125	130	135
Val Ile Tyr Phe Asn	Tyr Leu Ser Glu Leu	His Glu His Leu Lys	
	140	145	150
Tyr Asp Gln Leu Val	Ile Pro Pro Glu Val	Leu Arg Tyr Asp Glu	
	155	160	165
Lys Leu Gln Ser Leu	His Glu Gly Arg Thr	Pro Pro Pro Thr Lys	
	170	175	180

Thr	Pro	Pro	Pro	Arg	Pro	Pro	Leu	Pro	Thr	Gln	Gln	Phe	Gly	Val
				185					190					195
Ser	Leu	Gln	Tyr	Leu	Lys	Asp	Lys	Asn	Gln	Gly	Glu	Leu	Ile	Pro
				200					205					210
Pro	Val	Leu	Arg	Phe	Thr	Val	Thr	Tyr	Leu	Arg	Glu	Lys	Gly	Leu
				215					220					225
Arg	Thr	Glu	Gly	Leu	Phe	Arg	Arg	Ser	Ala	Ser	Val	Gln	Thr	Val
				230					235					240
Arg	Glu	Ile	Gln	Arg	Leu	Tyr	Asn	Gln	Gly	Lys	Pro	Val	Asn	Phe
				245					250					255
Asp	Asp	Tyr	Gly	Asp	Ile	His	Ile	Pro	Ala	Val	Ile	Leu	Lys	Thr
				260					265					270
Phe	Leu	Arg	Glu	Leu	Pro	Gln	Pro	Leu	Leu	Thr	Phe	Gln	Ala	Tyr
				275					280					285
Glu	Gln	Ile	Leu	Gly	Ile	Thr	Cys	Val	Glu	Ser	Ser	Leu	Arg	Val
				290					295					300
Thr	Gly	Cys	Arg	Gln	Ile	Leu	Arg	Ser	Leu	Pro	Glu	His	Asn	Tyr
				305					310					315
Val	Val	Leu	Arg	Tyr	Leu	Met	Gly	Phe	Leu	His	Ala	Val	Ser	Arg
				320					325					330
Glu	Ser	Ile	Phe	Asn	Lys	Met	Asn	Ser	Ser	Asn	Leu	Ala	Cys	Val
				335					340					345
Phe	Gly	Leu	Asn	Leu	Ile	Trp	Pro	Ser	Gln	Gly	Val	Ser	Ser	Leu
				350					355					360
Ser	Ala	Leu	Val	Pro	Leu	Asn	Met	Phe	Thr	Glu	Leu	Leu	Ile	Glu
				365					370					375
Tyr	Tyr	Glu	Lys	Ile	Phe	Ser	Thr	Pro	Glu	Ala	Pro	Gly	Glu	His
				380					385					390
Gly	Leu	Ala	Pro	Trp	Glu	Gln	Gly	Ser	Arg	Ala	Ala	Pro	Leu	Gln
				395					400					405
Glu	Ala	Val	Pro	Arg	Thr	Gln	Ala	Thr	Gly	Leu	Thr	Lys	Pro	Thr
				410					415					420
Leu	Pro	Pro	Ser	Pro	Leu	Met	Ala	Ala	Arg	Arg	Arg	Leu		
				425					430					

<210> 23

<211> 406

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5159072CD1

<400> 23

Met	Ala	Asp	Gly	Asn	Glu	Asp	Leu	Arg	Ala	Asp	Asp	Leu	Pro	Gly
1				5					10					15
Pro	Ala	Phe	Glu	Ser	Tyr	Glu	Ser	Met	Glu	Leu	Ala	Cys	Pro	Ala
				20					25					30
Glu	Arg	Ser	Gly	His	Val	Ala	Val	Ser	Asp	Gly	Arg	His	Met	Phe
				35					40					45
Val	Trp	Gly	Gly	Tyr	Lys	Ser	Asn	Gln	Val	Arg	Gly	Leu	Tyr	Asp
				50					55					60
Phe	Tyr	Leu	Pro	Arg	Glu	Glu	Leu	Trp	Ile	Tyr	Asn	Met	Glu	Thr
				65					70					75
Gly	Arg	Trp	Lys	Lys	Ile	Asn	Thr	Glu	Gly	Asp	Val	Pro	Pro	Ser
				80					85					90
Met	Ser	Gly	Ser	Cys	Ala	Val	Cys	Val	Asp	Arg	Val	Leu	Tyr	Leu
				95					100					105
Phe	Gly	Gly	His	His	Ser	Arg	Gly	Asn	Thr	Asn	Lys	Phe	Tyr	Met
				110					115					120
Leu	Asp	Ser	Arg	Ser	Thr	Asp	Arg	Val	Leu	Gln	Trp	Glu	Arg	Ile
				125					130					135
Asp	Cys	Gln	Gly	Ile	Pro	Pro	Ser	Ser	Lys	Asp	Lys	Leu	Gly	Val

	140		145		150
Trp Val Tyr Lys	Asn Lys Leu Ile Phe	Phe Gly Gly Tyr Gly Tyr			
	155		160		165
Leu Pro Glu Asp	Lys Val Leu Gly Thr	Phe Glu Phe Asp Glu Thr			
	170		175		180
Ser Phe Trp Asn	Ser Ser His Pro Arg	Gly Trp Asn Asp His Val			
	185		190		195
His Ile Leu Asp	Thr Glu Thr Phe Thr	Trp Ser Gln Pro Ile Thr			
	200		205		210
Thr Gly Lys Ala	Pro Ser Pro Arg Ala	Ala His Ala Cys Ala Thr			
	215		220		225
Val Gly Asn Arg	Gly Phe Val Phe Gly	Gly Arg Tyr Arg Asp Ala			
	230		235		240
Arg Met Asn Asp	Leu His Tyr Leu Asn	Leu Asp Thr Trp Glu Trp			
	245		250		255
Asn Glu Leu Ile	Pro Gln Gly Ile Cys	Pro Val Gly Arg Ser Trp			
	260		265		270
His Ser Leu Thr	Pro Val Ser Ser Asp	His Leu Phe Leu Phe Gly			
	275		280		285
Gly Phe Thr Thr	Asp Lys Gln Pro Leu	Ser Asp Ala Trp Thr Tyr			
	290		295		300
Cys Ile Ser Lys	Asn Glu Trp Ile Gln	Phe Asn His Pro Tyr Thr			
	305		310		315
Glu Lys Pro Arg	Leu Trp His Thr Ala	Cys Ala Ser Asp Glu Gly			
	320		325		330
Glu Val Ile Val	Phe Gly Gly Cys Ala	Asn Asn Leu Leu Val His			
	335		340		345
His Arg Ala Ala	His Ser Asn Glu Ile	Leu Ile Phe Ser Val Gln			
	350		355		360
Pro Lys Ser Leu	Val Arg Leu Ser Leu	Glu Ala Val Ile Cys Phe			
	365		370		375
Lys Glu Met Leu	Ala Asn Ser Trp Asn	Cys Leu Pro Lys His Leu			
	380		385		390
Leu His Ser Val	Asn Gln Arg Phe Gly	Ser Asn Asn Thr Ser Gly			
	395		400		405

Ser

<210> 24

<211> 229

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5519057CD1

<400> 24

Met Ala Glu Glu Met	Glu Ser Ser Leu Glu Ala Ser Phe Ser Ser
1	5 10 15
Ser Gly Ala Val Ser	Gly Ala Ser Gly Phe Leu Pro Pro Ala Arg
	20 25 30
Ser Arg Ile Phe Lys	Ile Ile Val Ile Gly Asp Ser Asn Val Gly
	35 40 45
Lys Thr Cys Leu Thr	Tyr Arg Phe Cys Ala Gly Arg Phe Pro Asp
	50 55 60
Arg Thr Glu Ala Thr	Ile Gly Val Asp Phe Arg Glu Arg Ala Val
	65 70 75
Glu Ile Asp Gly Glu	Arg Ile Lys Ile Gln Leu Trp Asp Thr Ala
	80 85 90
Gly Gln Glu Arg Phe	Arg Lys Ser Met Val Gln His Tyr Tyr Arg
	95 100 105
Asn Val His Ala Val	Val Phe Val Tyr Asp Met Thr Asn Met Ala
	110 115 120

Ser	Phe	His	Ser	Leu	Pro	Ser	Trp	Ile	Glu	Glu	Cys	Lys	Gln	His
				125					130					135
Leu	Leu	Ala	Asn	Asp	Ile	Pro	Arg	Ile	Leu	Val	Gly	Asn	Lys	Cys
				140					145					150
Asp	Leu	Arg	Ser	Ala	Ile	Gln	Val	Pro	Thr	Asp	Leu	Ala	Gln	Lys
				155					160					165
Phe	Ala	Asp	Thr	His	Ser	Met	Pro	Leu	Phe	Glu	Thr	Ser	Ala	Lys
				170					175					180
Asn	Pro	Asn	Asp	Asn	Asp	His	Val	Glu	Ala	Ile	Phe	Met	Thr	Leu
				185					190					195
Ala	His	Lys	Leu	Lys	Cys	His	Lys	Pro	Leu	Met	Leu	Ser	Gln	Pro
				200					205					210
Pro	Asp	Asn	Gly	Ile	Ile	Leu	Lys	Pro	Glu	Pro	Lys	Pro	Ala	Met
				215					220					225

Thr Cys Trp Cys

<210> 25

<211> 670

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 035379CD1

<400> 25

Met	Ser	Ser	Gly	Lys	Ser	Ala	Arg	Tyr	Asn	Arg	Phe	Ser	Gly	Gly
1				5					10					15
Pro	Ser	Asn	Leu	Pro	Thr	Pro	Asp	Val	Thr	Thr	Gly	Thr	Arg	Met
				20					25					30
Glu	Thr	Thr	Phe	Gly	Pro	Ala	Phe	Ser	Ala	Val	Thr	Thr	Ile	Thr
				35					40					45
Lys	Ala	Asp	Gly	Thr	Ser	Thr	Tyr	Lys	Gln	His	Cys	Arg	Thr	Pro
				50					55					60
Ser	Ser	Ser	Ser	Thr	Leu	Ala	Tyr	Ser	Pro	Arg	Asp	Glu	Glu	Asp
				65					70					75
Ser	Met	Pro	Pro	Ile	Ser	Thr	Pro	Arg	Arg	Ser	Asp	Ser	Ala	Ile
				80					85					90
Ser	Val	Arg	Ser	Leu	His	Ser	Glu	Ser	Ser	Met	Ser	Leu	Arg	Ser
				95					100					105
Thr	Phe	Ser	Leu	Pro	Glu	Glu	Glu	Glu	Glu	Pro	Glu	Pro	Leu	Val
				110					115					120
Phe	Ala	Glu	Gln	Pro	Ser	Val	Lys	Leu	Cys	Cys	Gln	Leu	Cys	Cys
				125					130					135
Ser	Val	Phe	Lys	Asp	Pro	Val	Ile	Thr	Thr	Cys	Gly	His	Thr	Phe
				140					145					150
Cys	Arg	Arg	Cys	Ala	Leu	Lys	Ser	Glu	Lys	Cys	Pro	Val	Asp	Asn
				155					160					165
Val	Lys	Leu	Thr	Val	Val	Val	Asn	Asn	Ile	Ala	Val	Ala	Glu	Gln
				170					175					180
Ile	Gly	Glu	Leu	Phe	Ile	His	Cys	Arg	His	Gly	Cys	Arg	Val	Ala
				185					190					195
Gly	Ser	Gly	Lys	Pro	Pro	Ile	Phe	Glu	Val	Asp	Pro	Arg	Gly	Cys
				200					205					210
Pro	Phe	Thr	Ile	Lys	Leu	Ser	Ala	Arg	Lys	Asp	His	Glu	Gly	Ser
				215					220					225
Cys	Asp	Tyr	Arg	Pro	Val	Arg	Cys	Pro	Asn	Asn	Pro	Ser	Cys	Pro
				230					235					240
Pro	Leu	Leu	Arg	Met	Asn	Leu	Glu	Ala	His	Leu	Lys	Glu	Cys	Glu
				245					250					255
His	Ile	Lys	Cys	Pro	His	Ser	Lys	Tyr	Gly	Cys	Thr	Phe	Ile	Gly
				260					265					270
Asn	Gln	Asp	Thr	Tyr	Glu	Thr	His	Leu	Glu	Thr	Cys	Arg	Phe	Glu

	275		280		285
Gly Leu Lys Glu Phe Leu Gln Gln Thr	290	Asp Asp Arg Phe His	295	Glu	300
Met His Val Ala Leu Ala Gln Lys Asp	305	Gln Glu Ile Ala Phe	310	Leu	315
Arg Ser Met Leu Gly Lys Leu Ser Glu	320	Lys Ile Asp Gln Leu	325	Glu	330
Lys Ser Leu Glu Leu Lys Phe Asp Val	335	Leu Asp Glu Asn Gln	340	Ser	345
Lys Leu Ser Glu Asp Leu Met Glu Phe	350	Arg Arg Asp Ala Ser	355	Met	360
Leu Asn Asp Glu Leu Ser His Ile Asn	365	Ala Arg Leu Asn Met	370	Gly	375
Ile Leu Gly Ser Tyr Asp Pro Gln Gln	380	Ile Phe Lys Cys Lys	385	Gly	390
Thr Phe Val Gly His Gln Gly Pro Val	395	Trp Cys Leu Cys Val	400	Tyr	405
Ser Met Gly Asp Leu Leu Phe Ser Gly	410	Ser Ser Asp Lys Thr	415	Ile	420
Lys Val Trp Asp Thr Cys Thr Thr Tyr	425	Lys Cys Gln Lys Thr	430	Leu	435
Glu Gly His Asp Gly Ile Val Leu Ala	440	Leu Cys Ile Gln Gly	445	Cys	450
Lys Leu Tyr Ser Gly Ser Ala Asp Cys	455	Thr Ile Ile Val Trp	460	Asp	465
Ile Gln Asn Leu Gln Lys Val Asn Thr	470	Ile Arg Ala His Asp	475	Asn	480
Pro Val Cys Thr Leu Val Ser Ser His	485	Asn Val Leu Phe Ser	490	Gly	495
Ser Leu Lys Ala Ile Lys Val Trp Asp	500	Ile Val Gly Thr Glu	505	Leu	510
Lys Leu Lys Lys Glu Leu Thr Gly Leu	515	Asn His Trp Val Arg	520	Ala	525
Leu Val Ala Ala Gln Ser Tyr Leu Tyr	530	Ser Gly Ser Tyr Gln	535	Thr	540
Ile Lys Ile Trp Asp Ile Arg Thr Leu	545	Asp Cys Ile His Val	550	Leu	555
Gln Thr Ser Gly Gly Ser Val Tyr Ser	560	Ile Ala Val Thr Asn	565	His	570
His Ile Val Cys Gly Thr Tyr Glu Asn	575	Leu Ile His Val Trp	580	Asp	585
Ile Glu Ser Lys Glu Gln Val Arg Thr	590	Leu Thr Gly His Val	595	Gly	600
Thr Val Tyr Ala Leu Ala Val Ile Ser	605	Thr Pro Asp Gln Thr	610	Lys	615
Val Phe Ser Ala Ser Tyr Asp Arg Ser	620	Leu Arg Val Trp Ser	625	Met	630
Asp Asn Met Ile Cys Thr Gln Thr Leu	635	Leu Arg His Gln Ser	640	Ser	645
Val Thr Ala Leu Ala Val Ser Arg Gly	650	Arg Leu Phe Ser Gly	655	Ala	660
Val Asp Ser Thr Val Lys Val Trp Thr	665	Cys	670		

<210> 26

<211> 445

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 275354CD1

<400> 26

Met	Lys	Val	Lys	Met	Leu	Ser	Arg	Asn	Pro	Asp	Asn	Tyr	Val	Arg
1				5					10					15
Glu	Thr	Lys	Leu	Asp	Leu	Gln	Arg	Val	Pro	Arg	Asn	Tyr	Asp	Pro
				20					25					30
Ala	Leu	His	Pro	Phe	Glu	Val	Pro	Arg	Glu	Tyr	Val	Arg	Ala	Leu
				35					40					45
Asn	Ala	Thr	Lys	Leu	Glu	Arg	Val	Phe	Ala	Lys	Pro	Phe	Leu	Ala
				50					55					60
Ser	Leu	Asp	Gly	His	Arg	Asp	Gly	Val	Asn	Cys	Leu	Ala	Lys	His
				65					70					75
Pro	Glu	Lys	Leu	Ala	Thr	Val	Leu	Ser	Gly	Ala	Cys	Asp	Gly	Glu
				80					85					90
Val	Arg	Ile	Trp	Asn	Leu	Thr	Gln	Arg	Asn	Cys	Ile	Arg	Thr	Ile
				95					100					105
Gln	Ala	His	Glu	Gly	Phe	Val	Arg	Gly	Ile	Cys	Thr	Arg	Phe	Cys
				110					115					120
Gly	Thr	Ser	Phe	Phe	Thr	Val	Gly	Asp	Asp	Lys	Thr	Val	Lys	Gln
				125					130					135
Trp	Lys	Met	Asp	Gly	Pro	Gly	Tyr	Gly	Asp	Glu	Glu	Glu	Pro	Leu
				140					145					150
His	Thr	Ile	Leu	Gly	Lys	Thr	Val	Tyr	Thr	Gly	Ile	Asp	His	His
				155					160					165
Trp	Lys	Glu	Ala	Val	Phe	Ala	Thr	Cys	Gly	Gln	Gln	Val	Asp	Ile
				170					175					180
Trp	Asp	Glu	Gln	Arg	Thr	Asn	Pro	Ile	Cys	Ser	Met	Thr	Trp	Gly
				185					190					195
Phe	Asp	Ser	Ile	Ser	Ser	Val	Lys	Phe	Asn	Pro	Ile	Glu	Thr	Phe
				200					205					210
Leu	Leu	Gly	Ser	Cys	Ala	Ser	Asp	Arg	Asn	Ile	Val	Leu	Tyr	Asp
				215					220					225
Met	Arg	Gln	Ala	Thr	Pro	Leu	Lys	Lys	Val	Ile	Leu	Asp	Met	Arg
				230					235					240
Thr	Asn	Thr	Ile	Cys	Trp	Asn	Pro	Met	Glu	Ala	Phe	Ile	Phe	Thr
				245					250					255
Ala	Ala	Asn	Glu	Asp	Tyr	Asn	Leu	Tyr	Thr	Phe	Asp	Met	Arg	Ala
				260					265					270
Leu	Asp	Thr	Pro	Val	Met	Val	His	Met	Asp	His	Val	Ser	Ala	Val
				275					280					285
Leu	Asp	Val	Asp	Tyr	Ser	Pro	Thr	Gly	Lys	Glu	Phe	Val	Ser	Ala
				290					295					300
Ser	Phe	Asp	Lys	Ser	Ile	Arg	Ile	Phe	Pro	Val	Asp	Lys	Ser	Arg
				305					310					315
Ser	Arg	Glu	Val	Tyr	His	Thr	Lys	Arg	Met	Gln	His	Val	Ile	Cys
				320					325					330
Val	Lys	Trp	Thr	Ser	Asp	Ser	Lys	Tyr	Ile	Met	Cys	Gly	Ser	Asp
				335					340					345
Glu	Met	Asn	Ile	Arg	Leu	Trp	Lys	Ala	Asn	Ala	Ser	Glu	Lys	Leu
				350					355					360
Gly	Val	Leu	Thr	Ser	Arg	Glu	Lys	Ala	Ala	Lys	Asp	Tyr	Asn	Gln
				365					370					375
Lys	Leu	Lys	Glu	Lys	Phe	Gln	His	Tyr	Pro	His	Ile	Lys	Arg	Ile
				380					385					390
Ala	Arg	His	Arg	His	Leu	Pro	Lys	Ser	Ile	Tyr	Ser	Gln	Ile	Gln
				395					400					405
Glu	Gln	Arg	Ile	Met	Lys	Glu	Ala	Arg	Arg	Arg	Lys	Glu	Val	Asn
				410					415					420
Arg	Ile	Lys	His	Ser	Lys	Pro	Gly	Ser	Val	Pro	Leu	Val	Ser	Glu
				425					430					435
Lys	Lys	Lys	His	Val	Val	Ala	Val	Val	Lys					
				440					445					

<210> 27
 <211> 236
 <212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 311658CD1

<400> 27

Met	Ser	Asp	Leu	Leu	Ser	Pro	Leu	Leu	Tyr	Val	Met	Glu	Asn	Glu	1	5	10	15
Val	Asp	Ala	Phe	Trp	Cys	Phe	Ala	Ser	Tyr	Met	Asp	Gln	Met	His	20	25	30	35
Gln	Asn	Phe	Glu	Glu	Gln	Met	Gln	Gly	Met	Lys	Thr	Gln	Leu	Ile	40	45	50	55
Gln	Leu	Ser	Thr	Leu	Leu	Arg	Leu	Leu	Asp	Ser	Gly	Phe	Cys	Ser	60	65	70	75
Tyr	Leu	Glu	Ser	Gln	Asp	Ser	Gly	Tyr	Leu	Tyr	Phe	Cys	Phe	Arg	80	85	90	95
Trp	Leu	Leu	Ile	Arg	Phe	Lys	Arg	Glu	Phe	Ser	Phe	Leu	Asp	Ile	100	105	110	115
Leu	Arg	Leu	Trp	Glu	Val	Met	Trp	Thr	Glu	Leu	Pro	Cys	Thr	Asn	120	125	130	135
Phe	His	Leu	Leu	Leu	Cys	Cys	Ala	Ile	Leu	Glu	Ser	Glu	Lys	Gln	140	145	150	155
Gln	Ile	Met	Glu	Lys	His	Tyr	Gly	Phe	Asn	Glu	Ile	Leu	Lys	His	160	165	170	175
Ile	Asn	Glu	Leu	Ser	Met	Lys	Ile	Asp	Val	Glu	Asp	Ile	Leu	Cys	180	185	190	195
Lys	Ala	Glu	Ala	Ile	Ser	Leu	Gln	Met	Val	Lys	Cys	Lys	Glu	Leu	200	205	210	215
Pro	Gln	Ala	Val	Cys	Glu	Ile	Leu	Gly	Leu	Gln	Gly	Ser	Glu	Val	220	225	230	235
Thr	Thr	Pro	Asp	Ser	Asp	Val	Gly	Glu	Asp	Glu	Asn	Val	Val	Met				
Thr	Pro	Cys	Pro	Thr	Ser	Ala	Phe	Gln	Ser	Asn	Ala	Leu	Pro	Thr				
Leu	Ser	Ala	Ser	Gly	Ala	Arg	Asn	Asp	Ser	Pro	Thr	Gln	Ile	Pro				
Val	Ser	Ser	Asp	Val	Cys	Arg	Leu	Thr	Pro	Ala								

<210> 28

<211> 498

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1251632CD1

<400> 28

Met	Gln	Glu	Ser	Gly	Cys	Arg	Leu	Glu	His	Pro	Ser	Ala	Thr	Lys	1	5	10	15
Phe	Arg	Asn	His	Val	Met	Glu	Gly	Asp	Trp	Asp	Lys	Ala	Glu	Asn	20	25	30	35
Asp	Leu	Asn	Glu	Leu	Lys	Pro	Leu	Val	His	Ser	Pro	His	Ala	Ile	40	45	50	55
Val	Arg	Met	Lys	Phe	Leu	Leu	Leu	Gln	Gln	Lys	Tyr	Leu	Glu	Tyr	60	65	70	75
Leu	Glu	Asp	Gly	Lys	Val	Leu	Glu	Ala	Leu	Gln	Val	Leu	Arg	Cys	80	85	90	95
Glu	Leu	Thr	Pro	Leu	Lys	Tyr	Asn	Thr	Glu	Arg	Ile	His	Val	Leu				
Ser	Gly	Tyr	Leu	Met	Cys	Ser	His	Ala	Glu	Asp	Leu	Arg	Ala	Lys				

Ala	Glu	Trp	Glu	Gly	Lys	Gly	Thr	Ala	Ser	Arg	Ser	Lys	Leu	Leu
				110					115					120
Asp	Lys	Leu	Gln	Thr	Tyr	Leu	Pro	Pro	Ser	Val	Met	Leu	Pro	Pro
				125					130					135
Arg	Arg	Leu	Gln	Thr	Leu	Leu	Arg	Gln	Ala	Val	Glu	Leu	Gln	Arg
				140					145					150
Asp	Arg	Cys	Leu	Tyr	His	Asn	Thr	Lys	Leu	Asp	Asn	Asn	Leu	Asp
				155					160					165
Ser	Val	Ser	Leu	Leu	Ile	Asp	His	Val	Cys	Ser	Arg	Arg	Gln	Phe
				170					175					180
Pro	Cys	Tyr	Thr	Gln	Gln	Ile	Leu	Thr	Glu	His	Cys	Asn	Glu	Val
				185					190					195
Trp	Phe	Cys	Lys	Phe	Ser	Asn	Asp	Gly	Thr	Lys	Leu	Ala	Thr	Gly
				200					205					210
Ser	Lys	Asp	Thr	Thr	Val	Ile	Ile	Trp	Gln	Val	Asp	Pro	Asp	Thr
				215					220					225
His	Leu	Leu	Lys	Leu	Leu	Lys	Thr	Leu	Glu	Gly	His	Ala	Tyr	Gly
				230					235					240
Val	Ser	Tyr	Ile	Ala	Trp	Ser	Pro	Asp	Asp	Asn	Tyr	Leu	Val	Ala
				245					250					255
Cys	Gly	Pro	Asp	Asp	Cys	Ser	Glu	Leu	Trp	Leu	Trp	Asn	Val	Gln
				260					265					270
Thr	Gly	Glu	Leu	Arg	Thr	Lys	Met	Ser	Gln	Ser	His	Glu	Asp	Ser
				275					280					285
Leu	Thr	Ser	Val	Ala	Trp	Asn	Pro	Asp	Gly	Lys	Arg	Phe	Val	Thr
				290					295					300
Gly	Gly	Gln	Arg	Gly	Gln	Phe	Tyr	Gln	Cys	Asp	Leu	Asp	Gly	Asn
				305					310					315
Leu	Leu	Asp	Ser	Trp	Glu	Gly	Val	Arg	Val	Gln	Cys	Leu	Trp	Cys
				320					325					330
Leu	Ser	Asp	Gly	Lys	Thr	Val	Leu	Ala	Ser	Asp	Thr	His	Gln	Arg
				335					340					345
Ile	Arg	Gly	Tyr	Asn	Phe	Glu	Asp	Leu	Thr	Asp	Arg	Asn	Ile	Val
				350					355					360
Gln	Glu	Asp	His	Pro	Ile	Met	Ser	Phe	Thr	Ile	Ser	Lys	Asn	Gly
				365					370					375
Arg	Leu	Ala	Leu	Leu	Asn	Val	Ala	Thr	Gln	Gly	Val	His	Leu	Trp
				380					385					390
Asp	Leu	Gln	Asp	Arg	Val	Leu	Val	Arg	Lys	Tyr	Gln	Gly	Val	Thr
				395					400					405
Gln	Gly	Phe	Tyr	Thr	Ile	His	Ser	Cys	Phe	Gly	Gly	His	Asn	Glu
				410					415					420
Asp	Phe	Ile	Ala	Ser	Gly	Ser	Glu	Asp	His	Lys	Val	Tyr	Ile	Trp
				425					430					435
His	Lys	Arg	Ser	Glu	Leu	Pro	Ile	Ala	Glu	Leu	Thr	Gly	His	Thr
				440					445					450
Arg	Thr	Val	Asn	Cys	Val	Ser	Trp	Asn	Pro	Gln	Ile	Pro	Ser	Met
				455					460					465
Met	Ala	Ser	Ala	Ser	Asp	Asp	Gly	Thr	Val	Arg	Ile	Trp	Gly	Pro
				470					475					480
Ala	Pro	Phe	Ile	Asp	His	Gln	Asn	Ile	Glu	Glu	Glu	Cys	Ser	Ser
				485					490					495

Met Asp Ser

<210> 29

<211> 334

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1331955CD1

<400> 29

```

Met Ala Thr Glu Glu Lys Lys Pro Glu Thr Glu Ala Ala Arg Ala
 1          5          10          15
Gln Pro Thr Pro Ser Ser Ser Ala Thr Gln Ser Lys Pro Thr Pro
          20          25          30
Val Lys Pro Asn Tyr Ala Leu Lys Phe Thr Leu Ala Gly His Thr
          35          40          45
Lys Ala Val Ser Ser Val Lys Phe Ser Pro Asn Gly Glu Trp Leu
          50          55          60
Ala Ser Ser Ser Ala Asp Lys Leu Ile Lys Ile Trp Gly Ala Tyr
          65          70          75
Asp Gly Lys Phe Glu Lys Thr Ile Ser Gly His Lys Leu Gly Ile
          80          85          90
Ser Asp Val Ala Trp Ser Ser Asp Ser Asn Leu Leu Val Ser Ala
          95          100          105
Ser Asp Asp Lys Thr Leu Lys Ile Trp Asp Val Ser Ser Gly Lys
          110          115          120
Cys Leu Lys Thr Leu Lys Gly His Ser Asn Tyr Val Phe Cys Cys
          125          130          135
Asn Phe Asn Pro Gln Ser Asn Leu Ile Val Ser Gly Ser Phe Asp
          140          145          150
Glu Ser Val Arg Ile Trp Asp Val Lys Thr Gly Lys Cys Leu Lys
          155          160          165
Thr Leu Pro Ala His Ser Asp Pro Val Ser Ala Val His Phe Asn
          170          175          180
Arg Asp Gly Ser Leu Ile Val Ser Ser Ser Tyr Asp Gly Leu Cys
          185          190          195
Arg Ile Trp Asp Thr Ala Ser Gly Gln Cys Leu Lys Thr Leu Ile
          200          205          210
Asp Asp Asp Asn Pro Pro Val Ser Phe Val Lys Phe Ser Pro Asn
          215          220          225
Gly Lys Tyr Ile Leu Ala Ala Thr Leu Asp Asn Thr Leu Lys Leu
          230          235          240
Trp Asp Tyr Ser Lys Gly Lys Cys Leu Lys Thr Tyr Thr Gly His
          245          250          255
Lys Asn Glu Lys Tyr Cys Ile Phe Ala Asn Phe Ser Val Thr Gly
          260          265          270
Gly Lys Trp Ile Val Ser Gly Ser Glu Asp Asn Leu Val Tyr Ile
          275          280          285
Trp Asn Leu Gln Thr Lys Glu Ile Val Gln Lys Leu Gln Gly His
          290          295          300
Thr Asp Val Val Ile Ser Thr Ala Cys His Pro Thr Glu Asn Ile
          305          310          315
Ile Ala Ser Ala Ala Leu Glu Asn Asp Lys Thr Ile Lys Leu Trp
          320          325          330
Lys Ser Asp Cys

```

<210> 30

<211> 292

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1412614CD1

<400> 30

```

Met Met Ala Phe Ala Pro Pro Lys Asn Thr Asp Gly Pro Lys Met
 1          5          10          15
Gln Thr Lys Met Ser Thr Trp Thr Pro Leu Asn His Gln Leu Leu
          20          25          30
Asn Asp Arg Val Phe Glu Glu Arg Arg Ala Leu Leu Gly Lys Trp
          35          40          45

```

```

Phe Asp Lys Trp Thr Asp Ser Gln Arg Arg Arg Ile Leu Thr Gly
      50      55      60
Leu Leu Glu Arg Cys Ser Leu Ser Gln Gln Lys Phe Cys Cys Arg
      65      70      75
Lys Leu Gln Glu Lys Ile Pro Ala Glu Ala Leu Asp Phe Thr Thr
      80      85      90
Lys Leu Pro Arg Val Leu Ser Leu Tyr Ile Phe Ser Phe Leu Asp
      95     100     105
Pro Arg Ser Leu Cys Arg Cys Ala Gln Val Cys Trp His Trp Lys
     110     115     120
Asn Leu Ala Glu Leu Asp Gln Leu Trp Met Leu Lys Cys Leu Arg
     125     130     135
Phe Asn Trp Tyr Ile Asn Phe Ser Pro Thr Pro Phe Glu Gln Gly
     140     145     150
Ile Trp Lys Lys His Tyr Ile Gln Met Val Lys Glu Leu His Ile
     155     160     165
Thr Lys Pro Lys Thr Pro Pro Lys Asp Gly Phe Val Ile Ala Asp
     170     175     180
Val Gln Leu Val Thr Ser Asn Ser Pro Glu Glu Lys Gln Ser Pro
     185     190     195
Leu Ser Ala Phe Arg Ser Ser Ser Ser Leu Arg Lys Lys Asn Asn
     200     205     210
Ser Gly Glu Lys Ala Leu Pro Pro Trp Arg Ser Ser Asp Lys His
     215     220     225
Pro Thr Asp Ile Ile Arg Phe Asn Tyr Leu Asp Asn Arg Asp Pro
     230     235     240
Met Glu Thr Val Gln Gln Gly Arg Arg Lys Arg Asn Gln Ile Thr
     245     250     255
Pro Asp Phe Ser Arg Gln Ser His Asp Lys Lys Asn Lys Leu Gln
     260     265     270
Asp Arg Thr Arg Leu Arg Lys Ala Gln Ser Met Met Ser Arg Arg
     275     280     285
Asn Pro Phe Pro Leu Cys Pro
     290

```

<210> 31

<211> 588

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1750781CD1

<400> 31

```

Met Ser Ser Gly Leu Arg Ala Ala Asp Phe Pro Arg Trp Lys Arg
  1      5      10
His Ile Ser Glu Gln Leu Arg Arg Arg Asp Arg Leu Gln Arg Gln
     20      25      30
Ala Phe Glu Glu Ile Leu Gln Tyr Asn Lys Leu Leu Glu Lys
     35      40      45
Ser Asp Leu His Ser Val Leu Ala Gln Lys Leu Gln Ala Glu Lys
     50      55      60
His Asp Val Pro Asn Arg His Glu Ile Ser Pro Gly His Asp Gly
     65      70      75
Thr Trp Asn Asp Asn Gln Leu Gln Glu Met Ala Gln Leu Arg Ile
     80      85      90
Lys His Gln Glu Glu Leu Thr Glu Leu His Lys Lys Arg Gly Glu
     95     100     105
Leu Ala Gln Leu Val Ile Asp Leu Asn Asn Gln Met Gln Arg Lys
    110     115     120
Asp Arg Glu Met Gln Met Asn Glu Ala Lys Ile Ala Glu Cys Leu
    125     130     135
Gln Thr Ile Ser Asp Leu Glu Thr Glu Cys Leu Asp Leu Arg Thr

```


	140		145		150
Lys Leu Cys Asp	Leu Glu Arg Ala Asn	Gln Thr Leu Lys Asp	Glu		
	155		160		165
Tyr Asp Ala Leu	Gln Ile Thr Phe Thr	Ala Leu Glu Gly Lys	Leu		
	170		175		180
Arg Lys Thr Thr	Glu Asn Gln Glu	Leu Val Thr Arg Trp	Met		
	185		190		195
Ala Glu Lys Ala	Gln Glu Ala Asn Arg	Leu Asn Ala Glu Asn	Glu		
	200		205		210
Lys Asp Ser Arg	Arg Arg Gln Ala Arg	Leu Gln Lys Glu Leu	Ala		
	215		220		225
Glu Ala Ala Lys	Glu Pro Leu Pro Val	Glu Gln Asp Asp Asp	Ile		
	230		235		240
Glu Val Ile Val	Asp Glu Thr Ser Asp	His Thr Glu Glu Thr	Ser		
	245		250		255
Pro Val Arg Ala	Ile Ser Arg Ala Ala	Thr Arg Arg Ser Val	Ser		
	260		265		270
Ser Phe Pro Val	Pro Gln Asp Asn Val	Asp Thr His Pro Gly	Ser		
	275		280		285
Gly Lys Glu Val	Arg Val Pro Ala Thr	Ala Leu Cys Val Phe	Asp		
	290		295		300
Ala His Asp Gly	Glu Val Asn Ala Val	Gln Phe Ser Pro Gly	Ser		
	305		310		315
Arg Leu Leu Ala	Thr Gly Gly Met Asp	Arg Arg Val Lys Leu	Trp		
	320		325		330
Glu Val Phe Gly	Glu Lys Cys Glu Phe	Lys Gly Ser Leu Ser	Gly		
	335		340		345
Ser Asn Ala Gly	Ile Thr Ser Ile Glu	Phe Asp Ser Ala Gly	Ser		
	350		355		360
Tyr Leu Leu Ala	Ala Ser Asn Asp Phe	Ala Ser Arg Ile Trp	Thr		
	365		370		375
Val Asp Asp Tyr	Arg Leu Arg His Thr	Leu Thr Gly His Ser	Gly		
	380		385		390
Lys Val Leu Ser	Ala Lys Phe Leu Leu	Asp Asn Ala Arg Ile	Val		
	395		400		405
Ser Gly Ser His	Asp Arg Thr Leu Lys	Leu Trp Asp Leu Arg	Ser		
	410		415		420
Lys Val Cys Ile	Lys Thr Val Phe Ala	Gly Ser Ser Cys Asn	Asp		
	425		430		435
Ile Val Cys Thr	Glu Gln Cys Val Met	Ser Gly His Phe Asp	Lys		
	440		445		450
Lys Ile Arg Phe	Trp Asp Ile Arg Ser	Glu Ser Ile Val Arg	Glu		
	455		460		465
Met Glu Leu Leu	Gly Lys Ile Thr Ala	Leu Asp Leu Asn Pro	Glu		
	470		475		480
Arg Thr Glu Leu	Leu Ser Cys Ser Arg	Asp Asp Leu Leu Lys	Val		
	485		490		495
Ile Asp Leu Arg	Thr Asn Ala Ile Lys	Gln Thr Phe Ser Ala	Pro		
	500		505		510
Gly Phe Lys Cys	Gly Ser Asp Trp Thr	Arg Val Val Phe Ser	Pro		
	515		520		525
Asp Gly Ser Tyr	Val Ala Ala Gly Ser	Ala Glu Gly Ser Leu	Tyr		
	530		535		540
Ile Trp Ser Val	Leu Thr Gly Lys Val	Glu Lys Val Leu Ser	Lys		
	545		550		555
Gln His Ser Ser	Ser Ile Asn Ala Val	Ala Trp Ser Pro Ser	Gly		
	560		565		570
Ser His Val Val	Ser Val Asp Lys Gly	Cys Lys Ala Val Leu	Trp		
	575		580		585
Ala Gln Tyr					

<210> 32

<211> 326

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1821658CD1

<400> 32

```

Met Lys Gln Asp Ala Ser Arg Asn Ala Ala Tyr Thr Val Asp Cys
 1          5          10          15
Glu Asp Tyr Val His Val Val Glu Phe Asn Pro Phe Glu Asn Gly
 20          25          30
Asp Ser Gly Asn Leu Ile Ala Tyr Gly Gly Asn Asn Tyr Val Val
 35          40          45
Ile Gly Thr Cys Thr Phe Gln Glu Glu Glu Ala Asp Val Glu Gly
 50          55          60
Ile Gln Tyr Lys Thr Leu Arg Thr Phe His His Gly Val Arg Val
 65          70          75
Asp Gly Ile Ala Trp Ser Pro Glu Thr Arg Leu Asp Ser Leu Pro
 80          85          90
Pro Val Ile Lys Phe Cys Thr Ser Ala Ala Asp Met Lys Ile Arg
 95          100          105
Leu Phe Thr Ser Asp Leu Gln Asp Lys Asn Glu Tyr Lys Val Leu
 110          115          120
Glu Gly His Thr Asp Phe Ile Asn Gly Leu Val Phe Asp Pro Lys
 125          130          135
Glu Gly Gln Glu Ile Ala Ser Val Ser Asp Asp His Thr Cys Arg
 140          145          150
Ile Trp Asn Leu Glu Gly Val Gln Thr Ala His Phe Val Leu His
 155          160          165
Ser Pro Gly Met Ser Val Cys Trp His Pro Glu Glu Thr Phe Lys
 170          175          180
Leu Met Val Ala Glu Lys Asn Gly Thr Ile Arg Phe Tyr Asp Leu
 185          190          195
Leu Ala Gln Gln Ala Ile Leu Ser Leu Glu Ser Glu Gln Val Pro
 200          205          210
Leu Met Ser Ala His Trp Cys Leu Lys Asn Thr Phe Lys Val Gly
 215          220          225
Ala Val Ala Gly Asn Asp Trp Leu Ile Trp Asp Ile Thr Arg Ser
 230          235          240
Ser Tyr Pro Gln Asn Lys Arg Pro Val His Met Asp Arg Ala Cys
 245          250          255
Leu Phe Arg Trp Ser Thr Ile Ser Glu Asn Leu Phe Ala Thr Thr
 260          265          270
Gly Tyr Pro Gly Lys Met Ala Ser Gln Phe Gln Ile His His Leu
 275          280          285
Gly His Pro Gln Pro Ile Leu Met Gly Ser Val Ala Val Gly Ser
 290          295          300
Gly Leu Ser Trp His Arg Thr Leu Pro Leu Cys Val Ile Gly Gly
 305          310          315
Asp His Lys Leu Leu Phe Trp Val Thr Glu Val
 320          325

```

<210> 33

<211> 453

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1872574CD1

<400> 33

```

Met Ala Arg Lys Val Val Ser Arg Lys Arg Lys Ala Pro Ala Ser

```

1	5	10	15
Pro Gly Ala Gly	Ser Asp Ala Gln Gly	Pro Gln Phe Gly Trp	Asp
	20	25	30
His Ser Leu His	Lys Arg Lys Arg Leu	Pro Pro Val Lys Arg	Ser
	35	40	45
Leu Val Tyr Tyr	Leu Lys Asn Arg Glu	Val Arg Leu Gln Asn	Glu
	50	55	60
Thr Ser Tyr Ser	Arg Val Leu His Gly	Tyr Ala Ala Gln Gln	Leu
	65	70	75
Pro Ser Leu Leu	Lys Glu Arg Glu Phe	His Leu Gly Thr Leu	Asn
	80	85	90
Lys Val Phe Ala	Ser Gln Trp Leu Asn	His Arg Gln Val Val	Cys
	95	100	105
Gly Thr Lys Cys	Asn Thr Leu Phe Val	Val Asp Val Gln Thr	Ser
	110	115	120
Gln Ile Thr Lys	Ile Pro Ile Leu Lys	Asp Arg Glu Pro Gly	Gly
	125	130	135
Val Thr Gln Gln	Gly Cys Gly Ile His	Ala Ile Glu Leu Asn	Pro
	140	145	150
Ser Arg Thr Leu	Leu Ala Thr Gly Gly	Asp Asn Pro Asn Ser	Leu
	155	160	165
Ala Ile Tyr Arg	Leu Pro Thr Leu Asp	Pro Val Cys Val Gly	Asp
	170	175	180
Asp Gly His Lys	Asp Trp Ile Phe Ser	Ile Ala Trp Ile Ser	Asp
	185	190	195
Thr Met Ala Val	Ser Gly Ser Arg Asp	Gly Ser Met Gly Leu	Trp
	200	205	210
Glu Val Thr Asp	Asp Val Leu Thr Lys	Ser Asp Ala Arg His	Asn
	215	220	225
Val Ser Arg Val	Pro Val Tyr Ala His	Ile Thr His Lys Ala	Leu
	230	235	240
Lys Asp Ile Pro	Lys Glu Asp Thr Asn	Pro Asp Asn Cys Lys	Val
	245	250	255
Arg Ala Leu Ala	Phe Asn Asn Lys Asn	Lys Glu Leu Gly Ala	Val
	260	265	270
Ser Leu Asp Gly	Tyr Phe His Leu Trp	Lys Ala Glu Asn Thr	Leu
	275	280	285
Ser Lys Leu Leu	Ser Thr Lys Leu Pro	Tyr Cys Arg Glu Asn	Val
	290	295	300
Cys Leu Ala Tyr	Gly Ser Glu Trp Ser	Val Tyr Ala Val Gly	Ser
	305	310	315
Gln Ala His Val	Ser Phe Leu Asp Pro	Arg Gln Pro Ser Tyr	Asn
	320	325	330
Val Lys Ser Val	Cys Ser Arg Glu Arg	Gly Ser Gly Ile Arg	Ser
	335	340	345
Val Ser Phe Tyr	Glu His Ile Ile Thr	Val Gly Thr Gly Gln	Gly
	350	355	360
Ser Leu Leu Phe	Tyr Asp Ile Arg Ala	Gln Arg Phe Leu Glu	Glu
	365	370	375
Arg Leu Ser Ala	Cys Tyr Gly Ser Lys	Pro Arg Leu Ala Gly	Glu
	380	385	390
Asn Leu Lys Leu	Thr Thr Gly Lys Gly	Trp Leu Asn His Asp	Glu
	395	400	405
Thr Trp Arg Asn	Tyr Phe Ser Asp Ile	Asp Phe Phe Pro Asn	Ala
	410	415	420
Val Tyr Thr His	Cys Tyr Asp Ser Ser	Gly Thr Lys Leu Phe	Val
	425	430	435
Ala Gly Gly Pro	Leu Pro Ser Gly Leu	His Gly Asn Tyr Ala	Gly
	440	445	450
Leu Trp Ser			

<210> 34

<211> 161

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2590967CD1

<400> 34

```

Met Ala Thr Glu Gly Gly Gly Lys Glu Met Asn Glu Ile Lys Thr
 1          5          10          15
Gln Phe Thr Thr Arg Glu Gly Leu Tyr Lys Leu Leu Pro His Ser
          20          25          30
Glu Tyr Ser Arg Pro Asn Arg Val Pro Phe Asn Ser Gln Gly Ser
          35          40          45
Asn Pro Val Arg Val Ser Phe Val Asn Leu Asn Asp Gln Ser Gly
          50          55          60
Asn Gly Asp Arg Leu Cys Phe Asn Val Gly Arg Glu Leu Tyr Phe
          65          70          75
Tyr Ile Tyr Lys Gly Val Arg Lys Ala Ala Asp Leu Ser Lys Pro
          80          85          90
Ile Asp Lys Arg Ile Tyr Lys Gly Thr Gln Pro Thr Cys His Asp
          95          100          105
Phe Asn His Leu Thr Ala Thr Ala Glu Ser Val Ser Leu Leu Val
          110          115          120
Gly Phe Ser Ala Gly Gln Val Gln Leu Ile Asp Pro Ile Lys Lys
          125          130          135
Glu Thr Ser Lys Leu Phe Asn Glu Glu Gly Ser Leu Ser Ser Pro
          140          145          150
Ser Gln Ala Ser Ser Pro Gly Gly Thr Val Val
          155          160

```

<210> 35

<211> 684

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2824491CD1

<400> 35

```

Met Ala Arg His Arg Asn Val Arg Gly Tyr Asn Tyr Asp Glu Asp
 1          5          10          15
Phe Glu Asp Asp Asp Leu Tyr Gly Gln Ser Val Glu Asp Asp Tyr
          20          25          30
Cys Ile Ser Pro Ser Thr Ala Ala Gln Phe Ile Tyr Ser Arg Arg
          35          40          45
Asp Lys Pro Ser Val Glu Pro Val Glu Glu Tyr Asp Tyr Glu Asp
          50          55          60
Leu Lys Glu Ser Ser Asn Ser Val Ser Asn His Gln Leu Ser Gly
          65          70          75
Phe Asp Gln Ala Arg Leu Tyr Ser Cys Leu Asp His Met Arg Glu
          80          85          90
Val Leu Gly Asp Ala Val Pro Asp Glu Ile Leu Ile Glu Ala Val
          95          100          105
Leu Lys Asn Lys Phe Asp Val Gln Lys Ala Leu Ser Gly Val Leu
          110          115          120
Glu Gln Asp Arg Val Gln Ser Leu Lys Asp Lys Asn Glu Ala Thr
          125          130          135
Val Ser Thr Gly Lys Ile Ala Lys Gly Lys Pro Val Asp Ser Gln
          140          145          150
Thr Ser Arg Ser Glu Ser Glu Ile Val Pro Lys Val Ala Lys Met
          155          160          165
Thr Val Ser Gly Lys Lys Gln Thr Met Gly Phe Glu Val Pro Gly

```

	170		175		180
Val Ser Ser Glu	Glu Asn Gly His Ser	Phe His Thr Pro Gln Lys			
	185	190			195
Gly Pro Pro Ile	Glu Asp Ala Ile Ala	Ser Ser Asp Val Leu Glu			
	200	205			210
Thr Ala Ser Lys	Ser Ala Asn Pro Pro	His Thr Ile Gln Ala Ser			
	215	220			225
Glu Glu Gln Ser	Ser Thr Pro Ala Pro	Val Lys Lys Ser Gly Lys			
	230	235			240
Leu Arg Gln Gln	Ile Asp Val Lys Ala	Glu Leu Glu Lys Arg Gln			
	245	250			255
Gly Gly Lys Gln	Leu Leu Asn Leu Val	Val Ile Gly His Val Asp			
	260	265			270
Ala Gly Lys Ser	Thr Leu Met Gly His	Met Leu Tyr Leu Leu Gly			
	275	280			285
Asn Ile Asn Lys	Arg Thr Met His Lys	Tyr Glu Gln Glu Ser Lys			
	290	295			300
Lys Ala Gly Lys	Ala Ser Phe Ala Tyr	Ala Trp Val Leu Asp Glu			
	305	310			315
Thr Gly Glu Glu	Arg Glu Arg Gly Val	Thr Met Asp Val Gly Met			
	320	325			330
Thr Lys Phe Glu	Thr Thr Lys Val	Ile Thr Leu Met Asp Ala			
	335	340			345
Pro Gly His Lys	Asp Phe Ile Pro Asn	Met Ile Thr Gly Ala Ala			
	350	355			360
Gln Ala Asp Val	Ala Val Leu Val Val	Asp Ala Ser Arg Gly Glu			
	365	370			375
Phe Glu Ala Gly	Phe Glu Thr Gly Gly	Gln Thr Arg Glu His Gly			
	380	385			390
Leu Leu Val Arg	Ser Leu Gly Val Thr	Gln Leu Ala Val Ala Val			
	395	400			405
Asn Lys Met Asp	Gln Val Asn Trp Gln	Gln Glu Arg Phe Gln Glu			
	410	415			420
Ile Thr Gly Lys	Leu Gly His Phe Leu	Lys Gln Ala Gly Phe Lys			
	425	430			435
Glu Ser Asp Val	Gly Phe Ile Pro Thr	Ser Gly Leu Ser Gly Glu			
	440	445			450
Asn Leu Ile Thr	Arg Ser Gln Ser Ser	Glu Leu Thr Lys Trp Tyr			
	455	460			465
Lys Gly Leu Cys	Leu Leu Glu Gln Ile	Asp Ser Phe Lys Pro Pro			
	470	475			480
Gln Arg Ser Ile	Asp Lys Pro Phe Arg	Leu Cys Val Ser Asp Val			
	485	490			495
Phe Lys Asp Gln	Gly Ser Gly Phe Cys	Ile Thr Gly Lys Ile Glu			
	500	505			510
Ala Gly Tyr Ile	Gln Thr Gly Asp Arg	Leu Leu Ala Met Pro Pro			
	515	520			525
Asn Glu Thr Cys	Thr Val Lys Gly Ile	Thr Leu His Asp Glu Pro			
	530	535			540
Val Asp Trp Ala	Ala Ala Gly Asp His	Val Ser Leu Thr Leu Val			
	545	550			555
Gly Met Asp Ile	Ile Lys Ile Asn Val	Gly Cys Ile Phe Cys Gly			
	560	565			570
Pro Lys Val Pro	Ile Lys Ala Cys Thr	Arg Phe Arg Ala Arg Ile			
	575	580			585
Leu Ile Phe Asn	Ile Glu Ile Pro Ile	Thr Lys Gly Phe Pro Val			
	590	595			600
Leu Leu His Tyr	Gln Thr Val Ser Glu	Pro Ala Val Ile Lys Arg			
	605	610			615
Leu Ile Ser Val	Leu Asn Lys Ser Thr	Gly Glu Val Thr Lys Lys			
	620	625			630
Lys Pro Lys Phe	Leu Thr Lys Gly Gln	Asn Ala Leu Val Glu Leu			
	635	640			645

Gln Thr Gln Arg Pro Ile Ala Leu Glu Leu Tyr Lys Asp Phe Lys
 650 655 660
 Glu Leu Gly Arg Phe Met Leu Arg Tyr Gly Gly Ser Thr Ile Ala
 665 670 675
 Ala Gly Val Val Thr Glu Ile Lys Glu
 680

<210> 36

<211> 366

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2825460CD1

<400> 36

Met Ala Ala Ala Ala Ala Arg Trp Asn His Val Trp Val Gly Thr
 1 5 10 15
 Glu Thr Gly Ile Leu Lys Gly Val Asn Leu Gln Arg Lys Gln Ala
 20 25 30
 Ala Asn Phe Thr Ala Gly Gly Gln Pro Arg Arg Glu Glu Ala Val
 35 40 45
 Ser Ala Leu Cys Trp Gly Thr Gly Gly Glu Thr Gln Met Leu Val
 50 55 60
 Gly Cys Ala Asp Arg Thr Val Lys His Phe Ser Thr Glu Asp Gly
 65 70 75
 Ile Phe Gln Gly Gln Arg His Cys Pro Gly Gly Glu Gly Met Phe
 80 85 90
 Arg Gly Leu Ala Gln Ala Asp Gly Thr Leu Ile Thr Cys Val Asp
 95 100 105
 Ser Gly Ile Leu Arg Val Trp His Asp Lys Asp Lys Asp Thr Ser
 110 115 120
 Ser Asp Pro Leu Leu Glu Leu Arg Val Gly Pro Gly Val Cys Arg
 125 130 135
 Met Arg Gln Asp Pro Ala His Pro His Val Val Ala Thr Gly Gly
 140 145 150
 Lys Glu Asn Ala Leu Lys Ile Trp Asp Leu Gln Gly Ser Glu Glu
 155 160 165
 Pro Val Phe Arg Ala Lys Asn Val Arg Asn Asp Trp Leu Asp Leu
 170 175 180
 Arg Val Pro Ile Trp Asp Gln Asp Ile Gln Phe Leu Pro Gly Ser
 185 190 195
 Gln Lys Leu Val Thr Cys Thr Gly Tyr His Gln Val Arg Val Tyr
 200 205 210
 Asp Pro Ala Ser Pro Gln Arg Arg Pro Val Leu Glu Thr Thr Tyr
 215 220 225
 Gly Glu Tyr Pro Leu Thr Ala Met Thr Leu Thr Pro Gly Gly Asn
 230 235 240
 Ser Val Ile Val Gly Asn Thr His Gly Gln Leu Ala Glu Ile Asp
 245 250 255
 Leu Arg Gln Gly Arg Leu Leu Gly Cys Leu Lys Gly Leu Ala Gly
 260 265 270
 Ser Val Arg Gly Leu Gln Cys His Pro Ser Lys Pro Leu Leu Ala
 275 280 285
 Ser Cys Gly Leu Asp Arg Val Leu Arg Ile His Arg Ile Gln Asn
 290 295 300
 Pro Arg Gly Leu Glu His Lys Asp Glu Pro Gln Glu Pro Gln Glu
 305 310 315
 Pro Asn Lys Val Pro Leu Glu Asp Thr Glu Thr Asp Glu Leu Trp
 320 325 330
 Ala Ser Leu Glu Ala Ala Ala Lys Arg Lys Leu Ser Gly Leu Glu
 335 340 345
 Gln Pro Gln Gly Ala Leu Gln Thr Arg Arg Arg Lys Lys Lys Arg

```

350                               355                               360
Pro Gly Ser Thr Ser Pro
365
<210> 37
<211> 339
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2871116CD1

<400> 37
Met Ala Thr Glu Ile Gly Ser Pro Pro Arg Phe Phe His Met Pro
 1          5          10          15
Arg Phe Gln His Gln Ala Pro Arg Gln Leu Phe Tyr Lys Arg Pro
 20          25          30
Asp Phe Ala Gln Gln Gln Ala Met Gln Gln Leu Thr Phe Asp Gly
 35          40          45
Lys Arg Met Arg Lys Ala Val Asn Arg Lys Thr Ile Asp Tyr Asn
 50          55          60
Pro Ser Val Ile Lys Tyr Leu Glu Asn Arg Ile Trp Gln Arg Asp
 65          70          75
Gln Arg Asp Met Arg Ala Ile Gln Pro Asp Ala Gly Tyr Tyr Asn
 80          85          90
Asp Leu Val Pro Pro Ile Gly Met Leu Asn Asn Pro Met Asn Ala
 95          100         105
Val Thr Thr Lys Phe Val Arg Thr Ser Thr Asn Lys Val Lys Cys
110         115         120
Pro Val Phe Val Val Arg Leu Gln Glu Glu Phe Glu Ser Leu Ser
125         130         135
Val Leu Lys Ser Trp Thr Pro Glu Gly Arg Arg Leu Val Thr Gly
140         145         150
Ala Ser Ser Gly Glu Phe Thr Leu Trp Asn Gly Leu Thr Phe Asn
155         160         165
Phe Glu Thr Ile Leu Gln Ala His Asp Ser Pro Val Arg Ala Met
170         175         180
Thr Trp Ser His Asn Asp Met Trp Met Leu Thr Ala Asp His Gly
185         190         195
Gly Tyr Val Lys Tyr Trp Gln Ser Asn Met Asn Asn Val Lys Met
200         205         210
Phe Gln Ala His Lys Glu Ala Ile Arg Glu Ala Arg Phe Ile His
215         220         225
Asn Ile Pro Phe Ser Val Val Pro Ile Val Met Val Lys Leu Phe
230         235         240
Ser Lys Cys Ile Leu Gly Ala Glu Met His Gly Leu Cys Gln Phe
245         250         255
Leu Gly Asn Phe Leu His Pro Ile Asn Thr Ile Phe Phe Phe Val
260         265         270
Phe Thr His Ser Pro Phe Cys Trp His Leu Ser Glu Val Val Leu
275         280         285
Ser Arg Tyr Gln Pro Leu Gln Tyr Val Arg Asp Val Leu Ser Ala
290         295         300
Ala Phe Cys Thr Gly Phe Leu Phe Ser Phe Met Ile Asn Asn Val
305         310         315
Tyr Thr Leu Phe Leu Phe Ile Ile Tyr Cys Val Arg Gln Glu Tyr
320         325         330
Phe Ile Pro Asn Lys Glu Phe Ser Leu
335
<210> 38
<211> 213
<212> PRT
<213> Homo sapiens

```

<220>

<221> misc_feature

<223> Incyte ID No: 2942212CD1

<400> 38

```

Met Glu Ala Ile Trp Leu Tyr Gln Phe Arg Leu Ile Val Ile Gly
 1          5          10          15
Asp Ser Thr Val Gly Lys Ser Cys Leu Ile Arg Arg Phe Thr Glu
          20          25          30
Gly Arg Phe Ala Gln Val Ser Asp Pro Thr Val Gly Val Asp Phe
          35          40          45
Phe Ser Arg Leu Val Glu Ile Glu Pro Gly Lys Arg Ile Lys Leu
          50          55          60
Gln Ile Trp Asp Thr Ala Gly Gln Glu Arg Phe Arg Ser Ile Thr
          65          70          75
Arg Ala Tyr Tyr Arg Asn Ser Val Gly Gly Leu Leu Leu Phe Ala
          80          85          90
Ile Thr Asn Arg Arg Ser Phe Gln Asn Val His Glu Trp Leu Glu
          95          100          105
Glu Thr Lys Val His Val Gln Pro Tyr Gln Ile Val Phe Val Leu
          110          115          120
Val Gly His Lys Cys Asp Leu Asp Thr Gln Arg Gln Val Thr Arg
          125          130          135
His Glu Ala Glu Lys Leu Ala Ala Ala Tyr Gly Met Lys Tyr Ile
          140          145          150
Glu Thr Ser Ala Arg Asp Ala Ile Asn Val Glu Lys Ala Phe Thr
          155          160          165
Asp Leu Thr Arg Asp Ile Tyr Glu Leu Val Lys Arg Gly Glu Ile
          170          175          180
Thr Ile Gln Glu Gly Trp Glu Gly Val Lys Ser Gly Phe Val Pro
          185          190          195
Asn Val Val His Ser Ser Glu Glu Val Val Lys Ser Glu Arg Arg
          200          205          210
Cys Leu Cys

```

<210> 39

<211> 393

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3685151CD1

<400> 39

```

Met Glu Leu Val Ala Gly Cys Tyr Glu Gln Val Leu Phe Gly Phe
 1          5          10          15
Ala Val His Pro Glu Pro Glu Ala Cys Gly Asp His Glu Gln Gln
          20          25          30
Trp Thr Leu Val Ala Asp Phe Thr His His Ala His Thr Ala Ser
          35          40          45
Leu Ser Ala Val Ala Val Asn Ser Arg Phe Val Val Thr Gly Ser
          50          55          60
Lys Asp Glu Thr Ile His Ile Tyr Asp Met Lys Lys Lys Ile Glu
          65          70          75
His Gly Ala Leu Val His His Ser Gly Thr Ile Thr Cys Leu Thr
          80          85          90
Phe Tyr Gly Asn Arg His Leu Ile Ser Gly Ala Glu Asp Gly Leu
          95          100          105
Ile Cys Ile Trp Asp Ala Lys Lys Trp Glu Ser Leu Thr Ser Ile
          110          115          120
Lys Ala His Lys Gly Gln Val Thr Phe Leu Ser Ile His Pro Ser
          125          130          135

```


Gly	Lys	Leu	Ala	Leu	Ser	Val	Gly	Thr	Asp	Lys	Thr	Leu	Arg	Thr
				140					145					150
Trp	Asn	Leu	Val	Glu	Gly	Arg	Ser	Ala	Phe	Ile	Lys	Asn	Ile	Lys
				155					160					165
Gln	Asn	Ala	His	Ile	Val	Glu	Trp	Ser	Pro	Arg	Gly	Glu	Gln	Tyr
				170					175					180
Val	Val	Ile	Ile	Gln	Asn	Lys	Ile	Asp	Ile	Tyr	Gln	Leu	Asp	Thr
				185					190					195
Ala	Ser	Ile	Ser	Gly	Thr	Ile	Thr	Asn	Glu	Lys	Arg	Ile	Ser	Ser
				200					205					210
Val	Lys	Phe	Leu	Ser	Glu	Ser	Val	Leu	Ala	Val	Ala	Gly	Asp	Glu
				215					220					225
Glu	Val	Ile	Arg	Phe	Phe	Asp	Cys	Asp	Ser	Leu	Val	Cys	Leu	Cys
				230					235					240
Glu	Phe	Lys	Ala	His	Glu	Asn	Arg	Val	Lys	Asp	Met	Phe	Ser	Phe
				245					250					255
Glu	Ile	Pro	Glu	His	His	Val	Ile	Val	Ser	Ala	Ser	Ser	Asp	Gly
				260					265					270
Phe	Ile	Lys	Met	Trp	Lys	Leu	Lys	Gln	Asp	Lys	Lys	Val	Pro	Pro
				275					280					285
Ser	Leu	Leu	Cys	Glu	Ile	Asn	Thr	Asn	Ala	Arg	Leu	Thr	Cys	Leu
				290					295					300
Gly	Val	Trp	Leu	Asp	Lys	Val	Ala	Asp	Met	Lys	Glu	Ser	Leu	Pro
				305					310					315
Pro	Ala	Ala	Glu	Pro	Ser	Pro	Val	Ser	Lys	Glu	Gln	Ser	Lys	Ile
				320					325					330
Gly	Lys	Lys	Glu	Pro	Gly	Asp	Thr	Val	His	Lys	Glu	Glu	Lys	Arg
				335					340					345
Ser	Lys	Pro	Asn	Thr	Lys	Lys	Arg	Gly	Leu	Thr	Gly	Asp	Ser	Lys
				350					355					360
Lys	Ala	Thr	Lys	Glu	Ser	Gly	Leu	Ile	Ser	Thr	Lys	Lys	Arg	Lys
				365					370					375
Met	Val	Glu	Met	Leu	Glu	Lys	Lys	Arg	Lys	Lys	Lys	Lys	Ile	Lys
				380					385					390

Thr Met Gln

<210> 40

<211> 399

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4881515CD1

<400> 40

Met	Ser	Leu	Gln	Tyr	Gly	Ala	Glu	Glu	Thr	Pro	Leu	Ala	Gly	Ser
1				5					10					15
Tyr	Gly	Ala	Ala	Asp	Ser	Phe	Pro	Lys	Asp	Phe	Gly	Tyr	Gly	Val
				20					25					30
Glu	Glu	Glu	Glu	Glu	Glu	Ala	Ala	Ala	Ala	Gly	Gly	Gly	Val	Gly
				35					40					45
Ala	Gly	Ala	Gly	Gly	Gly	Cys	Gly	Pro	Gly	Gly	Ala	Asp	Ser	Ser
				50					55					60
Lys	Pro	Arg	Ile	Leu	Leu	Met	Gly	Leu	Arg	Arg	Ser	Gly	Lys	Ser
				65					70					75
Ser	Ile	Gln	Lys	Val	Val	Phe	His	Lys	Met	Ser	Pro	Asn	Glu	Thr
				80					85					90
Leu	Phe	Leu	Glu	Ser	Thr	Asn	Lys	Ile	Tyr	Lys	Asp	Asp	Ile	Ser
				95					100					105
Asn	Ser	Ser	Phe	Val	Asn	Phe	Gln	Ile	Trp	Asp	Phe	Pro	Gly	Gln
				110					115					120
Met	Asp	Phe	Phe	Asp	Pro	Thr	Phe	Asp	Tyr	Glu	Met	Ile	Phe	Arg

				125						130					135
Gly	Thr	Gly	Ala	Leu	Ile	Tyr	Val	Ile	Asp	Ala	Gln	Asp	Asp	Tyr	
				140						145					150
Met	Glu	Ala	Leu	Thr	Arg	Leu	His	Ile	Thr	Val	Ser	Lys	Ala	Tyr	
				155						160					165
Lys	Val	Asn	Pro	Asp	Met	Asn	Phe	Glu	Val	Phe	Ile	His	Lys	Val	
				170						175					180
Asp	Gly	Leu	Ser	Asp	Asp	His	Lys	Ile	Glu	Thr	Gln	Arg	Asp	Ile	
				185						190					195
His	Gln	Arg	Ala	Asn	Asp	Asp	Leu	Ala	Asp	Ala	Gly	Leu	Glu	Lys	
				200						205					210
Leu	His	Leu	Ser	Phe	Tyr	Leu	Thr	Ser	Ile	Tyr	Asp	His	Ser	Ile	
				215						220					225
Phe	Glu	Ala	Phe	Ser	Lys	Val	Val	Gln	Lys	Leu	Ile	Pro	Gln	Leu	
				230						235					240
Pro	Thr	Leu	Glu	Asn	Leu	Leu	Asn	Ile	Phe	Ile	Ser	Asn	Ser	Gly	
				245						250					255
Ile	Glu	Lys	Ala	Phe	Leu	Phe	Asp	Val	Val	Ser	Lys	Ile	Tyr	Ile	
				260						265					270
Ala	Thr	Asp	Ser	Ser	Pro	Val	Asp	Met	Gln	Ser	Tyr	Glu	Leu	Cys	
				275						280					285
Cys	Asp	Met	Ile	Asp	Val	Val	Ile	Asp	Val	Ser	Cys	Ile	Tyr	Gly	
				290						295					300
Leu	Lys	Glu	Asp	Gly	Ser	Gly	Ser	Ala	Tyr	Asp	Lys	Glu	Ser	Met	
				305						310					315
Ala	Ile	Ile	Lys	Leu	Asn	Asn	Thr	Thr	Val	Leu	Tyr	Leu	Lys	Glu	
				320						325					330
Val	Thr	Lys	Phe	Leu	Ala	Leu	Val	Cys	Ile	Leu	Arg	Glu	Glu	Ser	
				335						340					345
Phe	Glu	Arg	Lys	Gly	Leu	Ile	Asp	Tyr	Asn	Phe	His	Cys	Phe	Arg	
				350						355					360
Lys	Ala	Ile	His	Glu	Val	Phe	Glu	Val	Gly	Val	Thr	Ser	His	Arg	
				365						370					375
Ser	Cys	Gly	His	Gln	Thr	Ser	Ala	Ser	Ser	Leu	Lys	Ala	Leu	Thr	
				380						385					390
His	Asn	Gly	Thr	Pro	Arg	Asn	Ala	Ile							
				395											

<210> 41

<211> 412

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5324681CD1

<400> 41

Met	Ala	Gly	Ser	Val	Gly	Leu	Ala	Leu	Cys	Gly	Gln	Thr	Leu	Val	
1				5					10						15
Val	Arg	Gly	Gly	Ser	Arg	Phe	Leu	Ala	Thr	Ser	Ile	Ala	Ser	Ser	
				20					25						30
Asp	Asp	Asp	Ser	Leu	Phe	Ile	Tyr	Asp	Cys	Ser	Ala	Ala	Glu	Lys	
				35					40						45
Lys	Ser	Gln	Glu	Asn	Lys	Gly	Glu	Asp	Ala	Pro	Leu	Asp	Gln	Gly	
				50					55						60
Ser	Gly	Ala	Ile	Leu	Ala	Ser	Thr	Phe	Ser	Lys	Ser	Gly	Ser	Tyr	
				65					70						75
Phe	Ala	Leu	Thr	Asp	Asp	Ser	Lys	Arg	Leu	Ile	Leu	Phe	Arg	Thr	
				80					85						90
Lys	Pro	Trp	Gln	Cys	Leu	Ser	Val	Arg	Thr	Val	Ala	Arg	Arg	Cys	
				95					100						105
Thr	Ala	Leu	Thr	Phe	Ile	Ala	Ser	Glu	Glu	Lys	Val	Leu	Val	Ala	
				110					115						120

Asp	Lys	Ser	Gly	Asp	Val	Tyr	Ser	Phe	Ser	Val	Leu	Glu	Pro	His	
				125					130					135	
Gly	Cys	Gly	Arg	Leu	Glu	Leu	Gly	His	Leu	Ser	Met	Leu	Leu	Asp	
				140					145					150	
Val	Ala	Val	Ser	Pro	Asp	Asp	Arg	Phe	Ile	Leu	Thr	Ala	Asp	Arg	
				155					160					165	
Asp	Glu	Lys	Ile	Arg	Val	Ser	Trp	Ala	Ala	Ala	Pro	His	Ser	Ile	
				170					175					180	
Glu	Ser	Phe	Cys	Leu	Gly	His	Thr	Glu	Phe	Val	Ser	Arg	Ile	Ser	
				185					190					195	
Val	Val	Pro	Thr	Gln	Pro	Gly	Leu	Leu	Leu	Ser	Ser	Ser	Gly	Asp	
				200					205					210	
Gly	Thr	Leu	Arg	Leu	Trp	Glu	Tyr	Arg	Ser	Gly	Arg	Gln	Leu	His	
				215					220					225	
Cys	Cys	His	Leu	Ala	Ser	Leu	Gln	Glu	Leu	Val	Asp	Pro	Gln	Ala	
				230					235					240	
Pro	Gln	Lys	Phe	Ala	Ala	Ser	Arg	Ile	Ala	Phe	Trp	Cys	Gln	Glu	
				245					250					255	
Asn	Cys	Val	Ala	Leu	Leu	Cys	Asp	Gly	Thr	Pro	Val	Val	Tyr	Ile	
				260					265					270	
Phe	Gln	Leu	Asp	Ala	Arg	Arg	Gln	Gln	Leu	Val	Tyr	Arg	Gln	Gln	
				275					280					285	
Leu	Ala	Phe	Gln	His	Gln	Val	Trp	Asp	Val	Ala	Phe	Glu	Glu	Thr	
				290					295					300	
Gln	Gly	Leu	Trp	Val	Leu	Gln	Asp	Cys	Gln	Glu	Ala	Pro	Leu	Val	
				305					310					315	
Leu	Tyr	Arg	Pro	Val	Gly	Asp	Gln	Trp	Gln	Ser	Val	Pro	Glu	Ser	
				320					325					330	
Thr	Val	Leu	Lys	Lys	Val	Ser	Gly	Val	Leu	Arg	Gly	Asn	Trp	Ala	
				335					340					345	
Met	Leu	Glu	Gly	Ser	Ala	Gly	Ala	Asp	Ala	Ser	Phe	Ser	Ser	Leu	
				350					355					360	
Tyr	Lys	Ala	Thr	Phe	Asp	Asn	Val	Thr	Ser	Tyr	Leu	Lys	Lys	Lys	
				365					370					375	
Glu	Glu	Arg	Leu	Gln	Gln	Gln	Leu	Glu	Lys	Lys	Gln	Arg	Arg	Arg	
				380					385					390	
Ser	Pro	Pro	Pro	Gly	Pro	Asp	Gly	His	Ala	Lys	Lys	Met	Arg	Pro	
				395					400					405	
Gly	Glu	Ala	Thr	Leu	Ser	Cys									
				410											

<210> 42

<211> 163

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5387651CD1

<400> 42

Met	Asp	Ala	Leu	Glu	Gly	Glu	Ser	Phe	Ala	Leu	Ser	Phe	Ser	Ser	
1				5					10					15	
Ala	Ser	Asp	Ala	Glu	Phe	Asp	Ala	Val	Val	Gly	Tyr	Leu	Glu	Asp	
				20					25					30	
Ile	Ile	Met	Asp	Asp	Glu	Phe	Gln	Leu	Leu	Gln	Arg	Asn	Phe	Met	
				35					40					45	
Asp	Lys	Tyr	Tyr	Leu	Glu	Phe	Glu	Asp	Thr	Glu	Glu	Asn	Lys	Leu	
				50					55					60	
Ile	Tyr	Thr	Pro	Ile	Phe	Asn	Glu	Tyr	Ile	Ser	Leu	Val	Glu	Lys	
				65					70					75	
Tyr	Ile	Glu	Glu	Gln	Leu	Leu	Gln	Arg	Ile	Pro	Glu	Phe	Asn	Met	
				80					85					90	
Ala	Ala	Phe	Thr	Thr	Thr	Leu	Gln	His	His	Lys	Asp	Glu	Val	Ala	

	95		100		105
Gly Asp Ile Phe	Asp Met Leu Leu Thr	Phe Thr Asp Phe Leu	Ala		
	110		115		120
Phe Lys Glu Met	Phe Leu Asp Tyr Arg	Ala Glu Lys Glu Gly	Arg		
	125		130		135
Gly Leu Asp Leu	Ser Ser Gly Leu Val	Val Thr Ser Leu Cys	Lys		
	140		145		150
Ser Ser Ser Leu	Pro Ala Ser Gln Asn	Asn Leu Arg His			
	155		160		

<210> 43

<211> 514

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5595679CD1

<400> 43

Met Gln Glu Ser Gly	Cys Arg Leu Glu His	Pro Ser Ala Thr Lys
1	5	10
Phe Arg Asn His Val	Met Glu Gly Asp Trp	Asp Lys Ala Glu Asn
	20	25
Asp Leu Asn Glu Leu	Lys Pro Leu Val His	Ser Pro His Ala Ile
	35	40
Val Val Arg Gly Ala	Leu Glu Ile Ser Gln	Thr Leu Leu Gly Ile
	50	55
Ile Val Arg Met Lys	Phe Leu Leu Leu Gln	Gln Lys Tyr Leu Glu
	65	70
Tyr Leu Glu Asp Gly	Lys Val Leu Glu Ala	Leu Gln Val Leu Arg
	80	85
Cys Glu Leu Thr Pro	Leu Lys Tyr Asn Thr	Glu Arg Ile His Val
	95	100
Leu Ser Gly Tyr Leu	Met Cys Ser His Ala	Glu Asp Leu Arg Ala
	110	115
Lys Ala Glu Trp Glu	Gly Lys Gly Thr Ala	Ser Arg Ser Lys Leu
	125	130
Leu Asp Lys Leu Gln	Thr Tyr Leu Pro Pro	Ser Val Met Leu Pro
	140	145
Pro Arg Arg Leu Gln	Thr Leu Leu Arg Gln	Ala Val Glu Leu Gln
	155	160
Arg Asp Arg Cys Leu	Tyr His Asn Thr Lys	Leu Asp Asn Asn Leu
	170	175
Asp Ser Val Ser Leu	Leu Ile Asp His Val	Cys Ser Arg Arg Gln
	185	190
Phe Pro Cys Tyr Thr	Gln Gln Ile Leu Thr	Glu His Cys Asn Glu
	200	205
Val Trp Phe Cys Lys	Phe Ser Asn Asp Gly	Thr Lys Leu Ala Thr
	215	220
Gly Ser Lys Asp Thr	Thr Val Ile Ile Trp	Gln Val Asp Pro Asp
	230	235
Thr His Leu Leu Lys	Leu Leu Lys Thr Leu	Glu Gly His Ala Tyr
	245	250
Gly Val Ser Tyr Ile	Ala Trp Ser Pro Asp	Asp Asn Tyr Leu Val
	260	265
Ala Cys Gly Pro Asp	Asp Cys Ser Glu Leu	Trp Leu Trp Asn Val
	275	280
Gln Thr Gly Glu Leu	Arg Thr Lys Met Ser	Gln Ser His Glu Asp
	290	295
Ser Leu Thr Ser Val	Ala Trp Asn Pro Asp	Gly Lys Arg Phe Val
	305	310
Thr Gly Gly Gln Arg	Gly Gln Phe Tyr Gln	Cys Asp Leu Asp Gly
	320	325
		330

```

Asn Leu Leu Asp Ser Trp Glu Gly Val Arg Val Gln Cys Leu Trp
    335                      340                      345
Cys Leu Ser Asp Gly Lys Thr Val Leu Ala Ser Asp Thr His Gln
    350                      355                      360
Arg Ile Arg Gly Tyr Asn Phe Glu Asp Leu Thr Asp Arg Asn Ile
    365                      370                      375
Val Gln Glu Asp His Pro Ile Met Ser Phe Thr Ile Ser Lys Asn
    380                      385                      390
Gly Arg Leu Ala Leu Leu Asn Val Ala Thr Gln Gly Val His Leu
    395                      400                      405
Trp Asp Leu Gln Asp Arg Val Leu Val Arg Lys Tyr Gln Gly Val
    410                      415                      420
Thr Gln Gly Phe Tyr Thr Ile His Ser Cys Phe Gly Gly His Asn
    425                      430                      435
Glu Asp Phe Ile Ala Ser Gly Ser Glu Asp His Lys Val Tyr Ile
    440                      445                      450
Trp His Lys Arg Ser Glu Leu Pro Ile Ala Glu Leu Thr Gly His
    455                      460                      465
Thr Arg Thr Val Asn Cys Val Ser Trp Asn Pro Gln Ile Pro Ser
    470                      475                      480
Met Met Ala Ser Ala Ser Asp Asp Gly Thr Val Arg Ile Trp Gly
    485                      490                      495
Pro Ala Pro Phe Ile Asp His Gln Asn Ile Glu Glu Glu Cys Ser
    500                      505                      510
Ser Met Asp Ser

```

<210> 44

<211> 67

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5782457CD1

<400> 44

```

Met Glu Glu Trp Asp Val Pro Gln Met Lys Lys Glu Val Glu Ser
    1           5           10           15
Leu Lys Tyr Gln Leu Ala Phe Gln Arg Glu Met Ala Ser Lys Thr
    20           25           30
Ile Pro Glu Leu Leu Lys Trp Ile Glu Asp Gly Ile Pro Lys Asp
    35           40           45
Pro Phe Leu Asn Pro Asp Leu Met Lys Asn Asn Pro Trp Val Glu
    50           55           60
Lys Gly Lys Cys Thr Ile Leu
    65

```

<210> 45

<211> 315

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 760677CD1

<400> 45

```

Met Ala Phe Pro Glu Pro Lys Pro Arg Pro Pro Glu Leu Pro Gln
    1           5           10           15
Lys Arg Leu Lys Thr Leu Asp Cys Gly Gln Gly Ala Val Arg Ala
    20           25           30
Val Arg Phe Asn Val Asp Gly Asn Tyr Cys Leu Thr Cys Gly Ser
    35           40           45
Asp Lys Thr Leu Lys Leu Trp Asn Pro Leu Arg Gly Thr Leu Leu

```

50	55	60
Arg Thr Tyr Ser Gly His Gly Tyr Glu Val Leu Asp Ala Ala Gly		
65	70	75
Ser Phe Asp Asn Ser Ser Leu Cys Ser Gly Gly Gly Asp Lys Ala		
80	85	90
Val Val Leu Trp Asn Val Ala Ser Gly Gln Val Val Arg Lys Phe		
95	100	105
Arg Gly His Ala Gly Lys Val Asn Thr Val Gln Phe Ser Glu Glu		
110	115	120
Ala Thr Val Ile Leu Ser Gly Ser Ile Asp Ser Ser Ile Arg Cys		
125	130	135
Trp Asp Cys Arg Ser Arg Arg Pro Glu Pro Val Gln Thr Leu Asp		
140	145	150
Glu Ala Arg Asp Gly Val Ser Ser Val Lys Val Ser Asp His Glu		
155	160	165
Ile Leu Ala Gly Ser Val Asp Gly Arg Val Arg Arg Tyr Asp Leu		
170	175	180
Arg Met Gly Gln Leu Phe Ser Asp Tyr Val Gly Ser Pro Ile Thr		
185	190	195
Cys Thr Cys Phe Ser Arg Asp Gly Gln Cys Thr Leu Val Ser Ser		
200	205	210
Leu Asp Ser Thr Leu Arg Leu Leu Asp Lys Asp Thr Gly Glu Leu		
215	220	225
Leu Gly Glu Tyr Lys Gly His Lys Asn Gln Glu Tyr Lys Leu Asp		
230	235	240
Cys Cys Leu Ser Glu Arg Asp Thr His Val Val Ser Cys Ser Glu		
245	250	255
Asp Gly Lys Val Phe Phe Trp Asp Leu Val Glu Gly Ala Leu Ala		
260	265	270
Leu Ala Leu Pro Val Gly Ser Gly Val Val Gln Ser Leu Asp Tyr		
275	280	285
His Pro Thr Glu Pro Cys Leu Leu Thr Ala Met Gly Gly Ser Val		
290	295	300
Gln Cys Trp Arg Glu Glu Ala Tyr Glu Ala Glu Asp Gly Ala Gly		
305	310	315

<210> 46

<211> 504

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1348567CD1

<400> 46

Met Ser Leu Ile Cys Ser Ile Ser Asn Glu Val Pro Glu His Pro		
1	5	10
Cys Val Ser Pro Val Ser Asn His Val Tyr Glu Arg Arg Leu Ile		
20	25	30
Glu Lys Tyr Ile Ala Glu Asn Gly Thr Asp Pro Ile Asn Asn Gln		
35	40	45
Pro Leu Ser Glu Glu Gln Leu Ile Asp Ile Lys Val Ala His Pro		
50	55	60
Ile Arg Pro Lys Pro Pro Ser Ala Thr Ser Ile Pro Ala Ile Leu		
65	70	75
Lys Ala Leu Gln Asp Glu Trp Asp Ala Val Met Pro His Ser Phe		
80	85	90
Thr Leu Arg Gln Gln Leu Gln Thr Thr Arg Gln Glu Leu Ser His		
95	100	105
Ala Leu Tyr Gln His Asp Ala Ala Cys Arg Val Ile Ala Arg Leu		
110	115	120
Thr Lys Glu Val Thr Ala Ala Arg Glu Ala Leu Ala Thr Leu Lys		

	125		130		135
Pro Gln Ala Gly	Leu Ile Val Pro Gln Ala Val Pro Ser Ser	Gln			
	140		145		150
Pro Ser Val Val	Gly Ala Gly Glu Pro Met Asp Leu Gly Glu	Leu			
	155		160		165
Val Gly Met Thr	Pro Glu Ile Ile Gln Lys Leu Gln Asp Lys	Ala			
	170		175		180
Thr Val Leu Thr	Thr Glu Arg Lys Lys Arg Gly Lys Thr Val	Pro			
	185		190		195
Glu Glu Leu Val	Lys Pro Glu Glu Leu Ser Lys Tyr Arg Gln	Val			
	200		205		210
Ala Ser His Val	Gly Leu His Ser Ala Ser Ile Pro Gly Ile	Leu			
	215		220		225
Ala Leu Asp Leu	Cys Pro Ser Asp Thr Asn Lys Ile Leu Thr	Gly			
	230		235		240
Gly Ala Asp Lys	Asn Val Val Val Phe Asp Lys Ser Ser Glu	Gln			
	245		250		255
Ile Leu Ala Thr	Leu Lys Gly His Thr Lys Lys Val Thr Ser	Val			
	260		265		270
Val Phe His Pro	Ser Gln Asp Leu Val Phe Ser Ala Ser Pro	Asp			
	275		280		285
Ala Thr Ile Arg	Ile Trp Ser Val Pro Asn Ala Ser Cys Val	Gln			
	290		295		300
Val Val Arg Ala	His Glu Ser Ala Val Thr Gly Leu Ser Leu	His			
	305		310		315
Ala Thr Gly Asp	Tyr Leu Leu Ser Ser Ser Asp Asp Gln Tyr	Trp			
	320		325		330
Ala Phe Ser Asp	Ile Gln Thr Gly Arg Val Leu Thr Lys Val	Thr			
	335		340		345
Asp Glu Thr Ser	Gly Cys Ser Leu Thr Cys Ala Gln Phe His	Pro			
	350		355		360
Asp Gly Leu Ile	Phe Gly Thr Gly Thr Met Asp Ser Gln Ile	Lys			
	365		370		375
Ile Trp Asp Leu	Lys Glu Arg Thr Asn Val Ala Asn Phe Pro	Gly			
	380		385		390
His Ser Gly Pro	Ile Thr Ser Ile Ala Phe Ser Glu Asn Gly	Tyr			
	395		400		405
Tyr Leu Ala Thr	Ala Ala Asp Asp Ser Ser Val Lys Leu Trp	Asp			
	410		415		420
Leu Arg Lys Leu	Lys Asn Phe Lys Thr Leu Gln Leu Asp Asn	Asn			
	425		430		435
Phe Glu Val Lys	Ser Leu Ile Phe Asp Gln Ser Gly Thr Tyr	Leu			
	440		445		450
Ala Leu Gly Gly	Thr Asp Val Gln Ile Tyr Ile Cys Lys Gln	Trp			
	455		460		465
Thr Glu Ile Leu	His Phe Thr Glu His Ser Gly Leu Thr Thr	Gly			
	470		475		480
Val Ala Phe Gly	His His Ala Lys Phe Ile Ala Ser Thr Gly	Met			
	485		490		495
Asp Arg Ser Leu	Lys Phe Tyr Ser Leu				
	500				

<210> 47
 <211> 522
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <223> Incyte ID No: 1751354CD1

 <400> 47
 Met Ala Phe Leu Asp Asn Pro Thr Ile Ile Leu Ala His Ile Arg
 1 5 10 15

Gln	Ser	His	Val	Thr	Ser	Asp	Asp	Thr	Gly	Met	Cys	Glu	Met	Val
			20						25					30
Leu	Ile	Asp	His	Asp	Val	Asp	Leu	Glu	Lys	Ile	His	Pro	Pro	Ser
			35						40					45
Met	Pro	Gly	Asp	Ser	Gly	Ser	Glu	Ile	Gln	Gly	Ser	Asn	Gly	Glu
			50						55					60
Thr	Gln	Gly	Tyr	Val	Tyr	Ala	Gln	Ser	Val	Asp	Ile	Thr	Ser	Ser
			65						70					75
Trp	Asp	Phe	Gly	Ile	Arg	Arg	Arg	Ser	Asn	Thr	Ala	Gln	Arg	Leu
			80						85					90
Glu	Arg	Leu	Arg	Lys	Glu	Arg	Gln	Asn	Gln	Ile	Lys	Cys	Lys	Asn
			95						100					105
Ile	Gln	Trp	Lys	Glu	Arg	Asn	Ser	Lys	Gln	Ser	Ala	Gln	Glu	Leu
			110						115					120
Lys	Ser	Leu	Phe	Glu	Lys	Lys	Ser	Leu	Lys	Glu	Lys	Pro	Pro	Ile
			125						130					135
Ser	Gly	Lys	Gln	Ser	Ile	Leu	Ser	Val	Arg	Leu	Glu	Gln	Cys	Pro
			140						145					150
Leu	Gln	Leu	Asn	Asn	Pro	Phe	Asn	Glu	Tyr	Ser	Lys	Phe	Asp	Gly
			155						160					165
Lys	Gly	His	Val	Gly	Thr	Thr	Ala	Thr	Lys	Lys	Ile	Asp	Val	Tyr
			170						175					180
Leu	Pro	Leu	His	Ser	Ser	Gln	Asp	Arg	Leu	Leu	Pro	Met	Thr	Val
			185						190					195
Val	Thr	Met	Ala	Ser	Ala	Arg	Val	Gln	Asp	Leu	Ile	Gly	Leu	Ile
			200						205					210
Cys	Trp	Gln	Tyr	Thr	Ser	Glu	Gly	Arg	Glu	Pro	Lys	Leu	Asn	Asp
			215						220					225
Asn	Val	Ser	Ala	Tyr	Cys	Leu	His	Ile	Ala	Glu	Asp	Asp	Gly	Glu
			230						235					240
Val	Asp	Thr	Asp	Phe	Pro	Pro	Leu	Asp	Ser	Asn	Glu	Pro	Ile	His
			245						250					255
Lys	Phe	Gly	Phe	Ser	Thr	Leu	Ala	Leu	Val	Glu	Lys	Tyr	Ser	Ser
			260						265					270
Pro	Gly	Leu	Thr	Ser	Lys	Glu	Ser	Leu	Phe	Val	Arg	Ile	Asn	Ala
			275						280					285
Ala	His	Gly	Phe	Ser	Leu	Ile	Gln	Val	Asp	Asn	Thr	Lys	Val	Thr
			290						295					300
Met	Lys	Glu	Ile	Leu	Leu	Lys	Ala	Val	Lys	Arg	Arg	Lys	Gly	Ser
			305						310					315
Gln	Lys	Val	Ser	Gly	Pro	Gln	Tyr	Arg	Leu	Glu	Lys	Gln	Ser	Glu
			320						325					330
Pro	Asn	Val	Ala	Val	Asp	Leu	Asp	Ser	Thr	Leu	Glu	Ser	Gln	Ser
			335						340					345
Ala	Trp	Glu	Phe	Cys	Leu	Val	Arg	Glu	Asn	Ser	Ser	Arg	Ala	Asp
			350						355					360
Gly	Val	Phe	Glu	Glu	Asp	Ser	Gln	Ile	Asp	Ile	Ala	Thr	Val	Gln
			365						370					375
Asp	Met	Leu	Ser	Ser	His	His	Tyr	Lys	Ser	Phe	Lys	Val	Ser	Met
			380						385					390
Ile	His	Arg	Leu	Arg	Phe	Thr	Thr	Asp	Val	Gln	Leu	Gly	Ile	Ser
			395						400					405
Gly	Asp	Lys	Val	Glu	Ile	Asp	Pro	Val	Thr	Asn	Gln	Lys	Ala	Ser
			410						415					420
Thr	Lys	Phe	Trp	Ile	Lys	Gln	Lys	Pro	Ile	Ser	Ile	Asp	Ser	Asp
			425						430					435
Leu	Leu	Cys	Ala	Cys	Asp	Leu	Ala	Glu	Glu	Lys	Ser	Pro	Ser	His
			440						445					450
Ala	Ile	Phe	Lys	Leu	Thr	Tyr	Leu	Ser	Asn	His	Asp	Tyr	Lys	His
			455						460					465
Leu	Tyr	Phe	Glu	Ser	Asp	Ala	Ala	Thr	Val	Asn	Glu	Ile	Val	Leu
			470						475					480
Lys	Val	Asn	Tyr	Ile	Leu	Glu	Ser	Arg	Ala	Ser	Thr	Ala	Arg	Ala

	485		490		495
Asp Tyr Phe Ala	Gln Lys Gln Arg Lys	Leu Asn Arg Arg Thr	Ser		
	500		505		510
Phe Ser Phe Gln	Lys Glu Lys Lys Ser	Gly Gln Gln			
	515		520		

<210> 48

<211> 316

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1976780CD1

<400> 48

Met Ala Ser Lys Asp	Lys Ser Ser Lys	Lys Asn Val Phe Glu Leu	
1	5	10	15
Lys Thr Arg Gln Gly	Thr Glu Leu Leu Ile	Gln Ser Asp Asn Asp	
	20	25	30
Thr Val Ile Asn Asp	Trp Phe Lys Val	Leu Ser Ser Thr Ile Asn	
	35	40	45
Asn Gln Ala Val Glu	Thr Asp Glu Gly Ile	Glu Glu Glu Ile Pro	
	50	55	60
Asp Ser Pro Gly Ile	Glu Lys His Asp Lys	Glu Lys Glu Gln Lys	
	65	70	75
Asp Pro Lys Lys Leu	Arg Ser Phe Lys Val	Ser Ser Ile Asp Ser	
	80	85	90
Ser Glu Gln Lys Lys	Thr Lys Lys Asn Leu	Lys Lys Phe Leu Thr	
	95	100	105
Arg Arg Pro Thr Leu	Gln Ala Val Arg Glu	Lys Gly Tyr Ile Lys	
	110	115	120
Asp Gln Val Phe Gly	Ser Asn Leu Ala Asn	Leu Cys Gln Arg Glu	
	125	130	135
Asn Gly Thr Val Pro	Lys Phe Val Lys Leu	Cys Ile Glu His Val	
	140	145	150
Glu Glu His Gly Leu	Asp Ile Asp Gly Ile	Tyr Arg Val Ser Gly	
	155	160	165
Asn Leu Ala Val Ile	Gln Lys Leu Arg Phe	Ala Val Asn His Asp	
	170	175	180
Glu Lys Leu Asp Leu	Asn Asp Ser Lys Trp	Glu Asp Ile His Val	
	185	190	195
Ile Thr Gly Ala Leu	Lys Met Phe Phe Arg	Glu Leu Pro Glu Pro	
	200	205	210
Leu Phe Thr Phe Asn	His Phe Asn Asp Phe	Val Asn Ala Ile Lys	
	215	220	225
Gln Glu Pro Arg Gln	Arg Val Ala Ala Val	Lys Asp Leu Ile Arg	
	230	235	240
Gln Leu Pro Lys Pro	Asn Gln Asp Thr Met	Gln Ile Leu Phe Arg	
	245	250	255
His Leu Arg Arg Val	Ile Glu Asn Gly Glu	Lys Asn Arg Met Thr	
	260	265	270
Tyr Gln Ser Ile Ala	Ile Val Phe Gly Pro	Thr Leu Leu Lys Pro	
	275	280	285
Glu Lys Glu Thr Gly	Asn Ile Ala Val His	Thr Val Tyr Gln Asn	
	290	295	300
Gln Ile Val Glu Leu	Ile Leu Leu Glu Leu	Ser Ser Ile Phe Gly	
	305	310	315

Arg

<210> 49

<211> 387

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2048234CD1

<400> 49

Met	Val	His	Cys	Ser	Cys	Val	Leu	Phe	Arg	Lys	Tyr	Gly	Asn	Phe	1	5	10	15
Ile	Asp	Lys	Leu	Arg	Leu	Phe	Thr	Arg	Gly	Gly	Ser	Gly	Gly	Met	20	25	30	35
Gly	Tyr	Pro	Arg	Leu	Gly	Gly	Glu	Gly	Gly	Lys	Gly	Gly	Asp	Val	40	45	50	55
Trp	Val	Val	Ala	Gln	Asn	Arg	Met	Thr	Leu	Lys	Gln	Leu	Lys	Asp	60	65	70	75
Arg	Tyr	Pro	Arg	Lys	Arg	Phe	Val	Ala	Gly	Val	Gly	Ala	Asn	Ser	80	85	90	95
Lys	Ile	Ser	Ala	Leu	Lys	Gly	Ser	Lys	Gly	Lys	Asp	Trp	Glu	Ile	100	105	110	115
Pro	Val	Pro	Val	Gly	Ile	Ser	Val	Thr	Asp	Glu	Asn	Gly	Lys	Ile	120	125	130	135
Ile	Gly	Glu	Leu	Ser	Lys	Glu	Asn	Asp	Arg	Ile	Leu	Val	Ala	Gln	140	145	150	155
Gly	Gly	Leu	Gly	Gly	Lys	Leu	Leu	Thr	Asn	Phe	Leu	Pro	Leu	Lys	160	165	170	175
Gly	Gln	Lys	Arg	Ile	Ile	His	Leu	Asp	Leu	Lys	Leu	Ile	Ala	Asp	180	185	190	195
Val	Gly	Leu	Val	Gly	Phe	Pro	Asn	Ala	Gly	Lys	Ser	Ser	Leu	Leu	200	205	210	215
Ser	Cys	Val	Ser	His	Ala	Lys	Pro	Ala	Ile	Ala	Asp	Tyr	Ala	Phe	220	225	230	235
Thr	Thr	Leu	Lys	Leu	Lys	Leu	Gly	Lys	Ile	Met	Tyr	Ser	Asp	Phe	240	245	250	255
Lys	Gln	Ile	Ser	Val	Ala	Asp	Leu	Pro	Gly	Leu	Ile	Glu	Gly	Ala	260	265	270	275
His	Met	Asn	Lys	Gly	Met	Gly	His	Lys	Phe	Leu	Lys	His	Ile	Glu	280	285	290	295
Arg	Thr	Arg	Gln	Leu	Leu	Phe	Val	Val	Asp	Ile	Ser	Gly	Phe	Gln	300	305	310	315
Leu	Ser	Ser	His	Thr	Gln	Tyr	Arg	Thr	Ala	Phe	Glu	Thr	Ile	Ile	320	325	330	335
Leu	Leu	Thr	Lys	Glu	Leu	Glu	Leu	Tyr	Lys	Glu	Glu	Leu	Gln	Thr	340	345	350	355
Lys	Pro	Ala	Leu	Leu	Ala	Val	Asn	Lys	Met	Asp	Leu	Pro	Asp	Ala	360	365	370	375
Gln	Asp	Lys	Phe	His	Glu	Leu	Met	Ser	Gln	Leu	Gln	Asn	Pro	Lys	380	385		
Asp	Phe	Leu	His	Leu	Phe	Glu	Lys	Asn	Met	Ile	Pro	Glu	Arg	Thr				
Val	Glu	Phe	Gln	His	Ile	Ile	Pro	Ile	Ser	Ala	Val	Thr	Gly	Glu				
Gly	Ile	Glu	Glu	Leu	Lys	Asn	Cys	Ile	Arg	Lys	Ser	Leu	Asp	Glu				
Gln	Ala	Asn	Gln	Glu	Asn	Asp	Ala	Leu	His	Lys	Lys	Gln	Leu	Leu				
Asn	Leu	Trp	Ile	Ser	Asp	Thr	Met	Ser	Ser	Thr	Glu	Pro	Pro	Ser				
Lys	His	Ala	Val	Thr	Thr	Ser	Lys	Met	Asp	Ile	Ile							

<210> 50

<211> 334

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2111754CD1

<400> 50

```

Met Pro Ser Gly Pro Arg Ala Ala Leu Arg Trp Ala Ser Pro Ser
 1          5          10          15
Gln Leu Val Ser Tyr His Val Leu Arg Asn Gly Ile Tyr Ala Cys
 20          25          30
Tyr Pro His Ser Leu Arg Pro Arg Thr Pro Leu Leu Cys Ala Ser
 35          40          45
Arg Asn Ile Lys Pro Arg Arg Ser Glu Leu Leu Gly Cys Pro Val
 50          55          60
Gly Cys Arg Gly Ser Leu Ser Glu Gln Arg Ile Cys Leu Leu Gly
 65          70          75
Cys Leu Val Arg Ala Ser Glu Lys Gly Val Ser Cys Cys Gln Leu
 80          85          90
Ser Val Gly Glu Leu Val His Val Ser Pro Leu Arg Ile Pro Thr
 95          100         105
Met Gly Asn Ala Ser Phe Gly Ser Lys Glu Gln Lys Leu Leu Lys
110          115         120
Arg Leu Arg Leu Leu Pro Ala Leu Leu Ile Leu Arg Ala Phe Lys
125          130         135
Pro His Arg Lys Ile Arg Asp Tyr Arg Val Val Val Val Gly Thr
140          145         150
Ala Gly Val Gly Lys Ser Thr Leu Leu His Lys Trp Ala Ser Gly
155          160         165
Asn Phe Arg His Glu Tyr Leu Pro Thr Ile Glu Asn Thr Tyr Cys
170          175         180
Gln Leu Leu Gly Cys Ser His Gly Val Leu Ser Leu His Ile Thr
185          190         195
Asp Ser Lys Ser Gly Asp Gly Asn Arg Ala Leu Gln Arg His Val
200          205         210
Ile Ala Arg Gly His Ala Phe Val Leu Val Tyr Ser Val Thr Lys
215          220         225
Lys Glu Thr Leu Glu Glu Leu Lys Ala Phe Tyr Glu Leu Ile Cys
230          235         240
Lys Ile Lys Gly Asn Asn Leu His Lys Phe Pro Ile Val Leu Val
245          250         255
Gly Asn Lys Ser Asp Asp Thr His Arg Glu Val Ala Leu Asn Asp
260          265         270
Gly Ala Thr Cys Ala Met Glu Trp Asn Cys Ala Phe Met Glu Ile
275          280         285
Ser Ala Lys Thr Asp Val Asn Val Gln Glu Leu Phe His Met Leu
290          295         300
Leu Asn Tyr Lys Lys Lys Pro Thr Thr Gly Leu Gln Glu Pro Glu
305          310         315
Lys Lys Ser Gln Met Pro Asn Thr Thr Glu Lys Leu Leu Asp Lys
320          325         330
Cys Ile Ile Met

```

<210> 51

<211> 551

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2123286CD1

<400> 51

```

Met Glu Glu Glu Leu Pro Leu Phe Ser Gly Asp Ser Gly Lys Pro
 1          5          10          15
Val Gln Ala Thr Leu Ser Ser Leu Lys Met Leu Asp Val Gly Lys

```

	20		25		30									
Trp	Pro	Ile	Phe	Ser	Leu	Cys	Ser	Glu	Glu	Leu	Gln	Leu	Ile	
	35								40				45	
Arg	Gln	Ala	Cys	Val	Phe	Gly	Ser	Ala	Gly	Asn	Glu	Val	Leu	Tyr
	50								55					60
Thr	Thr	Val	Asn	Asp	Glu	Ile	Phe	Val	Leu	Gly	Thr	Asn	Cys	Cys
	65								70					75
Gly	Cys	Leu	Gly	Leu	Gly	Asp	Val	Gln	Ser	Thr	Ile	Glu	Pro	Arg
	80								85					90
Arg	Leu	Asp	Ser	Leu	Asn	Gly	Lys	Lys	Ile	Ala	Cys	Leu	Ser	Tyr
	95								100					105
Gly	Ser	Gly	Pro	His	Ile	Val	Leu	Ala	Thr	Thr	Glu	Gly	Glu	Val
	110								115					120
Phe	Thr	Trp	Gly	His	Asn	Ala	Tyr	Ser	Gln	Leu	Gly	Asn	Gly	Thr
	125								130					135
Thr	Asn	His	Gly	Leu	Val	Pro	Cys	His	Ile	Ser	Thr	Asn	Leu	Ser
	140								145					150
Asn	Lys	Gln	Val	Ile	Glu	Val	Ala	Cys	Gly	Ser	Tyr	His	Ser	Leu
	155								160					165
Val	Leu	Thr	Ser	Asp	Gly	Glu	Val	Phe	Ala	Trp	Gly	Tyr	Asn	Asn
	170								175					180
Ser	Gly	Gln	Val	Gly	Ser	Gly	Ser	Thr	Val	Asn	Gln	Pro	Ile	Pro
	185								190					195
Arg	Arg	Val	Thr	Gly	Cys	Leu	Gln	Asn	Lys	Val	Val	Val	Thr	Ile
	200								205					210
Ala	Cys	Gly	Gln	Met	Cys	Cys	Met	Ala	Val	Val	Asp	Thr	Gly	Glu
	215								220					225
Val	Tyr	Val	Trp	Gly	Tyr	Asn	Gly	Asn	Gly	Gln	Leu	Gly	Leu	Gly
	230								235					240
Asn	Ser	Gly	Asn	Gln	Pro	Thr	Pro	Cys	Arg	Val	Ala	Ala	Leu	Gln
	245								250					255
Gly	Ile	Arg	Val	Gln	Arg	Val	Ala	Cys	Gly	Tyr	Ala	His	Thr	Leu
	260								265					270
Val	Leu	Thr	Asp	Glu	Gly	Gln	Val	Tyr	Ala	Trp	Gly	Ala	Asn	Ser
	275								280					285
Tyr	Gly	Gln	Leu	Gly	Thr	Gly	Asn	Lys	Ser	Asn	Gln	Ser	Tyr	Pro
	290								295					300
Thr	Pro	Val	Thr	Val	Glu	Lys	Asp	Arg	Ile	Ile	Glu	Ile	Ala	Ala
	305								310					315
Cys	His	Ser	Thr	His	Thr	Ser	Ala	Ala	Lys	Thr	Gln	Gly	Gly	His
	320								325					330
Val	Tyr	Met	Trp	Gly	Gln	Cys	Arg	Gly	Gln	Ser	Val	Ile	Leu	Pro
	335								340					345
His	Leu	Thr	His	Phe	Ser	Cys	Thr	Asp	Asp	Val	Phe	Ala	Cys	Phe
	350								355					360
Ala	Thr	Pro	Ala	Val	Thr	Trp	Arg	Leu	Leu	Ser	Val	Glu	Pro	Asp
	365								370					375
Asp	His	Leu	Thr	Val	Ala	Glu	Ser	Leu	Lys	Arg	Glu	Phe	Asp	Asn
	380								385					390
Pro	Asp	Thr	Ala	Asp	Leu	Lys	Phe	Leu	Val	Asp	Gly	Lys	Tyr	Ile
	395								400					405
Tyr	Ala	His	Lys	Val	Leu	Leu	Lys	Ile	Arg	Cys	Glu	His	Phe	Arg
	410								415					420
Ser	Ser	Leu	Glu	Asp	Asn	Glu	Asp	Asp	Ile	Val	Glu	Met	Ser	Glu
	425								430					435
Phe	Ser	Tyr	Pro	Val	Tyr	Arg	Ala	Phe	Leu	Glu	Tyr	Leu	Tyr	Thr
	440								445					450
Asp	Ser	Ile	Ser	Leu	Ser	Pro	Glu	Glu	Ala	Val	Gly	Leu	Leu	Asp
	455								460					465
Leu	Ala	Thr	Phe	Tyr	Arg	Glu	Asn	Arg	Leu	Lys	Lys	Leu	Cys	Gln
	470								475					480
Gln	Thr	Ile	Lys	Gln	Gly	Ile	Cys	Glu	Glu	Asn	Ala	Ile	Ala	Leu
	485								490					495

Leu Ser Ala Ala Val Lys Tyr Asp Ala Gln Asp Leu Glu Glu Phe
 500 505 510
 Cys Phe Arg Phe Cys Ile Asn His Leu Thr Val Val Thr Gln Thr
 515 520 525
 Ser Gly Phe Ala Glu Met Asp His Asp Leu Leu Lys Asn Phe Ile
 530 535 540
 Ser Lys Ala Ser Arg Val Gly Ala Phe Lys Asn
 545 550

<210> 52

<211> 308

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2477507CD1

<400> 52

Met Ile His Asp Ala Gln Met Asp Tyr Tyr Gly Thr Arg Leu Ala
 1 5 10 15
 Thr Cys Ser Ser Asp Arg Ser Val Lys Ile Phe Asp Val Arg Asn
 20 25 30
 Gly Gly Gln Ile Leu Ile Ala Asp Leu Arg Gly His Glu Gly Pro
 35 40 45
 Val Trp Gln Val Ala Trp Ala His Pro Met Tyr Gly Asn Ile Leu
 50 55 60
 Ala Ser Cys Ser Tyr Asp Arg Lys Val Ile Ile Trp Arg Glu Glu
 65 70 75
 Asn Gly Thr Trp Glu Lys Ser His Glu His Ala Gly His Asp Ser
 80 85 90
 Ser Val Asn Ser Val Cys Trp Ala Pro His Asp Tyr Gly Leu Ile
 95 100 105
 Leu Ala Cys Gly Ser Ser Asp Gly Ala Ile Ser Leu Leu Thr Tyr
 110 115 120
 Thr Gly Glu Gly Gln Trp Glu Val Lys Lys Ile Asn Asn Ala His
 125 130 135
 Thr Ile Gly Cys Asn Ala Val Ser Trp Ala Pro Ala Val Val Pro
 140 145 150
 Gly Ser Leu Ile Asp His Pro Ser Gly Gln Lys Pro Asn Tyr Ile
 155 160 165
 Lys Arg Phe Ala Ser Gly Gly Cys Asp Asn Leu Ile Lys Leu Trp
 170 175 180
 Lys Glu Glu Glu Asp Gly Gln Trp Lys Glu Glu Lys Leu Glu
 185 190 195
 Ala His Ser Asp Trp Val Arg Asp Val Ala Trp Ala Pro Ser Ile
 200 205 210
 Gly Leu Pro Thr Ser Thr Ile Ala Ser Cys Ser Gln Asp Gly Arg
 215 220 225
 Val Phe Ile Trp Thr Cys Asp Asp Ala Ser Ser Asn Thr Trp Ser
 230 235 240
 Pro Lys Leu Leu His Lys Phe Asn Asp Val Val Trp His Val Ser
 245 250 255
 Trp Ser Ile Thr Ala Asn Ile Leu Ala Val Ser Gly Gly Asp Asn
 260 265 270
 Lys Val Thr Leu Trp Lys Glu Ser Val Asp Gly Gln Trp Val Cys
 275 280 285
 Ile Ser Asp Val Asn Lys Gly Gln Gly Ser Val Ser Ala Ser Val
 290 295 300
 Thr Glu Gly Gln Gln Asn Glu Gln
 305

<210> 53

<211> 949

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2759119CD1

<400> 53

```

Met Asp Ala Leu Glu Asp Tyr Val Trp Pro Arg Ala Thr Ser Glu
 1          5          10          15
Leu Ile Leu Leu Pro Val Thr Gly Leu Glu Cys Val Gly Asp Arg
 20          25          30
Leu Leu Ala Gly Glu Gly Pro Asp Val Leu Val Tyr Ser Leu Asp
 35          40          45
Phe Gly Gly His Leu Arg Met Ile Lys Arg Val Gln Asn Leu Leu
 50          55          60
Gly His Tyr Leu Ile His Gly Phe Arg Val Arg Pro Glu Pro Asn
 65          70          75
Gly Asp Leu Asp Leu Glu Ala Met Val Ala Val Phe Gly Ser Lys
 80          85          90
Gly Leu Arg Val Val Lys Ile Ser Trp Gly Gln Gly His Phe Trp
 95          100         105
Glu Leu Trp Arg Ser Gly Leu Trp Asn Met Ser Asp Trp Ile Trp
 110         115         120
Asp Ala Arg Trp Leu Glu Gly Asn Ile Ala Leu Ala Leu Gly His
 125         130         135
Asn Ser Val Val Leu Tyr Asp Pro Val Val Gly Cys Ile Leu Gln
 140         145         150
Glu Val Pro Cys Thr Asp Arg Cys Thr Leu Ser Ser Ala Cys Leu
 155         160         165
Ile Gly Asp Ala Trp Lys Glu Leu Thr Ile Val Ala Gly Ala Val
 170         175         180
Ser Asn Gln Leu Leu Val Trp Tyr Pro Ala Thr Ala Leu Ala Asp
 185         190         195
Asn Lys Pro Val Ala Pro Asp Arg Arg Ile Ser Gly His Val Gly
 200         205         210
Ile Ile Phe Ser Met Ser Tyr Leu Glu Ser Lys Gly Leu Leu Ala
 215         220         225
Thr Ala Ser Glu Asp Arg Ser Val Arg Ile Trp Lys Val Gly Asp
 230         235         240
Leu Arg Val Pro Gly Gly Arg Val Gln Asn Ile Gly His Cys Phe
 245         250         255
Gly His Ser Ala Arg Val Trp Gln Val Lys Leu Leu Glu Asn Tyr
 260         265         270
Leu Ile Ser Ala Gly Glu Asp Cys Val Cys Leu Val Trp Ser His
 275         280         285
Glu Gly Glu Ile Leu Gln Ala Phe Arg Gly His Gln Gly Arg Gly
 290         295         300
Ile Arg Ala Ile Ala Ala His Glu Arg Gln Ala Trp Val Ile Thr
 305         310         315
Gly Gly Asp Asp Ser Gly Ile Arg Leu Trp His Leu Val Gly Arg
 320         325         330
Gly Tyr Arg Gly Leu Gly Val Ser Ala Leu Cys Phe Lys Ser Arg
 335         340         345
Ser Arg Pro Gly Thr Leu Lys Ala Val Thr Leu Ala Gly Ser Trp
 350         355         360
Arg Leu Leu Ala Val Thr Asp Thr Gly Ala Leu Tyr Leu Tyr Asp
 365         370         375
Val Glu Val Lys Cys Trp Glu Gln Leu Leu Glu Asp Lys His Phe
 380         385         390
Gln Ser Tyr Cys Leu Leu Glu Ala Ala Pro Gly Pro Glu Gly Phe
 395         400         405
Gly Leu Cys Ala Met Ala Asn Gly Glu Gly Arg Val Lys Val Val
 410         415         420

```

Pro	Ile	Asn	Thr	Pro	Thr	Ala	Ala	Val	Asp	Gln	Thr	Leu	Phe	Pro
				425					430					435
Gly	Lys	Val	His	Ser	Leu	Ser	Trp	Ala	Leu	Arg	Gly	Tyr	Glu	Glu
				440					445					450
Leu	Leu	Leu	Leu	Ala	Ser	Gly	Pro	Gly	Gly	Val	Val	Ala	Cys	Leu
				455					460					465
Glu	Ile	Ser	Ala	Ala	Pro	Ser	Gly	Lys	Ala	Ile	Phe	Val	Lys	Glu
				470					475					480
Arg	Cys	Arg	Tyr	Leu	Leu	Pro	Pro	Ser	Lys	Gln	Arg	Trp	His	Thr
				485					490					495
Cys	Ser	Ala	Phe	Leu	Pro	Pro	Gly	Asp	Phe	Leu	Val	Cys	Gly	Asp
				500					505					510
Arg	Arg	Gly	Ser	Val	Leu	Leu	Phe	Pro	Ser	Arg	Pro	Gly	Leu	Leu
				515					520					525
Lys	Asp	Pro	Gly	Val	Gly	Gly	Lys	Ala	Arg	Ala	Gly	Ala	Gly	Ala
				530					535					540
Pro	Val	Val	Gly	Ser	Gly	Ser	Ser	Gly	Gly	Gly	Asn	Ala	Phe	Thr
				545					550					555
Gly	Leu	Gly	Pro	Val	Ser	Thr	Leu	Pro	Ser	Leu	His	Gly	Lys	Gln
				560					565					570
Gly	Val	Thr	Ser	Val	Thr	Cys	His	Gly	Gly	Tyr	Val	Tyr	Thr	Ile
				575					580					585
Gly	Arg	Asp	Gly	Ala	Tyr	Tyr	Gln	Leu	Phe	Val	Arg	Asp	Gly	Gln
				590					595					600
Leu	Gln	Pro	Val	Leu	Arg	Gln	Lys	Ser	Cys	Arg	Gly	Met	Asn	Trp
				605					610					615
Leu	Ala	Gly	Leu	Arg	Ile	Val	Pro	Asp	Gly	Ser	Met	Val	Ile	Leu
				620					625					630
Gly	Phe	His	Ala	Asn	Glu	Phe	Val	Val	Trp	Asn	Pro	Arg	Ser	His
				635					640					645
Glu	Lys	Leu	His	Ile	Val	Asn	Cys	Gly	Gly	Gly	His	Arg	Ser	Trp
				650					655					660
Ala	Phe	Ser	Asp	Thr	Glu	Ala	Ala	Met	Ala	Phe	Ala	Tyr	Leu	Lys
				665					670					675
Asp	Gly	Asp	Val	Met	Leu	Tyr	Arg	Ala	Leu	Gly	Gly	Cys	Thr	Arg
				680					685					690
Pro	His	Val	Ile	Leu	Arg	Glu	Gly	Leu	His	Gly	Arg	Glu	Ile	Thr
				695					700					705
Cys	Val	Lys	Arg	Val	Gly	Thr	Ile	Thr	Leu	Gly	Pro	Glu	Tyr	Gly
				710					715					720
Val	Pro	Ser	Phe	Met	Gln	Pro	Asp	Asp	Leu	Glu	Pro	Gly	Ser	Glu
				725					730					735
Gly	Pro	Asp	Leu	Thr	Asp	Ile	Val	Ile	Thr	Cys	Ser	Glu	Asp	Thr
				740					745					750
Thr	Val	Cys	Val	Leu	Ala	Leu	Pro	Thr	Thr	Thr	Gly	Ser	Ala	His
				755					760					765
Ala	Leu	Thr	Ala	Val	Cys	Asn	His	Ile	Ser	Ser	Val	Arg	Ala	Val
				770					775					780
Ala	Val	Trp	Gly	Ile	Gly	Thr	Pro	Gly	Gly	Pro	Gln	Asp	Pro	Gln
				785					790					795
Pro	Gly	Leu	Thr	Ala	His	Val	Val	Ser	Ala	Gly	Gly	Arg	Ala	Glu
				800					805					810
Met	His	Cys	Phe	Ser	Ile	Met	Val	Thr	Pro	Asp	Pro	Ser	Thr	Pro
				815					820					825
Ser	Arg	Leu	Ala	Cys	His	Val	Met	His	Leu	Ser	Ser	His	Arg	Leu
				830					835					840
Asp	Glu	Tyr	Trp	Asp	Arg	Gln	Arg	Asn	Arg	His	Arg	Met	Val	Lys
				845					850					855
Val	Asp	Pro	Glu	Thr	Arg	Tyr	Met	Ser	Leu	Ala	Val	Cys	Glu	Leu
				860					865					870
Asp	Gln	Pro	Gly	Leu	Gly	Pro	Leu	Val	Ala	Ala	Ala	Cys	Ser	Asp
				875					880					885
Gly	Ala	Val	Ser	Ser	Phe	Phe	Cys	Arg	Ile	Leu	Gly	Gly	Phe	Cys

				890					895				900	
Ser	Ser	Leu	Leu	Lys	Pro	Ser	Thr	Ile	Ser	Asp	Val	Ser	Ser	Arg
				905					910					915
Ser	Thr	Pro	Leu	His	Thr	Arg	His	Pro	Thr	Arg	Gly	Gly	Gly	Ser
				920					925					930
Ser	Cys	Ala	Ala	Gln	Leu	Leu	Met	Ala	Ala	Trp	Leu	Ser	Gly	Ile
				935					940					945

Ser Pro Pro Cys

<210> 54

<211> 227

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2823818CD1

<400> 54

Met	Arg	His	Glu	Ala	Pro	Met	Gln	Met	Ala	Ser	Ala	Gln	Asp	Ala
1				5					10					15
Arg	Tyr	Gly	Gln	Lys	Asp	Ser	Ser	Asp	Gln	Asn	Phe	Asp	Tyr	Met
				20					25					30
Phe	Lys	Leu	Leu	Ile	Ile	Gly	Asn	Ser	Ser	Val	Gly	Lys	Thr	Ser
				35					40					45
Phe	Leu	Phe	Arg	Tyr	Ala	Asp	Asp	Ser	Phe	Thr	Ser	Ala	Phe	Val
				50					55					60
Ser	Thr	Val	Gly	Ile	Asp	Phe	Lys	Val	Lys	Thr	Val	Phe	Lys	Asn
				65					70					75
Val	Lys	Arg	Ile	Lys	Leu	Gln	Ile	Trp	Asp	Thr	Ala	Gly	Gln	Glu
				80					85					90
Arg	Tyr	Arg	Thr	Ile	Thr	Thr	Ala	Tyr	Tyr	Arg	Gly	Ala	Met	Gly
				95					100					105
Phe	Ile	Leu	Met	Tyr	Asp	Ile	Thr	Asn	Glu	Glu	Ser	Phe	Asn	Ala
				110					115					120
Val	Gln	Asp	Trp	Ser	Thr	Gln	Ile	Lys	Thr	Tyr	Ser	Trp	Asp	Asn
				125					130					135
Ala	Gln	Val	Ile	Leu	Val	Gly	Asn	Lys	Cys	Asp	Met	Glu	Asp	Glu
				140					145					150
Arg	Val	Ile	Ser	Thr	Glu	Arg	Gly	Gln	His	Leu	Gly	Glu	Gln	Leu
				155					160					165
Gly	Phe	Glu	Phe	Phe	Glu	Thr	Ser	Ala	Lys	Asp	Asn	Ile	Asn	Val
				170					175					180
Lys	Gln	Thr	Phe	Glu	Arg	Leu	Val	Asp	Ile	Ile	Cys	Asp	Lys	Met
				185					190					195
Ser	Glu	Ser	Leu	Glu	Thr	Asp	Pro	Ala	Ile	Thr	Ala	Ala	Lys	Gln
				200					205					210
Asn	Thr	Arg	Leu	Lys	Glu	Thr	Pro	Pro	Pro	Pro	Gln	Pro	Asn	Cys
				215					220					225

Ala Cys

<210> 55

<211> 474

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2859730CD1

<400> 55

Met	Arg	Arg	Val	Val	Arg	Gln	Ser	Lys	Phe	Arg	His	Val	Phe	Gly
1				5					10					15

Gln	Ala	Val	Lys	Asn	Asp	Gln	Cys	Tyr	Asp	Asp	Ile	Arg	Val	Ser
				20					25					30
Arg	Val	Thr	Trp	Asp	Ser	Ser	Phe	Cys	Ala	Val	Asn	Pro	Arg	Phe
				35					40					45
Val	Ala	Ile	Ile	Ile	Glu	Ala	Ser	Gly	Gly	Gly	Ala	Phe	Leu	Val
				50					55					60
Leu	Pro	Leu	Arg	Lys	Thr	Gly	Arg	Ile	Asp	Lys	Ser	Tyr	Pro	Thr
				65					70					75
Val	Cys	Gly	His	Thr	Gly	Pro	Val	Leu	Asp	Ile	Asp	Trp	Cys	Pro
				80					85					90
His	Asn	Asp	Gln	Val	Ile	Ala	Ser	Gly	Ser	Glu	Asp	Cys	Thr	Val
				95					100					105
Met	Val	Trp	Gln	Ile	Pro	Glu	Asn	Gly	Leu	Thr	Leu	Ser	Leu	Thr
				110					115					120
Glu	Pro	Val	Val	Ile	Leu	Glu	Gly	His	Ser	Lys	Arg	Val	Gly	Ile
				125					130					135
Val	Ala	Trp	His	Pro	Thr	Ala	Arg	Asn	Val	Leu	Leu	Ser	Ala	Gly
				140					145					150
Cys	Asp	Asn	Ala	Ile	Ile	Ile	Trp	Asn	Val	Gly	Thr	Gly	Glu	Ala
				155					160					165
Leu	Ile	Asn	Leu	Asp	Asp	Met	His	Ser	Asp	Met	Ile	Tyr	Asn	Val
				170					175					180
Ser	Trp	Asn	Arg	Asn	Gly	Ser	Leu	Ile	Cys	Thr	Ala	Ser	Lys	Asp
				185					190					195
Lys	Lys	Val	Arg	Val	Ile	Asp	Pro	Arg	Lys	Gln	Glu	Ile	Val	Ala
				200					205					210
Glu	Lys	Glu	Lys	Ala	His	Glu	Gly	Ala	Arg	Pro	Met	Arg	Ala	Ile
				215					220					225
Phe	Leu	Ala	Asp	Gly	Asn	Val	Phe	Thr	Thr	Gly	Phe	Ser	Arg	Met
				230					235					240
Ser	Glu	Arg	Gln	Leu	Ala	Leu	Trp	Asn	Pro	Lys	Asn	Met	Gln	Glu
				245					250					255
Pro	Ile	Ala	Leu	His	Glu	Met	Asp	Thr	Ser	Asn	Gly	Val	Leu	Leu
				260					265					270
Pro	Phe	Tyr	Asp	Pro	Asp	Thr	Ser	Ile	Ile	Tyr	Leu	Cys	Gly	Lys
				275					280					285
Gly	Asp	Ser	Ser	Ile	Arg	Tyr	Phe	Glu	Ile	Thr	Asp	Glu	Ser	Pro
				290					295					300
Tyr	Val	His	Tyr	Leu	Asn	Thr	Phe	Ser	Ser	Lys	Glu	Pro	Gln	Arg
				305					310					315
Gly	Met	Gly	Tyr	Met	Pro	Lys	Arg	Gly	Leu	Asp	Val	Asn	Lys	Cys
				320					325					330
Glu	Ile	Ala	Arg	Phe	Phe	Lys	Leu	His	Glu	Arg	Lys	Cys	Glu	Pro
				335					340					345
Ile	Ile	Met	Thr	Val	Pro	Arg	Lys	Ser	Asp	Leu	Phe	Gln	Asp	Asp
				350					355					360
Leu	Tyr	Pro	Asp	Thr	Ala	Gly	Pro	Glu	Ala	Ala	Leu	Glu	Ala	Glu
				365					370					375
Glu	Trp	Phe	Glu	Gly	Lys	Asn	Ala	Asp	Pro	Ile	Leu	Ile	Ser	Leu
				380					385					390
Lys	His	Gly	Tyr	Ile	Pro	Gly	Lys	Asn	Arg	Asp	Leu	Lys	Val	Val
				395					400					405
Lys	Lys	Asn	Ile	Leu	Asp	Ser	Lys	Pro	Thr	Ala	Asn	Lys	Lys	Cys
				410					415					420
Asp	Leu	Ile	Ser	Ile	Pro	Lys	Lys	Thr	Thr	Asp	Thr	Ala	Ser	Val
				425					430					435
Gln	Asn	Glu	Ala	Lys	Leu	Asp	Glu	Ile	Leu	Lys	Glu	Ile	Lys	Ser
				440					445					450
Ile	Lys	Asp	Thr	Ile	Cys	Asn	Gln	Asp	Glu	Arg	Ile	Ser	Lys	Leu
				455					460					465
Glu	Gln	Gln	Met	Ala	Lys	Ile	Ala	Ala						
				470										

<210> 56

<211> 547
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2861155CD1

<400> 56

Met	Lys	Thr	Leu	Glu	Thr	Gln	Pro	Leu	Ala	Pro	Asp	Cys	Cys	Pro	1	5	10	15
Ser	Asp	Gln	Asp	Pro	Ala	Pro	Ala	His	Pro	Ser	Pro	His	Ala	Ser	20	25	30	35
Pro	Met	Asn	Lys	Asn	Ala	Asp	Ser	Glu	Leu	Met	Pro	Pro	Pro	Pro	40	45	50	55
Glu	Arg	Gly	Asp	Pro	Pro	Arg	Leu	Ser	Pro	Asp	Pro	Val	Ala	Gly	60	65	70	75
Ser	Ala	Val	Ser	Gln	Glu	Leu	Arg	Glu	Gly	Asp	Pro	Val	Ser	Leu	80	85	90	95
Ser	Thr	Pro	Leu	Glu	Thr	Glu	Phe	Gly	Ser	Pro	Ser	Glu	Leu	Ser	100	105	110	115
Pro	Arg	Ile	Glu	Glu	Gln	Glu	Leu	Ser	Glu	Asn	Thr	Ser	Leu	Pro	120	125	130	135
Ala	Glu	Glu	Ala	Asn	Gly	Ser	Leu	Ser	Glu	Glu	Glu	Ala	Asn	Gly	140	145	150	155
Pro	Glu	Leu	Gly	Ser	Gly	Lys	Ala	Met	Glu	Asp	Thr	Ser	Gly	Glu	160	165	170	175
Pro	Ala	Ala	Glu	Asp	Glu	Gly	Asp	Thr	Ala	Trp	Asn	Tyr	Ser	Phe	180	185	190	195
Ser	Gln	Leu	Pro	Arg	Phe	Leu	Ser	Gly	Ser	Trp	Ser	Glu	Phe	Ser	200	205	210	215
Thr	Gln	Pro	Glu	Asn	Phe	Leu	Lys	Gly	Cys	Lys	Trp	Ala	Pro	Asp	220	225	230	235
Gly	Ser	Cys	Ile	Leu	Thr	Asn	Ser	Ala	Asp	Asn	Ile	Leu	Arg	Ile	240	245	250	255
Tyr	Asn	Leu	Pro	Pro	Glu	Leu	Tyr	His	Glu	Gly	Glu	Gln	Val	Glu	260	265	270	275
Tyr	Ala	Glu	Met	Val	Pro	Val	Leu	Arg	Met	Val	Glu	Gly	Asp	Thr	280	285	290	295
Ile	Tyr	Asp	Tyr	Cys	Trp	Tyr	Ser	Leu	Met	Ser	Ser	Ala	Gln	Pro	300	305	310	315
Asp	Thr	Ser	Tyr	Val	Ala	Ser	Ser	Ser	Arg	Glu	Asn	Pro	Ile	His	320	325	330	335
Ile	Trp	Asp	Ala	Phe	Thr	Gly	Glu	Leu	Arg	Ala	Ser	Phe	Arg	Ala	340	345	350	355
Tyr	Asn	His	Leu	Asp	Glu	Leu	Thr	Ala	Ala	His	Ser	Leu	Cys	Phe	360	365	370	375
Ser	Pro	Asp	Gly	Ser	Gln	Leu	Phe	Cys	Gly	Phe	Asn	Arg	Thr	Val	380	385	390	395
Arg	Val	Phe	Ser	Thr	Ala	Arg	Pro	Gly	Arg	Asp	Cys	Glu	Val	Arg	400	405		
Ala	Thr	Phe	Ala	Lys	Lys	Gln	Gly	Gln	Ser	Gly	Ile	Ile	Ser	Cys				
Ile	Ala	Phe	Ser	Pro	Ala	Gln	Pro	Leu	Tyr	Ala	Cys	Gly	Ser	Tyr				
Gly	Arg	Ser	Leu	Gly	Leu	Tyr	Ala	Trp	Asp	Asp	Gly	Ser	Pro	Leu				
Ala	Leu	Leu	Gly	Gly	His	Gln	Gly	Gly	Ile	Thr	His	Leu	Cys	Phe				
His	Pro	Asp	Gly	Asn	Arg	Phe	Phe	Ser	Gly	Ala	Arg	Lys	Asp	Ala				
Glu	Leu	Leu	Cys	Trp	Asp	Leu	Arg	Gln	Ser	Gly	Tyr	Pro	Leu	Trp				

```

Ser Leu Gly Arg Glu Val Thr Thr Asn Gln Arg Ile Tyr Phe Asp
410 415 420
Leu Asp Pro Thr Gly Gln Phe Leu Val Ser Gly Ser Thr Ser Gly
425 430 435
Ala Val Ser Val Trp Asp Thr Asp Gly Pro Gly Asn Asp Gly Lys
440 445 450
Pro Glu Pro Val Leu Ser Phe Leu Pro Gln Lys Asp Cys Thr Asn
455 460 465
Gly Val Ser Leu His Pro Ser Leu Pro Leu Leu Ala Thr Ala Ser
470 475 480
Gly Gln Arg Val Phe Pro Glu Pro Thr Glu Ser Gly Asp Glu Gly
485 490 495
Glu Glu Leu Gly Leu Pro Leu Leu Ser Thr Arg His Val His Leu
500 505 510
Glu Cys Arg Leu Gln Leu Trp Trp Cys Gly Gly Gly Pro Asp Ser
515 520 525
Ser Ile Pro Asp Asp His Gln Gly Glu Lys Gly Gln Gly Gly Thr
530 535 540
Gly Gly Arg Ser Trp Gly Ala
545

```

<210> 57

<211> 686

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3002667CD1

<400> 57

```

Met Gly Glu Phe Lys Val His Arg Val Arg Phe Phe Asn Tyr Val
1 5 10 15
Pro Ser Gly Ile Arg Cys Val Ala Tyr Asn Asn Gln Ser Asn Arg
20 25 30
Leu Ala Val Ser Arg Thr Asp Gly Thr Val Glu Ile Tyr Asn Leu
35 40 45
Ser Ala Asn Tyr Phe Gln Glu Lys Phe Phe Pro Gly His Glu Ser
50 55 60
Arg Ala Thr Glu Ala Leu Cys Trp Ala Glu Gly Gln Arg Leu Phe
65 70 75
Ser Ala Gly Leu Asn Gly Glu Ile Met Glu Tyr Asp Leu Gln Ala
80 85 90
Leu Asn Ile Lys Tyr Ala Met Asp Ala Phe Gly Gly Pro Ile Trp
95 100 105
Ser Met Ala Ala Ser Pro Ser Gly Ser Gln Leu Leu Val Gly Cys
110 115 120
Glu Asp Gly Ser Val Lys Leu Phe Gln Ile Thr Pro Asp Lys Ile
125 130 135
Gln Phe Glu Arg Asn Phe Asp Arg Gln Lys Ser Arg Ile Leu Ser
140 145 150
Leu Ser Trp His Pro Ser Gly Thr His Ile Ala Ala Gly Ser Ile
155 160 165
Asp Tyr Ile Ser Val Phe Asp Val Lys Ser Gly Ser Ala Val His
170 175 180
Lys Met Ile Val Asp Arg Gln Tyr Met Gly Val Ser Lys Arg Lys
185 190 195
Cys Ile Val Trp Gly Val Ala Phe Leu Ser Asp Gly Thr Ile Ile
200 205 210
Ser Val Asp Ser Ala Gly Lys Val Gln Phe Trp Asp Ser Ala Thr
215 220 225
Gly Thr Leu Val Lys Ser His Leu Ile Ala Asn Ala Asp Val Gln
230 235 240
Ser Ile Ala Val Ala Asp Gln Glu Asp Ser Phe Val Val Gly Thr

```

	245		250		255
Ala Glu Gly Thr	Val Phe His Phe Gln	Leu Val Pro Val Thr	Ser		
	260		265		270
Asn Ser Ser Glu	Lys Gln Trp Val Arg	Thr Lys Pro Phe Gln	His		
	275		280		285
His Thr His Asp	Val Arg Thr Val Ala	His Ser Pro Thr Ala	Leu		
	290		295		300
Ile Ser Gly Gly	Thr Asp Thr His Leu	Val Phe Arg Pro Leu	Met		
	305		310		315
Glu Lys Val Glu	Val Lys Asn Tyr Asp	Ala Ala Leu Arg Lys	Ile		
	320		325		330
Thr Phe Pro His	Arg Cys Leu Ile Ser	Cys Ser Lys Lys Arg	Gln		
	335		340		345
Leu Leu Leu Phe	Gln Phe Ala His His	Leu Glu Leu Trp Arg	Leu		
	350		355		360
Gly Ser Thr Val	Ala Thr Gly Lys Asn	Gly Asp Thr Leu Pro	Leu		
	365		370		375
Ser Lys Asn Ala	Asp His Leu Leu His	Leu Lys Thr Lys Gly	Pro		
	380		385		390
Glu Asn Ile Ile	Cys Ser Cys Ile Ser	Pro Cys Gly Ser Trp	Ile		
	395		400		405
Ala Tyr Ser Thr	Val Ser Arg Phe Phe	Leu Tyr Arg Leu Asn	Tyr		
	410		415		420
Glu His Asp Asn	Ile Ser Leu Lys Arg	Val Ser Lys Met Pro	Ala		
	425		430		435
Phe Leu Arg Ser	Ala Leu Gln Ile Leu	Phe Ser Glu Asp Ser	Thr		
	440		445		450
Lys Leu Phe Val	Ala Ser Asn Gln Gly	Ala Leu His Ile Val	Gln		
	455		460		465
Leu Ser Gly Gly	Ser Phe Lys His Leu	His Ala Phe Gln Pro	Gln		
	470		475		480
Ser Gly Thr Val	Glu Ala Met Cys Leu	Leu Ala Val Ser Pro	Asp		
	485		490		495
Gly Asn Trp Leu	Ala Ala Ser Gly Thr	Ser Ala Gly Val His	Val		
	500		505		510
Tyr Asn Val Lys	Gln Leu Lys Leu His	Cys Thr Val Pro Ala	Tyr		
	515		520		525
Asn Phe Pro Val	Thr Ala Met Ala Ile	Ala Pro Asn Thr Asn	Asn		
	530		535		540
Leu Val Ile Ala	His Ser Asp Gln Gln	Val Phe Glu Tyr Ser	Ile		
	545		550		555
Pro Asp Lys Gln	Tyr Thr Asp Trp Ser	Arg Thr Val Gln Lys	Gln		
	560		565		570
Gly Phe His His	Leu Trp Leu Gln Arg	Asp Thr Pro Ile Thr	His		
	575		580		585
Ile Ser Phe His	Pro Lys Arg Pro Met	His Ile Leu Leu His	Asp		
	590		595		600
Ala Tyr Met Phe	Cys Ile Ile Asp Lys	Ser Leu Pro Leu Pro	Asn		
	605		610		615
Asp Lys Thr Leu	Leu Tyr Asn Pro Phe	Pro Pro Thr Asn Glu	Ser		
	620		625		630
Asp Val Ile Arg	Arg Arg Thr Ala His	Ala Phe Lys Ile Ser	Lys		
	635		640		645
Ile Tyr Lys Pro	Leu Leu Phe Met Asp	Leu Leu Asp Glu Arg	Thr		
	650		655		660
Leu Val Ala Val	Glu Arg Pro Leu Asp	Asp Ile Ile Ala Gln	Leu		
	665		670		675
Pro Pro Pro Ile	Lys Lys Lys Lys Phe	Gly Thr			
	680		685		

<210> 58

<211> 93

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3043734CD1

<400> 58

```

Met Thr Ser Lys Arg Lys Pro Cys Gln Thr Gln Leu Arg Arg Ser
 1          5          10          15
Ile Ser Glu Gln Leu Arg Asp Ser Thr Ala Arg Ala Trp Asp Leu
          20          25          30
Leu Trp Lys Asn Val Arg Glu Arg Arg Leu Ala Glu Ile Glu Ala
          35          40          45
Lys Glu Ala Cys Asp Trp Leu Arg Ala Ala Gly Phe Pro Gln Tyr
          50          55          60
Ala Gln Leu Tyr Glu Asp Ser Gln Phe Pro Ile Asn Ile Val Ala
          65          70          75
Val Lys Asn Asp His Asp Phe Leu Glu Lys Asp Leu Val Glu Pro
          80          85          90
Leu Cys Arg

```

<210> 59

<211> 521

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3294893CD1

<400> 59

```

Met Arg Arg Gly His Gly Gln Arg Arg Gly Gln Glu Ala Ile Leu
 1          5          10          15
Glu Ala His Asn Ser Lys Leu Pro Gly Ser Ile Gln His Val Tyr
          20          25          30
Gly Ala Gln His Pro Pro Phe Asp Pro Leu Leu His Gly Thr Leu
          35          40          45
Leu Arg Ser Thr Ala Lys Met Pro Thr Thr Pro Val Lys Ala Lys
          50          55          60
Arg Val Ser Thr Phe Gln Glu Phe Glu Ser Asn Thr Ser Asp Ala
          65          70          75
Trp Asp Ala Gly Glu Asp Asp Asp Glu Leu Leu Ala Met Ala Ala
          80          85          90
Glu Ser Leu Asn Ser Glu Val Val Met Glu Thr Ala Asn Arg Val
          95          100          105
Leu Arg Asn His Ser Gln Arg Gln Gly Arg Pro Thr Leu Gln Glu
          110          115          120
Gly Pro Gly Leu Gln Gln Lys Pro Arg Pro Glu Ala Glu Pro Pro
          125          130          135
Ser Pro Pro Ser Gly Asp Leu Arg Leu Val Lys Ser Val Ser Glu
          140          145          150
Ser His Thr Ser Cys Pro Ala Glu Ser Ala Ser Asp Ala Ala Pro
          155          160          165
Leu Gln Arg Ser Gln Ser Leu Pro His Ser Ala Thr Val Thr Leu
          170          175          180
Gly Gly Thr Ser Asp Pro Ser Thr Leu Ser Ser Ser Ala Leu Ser
          185          190          195
Glu Arg Glu Ala Ser Arg Leu Asp Lys Phe Lys Gln Leu Leu Ala
          200          205          210
Gly Pro Asn Thr Asp Leu Glu Glu Leu Arg Arg Leu Ser Trp Ser
          215          220          225
Gly Ile Pro Lys Pro Val Arg Pro Met Thr Trp Lys Leu Leu Ser
          230          235          240
Gly Tyr Leu Pro Ala Asn Val Asp Arg Arg Pro Ala Thr Leu Gln
          245          250          255

```

Arg	Lys	Gln	Lys	Glu	Tyr	Phe	Ala	Phe	Ile	Glu	His	Tyr	Tyr	Asp	
				260					265					270	
Ser	Arg	Asn	Asp	Glu	Val	His	Gln	Asp	Thr	Tyr	Arg	Gln	Ile	His	
				275					280					285	
Ile	Asp	Ile	Pro	Arg	Met	Ser	Pro	Glu	Ala	Leu	Ile	Leu	Gln	Pro	
				290					295					300	
Lys	Val	Thr	Glu	Ile	Phe	Glu	Arg	Ile	Leu	Phe	Ile	Trp	Ala	Ile	
				305					310					315	
Arg	His	Pro	Ala	Ser	Gly	Tyr	Val	Gln	Gly	Ile	Asn	Asp	Leu	Val	
				320					325					330	
Thr	Pro	Phe	Phe	Val	Val	Phe	Ile	Cys	Glu	Tyr	Ile	Glu	Ala	Glu	
				335					340					345	
Glu	Val	Asp	Thr	Val	Asp	Val	Ser	Gly	Val	Pro	Ala	Glu	Val	Leu	
				350					355					360	
Cys	Asn	Ile	Glu	Ala	Asp	Thr	Tyr	Trp	Cys	Met	Ser	Lys	Leu	Leu	
				365					370					375	
Asp	Gly	Ile	Gln	Asp	Asn	Tyr	Thr	Phe	Ala	Gln	Pro	Gly	Ile	Gln	
				380					385					390	
Met	Lys	Val	Lys	Met	Leu	Glu	Glu	Leu	Val	Ser	Arg	Ile	Asp	Glu	
				395					400					405	
Gln	Val	His	Arg	His	Leu	Asp	Gln	His	Glu	Val	Arg	Tyr	Leu	Gln	
				410					415					420	
Phe	Ala	Phe	Arg	Trp	Met	Asn	Asn	Leu	Leu	Met	Arg	Glu	Val	Pro	
				425					430					435	
Leu	Arg	Cys	Thr	Ile	Arg	Leu	Trp	Asp	Thr	Tyr	Gln	Ser	Glu	Pro	
				440					445					450	
Asp	Gly	Phe	Ser	His	Phe	His	Leu	Tyr	Val	Cys	Ala	Ala	Phe	Leu	
				455					460					465	
Val	Arg	Trp	Arg	Lys	Glu	Ile	Leu	Glu	Glu	Lys	Asp	Phe	Gln	Glu	
				470					475					480	
Leu	Leu	Leu	Phe	Leu	Gln	Asn	Leu	Pro	Thr	Ala	His	Trp	Asp	Asp	
				485					490					495	
Glu	Asp	Ile	Ser	Leu	Leu	Leu	Ala	Glu	Ala	Tyr	Arg	Leu	Lys	Phe	
				500					505					510	
Ala	Phe	Ala	Asp	Ala	Pro	Asn	His	Tyr	Lys	Lys					
				515					520						

<210> 60

<211> 751

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3349052CD1

<400> 60

Met	Arg	Leu	Leu	Gly	Ala	Ala	Ala	Val	Ala	Ala	Leu	Gly	Arg	Gly	
1				5					10					15	
Arg	Ala	Pro	Ala	Ser	Leu	Gly	Trp	Gln	Arg	Lys	Gln	Val	Asn	Trp	
				20					25					30	
Lys	Ala	Cys	Arg	Trp	Ser	Ser	Ser	Gly	Val	Ile	Pro	Asn	Glu	Lys	
				35					40					45	
Ile	Arg	Asn	Ile	Gly	Ile	Ser	Ala	His	Ile	Asp	Ser	Gly	Lys	Thr	
				50					55					60	
Thr	Leu	Thr	Glu	Arg	Val	Leu	Tyr	Tyr	Thr	Gly	Arg	Ile	Ala	Lys	
				65					70					75	
Met	His	Glu	Val	Lys	Gly	Lys	Asp	Gly	Val	Gly	Ala	Val	Met	Asp	
				80					85					90	
Ser	Met	Glu	Leu	Glu	Arg	Gln	Arg	Gly	Ile	Thr	Ile	Gln	Ser	Ala	
				95					100					105	
Ala	Thr	Tyr	Thr	Met	Trp	Lys	Asp	Val	Asn	Ile	Asn	Ile	Ile	Asp	
				110					115					120	
Thr	Pro	Gly	His	Val	Asp	Phe	Thr	Ile	Glu	Val	Glu	Arg	Ala	Leu	

	125		130		135
Arg Val Leu Asp	Gly Ala Val Leu Val	Leu Cys Ala Val Gly	Gly		
	140		145		150
Val Gln Cys Gln	Thr Met Thr Val Asn	Arg Gln Met Lys Arg	Tyr		
	155		160		165
Asn Val Pro Phe	Leu Thr Phe Ile Asn	Lys Leu Asp Arg Met	Gly		
	170		175		180
Ser Asn Pro Ala	Arg Ala Leu Gln Gln	Met Arg Ser Lys Leu	Asn		
	185		190		195
His Asn Ala Ala	Phe Met Gln Ile Pro	Met Gly Leu Glu Gly	Asn		
	200		205		210
Phe Lys Gly Ile	Ile Asp Leu Ile Glu	Glu Arg Ala Ile Tyr	Phe		
	215		220		225
Asp Gly Asp Phe	Gly Gln Ile Val Arg	Tyr Gly Glu Ile Pro	Ala		
	230		235		240
Glu Leu Arg Ala	Ala Ala Thr Asp His	Arg Gln Glu Leu Ile	Glu		
	245		250		255
Cys Val Ala Asn	Ser Asp Glu Gln Leu	Gly Glu Met Phe Leu	Glu		
	260		265		270
Glu Lys Ile Pro	Ser Ile Ser Asp Leu	Lys Leu Ala Ile Arg	Arg		
	275		280		285
Ala Thr Leu Lys	Arg Ser Phe Thr Pro	Val Phe Leu Gly Ser	Ala		
	290		295		300
Leu Lys Asn Lys	Gly Val Gln Pro Leu	Leu Asp Ala Val Leu	Glu		
	305		310		315
Tyr Leu Pro Asn	Pro Ser Glu Val Gln	Asn Tyr Ala Ile Leu	Asn		
	320		325		330
Lys Glu Asp Asp	Ser Lys Glu Lys Thr	Lys Ile Leu Met Asn	Ser		
	335		340		345
Ser Arg Asp Asn	Ser His Pro Phe Val	Gly Leu Ala Phe Lys	Leu		
	350		355		360
Glu Val Gly Arg	Phe Gly Gln Leu Thr	Tyr Val Arg Ser Tyr	Gln		
	365		370		375
Gly Glu Leu Lys	Lys Gly Asp Thr Ile	Tyr Asn Thr Arg Thr	Arg		
	380		385		390
Lys Lys Val Arg	Leu Gln Arg Leu Ala	Arg Met His Ala Asp	Met		
	395		400		405
Met Glu Asp Val	Glu Glu Val Tyr Ala	Gly Asp Ile Cys Ala	Leu		
	410		415		420
Phe Gly Ile Asp	Cys Ala Ser Gly Asp	Thr Phe Thr Asp Lys	Ala		
	425		430		435
Asn Ser Gly Leu	Ser Met Glu Ser Ile	His Val Pro Asp Pro	Val		
	440		445		450
Ile Ser Ile Ala	Met Lys Pro Ser Asn	Lys Asn Asp Leu Glu	Lys		
	455		460		465
Phe Ser Lys Gly	Ile Gly Arg Phe Thr	Arg Glu Asp Pro Thr	Phe		
	470		475		480
Lys Val Tyr Phe	Asp Thr Glu Asn Lys	Glu Thr Val Ile Ser	Gly		
	485		490		495
Met Gly Glu Leu	His Leu Glu Ile Tyr	Ala Gln Arg Leu Glu	Arg		
	500		505		510
Glu Tyr Gly Cys	Pro Cys Ile Thr Gly	Lys Pro Lys Val Ala	Phe		
	515		520		525
Arg Glu Thr Ile	Thr Ala Pro Val Pro	Phe Asp Phe Thr His	Lys		
	530		535		540
Lys Gln Ser Gly	Gly Ala Gly Gln Tyr	Gly Lys Val Ile Gly	Val		
	545		550		555
Leu Glu Pro Leu	Asp Pro Glu Asp Tyr	Thr Lys Leu Glu Phe	Ser		
	560		565		570
Asp Glu Thr Phe	Gly Ser Asn Ile Pro	Lys Gln Phe Val Pro	Ala		
	575		580		585
Val Glu Lys Gly	Phe Leu Asp Ala Cys	Glu Lys Gly Pro Leu	Ser		
	590		595		600

Gly	His	Lys	Leu	Ser	Gly	Leu	Arg	Phe	Val	Leu	Gln	Asp	Gly	Ala	
				605					610					615	
His	His	Met	Val	Asp	Ser	Asn	Glu	Ile	Ser	Phe	Ile	Arg	Ala	Gly	
				620					625					630	
Glu	Gly	Ala	Leu	Lys	Gln	Ala	Leu	Ala	Asn	Ala	Thr	Leu	Cys	Ile	
				635					640					645	
Leu	Glu	Pro	Ile	Met	Ala	Val	Glu	Val	Val	Ala	Pro	Asn	Glu	Phe	
				650					655					660	
Gln	Gly	Gln	Val	Ile	Ala	Gly	Ile	Asn	Arg	Arg	His	Gly	Val	Ile	
				665					670					675	
Thr	Gly	Gln	Asp	Gly	Val	Glu	Asp	Tyr	Phe	Thr	Leu	Tyr	Ala	Asp	
				680					685					690	
Val	Pro	Leu	Asn	Asp	Met	Phe	Gly	Tyr	Ser	Thr	Glu	Leu	Arg	Ser	
				695					700					705	
Cys	Thr	Glu	Gly	Lys	Gly	Glu	Tyr	Thr	Met	Glu	Tyr	Ser	Arg	Tyr	
				710					715					720	
Gln	Pro	Cys	Leu	Pro	Ser	Thr	Gln	Glu	Asp	Val	Ile	Asn	Lys	Tyr	
				725					730					735	
Leu	Glu	Ala	Thr	Gly	Gln	Leu	Pro	Val	Lys	Lys	Gly	Lys	Ala	Lys	
				740					745					750	

Asn

<210> 61

<211> 666

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3357264CD1

<220>

<221> unsure

<222> 281

<223> unknown or other

<400> 61

Met	Cys	Gly	Ala	Val	Ile	Pro	Leu	His	Lys	Pro	Ala	Gly	Arg	Lys	
1				5					10					15	
Leu	Gln	Asn	Gln	Arg	Ala	Ala	Leu	Asn	Gln	Gln	Ile	Leu	Lys	Ala	
				20					25					30	
Val	Arg	Met	Arg	Thr	Gly	Ala	Glu	Asn	Leu	Leu	Lys	Val	Ala	Thr	
				35					40					45	
Asn	Ser	Lys	Val	Arg	Glu	Gln	Val	Arg	Leu	Glu	Leu	Ser	Phe	Val	
				50					55					60	
Asn	Ser	Asp	Leu	Gln	Met	Leu	Lys	Glu	Glu	Leu	Glu	Gly	Leu	Asn	
				65					70					75	
Ile	Ser	Val	Gly	Val	Tyr	Gln	Asn	Thr	Glu	Glu	Ala	Phe	Thr	Ile	
				80					85					90	
Pro	Leu	Ile	Pro	Leu	Gly	Leu	Lys	Glu	Thr	Lys	Asp	Val	Asp	Phe	
				95					100					105	
Ala	Val	Val	Leu	Lys	Asp	Phe	Ile	Leu	Glu	His	Tyr	Ser	Glu	Asp	
				110					115					120	
Gly	Tyr	Leu	Tyr	Glu	Asp	Glu	Ile	Ala	Asp	Leu	Met	Asp	Leu	Arg	
				125					130					135	
Gln	Ala	Cys	Arg	Thr	Pro	Ser	Arg	Asp	Glu	Ala	Gly	Val	Glu	Leu	
				140					145					150	
Leu	Met	Thr	Tyr	Phe	Ile	Gln	Leu	Gly	Phe	Val	Glu	Ser	Arg	Phe	
				155					160					165	
Phe	Pro	Pro	Thr	Arg	Gln	Met	Gly	Leu	Leu	Phe	Thr	Trp	Tyr	Asp	
				170					175					180	
Ser	Leu	Thr	Gly	Val	Pro	Val	Ser	Gln	Gln	Asn	Leu	Leu	Leu	Glu	
				185					190					195	

Lys	Ala	Ser	Val	Leu	Phe	Asn	Thr	Gly	Ala	Leu	Tyr	Thr	Gln	Ile
				200					205					210
Gly	Thr	Arg	Cys	Asp	Arg	Gln	Thr	Gln	Ala	Gly	Leu	Glu	Ser	Ala
				215					220					225
Ile	Asp	Ala	Phe	Gln	Arg	Ala	Ala	Gly	Val	Leu	Asn	Tyr	Leu	Lys
				230					235					240
Asp	Thr	Phe	Thr	His	Thr	Pro	Ser	Tyr	Asp	Met	Ser	Pro	Ala	Met
				245					250					255
Leu	Ser	Val	Leu	Val	Lys	Met	Met	Leu	Ala	Gln	Ala	Gln	Glu	Ser
				260					265					270
Val	Phe	Glu	Lys	Ile	Ser	Leu	Pro	Gly	Ile	Xaa	Asn	Glu	Phe	Phe
				275					280					285
Met	Leu	Val	Lys	Val	Ala	Gln	Glu	Ala	Ala	Lys	Val	Gly	Glu	Val
				290					295					300
Tyr	Gln	Gln	Leu	His	Ala	Ala	Met	Ser	Gln	Ala	Pro	Val	Lys	Glu
				305					310					315
Asn	Ile	Pro	Tyr	Ser	Trp	Ala	Ser	Leu	Ala	Cys	Val	Lys	Ala	His
				320					325					330
His	Tyr	Ala	Ala	Leu	Ala	His	Tyr	Phe	Thr	Ala	Ile	Leu	Leu	Ile
				335					340					345
Asp	His	Gln	Val	Lys	Pro	Gly	Thr	Asp	Leu	Asp	His	Gln	Glu	Lys
				350					355					360
Cys	Leu	Ser	Gln	Leu	Tyr	Asp	His	Met	Pro	Glu	Gly	Leu	Thr	Pro
				365					370					375
Leu	Ala	Thr	Leu	Lys	Asn	Asp	Gln	Gln	Arg	Arg	Gln	Leu	Gly	Lys
				380					385					390
Ser	His	Leu	Arg	Arg	Ala	Met	Ala	His	His	Glu	Glu	Ser	Val	Arg
				395					400					405
Glu	Ala	Ser	Leu	Cys	Lys	Lys	Leu	Arg	Thr	Ile	Glu	Val	Leu	Gln
				410					415					420
Lys	Val	Leu	Cys	Ala	Ala	Gln	Glu	Arg	Ser	Arg	Leu	Thr	Tyr	Ala
				425					430					435
Gln	His	Gln	Glu	Glu	Asp	Asp	Leu	Leu	Asn	Leu	Ile	Asp	Ala	Pro
				440					445					450
Ser	Val	Val	Ala	Lys	Thr	Glu	Gln	Glu	Val	Asp	Ile	Ile	Leu	Pro
				455					460					465
Gln	Phe	Ser	Lys	Leu	Thr	Val	Thr	Asp	Phe	Phe	Gln	Lys	Leu	Gly
				470					475					480
Pro	Leu	Ser	Val	Phe	Ser	Ala	Asn	Lys	Arg	Trp	Thr	Pro	Pro	Arg
				485					490					495
Ser	Ile	Arg	Phe	Thr	Ala	Glu	Glu	Gly	Asp	Leu	Gly	Phe	Thr	Leu
				500					505					510
Arg	Gly	Asn	Ala	Pro	Val	Gln	Val	His	Phe	Leu	Asp	Pro	Tyr	Cys
				515					520					525
Ser	Ala	Ser	Val	Ala	Gly	Ala	Arg	Glu	Gly	Asp	Tyr	Ile	Val	Ser
				530					535					540
Ile	Gln	Leu	Val	Asp	Cys	Lys	Trp	Leu	Thr	Leu	Ser	Glu	Val	Met
				545					550					555
Lys	Leu	Leu	Lys	Ser	Phe	Gly	Glu	Asp	Glu	Ile	Glu	Met	Lys	Val
				560					565					570
Val	Ser	Leu	Leu	Asp	Ser	Thr	Ser	Ser	Met	His	Asn	Lys	Ser	Ala
				575					580					585
Thr	Tyr	Ser	Val	Gly	Met	Gln	Lys	Thr	Tyr	Ser	Met	Ile	Cys	Leu
				590					595					600
Ala	Ile	Asp	Asp	Asp	Lys	Thr	Asp	Lys	Lys	Thr	Lys	Lys	Ile	Ser
				605					610					615
Lys	Lys	Leu	Ser	Phe	Leu	Ser	Trp	Gly	Thr	Asn	Lys	Asn	Arg	Gln
				620					625					630
Lys	Ser	Ala	Ser	Thr	Leu	Cys	Leu	Pro	Ser	Val	Gly	Ala	Ala	Arg
				635					640					645
Pro	Gln	Val	Lys	Lys	Lys	Leu	Pro	Ser	Pro	Phe	Ser	Leu	Leu	Asn
				650					655					660
Ser	Asp	Ser	Ser	Trp	Tyr									

665

<210> 62

<211> 746

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3576329CD1

<400> 62

```

Met Ala Gly Ser Arg Gly Ala Gly Arg Thr Ala Ala Pro Ser Val
 1          5          10          15
Arg Pro Glu Lys Arg Arg Ser Glu Pro Glu Leu Glu Pro Glu Pro
          20          25          30
Glu Pro Glu Pro Pro Leu Leu Cys Thr Ser Pro Leu Ser His Ser
          35          40          45
Thr Gly Ser Asp Ser Gly Val Ser Asp Ser Glu Glu Ser Val Phe
          50          55          60
Ser Gly Leu Glu Asp Ser Gly Ser Asp Ser Ser Glu Asp Asp Asp
          65          70          75
Glu Gly Asp Glu Glu Gly Glu Asp Gly Ala Leu Asp Asp Glu Gly
          80          85          90
His Ser Gly Ile Lys Lys Thr Thr Glu Glu Gln Val Gln Ala Ser
          95          100          105
Thr Pro Cys Pro Arg Thr Glu Met Ala Ser Ala Arg Ile Gly Asp
          110          115          120
Glu Tyr Ala Glu Asp Ser Ser Asp Glu Glu Asp Ile Arg Asn Thr
          125          130          135
Val Gly Asn Val Pro Leu Glu Trp Tyr Asp Asp Phe Pro His Val
          140          145          150
Gly Tyr Asp Leu Asp Gly Arg Arg Ile Tyr Lys Pro Leu Arg Thr
          155          160          165
Arg Asp Glu Leu Asp Gln Phe Leu Asp Lys Met Asp Asp Pro Asp
          170          175          180
Tyr Trp Arg Thr Val Gln Asp Pro Met Thr Gly Arg Asp Leu Arg
          185          190          195
Leu Thr Asp Glu Gln Val Ala Leu Val Arg Arg Leu Gln Ser Gly
          200          205          210
Gln Phe Gly Asp Val Gly Phe Asn Pro Tyr Glu Pro Ala Val Asp
          215          220          225
Phe Phe Ser Gly Asp Val Met Ile His Pro Val Thr Asn Arg Pro
          230          235          240
Ala Asp Lys Arg Ser Phe Ile Pro Ser Leu Val Glu Lys Glu Lys
          245          250          255
Val Ser Arg Met Val His Ala Ile Lys Met Gly Trp Ile Gln Pro
          260          265          270
Arg Arg Pro Arg Asp Pro Thr Pro Ser Phe Tyr Asp Leu Trp Ala
          275          280          285
Gln Glu Asp Pro Asn Ala Val Leu Gly Arg His Lys Met His Val
          290          295          300
Pro Ala Pro Lys Leu Ala Leu Pro Gly His Ala Glu Ser Tyr Asn
          305          310          315
Pro Pro Pro Glu Tyr Leu Leu Ser Glu Glu Glu Arg Leu Ala Trp
          320          325          330
Glu Gln Gln Glu Pro Gly Glu Arg Lys Leu Gly Phe Leu Pro Arg
          335          340          345
Lys Phe Pro Ser Leu Arg Ala Val Pro Ala Tyr Gly Arg Phe Ile
          350          355          360
Gln Glu Arg Phe Glu Arg Cys Leu Asp Leu Tyr Leu Cys Pro Arg
          365          370          375
Gln Arg Lys Met Arg Val Asn Val Asp Pro Glu Asp Leu Ile Pro
          380          385          390

```

```

Lys Leu Pro Arg Pro Arg Asp Leu Gln Pro Phe Pro Thr Cys Gln
395 400 405
Ala Leu Val Tyr Arg Gly His Ser Asp Leu Val Arg Cys Leu Ser
410 415 420
Val Ser Pro Gly Gly Gln Trp Leu Val Ser Gly Ser Asp Asp Gly
425 430 435
Ser Leu Arg Leu Trp Glu Val Ala Thr Ala Arg Cys Val Arg Thr
440 445 450
Val Pro Val Gly Gly Val Val Lys Ser Val Ala Trp Asn Pro Ser
455 460 465
Pro Ala Val Cys Leu Val Ala Ala Ala Val Glu Asp Ser Val Leu
470 475 480
Leu Leu Asn Pro Ala Leu Gly Asp Arg Leu Val Ala Gly Ser Thr
485 490 495
Asp Gln Leu Leu Ser Ala Phe Val Pro Pro Glu Glu Pro Pro Leu
500 505 510
Gln Pro Ala Arg Trp Leu Glu Ala Ser Glu Glu Glu Arg Gln Val
515 520 525
Gly Leu Arg Leu Arg Ile Cys His Gly Lys Pro Val Thr Gln Val
530 535 540
Thr Trp His Gly Arg Gly Asp Tyr Leu Ala Val Val Leu Ala Thr
545 550 555
Gln Gly His Thr Gln Val Leu Ile His Gln Leu Ser Arg Arg Arg
560 565 570
Ser Gln Ser Pro Phe Arg Arg Ser His Gly Gln Val Gln Arg Val
575 580 585
Ala Phe His Pro Ala Arg Pro Phe Leu Leu Val Ala Ser Gln Arg
590 595 600
Ser Val Arg Leu Tyr His Leu Leu Arg Gln Glu Leu Thr Lys Lys
605 610 615
Leu Met Pro Asn Cys Lys Trp Val Ser Ser Leu Ala Val His Pro
620 625 630
Ala Gly Asp Asn Val Ile Cys Gly Ser Tyr Asp Ser Lys Leu Val
635 640 645
Trp Phe Asp Leu Asp Leu Ser Thr Lys Pro Tyr Arg Met Leu Arg
650 655 660
His His Lys Lys Ala Leu Arg Ala Val Ala Phe His Pro Arg Tyr
665 670 675
Pro Leu Phe Ala Ser Gly Ser Asp Asp Gly Ser Val Ile Val Cys
680 685 690
His Gly Met Val Tyr Asn Asp Leu Leu Gln Asn Pro Leu Leu Val
695 700 705
Pro Val Lys Val Leu Lys Gly His Val Leu Thr Arg Asp Leu Gly
710 715 720
Val Leu Asp Val Ile Phe His Pro Thr Gln Pro Trp Val Phe Ser
725 730 735
Ser Gly Ala Asp Gly Thr Val Arg Leu Phe Thr
740 745

```

<210> 63

<211> 212

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3805550CD1

<400> 63

```

Met Ala Gly Pro Gly Pro Gly Pro Gly Asp Pro Asp Glu Gln Tyr
1 5 10 15
Asp Phe Leu Phe Lys Leu Val Leu Val Gly Asp Ala Ser Val Gly
20 25 30
Lys Thr Cys Val Val Gln Arg Phe Lys Thr Gly Ala Phe Ser Glu

```

	35		40		45
Arg Gln Gly Ser Thr	Ile Gly Val Asp Phe	Thr Met Lys Thr	Leu		
	50		55		60
Glu Ile Gln Gly Lys	Arg Val Lys Leu Gln	Ile Trp Asp Thr	Ala		
	65		70		75
Gly Gln Glu Arg Phe	Arg Thr Ile Thr Gln	Ser Tyr Tyr Arg	Ser		
	80		85		90
Ala Asn Gly Ala Ile	Leu Ala Tyr Asp Ile	Thr Lys Arg Ser	Ser		
	95		100		105
Phe Leu Ser Val Pro	His Trp Ile Glu Asp	Val Arg Lys Tyr	Ala		
	110		115		120
Gly Ser Asn Ile Val	Gln Leu Leu Ile Gly	Asn Lys Ser Asp	Leu		
	125		130		135
Ser Glu Leu Arg Glu	Val Ser Leu Ala Glu	Ala Gln Ser Leu	Ala		
	140		145		150
Glu His Tyr Asp Ile	Leu Cys Ala Ile Glu	Thr Ser Ala Lys	Asp		
	155		160		165
Ser Ser Asn Val Glu	Ala Phe Leu Arg Val	Ala Thr Glu	Leu		
	170		175		180
Ile Met Arg His Gly	Gly Pro Leu Phe Ser	Glu Lys Ser Pro	Asp		
	185		190		195
His Ile Gln Leu Asn	Ser Lys Asp Ile Gly	Glu Gly Trp Gly	Cys		
	200		205		210

Gly Cys

<210> 64

<211> 307

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4546403CD1

<400> 64

Met Arg Cys Leu His	Ser Glu Lys Ala His	Asp Leu Gly Ile Thr		
1	5	10		15
Cys Cys Asp Phe Ser	Ser Gln Pro Val Ser	Asp Gly Glu Gln Gly		
	20	25		30
Leu Gln Phe Phe Arg	Leu Ala Ser Cys Gly	Gln Asp Cys Gln Val		
	35	40		45
Lys Ile Trp Ile Val	Ser Phe Thr His Ile	Leu Gly Phe Glu Leu		
	50	55		60
Lys Tyr Lys Ser Thr	Leu Ser Gly His Cys	Ala Pro Val Leu Ala		
	65	70		75
Cys Ala Phe Ser His	Asp Gly Gln Met Leu	Val Ser Gly Ser Val		
	80	85		90
Asp Lys Ser Val Ile	Val Tyr Asp Thr Asn	Thr Glu Asn Ile Leu		
	95	100		105
His Thr Leu Thr Gln	His Thr Arg Tyr Val	Thr Thr Cys Ala Phe		
	110	115		120
Ala Pro Asn Thr Leu	Leu Leu Ala Thr Gly	Ser Met Asp Lys Thr		
	125	130		135
Val Asn Ile Trp Gln	Phe Asp Leu Glu Thr	Leu Cys Gln Ala Arg		
	140	145		150
Ser Thr Glu His Gln	Leu Lys Gln Phe Thr	Glu Asp Trp Ser Glu		
	155	160		165
Glu Asp Val Ser Thr	Trp Leu Cys Ala Gln	Asp Leu Lys Asp Leu		
	170	175		180
Val Gly Ile Phe Lys	Met Asn Asn Ile Asp	Gly Lys Glu Leu Leu		
	185	190		195
Asn Leu Thr Lys Glu	Ser Leu Ala Asp Asp	Leu Lys Ile Glu Ser		
	200	205		210

Leu Gly Leu Arg	Ser Lys Val Leu Arg	Lys Ile Glu Glu Leu Arg	
215		220	225
Thr Lys Val Lys	Ser Leu Ser Ser Gly	Ile Pro Asp Glu Phe Ile	
230		235	240
Cys Pro Ile Thr	Arg Glu Leu Met Lys	Asp Pro Val Ile Ala Ser	
245		250	255
Asp Gly Tyr Ser	Tyr Glu Lys Glu Ala	Met Glu Asn Trp Ile Ser	
260		265	270
Lys Lys Lys Arg	Thr Ser Pro Met Thr	Asn Leu Val Leu Pro Ser	
275		280	285
Ala Val Leu Thr	Pro Asn Arg Thr Leu	Lys Met Ala Ile Asn Arg	
290		295	300
Trp Leu Glu Thr	His Gln Lys		
	305		

<210> 65

<211> 378

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4767318CD1

<400> 65

Met Arg Ala Ala	Ala Ala Pro Gly Leu Thr	Ala Pro Trp Arg Leu	
1	5	10	15
Leu Gln Cys Cys	Glu Leu Glu Ala Gly	Glu Leu Gly Met Ala Val	
20		25	30
Pro Ala Ala Ala	Met Gly Pro Ser Ala	Leu Gly Gln Ser Gly Pro	
35		40	45
Gly Ser Met Ala	Pro Trp Cys Ser Val	Ser Ser Gly Pro Ser Arg	
50		55	60
Tyr Val Leu Gly	Met Gln Glu Leu Phe	Arg Gly His Ser Lys Thr	
65		70	75
Arg Glu Phe Leu	Ala His Ser Ala Lys	Val His Ser Val Ala Trp	
80		85	90
Ser Cys Asp Gly	Arg Arg Leu Ala Ser	Gly Ser Phe Asp Lys Thr	
95		100	105
Ala Ser Val Phe	Leu Leu Glu Lys Asp	Arg Leu Val Lys Glu Asn	
110		115	120
Asn Tyr Arg Gly	His Gly Asp Ser Val	Asp Gln Leu Cys Trp His	
125		130	135
Pro Ser Asn Pro	Asp Leu Phe Val Thr	Ala Ser Gly Asp Lys Thr	
140		145	150
Ile Arg Ile Trp	Asp Val Arg Thr Thr	Lys Cys Ile Ala Thr Val	
155		160	165
Asn Thr Lys Gly	Glu Asn Ile Asn Ile	Cys Trp Ser Pro Asp Gly	
170		175	180
Gln Thr Ile Ala	Val Gly Asn Lys Asp	Asp Val Val Thr Phe Ile	
185		190	195
Asp Ala Lys Thr	His Arg Ser Lys Ala	Glu Glu Gln Phe Lys Phe	
200		205	210
Glu Val Asn Glu	Ile Ser Trp Asn Asn	Asp Asn Asn Met Phe Phe	
215		220	225
Leu Thr Asn Gly	Asn Gly Cys Ile Asn	Ile Leu Ser Tyr Pro Glu	
230		235	240
Leu Lys Pro Val	Gln Ser Ile Asn Ala	His Pro Ser Asn Cys Ile	
245		250	255
Cys Ile Lys Phe	Asp Pro Met Gly Lys	Tyr Phe Ala Thr Gly Ser	
260		265	270
Ala Asp Ala Leu	Val Ser Leu Trp Asp	Val Asp Glu Leu Val Cys	
275		280	285
Val Arg Cys Phe	Ser Arg Leu Asp Trp	Pro Val Arg Thr Leu Ser	

	290		295		300
Phe Ser His Asp Gly Lys Met Leu Ala Ser Ala Ser Glu Asp His					
	305		310		315
Phe Ile Asp Ile Ala Glu Val Glu Thr Gly Asp Lys Leu Trp Glu					
	320		325		330
Val Gln Cys Glu Ser Pro Thr Phe Thr Val Ala Trp His Pro Lys					
	335		340		345
Arg Pro Leu Leu Ala Phe Ala Cys Asp Asp Lys Asp Gly Lys Tyr					
	350		355		360
Asp Ser Ser Arg Glu Ala Gly Thr Val Lys Leu Phe Gly Leu Pro					
	365		370		375
Asn Asp Ser					

<210> 66

<211> 466

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4834527CD1

<400> 66

Met Pro Gln Thr Leu Ser Ala Ser Asp Met Val Thr Pro Gly Ser					
1 5 10 15					
Leu Ser Pro Pro Pro Thr Glu Pro Thr Asp Gly Glu Gln Ala Gly					
20 25 30					
Gln Pro Leu Leu Asp Gly Ala Pro Ser Ser Ala Ser Leu Glu Thr					
35 40 45					
Leu Ile Gln His Leu Val Pro Thr Ala Asp Tyr Tyr Pro Glu Lys					
50 55 60					
Ala Tyr Ile Phe Thr Phe Leu Leu Ser Ser Arg Leu Phe Ile Glu					
65 70 75					
Pro Arg Glu Leu Leu Ala Arg Val Cys His Leu Cys Ile Glu Gln					
80 85 90					
Gln Gln Leu Asp Lys Pro Val Leu Asp Lys Ala Arg Val Arg Lys					
95 100 105					
Phe Gly Pro Lys Leu Leu Gln Leu Leu Ala Glu Trp Thr Glu Thr					
110 115 120					
Phe Pro Arg Asp Phe Gln Glu Glu Ser Thr Ile Gly His Leu Lys					
125 130 135					
Asp Val Val Gly Arg Ile Ala Pro Cys Asp Glu Ala Tyr Arg Lys					
140 145 150					
Arg Met His Gln Leu Leu Gln Ala Leu His Gln Lys Leu Ala Ala					
155 160 165					
Leu Arg Gln Gly Pro Glu Gly Leu Val Gly Ala Asp Lys Pro Ile					
170 175 180					
Ser Tyr Arg Thr Lys Pro Pro Ala Ser Ile His Arg Glu Leu Leu					
185 190 195					
Gly Val Cys Ser Asp Pro Tyr Thr Leu Ala Gln Gln Leu Thr His					
200 205 210					
Val Glu Leu Glu Arg Leu Arg His Ile Gly Pro Glu Glu Phe Val					
215 220 225					
Gln Ala Phe Val Asn Lys Asp Pro Leu Ala Ser Thr Lys Pro Cys					
230 235 240					
Phe Ser Asp Lys Thr Ser Asn Leu Glu Ala Tyr Val Lys Trp Phe					
245 250 255					
Asn Arg Leu Cys Tyr Leu Val Ala Thr Glu Ile Cys Met Pro Ala					
260 265 270					
Lys Lys Lys Gln Arg Ala Gln Val Ile Glu Phe Phe Ile Asp Val					
275 280 285					
Ala Arg Glu Cys Phe Asn Ile Gly Asn Phe Asn Ser Leu Met Ala					
290 295 300					

Ile	Ile	Ser	Gly	Met	Asn	Met	Ser	Pro	Val	Ser	Arg	Leu	Lys	Lys
				305					310					315
Thr	Trp	Ala	Lys	Val	Arg	Thr	Ala	Lys	Phe	Phe	Ile	Leu	Glu	His
				320					325					330
Gln	Met	Asp	Pro	Thr	Gly	Asn	Phe	Cys	Asn	Tyr	Arg	Thr	Ala	Leu
				335					340					345
Arg	Gly	Ala	Ala	His	Arg	Ser	Leu	Thr	Ala	His	Ser	Ser	Arg	Glu
				350					355					360
Lys	Ile	Val	Ile	Pro	Phe	Phe	Ser	Leu	Leu	Ile	Lys	Asp	Ile	Tyr
				365					370					375
Phe	Leu	Asn	Glu	Gly	Cys	Ala	Asn	Arg	Leu	Pro	Asn	Gly	His	Val
				380					385					390
Asn	Phe	Glu	Lys	Phe	Leu	Glu	Leu	Ala	Lys	Gln	Val	Gly	Glu	Phe
				395					400					405
Ile	Thr	Trp	Lys	Gln	Val	Glu	Cys	Pro	Phe	Glu	Gln	Asp	Ala	Ser
				410					415					420
Ile	Thr	His	Tyr	Leu	Tyr	Thr	Ala	Pro	Ile	Phe	Ser	Glu	Asp	Gly
				425					430					435
Leu	Tyr	Leu	Ala	Ser	Tyr	Glu	Ser	Glu	Ser	Pro	Glu	Asn	Gln	Thr
				440					445					450
Glu	Lys	Glu	Arg	Trp	Lys	Ala	Leu	Arg	Ser	Ser	Ile	Leu	Gly	Lys
				455					460					465

Thr

<210> 67

<211> 891

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1405545CB1

<400> 67

```

ggagaatggc ggcgccgggc tgccggctggg agcggaaga ctctttgaaa tgcctgcggt 60
gctagagcga ctgagccgct ataatagcac gtcccaagct ttgctgagg tgctgcggt 120
gccgaagcag cagctgagga agctgctgta cccgctgcag gaagtagagc ggttcctcgc 180
cccctacggg aggcaagacc ttcacctgcg tatctttgac ccaagcccg aggacatagc 240
cagggcggac aacatcttca cggccactga acggaaccgc atcgactacg tcagctccgc 300
cgtccgtatc gaccacgccc cggaccttcc gcggccagag gtgtgtttta taggcagaag 360
caatgttgga aaatcatctc taatcaaggc tttatcttca ctggcccctg aggttgaagt 420
cagagtctcc aaaaaaccag gacacacaaa gaaaatgaat tttttcaaag ttggaaaaca 480
ttttacagtg gtggacatgc cagggttatgg cttagagca cctgaagatt ttgttgacat 540
gtagagacc tatctaaaag aacgaaggaa cttgaagaga acatttttat tagtgatag 600
cgtgttgga attcaaaaaa cagacaatat tgccatagaa atgtgtgaag aatttgcatt 660
accttatgtg attgtattaa caaaaattga caaatcttcc aaggacatc ttttaaaaca 720
agtgcttcag atccagaaat ttgttaacat gaaaactcaa ggatgttttc ctgagttggt 780
tcctgtaagt gctgtgacct tttctggaat ccacctgttg agatgcttta tagccagtg 840
aacaggaagt cttgactaat ggttcccggt ttagctgaag attcaaaaaa a 891

```

<210> 68

<211> 1512

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1451265CB1

<400> 68

```

gcccattggag gtggccgtgt gtacggactc ggccggcccg atgtggagct gcatcgtgtg 60
ggaacttcac tcgggcgcca acctgtcac ctaccgccc ggccaggcgg gaccccgcg 120
cctggcgctg ctcaatggcg agtatctgct ggccggcgag ctgggcaaga attacatcag 180

```

```

cgccctgggag ctccagcgga aggaccagct ccagcagaag atcatgtgcc ccgggcctgt 240
cacctgtctg actgcatcac ccaatggtct ctacgtcctg gcaggagtgt cagaaagcat 300
ccacctgtgg gaggtctcca ccgggaacct tctggtcatc ctgagtcgac actaccagga 360
cgtctcctgc cttcagttca caggggacag cagccacttc atctcagggg gcaaggactg 420
cctgggtgctg gtttgagcc tctgcagcgt gctgcaggcc gaccttcca ggattccggc 480
gcccaggcac gtctgggtctc accacacgct ccccatcacg gacctgcact gcggctttgg 540
gggccccctg gcccgggtgg ccacctcttc actggaccag acggtgaagc tatgggaggt 600
ctcctcgggg gagctgctgc tctcgtcctc etttgacgtg tccatcatgg cagtgacct 660
ggacctgggt gagcaccata tgttctgcgg gggcagtgag ggctccatct tccaggtcga 720
cctcttcacc tggcccgagc agagggagag gagcttccac ccagagcagg acgcccggaa 780
ggtcttcaaa gggcacagga accaggtgac ttgacctgca gtgtccactg acggcagcgt 840
gctgctctca ggctcccacg acgagaccgt gcgcctctgg gacgtgcaga gcaagcagtg 900
catccggagc gtggccctca aaggcccagt caccaatgcc gccatcctgc tggcgccgt 960
cagcatgctg agctcagact tcaggcccag cctgcccgtg ccccaactta acaagcacct 1020
gctgggcggc gagcacgggg acgagccgag ccacgggggc ctactctgc gcctgggcct 1080
ccaccagcag ggctcggagc ccagctacac ggaccgcacg gagcagctgc aggcgtcct 1140
gtgcagcacc atggagaaga gcgtgctcgg cggccaggac cagctgcggc tccgtgtgac 1200
ggagctggag gacgaggtgc gcaacctgag caagatcaat cgggacctgt tcgacttctc 1260
cacgcgcttc atcacgcggc cggccaagt agggccggag accccggccc gaggcgcca 1320
ggcctgagcc ccatgcctcc cagcaaccag ggcccgggg tgtggcccc accagcccag 1380
gcctggactc tctcagttc tgtgtcgtgt tcgggttttt cctctgtgac tgggcgctct 1440
tgggtgtctg tggcacgcgt cacagtgggt ctagtctgtt ttaacaaaa gaggatgaaa 1500
aaaaaaaaaa aa 1512

```

<210> 69

<211> 2536

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1556311CB1

<400> 69

```

caactcttgt tgaagctttt aggcgtcgca gactcttcat ttgtgagggc gacctctccc 60
gaggggctct tttcacacaa atatccccac ggcgtttctc ggaggcacc cgtcatacag 120
tcttgtctct cgcgacaatt ctctttgaag gcgaggcatt tcaccacaac tcttttcaac 180
caacctggcg acaacaccca gagcttacat tgaccccaat ttgaattttc atcggcccaa 240
ggctttcttt acactcaggg aactctcaca ctcttagagg ggaaaaaggc ttcgttaagg 300
gccttgcaag ggttaccggg ttccggaatt ttcccggggg cccctcggct ggccaggact 360
gaaacccaga cgagcatgcc agaaacagtc aaccataaca aacatgggaa cgtagctctc 420
cctggaacga aaccaactcc catccctcca ccccggtga agaagcaggc ttcttttctg 480
gaagcagagg gcggtgcaaa gaccttgagc ggcggccggc cgggcgcagg cccggagctg 540
gagctgggca cagctggcag ccaggtggg ccccgctg aggcggccc gggggattgc 600
acaagggccc cgccgcccag ctctgaatca cggcccccgt gccatggagg ccggcagcgg 660
ctgagcgaca tgagcatttc tacttctctc tccgactcgc tggagtctga ccggagcatg 720
cctctgtttg gctacgaggc ggacaccaac agcagcctgg aggactacga gggggaaagt 780
gaccaagaga ccatggcgcc ccccatcaag tccaaaaaga aaaggagcag ctcttctgtg 840
ctgcccgaag tcgtcaagtc ccagctgcag aaggtgagcg ggggtgtcag ctcttctatg 900
accccgagga agcggatggt ccgcaggatc gccgagcttt cccgggacaa atgcacctac 960
ttcgggtgct tagtgagga ctacgtgagc ttctgcagg agaacaagga gtgccacgtg 1020
tccagcaccg acatgctgca gaccatccgg cagttcatga cccaggtcaa gaactatttg 1080
tctcagagct cggagctgga cccccccatc gagtgcgtga tcctgaaga ccaaatagat 1140
gtggtgctgg aaaaagccat gcacaagtgc atcttgaagc ccctcaagg gacgtggag 1200
gccatgctga aggactttca catggccgat ggctcatgga agcaactcaa ggagaacctg 1260
cagcttgtgc ggcagaggaa tccgcaggag ctgggggtct tcgccccgac cctgatattt 1320
gtggatgtgg agaaaatcaa agtcaagtcc atgaccatgc agaagatgta ttcgccggaa 1380
aagaaggtca tgctgctgct gcgggtctgc aagctcattt acacggtcat ggagaacaac 1440
tcagggagga tgtatggcgc tgatgacttc ttgccagtc tgacctatgt catagcccag 1500
tgtgacatgc ttgaattgga cactgaaatc gagtacatga tggagctcct agacccatcg 1560
ctgttacatg gagaaggagg ctattacttg acaagcgcat atggagcact ttctctgata 1620
aagaatttcc aagaagaaca agcagcgca ctgctcagct cagaaaccag agacaccctg 1680
aggcagtgcc acaaacggag aaccaccaac cggaccatcc cctctgtgga cgacttccag 1740

```



```
aattacctcc gagttgcatt tcaggaggtc aacagtgggt gcacaggaaa gacctcctt 1800
gtgagacctt acatcaccac tgaggatgtg tgtcagatct gcgctgagaa gttcaagggtg 1860
ggggaccctg aggagtacag cctctttctc ttcgttgacg agacatggca gcagctggca 1920
gaggacactt accctcaaaa aatcaaggcg gagctgcaca gccgaccaca gccccacatc 1980
ttccactttg tctacaaacg catcaagaac gatccttatg gcatcatttt ccagaacggg 2040
gaagaagacc tcaccacctc ctagaagaca ggcgggactt cccagtgggt catccaaagg 2100
ggagctggaa gccttgacct cccgcttcta catgcttgag cttgaaaagc agtcacctcc 2160
tcggggaccc ctcagtgtag tgactaagcc atccacaggg caactcggcc aagggcaact 2220
ttagccacgc aaggtagctg aggtttgtga aacagtagga ttctcttttg gcaatggaga 2280
attgcatctg atggttcaag tgtcctgaga ttgtttgcta cctaccccca gtcaggttct 2340
aggttggctt acaggtatgt atatgtgcag aagaaacact taagatacaa gttcttttga 2400
attcaacagc agatgcttgc gatgcagtcg ttcaggtgat tctactcct gtggatggct 2460
tcacccctgc ctctcttctt ttcttttttc tttgtgtgtt tttttttttt ttttaaaaaa 2520
gccttcgggt tttaaa 2536
```

<210> 70

<211> 1415

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1901373CB1

<400> 70

```
gcgaggacgc gggccgagcc ggaagtggag tgcgtgcgg cgcgagctgg gccggcgggc 60
gtggttcgag agcgcgagca gtccagactg gcggcagggc ccgaggggcc gacctgcagc 120
gtccctggct tctccagccc tctactggaa ccgactgac aataccctcc cctcccttgg 180
gctggacccc tctctacagc taggagccaa tggcagaaga caaaaccaa ccgagtgaat 240
tggaaccaag gaagtatgat gctgatgaca acgtgaagat catctgcctg ggagacagcg 300
cagtgggcaa atccaaactc atggagagat ttctcatgga tggctttcag ccacagcagc 360
tgtccacgta cgccctgacc ctgtacaagc acacagccac ggtagatgga aggaccatcc 420
ttgtggactt ttgggacacg gcaggccagg agcggttcca gagcatgcat gcctcctact 480
accacaaggc ccacgcctgc atcatggtgt ttgatgtaca gaggaaagtc acctatagga 540
acctgagcac ctggtataca gagcttcggg agttcaggcc agagatccca tgcctcgtgg 600
tggaacaata aattgatgca gacataaacg tgacccaaaa aagcttcaat ttgccaaga 660
agttctccct gccctgtgat ttcgtctcgg ctgctgatgg taccaatgtt gtgaagctct 720
tcaatgatgc aattcgatta gctgtgtctt acaaacagaa ctcccaggac ttcattggatg 780
agatttttca ggagctcgag aacttcagac tggagcagga agaggaggac gtgccagacc 840
aggaacagag cagcagcatc gagaccccat cagaggaggt ggcctctccc cacagctgag 900
gggctggggc taggggtggg tggagccctt ttaaaatacc cttcccttca acaactctcc 960
agctctgaat ggagaaactc tctaggccat cccctcttct acctcctgca acccaccat 1020
cctattagcc tcccacattc aaggcccgtg atacagggat gaggtcagca ccagcaaact 1080
ctggactggg ggaagaattc cccaccagat ctccctgaag cagaattagg gatcagcatc 1140
attaacacct tccccacccc ctccccgag gcagacagtg aagagaatca gaaaacatga 1200
ttatgtgtca ctttaataca ggaaatttag gtgttttttg gtgtttttgt ttttgttttt 1260
gtttttcttc caaagctcac ctcggggaca attccttggg cttctcctga ggtaattgatt 1320
tcccccccca cccacagctg agtctgtgag gcccatcct ttccctacgt tttctcccat 1380
cttttttctt cttcagtcct ccagtcattc ggtttt 1415
```

<210> 71

<211> 1902

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2367767CB1

<400> 71

```
gcgaggtctg gctaggctac gggccacgcg ccgcccgcgc tgcccgcgcc actgtcctct 60
tcggaggcgc gggcccgacg gaaaccatgt ttgtggctcg cagcatcgcg gcggaccaca 120
aggatctcat ccacgatgtc tctttcgact tccacgggcg gcggatggca acctgctcca 180
```

```

gcgatcagag cgttaaggct tgggataaaa gtgaaagtgg tgattggcat tgtactgcta 240
gctggaagac acatagtggg tctgtatggc gtgtgacatg ggcccatcct gaatttgggc 300
aggttttggc ttcctgttct tttgaccgaa cagctgctgt atgggaagaa atagtaggag 360
aatcaaatga taaactgcca ggacagagcc actgggttaa aaggacaact ctgggtggata 420
gcagaacatc tgttactgat gtgaagtttg ctcccaagca catgggtctt atgttagcaa 480
cctgttccgc agatggtata gtaagaatct atgaggcacc agatgttatg aatctcagcc 540
agtgttcttt gcagcatgag atctcatgta agctaagctg tagttgtatt tcttggaaacc 600
cttcaagctc tctgtctcat tcccccatga tgcgcgtagg aagtgatgac agtagcccca 660
acgcaatggc caaggttcag atttttgaat ataatgaaaa caccaggaaa tatgcaaaaag 720
ctgaaactct tatgacagtc actgatcctg ttcatgatat tgcattcgct ccaaatttgg 780
gaagatcttt ccataattcta gcaatagcga ccaaagatgt gagaattttt acattaaagc 840
ctgtgaggaa agaactgact tcctctgggt ggccaacaaa gtttgaaatc catatagttg 900
ctcagttcga taatcataat tctcagggtc ggcgagttag ttggaatata acaggaacgg 960
tgctagcatc ttcaggagat gatgggtgtg taagattgtg gaaagctaata tatatggaca 1020
attggaagtg tactggtatt ttgaaaggta atgggagccc agtcaatggg agttctcagc 1080
agggaaacct aaatccttcc ctaggttcaa atattccaag tcttcagaat tcattaaatg 1140
gatcttctgc tggcagaaaag cacagctgag tacaagctaa ctggagtaac tttgctgttt 1200
tgctgtctgt tgcatgcaca caggaatgga aagcgagctc cttttccctt tccccagcgc 1260
cgtttgacct ctcccaagat acaccagcag cctgcttact actaaacgca atccaaaagg 1320
cctttaaaaa tacagtgtat attttttgta ctagtcatgt tattgacact atttgaaact 1380
tttgaaatat aaacggagag gctttctgtt gagacattgt caccaaaaaca attttttgaa 1440
atgttcctga aactaatttg ggtttaaaga ttaaaagggt tgttaccatt cttatctgag 1500
tagttgggag gagggaata ccactttagt tcatttggaa aatatagaca tatttctttt 1560
gctttcttaa aacagcttaa aatgatgaac ttttataatt ttaatttgaa gattgaataa 1620
atatttttta taaagattgt tttgagtgtc gatttgttta cttttttag atttgcttta 1680
tccatgatat tcagtacaac tctgtcattt ctttgtaata tttaaaaaat attagtaaaag 1740
gagtgaatta ataaagtagt aatagtaaaa tgaaaggaac ttgactgtac agtttgtagc 1800
caggttaaagc atttggtatt gtttcattta caatttggga ctaagatgga aacacttttt 1860
ttataagttt ttaattcata gtcactaaag agataaatgt tt 1902

```

<210> 72

<211> 1681

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3090433CB1

<400> 72

```

gggcagggct ttgctatggc taatgatccc ttggaaggct tccatgaagt aaaccttgct 60
tcacctactt ctccggacct tcttgggtgtg tatgaatcag gaactcaaga gcagactacc 120
tcaccaagtg tcatctaccg gccacaccct tcagctttat cctctgtacc tatccaggca 180
aatgcattag atgtttctga acttccctaca caaccctgtg attcatcccc cagacgttta 240
aattgtgcgg aaatatctag tatcagcttt catgttacag acccagcccc ttgctctacc 300
tctggagtca cagctggatt aactaaatta actacaagaa aggacaacta taatgcagag 360
agagagtttt tacagggtgc tactataaca gaggcttgcg atggcagtga tgatattttt 420
gggttgagta ctgatagtct gtctcgttta cgaagcccat ctgttttggg agttagagaa 480
aagggctatg aacgattaaa agaagaactc gcaaaagctc agagggaact gaagttaaaa 540
gatgaagaat gtgagaggct ttcaaaagtg cgagatcaac ttggacagga attggaagaa 600
ctcacagcta gtctatttga ggaagctcat aaaatgggtg gagaagcaaa tatcaagcag 660
gcaacagcag aaaaacagct aaaagaagca caaggaaaaa ttgatgtact tcaagctgaa 720
gtagctgcat tgaagacact tgtattgtcc agttctccaa catcacctac gcaggagcct 780
ttgccagggt gaaagacacc ttttaaaaag gggcatacaa gaaataaaaag cacaagcagt 840
gctatgagtg gcagtcacat ggacctcagt gtgatacagc caattgtaaa agactgcaaa 900
gaggctgact tatccttgta taatgaattc cgattgtgga aggatgagcc cacaatggac 960
aggacgtgtc ctttcttaga caaaatctac caggaagata tctttccatg tttaacattc 1020
tcaaaaagtg agttggcttc agctgttctg gaggctgtgg aaaacaatac tctaagcatt 1080
gaaccagtg gattacaacc tatccggttt gtgaaagctt ctgcagttag atgcccaggga 1140
ccaaaaaaat gtgctctcac tggccagagt aagtcctgta aacacagaat taaattaggg 1200
gactcaagca actattatta tatttctcct ttttgcagat acaggatcac tctgtatgt 1260
aactttttta catacattcg atacattcag cagggactcg tgaaacagca ggatgttgat 1320
cagatgtttt gggagggtat gcagttgaga aaagagatgt cattggcaaa gctgggttat 1380

```

```

ttcaaagagg aactctgatg ctctgcgtgg gaccatgcct gaactccccg aataactgaa 1440
aaatggctga atatttttat ggttacttga tattttattc caaggagtga gcctaagact 1500
tttttccctc ttgtcaaatt gctctaagaa gtaccatgat ttcttttaaa ctgatctatg 1560
ctgtgtttgc ttattcttta gttgaacaca ctatgaagaa ttccaggtgt actagtgaat 1620
gtaatttata gttgccaaaa aaaaaacaaa cctgaaataa ataatgttta gattgaaaaa 1680
a

```

```

<210> 73
<211> 1378
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 3800591CB1

```

```

<400> 73
ggcagatcct atctggcgca tgcgaacgct tctgtgccga ttccttgaag agcaggcgca 60
gactcaaggc tgttgcttcc gcccttactc cccgccgctc gtccctgggc ggggcgaagg 120
ctgggctggg ggaagaggcg tggcgcgctc gtgcgcgtgc acaaaagaga gctgaggggc 180
gggggcgctg cggcacagct ggtttgagca actgaactgg aaacaagatg caggacccca 240
acgcagacac tgaatggaat gacatcttac gcaaaaaggg tatcttacc cccaaggaaa 300
gtctgaaaga attggaagag gaggcagaag aggagcagcg catcctccag cagtcagtgg 360
tgaaaacata tgaagatatg actttggaag agctggagga tcatgaagac gagtttaatg 420
aggaggatga acgtgctatt gaaatgtaca gacggcggag actggctgag tggaaagcaa 480
ctaaactgaa gaataaatc ggagaagttt tggagatctc aggggaaggat tatgttcaag 540
aagttaccaa agctggcgag ggcttgtggg tcatcttgca cttttacaaa caaggaattc 600
ccctctgtgc cctgataaat cagcacctca gtggacttgc caggaagttt cctgatgtca 660
aatcttatcaa agccatttca acaacctgca tacccaatta tcctgatagg aatctgcccc 720
cgatatttgt ttacctggaa ggagatatca aggtcagtt tattggctct ctggtgtttg 780
gcggcatgaa cctgacaaga gatgagttgg aatggaaact gtctgaatct ggagcaatta 840
tgacagacct ggaggaaaac cctaagaagc cgattgaaga cgtgttgctg tcctcagtgc 900
ggcgctctgt cctcatgaag agggacagcg attccgagg tgactgaggc tacagcttct 960
atcacatgcc gaactttctt gtgacaaaatt gtctggattt tttaaaaaag gaaaaagcaa 1020
gaatgaatcc ttgtgtttt tagttttgta taaattatgt ttcaaactct tacatttttg 1080
aaataatcat tgctggagat tctgttaaat attttggaac tctttttttt taaattata 1140
gtatttcctc taaaaaaaat taaaaccagc catttgatg gcaaaaaaaa aaaagatact 1200
tcaatattag aattcaggtt tcctaatttt ctaaaaccta tgggaatttt ctaggatgga 1260
cgatcttagg aaggatcact tttggctgtt gtgagaaaac caaataaatt ttattacact 1320
ttaaaaatgt tttgtcataa tttagttaat attaaccttg ttttaacttta tagaaaga 1378

```

```

<210> 74
<211> 1444
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 5308471CB1

```

```

<400> 74
gcacgcagtg ccggaggccg cagcgccgga acctcagagg cgggtcgcag cggcgagag 60
gaggtcagct gcgggagcgt ttccggggac ggtgcgcga tgagattgac cccgcgcgcg 120
ctgtgcagcg cgcgccagcg cgctggcggg gagaacttcc ccctgtgcgg tcgcgacgtg 180
gcgcgctggt tccggggcca catggccaag gggctgaaga agatgcagag cagcctgaag 240
ctggtggact gtatcatcga ggteccagat gcccgatcc cactttcagg ccgcaacctt 300
ctgtttcagg aaacccttgg gcttaagcct cacttgctgg tcctcaacaa gatggacttg 360
gcgatctta cagagcagca gaaaattatg caacacttag aaggagaagg cctaaaaaat 420
gtcattttta ccaactgtgt aaaggatgaa aatgtcaagc agatcatccc gatggtcact 480
gaactgattg ggagaagcca ccgctaccac cgaaaagaga acctggagta ctgtatcatg 540
gtcattgggg tccccaacgt gggcaagtcc tccctcatca actccctccg gaggcagcac 600
ctcaggaaaag ggaaagccac cagggtgggt ggcgagcctg ggatcaccag agctgtgatg 660
tccaaaattc aggtctctga gcggcccctg atgttcctgt tggacactcc tggcgtgctg 720

```

```

gctcctcgga ttgaaagtgt ggagacaggg ctgaagctgg ccctgtgtgg aacgggtgctg 780
gaccacctgg tcggggagga gaccatggct gactacctgc tgtacaccct caacaaacac 840
cagcgctttg ggtacgtgca gactacggc ctgggcagtg cctgtgacaa cgtagagcgc 900
gtgctgaaga gtgtggctgt gaagctgggg aagacgcaga aggtgaaggt gctcacgggc 960
acgggtaacg tgaacgttat tcagcctaac tatcctgcgg cagcccgtga cttcctgcag 1020
actttccggc gtgggctgct gggttccgtg atgctggacc tcgacgtcct gcggggccac 1080
cccccggtg agactttgcc ctgaacttgt ccgggtaggg agggccggag gcatgtggcc 1140
tcccagacct cctgacctgg gtggttgagg ctcaagacag ctcaccgggt ccagaagctc 1200
catgctggtc actagggtgc tgtgtctctt ggcccccac agcctggcca gctccaggga 1260
ccccagttgc agggcccaag caggtggggg tggacaccag gcttcccagt ggacgtccct 1320
gagcagctcc gcatgcttgg ttctcccgga gcttcctgct caggcctctt gagaaatgga 1380
tgctgtctca gaaggagtta aagctataac ctgtaacctt taaaatctca aaaaaaaaaa 1440
aaaa 1444

```

<210> 75

<211> 2067

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5324322CB1

<400> 75

```

ggcactgtcc accagcactc agagctccat tatgtcccca gctgggggtt cagggtaggg 60
gggactgggg tgtcccccag cctcagcaga cggagggcct cagggatgag gctgccagga 120
tagcgccaga gaagcagctc agagcaaggg ctcttgagtg ggggcagggc tggggagaag 180
gtcatggggg ggctgcagta ggggtggtca ttgtgcaggc tgagttgaga gaagtgggtg 240
gccatgttct cctcagacag aaactgcttg cgcagaggct ccctggggag agatggcaga 300
gaggcaggct gggatactga cacaggaggc agcctgttgg ggaccagagg tgacagagat 360
cttggtggga gtccctccct gcccccaaac tcaactgtcc tctccaggc gccgcttggg 420
gctcatgggc acagctcctc ggagagggga gctggcgctc agggcccaag tcacccccaa 480
ggcgcccgcc gggaggcgct gggcccctcc ctgggggcct cgtgcaagg gctgctgcag 540
gatcattggg ttttggggtc ctgcgggtgg gatctgggag acaggggagg agtctctgag 600
ggcgtggcca agagaggatg ggcgtggctt taggcgggca cagccgcgag gttctgcgcg 660
ggcgcggaag acgggcggcg cgtggcggaa ggcaggcttg ctctcgggg tgggggaggg 720
tatccggctt aagggggctg cgggtggacac cacttcttaa tgcgggggt cttcgcgcg 780
ctcacctcgg ctcttagggg tcgggacggg acgcaccagc cacttctgcg ccgaaggcgg 840
tagggcgcca cggagaggaa ccgctctagg cagctaaggc ctctgtaggt tgcgtcgcg 900
gcggagcact ctgggacttg tagttctgga gatggagcga gctgtgccgc tcgcggtgcc 960
tctgggtcag acagaggtgt tccaggcctt gcagcggctc catatgacca tcttctccca 1020
gagcgtctca ccatgtggga agtttctggc ggctggcaac aattacgggc agattgccat 1080
cttcagctta tctctgctt tgagctcaga agccaaagag gaaagtaaga agccggtggg 1140
gactttccaa gccatgatg ggcccgctta tagcatggtt tccaccgatc gacatctgct 1200
tagtgctggg gatggggagg tgaaggcctg gctttgggag gagatgctca agaagggtg 1260
taaggagctg tggcgctgct agcctccata caggaccagc ctggaagtgc ctgagatcaa 1320
cgctttgctg ctggtcccca aggagaattc cctcatcctg gctgggggag actgtcagtt 1380
gcacactatg gaccttgaag ctgggacttt cagcaggggt ctcgggggac acacagacta 1440
catccactgc ctggcactgc gggaaaggag ccagagggtg ctgtcaggtg gcgaggatgg 1500
agctgttcga ctttgggacc tgcgcacagc caaggagggt cagacgatcg aggtctataa 1560
gcacgaggag tgctcgaggc cccacaatgg gcgctggatt ggatgttttg caactgattc 1620
cgactggatg gtctgtggag ggggcccagc cctcaccctc tggcacctcc gatcctccac 1680
acccaccacc atcttcccca tccgggcgac acagaagcac gtcaccttct accaggacct 1740
gattctgtca gctggccagg gccgctgcgt caaccagtgg cagctgagcg gggagctgaa 1800
ggccagggtg cctggctcct ccccagggtc gctcagcctc agcctcaacc gcagcctgc 1860
cgcgctgag tgcaaggtcc tgacagctgc aggcacagc tgccgggtgg atgtcttcac 1920
caacctgggt taccgagcct tctccctgtc cttctgatct ctgacgacac cccagccag 1980
ctcaggggtt tagagtgtt ttcatcttct tttttttttt ttttttataa taaagtttca 2040
ggctttttta ccaaaaaaaaa aaaaaaa 2067

```

<210> 76

<211> 2085

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 067184CB1

<400> 76

```

gtgttgcgcg actggccttg agggagagct ggggcctgct cccggagaga tacggctatg 60
tcgatcgaaa tcgaatcttc ggatgtgatc cgccttatta tgcagtactt gaaggagAAC 120
agttttacatc gggcgttagc caccttgCag gaggagacta ctgtgtctct gaatactgtg 180
gacagcattg agagttttgt ggctgacatt aacagtggcc attgggatac tgtgttgCag 240
gctatacagt ctctgaaatt gccagacaaa accctcattg acctctatga acaggttggt 300
ctggaattga tagagctccg tgaattgggt gctgccaggt cacttttgag acagactgat 360
cccatgatca tgttaaaaca aacacagcca gagcgatata ttcattctgga gaaccttttg 420
gccaggctctt actttgatcc tcgtgaggca taccCagatg gaagtagcaa agaaaagaga 480
agagcagcaa ttgcccaggc cttagctggc gaagtcagtg tggTgcctcc atctcgtctc 540
atggcattgc tgggacaggc actgaagtgg cagcagcatc agggattgct tcctcctggT 600
atgaccatag atttgtttcg aggcaaggca gctgtcaaag atgtggaaga agaaaagttt 660
cctacacaac tgagcaggca tattaagttt ggtcagaaat cacatgtgga gtgtgctcga 720
ttttctccag atggctcagta tttggTcact gggtctgttg atggattcat tgaagtatgg 780
aactttacta ctggaaaaat cagaaaggat cttaagtacc aggcccaaga taactttatg 840
atgatggatg atgctgtcct ctgcatgtgt ttcagcagag atacagaaat gttagcaact 900
ggggcccaag atggaaaaat caaggTgtgg aagattcaga gtggacaatg tttaaaggaga 960
tttgagaggg cacacagtaa gggTgtcacc tgtctaagct tttctaagga tagcagtcag 1020
atccttagtg cttcttttga ccagacaatt agaattcatg gtttaaaatc tgggaaaacc 1080
ctgaagggaat ttctgtggcca ttctcctttt gttaacgaag caacatttac acaagatgga 1140
cattacatta ttagtgcatc ctctgatggc actgtaaaga tctggaatat gaagaccaca 1200
gaatgttcaa atacctttaa atccctgggc agcaccgcag ggacagatat taccgtcaac 1260
agtgtgattc tacttcttaa aaaccctgag cactttgtgg tgtgcaacag atcaaacacg 1320
gtggTcatca tgaacatgca ggggcagatt gtcagaagct tcagtTctgg taaaagagaa 1380
ggTggggact ttgtttgctg tgccctctct ccccgTggTg aatggatcta ctgtgtaggg 1440
gaggactttg tgctctactg tttcagtaca gtcactggca aactggagag aactttgaca 1500
gtgcacgaga aggatgtgat tggTattgca catcaccctc atcagaacct gattgctacc 1560
tacagtgaag atggactcct aaagctctgg aaaccataat tcaacttttc tttttaaatc 1620
agctcgaaag catgtactta aatgaagcat attcatgtaa tgtgcttttt tttttttttt 1680
gccagctttt ctaagcaaat agattgtctg aattagtcac agaataattt tgtgaaaatt 1740
catgttttaag tagcaactac ctttcttttt tttatatatt ttttaaggat tagtttatct 1800
ctttctaact ggtgcagtca cttaatgttt tcattaatct tcgacctgga gagtgaaata 1860
tgataatttc tagaaaaaaa ttctactcct ctgattattt gaaatgctga ggaaaatgtc 1920
cctcccatag taaaacttgt aaataaggaa ctatatcata ttcagtagct gtgttctgtt 1980
ccatcttttt tttttttttt gagatggagt tttgcttgtt gcccaggctg gagtgcagcg 2040
gcacgatctt ggttcactgc aaCctccgcc tcccaggTtc aagcg 2085

```

<210> 77

<211> 2061

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 722896CB1

<400> 77

```

cgagccgCgg gacccggggc gtaccggggg ggggccgctc cgggccgcag cgcgagggca 60
gcgagggggc gcggggacct ggcaccgggc ggggccggcg gcagcgacca tgatcgcttt 120
gttcaacaag ctgctggact ggttcaaggc cctattctgg aaggaggaga tggagctcac 180
gctggtcggg cttcagtact cgggcaagac caccttcgtc aacgtgatcg cgtcaggaca 240
gttcaacgag gacatgatcc ccaccgtggg tttcaacatg cgaaaaatca ccaaagggaa 300
tgtgactatc aagctctggg acattggggg acagccgcgt ttccgcagca tgtgggagcg 360
ctactgccga ggagtgagcg ccacgtgtga actggTggat gctgctgacc aggagaagat 420
tgaggcctct aagaacgagc tccacaacct catggacaaa cctcagctgc agggcatccc 480
ggtcttagtc ctgggtaaca agcgagacct tccgggagca ttggatgaga aggagctgat 540
tgagaaaatg aatctgtctg ccatccagga ccgagagatc tgctgctact ccatctcttg 600

```

```

caaagaaaag gacaacattg acatcacccct acagtggcctt attcaacact cgaagtcacg 660
gagaagctga gactccagcc cttctccctc agaccaggga ccgtcatcat ctaaacctga 720
agccgagctc cccgcccacc cctgtcgtcc ccctaagccc acccctcctc acccagtggtg 780
aggaggggccc tctggggacc ccagagtcct gttctgtgta ggtttgaact cctgttttta 840
ttgtaaaata aattgcccc cttctgtgtc ccctaacttc tcacccttcc ccgtgcctt 900
tgtcccatca cccagccctg cctccctccc agcagccctg ggccacagcc cccgcccctg 960
gcttttcccc ggcccgtct tgtacctccc ttttcaacac tctctgttat tgtcctgtgt 1020
gtacagtata tatatgtata tatattttaa ttttttaatt taagcaaaga ctaaaatcaa 1080
ccatttgatg ctgcaggggc ctttcaggat ctgggagggg gcagtctgga gagaaggagg 1140
gagacgcagg tggacttggg gcaagttcag atcagaagag gtgcaggctg gcacctgcgg 1200
caggtaccag cctgggcact ggtggccgcc tccctgtccc gtgtgtttcc accgccaat 1260
ctggcctgtc ctggcagtg ttgaatgcca caggctggca ggggcctctg ggggcccctc 1320
ccctcgaccc ccagcctggg tagagccacc aggtacgacg accaggtacc agaaaccacc 1380
aggcacacgg ggcagaaagc cagcgtccat gcccagcag cccctcctg cctgttcctg 1440
gtcccagct cccgcccctc cccaggggcc ccacctccac ggcccacttc attttctgtt 1500
ctcattttgc agagttgcac aaggagagaa ctcagcatgg ggggttggtt ctttgggttc 1560
tgtttgttta tttgtttaat ttaatgattt gtaaaagtga gtccctcttc cttttttaca 1620
cttttcagct cataattaac ctctgtttgg aaaatgattc ttgtaactgt acattttttt 1680
gcttccctaat aacaatgaca acaaaaaaaaa taaatgacca gttttgtgtt ggggggggtg 1740
tatggtgctg gttacttttc cgcagttggc atgggttgcc ctacaggccc acagggccac 1800
cagcacaccc ccgcacgctg ggcaccaaca gagccacgga gcgcgagcac atgcccgcgc 1860
ggggagcaca atggcgctgc acaaaacggc ctcccacag tgcgtccagg ctcttgcgcc 1920
acctccttct cattctcttt tcagactttc atgtagtccc agctttgagc cagcagctgc 1980
cacttggggc tgcagcgtc tggtgagggg actgccagg gctgggtaga ggcagcaagg 2040
ggacagggct ggggtgctgtt t

```

<210> 78

<211> 981

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1571739CB1

<400> 78

```

gtagttccag aaaataggac tgaccaagaa gcagaaaagc aagatgaatg atgtgaagct 60
tgctgtcttg ggtgggtgaag gaacaggcaa atctgccctt acagtgaagt ttcttactaa 120
gcgattcatt ggagaatatg cttctaattt tgaatctatc tataagaagc acttgtgttt 180
ggaaaggaaa caactaaatc tagaaatata tgacccttgt tctcaaacac agaaagcaaa 240
attctccctc acaagtgagc ttcactgggc agatgggttt gttatttgtt atgacatcag 300
tgataggtct tcatlttgctt ttgcaaaagc gctgatctac agaatccggg agccacaaac 360
tagtcattgt aaaagagctg tggaatcagc agtgtttttg gttggcaaca aacgagatct 420
ttgtcatgtg cgagaggttg gctggggaaga agggcaaaag ctggcactgg aaaaccgatg 480
ccaattctgt gaactgtctg cagcagagca gtctctggag gtggaaatga tgtttatcag 540
aattatcaag gacatcctga taaacttcaa actcaaagaa aagagacgtc ccagtggatc 600
taaatcaatg gccaaattga tcaataatgt atttggaaag agaaggaaat ctgttttagta 660
gacaggtaat cctgggagat ttcctatatc agagagtttc aaacattcac atgataatta 720
aactaacctt tgatgcaat ttttttttgg taaaaagaat tctcttgagg atatgaaatg 780
attgagtatg aaccacagct gtgttttcaa atatgtagtt tgcctttttg gttgtgttac 840
cctgtcact ctccttcaca cagaaccttt cattttattgt acaacatcac actcacccta 900
acctactggc ggacagcgat cccagtttgc cttgccaaat aaactctgtt tatgtgaatt 960
tattaaacga caaaaaaaaa a

```

<210> 79

<211> 1375

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1739479CB1

<400> 79

```

aattctgtgc ttctccctct tgggccttca cacacttatg cttatgtaaa taattattaa 60
tcatattttc atgatgggtg agattcttat tcaccactac atcccatccc cagggcctgc 120
cacagaatag gcattcagta aatatttttt gaatgattga ctgagaaatc acacctctgt 180
ttcttttaaa cacatcctga tagctccata agtttcatca gggtcagtgg ttccatttgt 240
cctgactgct ggccacagtg acctgttctg tgctttatgt gacaagacct ctgaatgggt 300
ggacagtgat tcctgccaaa agtgtgatca gcctttcttc tggaaactca agcaaagtgt 360
ggacagtaag aaaattgggtc taagacagca ccactgccgc aagtgtggga aggcctctgt 420
tggcaagtgc agctccaagc gtcctcccat cccctgatg ggcttcgagt ttgaagtgtg 480
ggctctgtgac agctgccacg aggccatcac agatgaagaa cgtgcacca cagccacctt 540
ccatgacagt aaacataaca ttgtgcatgt gcatttcgat gcaaccagag gatggttact 600
gacttctgga actgacaagg ttattaaagt gtgggatatg accccagtcg tgtcttgatg 660
acttctccag gaatcagaaa gatagtattt actaaagaaa cggttgtttt aaccctaatg 720
attaccagag tggtaaagca gacatgtgag aagtaagaaa gaaactaaag accctgaatg 780
aatttgcaga ttacccatgt gcacagtggg gacctggcca gtgagcactc gcaaggggac 840
tcttccaact tgttcataca atataaaaga agctattttt ttaacaaatg gtttatacag 900
tctggctgtg ctgcattgtt ttgagtgtac cgaaaaatct gtgtgggggtg ttttaattttt 960
atacttttca acacccatt ttatttgttg ctttgtcaga gaaataaggg aggtatctac 1020
tcagagtatt ttggtcatta tactttctgt gtttacttca acatgtgtca cgtggccagc 1080
ggctttttct tctcttccct ctgcacctac ctgcaccttc tctgccttct ctggagggga 1140
tgtattttatg ttattttatc ccagtgttct tgctttcatg tcttctcag tggagagatt 1200
tggaaactca tcatgtggat tcaccagcca gctgtggaa ttgcctgaag agcgatttgt 1260
ttgtaatgtc tgctcattc acgttcttat gaagtagaaa agactgtgtt tctgcctcag 1320
ttgcctctgt ctttcccaca ttaaaaaaaa aaatgctgtg agaaaaaaa aaaaa 1375

```

<210> 80

<211> 2833

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1999147CB1

<400> 80

```

cggttgggac gcacacactc tgcgtcatgg agggctgagg ccgatgatga attccggagt 60
gcctgtcagg cttgctgtgt cactcggccc gctcggcgcg ccccttccca gccgcccctc 120
cgtaccggct ctcgggctct tccggctctc ggccgcccct tacttgacag ctcttctccc 180
gccgcggccc ggcgctctcc gagtcgcccc tgcggactgg tctcgacag tgcttgggca 240
ccgggcgcca gacagacact ggccatgacg agcggcgcaa ccaggtagcg gctgagctgc 300
tcgctccggg gccacgagct ggacgtacgg ggcctgggtg gctgcgccta tccgccggga 360
gcctttgtgt ccgtgtcccg agaccgcacc acccgccctc gggccccaga cagtccaaac 420
aggagcttta cagaaatgca ctgtatgagt ggccattcca attttgtatc ttgtgtatgc 480
atcataccct caagtgcacat ctaccctcat ccaccgggtg aaatgaccac 540
aatatatgca ttttctcact ggacagtcca atgccacttt atattctaaa aggccacaaa 600
aatactgttt gtagtctatc atctggaaaa tttgggacat tacttagtgg ttcattgggac 660
accactgcta aagtctggct gaatgacaag tgcatgatga ccttgcaggg tcatacagct 720
gcagtgtggg cggtaaagat cttacctgaa cagggcttaa tgttgactgg atcagcagac 780
aagactgtta aactgtggaa ggctggaaga tgtgagagga ctttttcagg gcatgaagac 840
tgtgtaagag gtttggcaat tttgagttaa acagaatttc tttcctgtgc aaatgatgct 900
agtattagaa ggtggcaaat cactggcgag tgtcttgaag tatattatgg acatacaaat 960
tatatttata gcatatccgt ttttccaaat tgtagagact ttgtgacaac agcagaggac 1020
agatctctga gaatctggaa acatggggaa tgtgtctaaa ctatccgact tccagctcag 1080
tctatatggg gctgctgtgt gctcgacaat ggtgacattg tggttgggtg gactgatggc 1140
attattagag tgtttacaga atcagaagat cgaacagcaa gtgctgaaga aatcaaggct 1200
tttgaaaaag aactgtctca cgcaaccatt gattctaaaa ctggcgattt aggggacatc 1260
aatgctgagc agcttctctg gaggaacat cttaatgaac ctggtactag agaaggacag 1320
actcgtctaa tcagagatgg ggagaaagtc gaagcctatc agtggagtgt tagtgagggg 1380
aggtggataa aaattgggtg tggtgttggc tcatctgggt ctaatcagca aacatctgga 1440
aaagttttat atgaaggga agaatttgat tatgttttct caattgatgt caatgaagg 1500
ggaccatcat ataaattgcc atataatacc agtgcagacc ctgggttaac tgcatacaac 1560
ttcttacaga agaattgatt gaatcctatg tttctggatc aagtagctaa atttattatt 1620
gataacacaa aaggtcaaat gttgggactt gggaatccca gcttttcaga tccatttaca 1680

```

```

ggtaggtggtc ggtatgttcc gggctcttcg ggatcttcta acacactacc cacagcagat 1740
cctttttacag gtgctgggtcg ttatgtacca ggttctgcaa gtatgggaac taccatggcc 1800
ggagttgatc catttacagg gaatagtgcc taccgatcag ctgcatctaa aacaatgaat 1860
atttatttcc ctaaaaaaga ggctgtcaca tttgaccaag caaacctac acaaataa 1920
ggtaaactga aggaacttaa tggaaactgca cctgaagaga agaagttaac tgaggatgac 1980
ttgatacttc ttgagaagat actgtctcta atatgtaata gttcttcaga aaaaccaca 2040
gtccagcaac ttcagatttt gtggaaagct attaaactgtc ctgaagatat tgtctttcct 2100
gcacttgaca ttcttcgggt gtcaattaaa caccctcagtg tgaatgagaa cttctgcaat 2160
gaaaaggaag gggctcagtt cagcagtcac cttatcaatc ttctgaacc taaaggaaag 2220
ccagcaaac agctgcttgc tctcaggact ttttgcaatt gttttgttg ccaggcagga 2280
caaaaactca tgatgtccca gagggaaatca ctgatgtccc atgcaataga actgaaatca 2340
gggagcaata agaacttca cattgctctg gctacattgg ccctgaacta ttctgtttgt 2400
tttcataaag accataacat tgaagggaaa gcccaatgtt tgtcactaat tagcacaatc 2460
ttggaagtag tacaagacct agaagccact tttagacttc ttgtggctct tggaacacct 2520
atcagtgatg attcaaatgc tgtacaatta gccaaactct taggtgttga ttctcaaata 2580
aaaaagtatt cctcagtatc agaaccagct aaagtaagtg aatgctgtag atttatccta 2640
aatttgctgt agcagtggg aagagggagc gatattttta attgattagt gtttttttcc 2700
tcacatttga catgactgat aacagataat taaaaaaga gaatacgggt gattaagtaa 2760
aattttacat cttgtaaagt ggtggggagg ggaaacagaa ataaaatttt tgcactgctg 2820
aaaaaaaaa aaa 2833

```

<210> 81

<211> 1752.

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2182085CB1

<400> 81

```

gcaggcagcc atcttgctg gagcctgaga aagggaggag agacagaagg aaccggcgac 60
agtgggtctca gggccgctcc ggggggctc aagaaccgga ggcagccccg gaggtgccc 120
cgggcggaata cgccagagga ggaggccggg gaatggccgc ggtgtggcag caagtcttag 180
cagtggacgc gaggtacaac gcgtaccgca caccaacgtt tccacagttt cggacgcagt 240
atatccgccc ggcgagcagc tgctgcggga gaatgccaa gctgggcacc cccagcgct 300
gcgtcggcag tacctgaggg ttccggggca gctgctgggc cagcgctacg gggccctctc 360
cgagccaggc agtgctcgtg cctatagcaa cagcatcgtc cgcagtagcc gcactactct 420
tgaccgcatg gaggaacttg aggatgatcc tcgggcccgt ggcccgtg ggaccgctc 480
ttctgtcagc agaggctcct accagctgca ggccgagatg aaccgtgccg tctatgagga 540
caggccccct ggcagcgtgg tgcccacgtc agcagcagag gcaagtcggg ccattggccg 600
ggacacgtca ctgagcgaga actatgcctt tgccggcatg tatcatgttt ttgaccagca 660
cgtggatgag gcagtcceaa ggggtgcgct cgccaatgat gaccgacacc gcctggcctg 720
ctgctcactc gacggcagca tctccctgtg ccagctgggt cctgccccac ccacagtgt 780
tcgctgtcta cggggccaca cccgtggtgt ctccgacttc gcctgggtcc tctccaatga 840
catcctcgtg tccacctcac tggatgccac catgcccact tgggcctctg aggatggtcg 900
ctgcatccga gagatccctg acccgatag cgctgaactg ctctgctgca ccttcagcc 960
tgtcaacaac aacctcactg tgggtgggaa cgccaagcac aacgtgcatg tcatgaacat 1020
ctccacaggc aagaaagtga aggggggctc cagcaagctg acaggccgtg tccttgctct 1080
gtcctttgat gccctggcc ggctgctctg ggccgggtgat gaccgtggca gtgtcttctc 1140
tttctcttt gatatggcca cagggaagct gaccaaagcc aagcgtttgg tgggtcatga 1200
ggggagccct gtgaccagca tctcagcccc gtcttggtgc agccgcgagg cccgggatcc 1260
ctcactgctc atcaatgctt gcctcaacaa gttgctgctc tacaggggtg tagacaacga 1320
ggggaccctg cagctgaaga gaagcttccc catcgagcag agctcacatc ctgtgcgag 1380
catcttctgt cccctcatgt ccttcggcca gggggcctgc gtggtgacgg gcagtggga 1440
catgtgcgtg cacttctttg atgtggagcg ggccggccaa gctgctgtca acaagctgca 1500
ggggcacagt gcacctgtgc ttgatgtcag cttcaactgc gacgagagcc tactggcctc 1560
cagtgcgccc agcggcatgg tcatcgtctg gaggcgggag cagaagtagg gtcctgtcgg 1620
ccctgctgct gtccctccatc cccccctct tactccagcc tcgtgttgta aataaagttt 1680
cgggtggtcat gctgagggcc ggctcccagc tctgcccggg acggacaggg cagagggcag 1740
cgggcagctg ca 1752

```

<210> 82

<211> 1854
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2216640CB1

<400> 82
cccacgcgtc cgcgcaggat ggcggcagca gtggcggacg aggcgggtggc gcgcgatgtg 60
cagcgggttg tagtgagtt ccaggatgag ggcgggcagc tgctgggttc cccgttcgac 120
gtgcccggtg acatcacccc ggacaggctg cagctcgtgt gcaacgcgct actggccag 180
gaggatcccc tgccactggc tttctttgtc cagcatgctg agatcgtctc ctactgggg 240
aagacgttgg agtcccaggc agtggagaca gagaagggtcc tagacatcat ctaccagcca 300
caggctatct tcagagtccg ggctgtgact cgctgcacca gctccttggg gggtcacagt 360
gaggcagtca tttctgtggc cttcagccct acgggaaagt acctggccag tggctctgga 420
gacaccaccg tgcgcttctg ggatctcagc acagagacac cacatttcac atgcaagggg 480
cacagacact gggctccttag tatatcctgg tctccagatg gcaagaagct ggcctcaggc 540
tgcaagaatg gccagattct cctctgggac ccaagcacag ggaagcaggt gggcaggacc 600
ctcgctggcc acagcaagtg gatcacaggc ctgagctggg agcccctcca tgcgaaccct 660
gagtggcgt atgtggccag cagctccaag gatggcagtg tgcggatctg ggacacaact 720
gcaggccgct gtgagcgcac cctcaccggg cacaccagc cggtcacctg tctccggtgg 780
ggagggggac ggcttctcta ctctgcctcc caggaccgca ccatcaaagt ctggagagct 840
catgacggtg tgctgtgccc gactctgcaa ggccacggcc actgggtgaa caccatggcc 900
ctcagcactg actatgccct gcgcactggg gcctttgaac ctgctgaggc ctgagttaat 960
ccccaaagac tccaaggatc cttgcaggag ttgaaggaga gggctctgag ccgatacaac 1020
ctcgtgcggg gccagggtcc agagaggctg gtgtctggct ccgacgactt caccttattc 1080
ctgtggtccc cagcagagga caaaaagcct ctactcggg tgacaggaca ccaagctctc 1140
atcaaccagg tgctcttctc tctgactccc cgcactcgtg ctagtgcctc ctttgacaag 1200
tccatcaagc tgtgggatgg caggacgggc aagtacctgg ctccctacg cggccacgtg 1260
gctgccgtgt accagattgc gtggtcagct gacagtcggc tcttggtcag cggcagcagt 1320
gacagcacac tgaaggtgtg ggatgtgaag gcccagaagc tggccatgga cctgcccggc 1380
cacgcggatg aggtatatgc tgttgactgg agtccagatg gccagagagt ggcaagtggg 1440
gggaaggaca aatgcctccg gatatggagg agatgagacg gcccgaagtt ctctctgacc 1500
cccacctcga ctgggctctc gccagctgcc ttccctgcca gagaacaaag gctgagatgg 1560
cagtgcacac accctcccca ccagtgggga cctgagaatg cgtgtggcct gctgtcctcg 1620
atagaccgga atggggtttt cccacagatc cccgcctgtg gcacacccca gagccagaaa 1680
tcgaaggtca caggaagtgg tcaactgaact tggcccgtgt ctgctactct gtaccttgct 1740
ggtacagaca ggggtggtgg gcagcaggc tctatgagtg ggcccctagt gtcagctctg 1800
tacagggtca gatcccaggt tctatgacca aataagtaac ttaaaaaaaaa aaaa 1854

<210> 83
<211> 862
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2417361CB1

<400> 83
ggcgtggcct caacagactt tcttttgcct gtctttgtcc cagagcctct tccctggccc 60
tgctgagacc actgctctaa gaagagacca ccagactgag agaggactcc cagctgccct 120
cagagcggag gccgagtgtc gcacagccac agctgctctg aagcccttcc atgaatcccc 180
ggaagaaggt ggacctgaaa ctcatattcg tcggagccat tgggtgtggg aagacctccc 240
tccctcacca atatgtgcac aagacgtttt atgaggaata ccagaccaca ctggggggcca 300
gcatectctc caagattatc atattgggtg acacaacttt gaagttacag atctgggaca 360
cgggcggtca ggagcggttc cgctccatgg tgtccacggt ctacaagggc tccgatggct 420
gcatectagc ttttgatgtc accgacctgg agtcttttga agccctggat atctggcggg 480
gtgatgtcct ggccaagatt gtccccatgg agcagtccta ccccatgggt ttgttgggga 540
acaagatcga tctggcagac cggaaggtag cccaggaagt agctcaaggc tgggtgtagg 600
agaaagatat tcttactttt gaagtcaagt ccaagaatga catcaatgtg gtgcaagcgt 660
ttgagatgct ggccagtagg gctctgtcga ggtaccagag catcttagaa aatcacctca 720

```

cagaatccat caagctctcg ccagaccagt caaggagcag atgctgctga cctccagacg 780
cctgctctgg aagcccagaa acagagcctg ccccgagcct ggtcacccca ggcttgagaa 840
caggtgacca tccccctcca gc                                     862

```

```

<210> 84
<211> 1406
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 2454384CB1

```

```

<400> 84
ctagagcctg gggctctcggc aacttcaggc ggcgaggagct gcagagcgca aggccccgcc 60
actgcgcgtg cgcttcggcc cggctcctcc tgcgcccccg gcccctgcga ctgggacttg 120
gtacggccgg gcggttgccg tctctgcgg ctctgccag gggcgggcct ttcaaactct 180
ccctttgaag gagtggcgac ggcccgaca gtctcggtg gagatggagg ggccgagcct 240
gaggggtcct gcgctccgcc tggcggggct tcccaccag caggactgca acattcaaga 300
aaaaatagac ttagaaattc gaatgcgaga aggaatatgg aaactccttt ctctgagcac 360
tcagaaagat caagttttac atgcagttaa gaatctcatg gtgtgcaatg ctcgactaat 420
ggcctataca tcggagctac agaaattaga agaacagatt gcaaatacaga ctggaagatg 480
tgatgtgaaa ttgaaagta aagaacgaac agcatgtaaa ggaaagattg ccatatcaga 540
tattcgaata ccactaatgt ggaaagactc tgatcacttc agcaataaag aacgatcacg 600
acgctatgcc attttttgtt tattcaaaat gggagctaag gtgtttgata ctgatgtgg 660
gaatgtggat aaaacaatca cagatatatg ttttgaaaat gtaaccatat tgtaagtatt 720
ttttaactct cagagaataa aaataattta aaattcttct tttttaaaag aaagtcttta 780
ttattgggtc ttggattca ttttatgttt aaatgtttta gtgatcttta aatgtttaat 840
atgattttta aaattatttt gttcagaaga agtccatttc tctatctgca gttttctgat 900
gtgaaataaa aatggaaatc ttgtaattac tattagcagt aaatatgtga cttattagat 960
atgaccatt tttaaattgt taataaatat agttcagtta ttaacaaagc tatgcataca 1020
acagaatatc ctgtaattgt atttgatata gagagaattt aagcataaaa caggattttt 1080
atctcatgta ggatatttgg ttgcagaaat actaaaatag tatagcgact ttatttaca 1140
gatagtcctg aagtacatgc tatataggaa gagcactttg aaattttggg gtgttctttt 1200
tcttatgggt cacttctttc atgtacttca aagcaataaa aaaaaatggg tgatctcagg 1260
gctgttttta ttgtccctgc tcttttacag gctcatttta ttgtgggtcat aatacagaac 1320
aagaaggaa ccttgggtga gccatagaaa tcatttttaa cttacatagt ttttctgccc 1380
ctccttcaaa ggttctatgt gcctaa                                     1406

```

```

<210> 85
<211> 1184
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 2610262CB1

```

```

<400> 85
gcggtttttg tgctgaagc agggagcgcg gactcgttcc cgagagaggc ggccaggcta 60
tgctcgccgg tttccggcgt tccgctccgg ccagccagag tctctgtctc aacctgtgtc 120
cgtgctccag cagtctctc agcccgcccc cgcgcccgcg ttggcgccgg cggccccagg 180
gcgccccctc ctccgatggc ggccggagatc cagcccaagc ctctgacccg caagccgatc 240
ctgctgcagc ggatggagggt gtcccaggag gtggtgaata tggccgtgat cgtgccccaa 300
gaggaggggc tcatcagcgt ctccgaggac aggacagttc gtgtttgggt aaagagagac 360
agtggacagt attggccaag cgtataccat gcaatgcctt ctccatgttc atgcatgtct 420
tttaaccggg aaacaagaag actgtccata ggtctagaca atggtacaat ctgagagttt 480
atattgtcag aagattataa caagatgact cctgtgaaaa actatcaagc gcatcagagc 540
agagtgcaga tgatcctgtt tgcctcggag ctggagtggt tgctgagcac aggacaggac 600
aagcaatttg cctggcactg ctctgagagt gggcagcgcc tgggagggtt tcggaccagt 660
gctgtggcct caggcctgca atttgatgtt gaaacccggc atgtgtttat cggtagacc 720
tcaggccaag taacaatcct caaactggag caagaaaact gcaccctggg cacaacattc 780
agaggacaca caggtggggg gaccgctctc tgttgggacc cagtccagcg ggtgttgttc 840

```

```

tcaggcagtt cagatcactc tgtcatcatg tgggacatcg gtgggagaaa aggaacagcc 900
atcgagctcc aaggacacaa cgacagagtc caggccctct cctatgcaca gcacacgcga 960
caattgatct cctgtggcgg tgatggtggg attgtcgtct ggaacatgga cgtggagagg 1020
caggagcctc tgtggagctg ctctcgtggt atgataagtg ctgtgtgatg ctcaccttgg 1080
gaggtctgcg acatatattg aagtcacttc taacctgaag tactgacaga ctttctggaa 1140
gaaaaggctt gtaggaggaa acttcagaat tctattaaat ggtg 1184

```

<210> 86

<211> 2965

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2700075CB1

<400> 86

```

ggcaccactg tgaaggtctg ggacgcagcc aagcagcagc ccctgacaga gctggcagcc 60
catgggggacc tgggtgcagag cgccgtctgg agccgagatg gagccctggg gggcacggcg 120
tgcaaggaca agcagctgcg gatctttgac ccagaaacaa agccgcgggc ctctcagagc 180
acgcaggccc atgagaacag cagggatagc cggctggcat ggatgggacac ctgggagcac 240
cttgtgtcta ctggattcaa ccagatgcgt gagcgcgaag tgaagctgtg ggacacgcgg 300
ttcttctcca gcgccctggc ctccctcacc ttggacacct cgcttgggtg tctcgtgcct 360
ctgctgggacc ctgactctgg gctcctggtc ctggcaggaa agggcgagag gcagctgtac 420
tgttacgagg tggteccgca gcagccggcg ctgagccag tgacccagtg tgtcctggag 480
agcgtgctgc gtggggctgc ccttgtgccc cggcaggcgc tggccgtcat gagctgcgag 540
gtactccgcg tcctacagct gagcgacaca gccatcgtgc ccatcggcta ccatgtgccc 600
cgcaaggctg tggagtcca cgaggacctg ttcccggaca ctgcccgtg tgtgctgccc 660
accgaccccc atagctgggt ggctggggac aaccagcagg tgcagaaggt cagcctcaac 720
cccgcctgcc ggcccacccc gagcttccact tctgtcttgg tgccccctgc ggagcccctc 780
cctgacacag cccagcctgc ggtgatggag acaccctgg gtgatgcaga cgcaagcgag 840
ggtttctctt cccctcccag ttcgctgacc tcgccctcca cgccctccag cctggggccc 900
tcactctcca gcaccagtgg catcgggacc agccccagtt tgaggtcgct gcagagcctg 960
ctgggccccca gtccaagtt ccgcctgctg cagggcactg tcttgacagg agacagccac 1020
atcaccaacc tcaaggggct caacctcacc acacctgggt agagtgcagg cttctgtgcc 1080
aacaagctgc gtgtggccgt gccgtgtctc agcagcgggg gacaggtggc tgtgcttgag 1140
ctacggaagc ctggccgcct gcccgacacg gcaactgccc cgctgcagaa tggggcagct 1200
gtgactgatc tggcctggga cccctttgac ccccatcgcc tcgctgtggc tggtaggagc 1260
gccaggatcc gactgtggcg ggtaccgcga gagggcctgg aagaggtgct caccacgcca 1320
gagactgtgc tcacaggcca caccgagaag atctgctccc tgcgcttcca cccactggca 1380
gccaatgtgc tggcctcgte ctccatgac ctcactgttc gcacttgga ccttcaggct 1440
ggagctgatc ggctgaagct gcagggccac caagaccaga tcttcagcct ggcctggagt 1500
cctgatgggc agcagctggc cactgtctgc aaggatgggc gtgtgcgggt ctacaggccc 1560
cggagtggcc ctgagccct gcaggaaggg ccagggccca agggaggacg cggagctgc 1620
attgtctggg tatgtgatgg tcgtgtctg ctggtgtctg gctttgacag ccaaagtgc 1680
cgccagctgc tcctatatga agctgaggcc ctggccggcg gacccttggc agtgttgggc 1740
ctggacgtgg ctccctcaac cctgtgccc agctacgacc cagacactgg cctggtgctc 1800
ctgaccgga agggcgacac ccgtgtatc ctgtacgagc tgcctcccga gtcctcttc 1860
ttcctggagt gcaacagctt cactgcgct gacccccaca agggcctcgt cctcctgctc 1920
aagacggagt gcgacgtgcg ggaagtggag ctgatgcggg gcctgcggct gcgtcagtcc 1980
tccctggagc ctgtggcctt ccggctgccc cgagtccgga aagagttctt ccaggatgac 2040
gtgttcccag acacggctgt gatctgggag cctgtgtctc gtgccgaggc ctggctgcaa 2100
ggcgctaagt ggcagccctg gcttctcagc ctgcagcctc ctgacatgag cccagtgcagc 2160
caagcccccc gagaggcccc tgctcgctcg gccccatcct cagcgcagta cctggaagaa 2220
aagtctgacc agcaaaagaa ggaggagctg ctgaatgcca tgggtggcaa actggggaac 2280
cgggaggacc cactccccca ggactccttt gaaggcgtgg acgaggacga gtgggactag 2340
cctgcgcccc cgtcacctcc acctcacctg tgctgccact tcctagtgc cactcacgg 2400
ctcatcctca agctggaaga tacctctctg gccccggcac atgtcaccct tgcactcctg 2460
ccttcccgtg ggcacttcca catcctctgg gcctctggca gttcccaggg actgttttca 2520
cctctgctgt ctctggggtc agctgctgct catcagctgc ccgctagcat gtggccaggg 2580
gtgcagggtg gcggggggtc agcagcatgt cctggggcag gccctgggca cctgtctcc 2640
cctggctctca ctgctgacct gggctgggtc cagcctggat tggcctcatc caggatcttt 2700
ggtcacccca cgctgccccca tcttgccctg tgttccagtt ctggtcaagg gccttggggg 2760

```

```

ctggccccc accaggcctt ctagagcagc accagtctca gggccctggg accagctgcc 2820
ctacttccca ggtttgtagc caggagaagg gggcatcaca gagctgatgg tccaataagg 2880
ggggtgtgag ccccgaggg actggccgc acctgccttg gatgttttca gcaattaaac 2940
ttttttaagc tggcaaaaaa aaaaa 2965

```

```

<210> 87
<211> 2823
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 2786701CB1

```

```

<400> 87
cggaggcagc ctagecctcgc gccccgcccg ttgcttctgc cctccggcct tcccgcgcgc 60
gtcgccggga ccagccgctc ggggcccggg tgatacagcc gcttcaccgt gcccctgccc 120
gcgaccatgg cctcctccga ggtggcgcgg cacctgctct ttcagtctca catggcaacg 180
aaaaacaactt gtatgtcttc acaaggatca gatgatgaac agataaaaag agaaaacatt 240
cgttcggtga ctatgtctgg ccatgttggt tttgagagtt tgcctgatca gctggtgaac 300
agatccattc agcaaggttt ctgctttaat attctctgtg tgggggaaac tggaaattga 360
aaatcaacac tgattgacac attgtttaat actaatattg aagactatga atcctcacat 420
ttttgcccac atgttaaaact taaagctcag acatatgaac tccaggaaag taatgttcaa 480
ttgaaattga ccattgtgaa tacagtggga tttggtgacc aaataaataa agaagagagc 540
taccaacca tagttgacta catagatgct cagtttgagg cctatctcca agaagaactg 600
aagattaagc gttctctctt tacctaccat gattctcgca tccatgtgtg tctctacttc 660
atctcaccga caggccactc tctgaagaca cttgatctct taaccatgaa gaaccttgac 720
agcaaggtaa acattatacc agtgattgcc aaagcagata cggtttctaa aactgaatta 780
cagaagttta agatcaagct catgagtga tttggtcagca atggcgctcca gatataccag 840
ttcccaacgg atgatgacac tattgctag gtcaacgctg caatgaatgg acagttgccg 900
tttgctgttg tgggaagtat ggatgaggta aaagtcggaa acaagatggg caaagctcgc 960
cagtaccctt ggggtgttgt acaagtggaa aatgaaaacc actgtgactt tgtaaagctg 1020
cgggaaatgc tcatttgtac aaatatggag gacctgcgag agcagaccca taccaggcac 1080
tatgagcttt acaggcgctg caaactggag gaaatgggct ttacagatgt gggcccagaa 1140
aacaagccag tcagtgttca agagacctat gaagccaaaa gacatgagtt ccatggtgaa 1200
cgtcagagga aggaagaaga aatgaaacag atgtttgtgc agcgagtaaa ggagaaaagaa 1260
gccatattga aagaagctga gagagagcta caggccaaat ttgagcacct taagagactt 1320
caccaagaag agagaatgaa gcttgaagaa aagagaagac ttttggaaaga agaaaataat 1380
gctttctcta aaaagaaagc tacctccgag atatttcaca gccagtcctt tctggcaaca 1440
ggcagcaacc tgaggaagga caaggaccgt aagaactcca atttttgtgta aacagaagt 1500
tccagagcac agaaggtcat catcacaagc aaactttatt aaaaaaaac tagaagtgtg 1560
ctttgatttt gctgttattt gttttatcac tttctatatt ggtgaacagc cacagttact 1620
gatattttat gaaaagtact ttcaagtaca aggtcaatac ataagccaga gtgaatgata 1680
ctacaagttg agcatctcta attcaaaaat ctgaaatcca gaagcttcaa aatctgaatc 1740
tttttgagca ctgacttgac ccacaaagt gaaaattccc caccgacac ctttgctttc 1800
tgatggttca gtttaaacag attttggttc ttgcacaaaa tttttgtata aattactttc 1860
aggctatatg tataaggttg atgtgaaaca tgaattatgt aattagagtc gggccccgtt 1920
gtgtatatgc agatattcca aacctgaaat ccaaaacact tctggtccct agcatttttg 1980
ataagggata ctcagcttgt acctatatat tcatatatat tctactgttg tagaaatgtt 2040
taagttgctg ttctgtgatg aatctaaatc ttttctcttg ctaccaagct attgtcactg 2100
cagtgcatga taccaaagag cgaagtcagt gccactgaaa atacagaacc cattaatatc 2160
gtggctatct gattacattt atattccaag atgaaccttt tttatatatg ctaaaaattt 2220
tggggaatat gttttgggat gtattatgga gctaaaactc taacctctta atagttttat 2280
agaacttaaa aattttttat acaattaccc aattggtgat atgatcttaa gcttttgtgt 2340
cagattattt aatatgatga cttcatgctt tattatgcct tattatggct gacgtattac 2400
tgtggtgaaa caaaatatct ttaaaagtta aaacatccag atatataagc tattttttcc 2460
taaggataaa gtacctttga gcatgagtg atcacagctt tcattaggaa aacttttcat 2520
tacatacttg tttaaactct gtcttccagg gtaaaaaata taaggttgaa tcattttatt 2580
aaaaatactt ttaagaaaa taactatgaa catctgaata ttaaagatat aaaaatgcac 2640
ataattcata tttcaggttg tatttgcat cagtgcctta ctggtattct cagaacattt 2700
taatgatttc taacatttct taacagtcac agatatatac attttcattt tttgtacttg 2760
aatattctaa ataaaaactga catttactct tgacaaataa aacatatatt tactaaaaaa 2820
aaa 2823

```

<210> 88
 <211> 1549
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3068538CB1

<400> 88
 gcagacccgg caccgaggtg ggggcccggc ggggtccgtg ccagagctgc agagagacaa 60
 gggggcggcg gctgctgtgc tgggtgcagt gaggaagagg ccctcgggtg tgcccatggc 120
 tggccaggat cctgcgctga gcacgagtca cccgttctac gacgtggcca gacatggcat 180
 tctgcaggtg gcaggggatg accgcttttg aagacgtgtt gtcacgttca gctgctgccg 240
 gatgccaccc tcccacgagc tggaccacca gcggctgctg gagtatttga agtacacact 300
 ggaccaatac gttgagaacg attataccat cgtctatttc cactacgggc tgaacagccg 360
 gaacaagcct tccctgggct ggctccagag cgcatacaag gagttcgata ggaagtacaa 420
 gaagaacttg aaggccctct acgtggtgca ccccaccagc ttcatacaag tcctgtggaa 480
 catcttgaag cccctcatca gtcacaagtt tgggaagaaa gtcattctatt tcaactacct 540
 gaggtagctc cacgaacacc ttaatacga ccagctggtc atccctcccg aagttttgcg 600
 gtacgatgag aagctccaga gcctgcacga gggcgggacg ccgcctccca ccaagacacc 660
 tccgcgcggc cccccgctgc ccacacagca gtttggcgct agtctgcaat acctcaaaga 720
 caaaaatcaa ggcaactca tccccctgt gctgaggttc acagtgaagt acctgagaga 780
 gaaaggcctg cgcaccgagg gcctgttccg gagatccgcc agcgtgcaga ccgtccgcga 840
 gatccagagg ctctacaacc aagggaagcc cgtgaacttt gacgactacg gggacattca 900
 catccctgcc gtgacctga agaccttccg gcgagagctg ccccagccgc ttctgacctt 960
 ccaggccctac gagcagattc tcgggatcac ctgtgtggag agcagcctgc gtgtcactgg 1020
 ctgccgccag atcttacgga gcctccaga gcacaactac gtcgtcctcc gctacctcat 1080
 gggcttccct catgagggtg cccgggagag catcttcaac aaaatgaaca gctctaacct 1140
 ggctgtgtgc ttccggctga atttgatctg gccatcccag ggggtctcct ccctgagtgc 1200
 ccttgtgccc ctgaacatgt tcaactgaact gctgatcgag tactatgaaa agatcttcag 1260
 caccgccggg gcacctgggg agcacggcct ggcaccatgg gaacagggga gcagggcagc 1320
 ccctttgcag gaggtgtgac caggacaca agccacgggc ctcaccaagc ctaccctacc 1380
 tccgagtccc ctgatggcag ccagaagacg tctctagtgt tgccaacact ctgtatatatt 1440
 cgagctacct cccacacctg tctgtgact tgtatgtttt ataaacttgg catctgtaaa 1500
 aataaccagc cattagatga attcagaacc ttctaataaa aaaaaaaaaa 1549

<210> 89
 <211> 1722
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5159072CB1

<400> 89
 gcaagaggga gccggcccga cgcggaccgc ttccctgcag tgccccgagt cccgggcccg 60
 cgccgcccgc gccgggctcc gctcgcggcc cctctgtctg caggcgtgac ccggcgccgg 120
 cggagagccg tccctggccg aggaggctgg gaaacgcgag cgcaggcggc agagaggcct 180
 caacgcccgc cctttcgcca ccgccttttc cttgcctcgc gccgctgtgc atttctctcc 240
 ttttcccttg ttttttggc ccctcgcggg tgtgggcatt gttggttagc aaaagtgcag 300
 cctcaagatg gctgatggca acgaggatct gcgggctgac gacttgccctg ggccagcctt 360
 cgagagctat gagtccatgg agcttgccctg ccccgtgag cgcagcggcc acgtagccgt 420
 cagcgacggg cgccacatgt tcgtctgggg cggctacaag agtaatacaag tcagaggatt 480
 atatgacttt tatctgccta gagaagaact atggatctac aacatggaga ctgggaagatg 540
 gaaaaaaatc aacactgaag gtgatgttcc tccttctatg tcaggaagct gtgctgtgtg 600
 tgtagacagg gtgctgtact tgtttggagg acaccattca agaggcaata ccaataagtt 660
 ctacatgctg gattcaaggt ctacagacag agtggttacag tgggaaagaa ttgattgcca 720
 aggaattcct ccatcatcaa aggacaaaact tgggtgtctg gtatataaaa acaagttaat 780
 attttttggg gggatggat atttgccctga agataaagta ttgggaactt ttgaattcga 840
 tgaacatct ttttggaaatt caagtcaccc aagaggatgg aatgatcatg tacatatattt 900
 agatactgaa acatttacct ggagccagcc tataactact ggtaaaagcac cttcacctcg 960

```

tgctgcccac gcctgtgcaa ctgtcggaata tagaggcttc gtgtttggag gcagatatcg 1020
agatgctaga atgaatgata ttcactatct taatctggat acatgggagt ggaatgaatt 1080
aattccacaa ggcataatgcc cagttggctc atcttggcac tctaatacac cagtttcttc 1140
agatcatctt tttctctttg gaggatttac cactgataaa cagccactaa gtgatgcctg 1200
gacttactgc atcagtaaaa atgaatggat acaatttaac catccatata ccgaaaaacc 1260
aaggttatgg cacacagctt gtgccagcga tgaaggagaa gtaattgttt ttgggtggatg 1320
tgccaacaac ttgcttgctc atcacagagc tgcacacagt aatgaaatac taatattttc 1380
agttcaacca aaatctcttg tacggctaag cttagaagca gtcatttgct ttaaagaaat 1440
gttagccaac tcatggaact gccttccaaa acacttactt cacagtgtta atcagagggt 1500
tggtagtaac aacacttctg gatcttaagg cttcataaat aatgcctatg atcaccttgc 1560
atggacagca atcctgtaaa catcacagag tggcatcatt tgtataatta tatgcattgt 1620
tgtagtttgc acctgttggt tttaattgtc atgtgaatgg cctagagaac ctatttttgt 1680
gtctaaagt tacaataaat gtatttaaca ccaaaaaaaa aa 1722

```

<210> 90

<211> 1264

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5519057CB1

<400> 90

```

agcgcgcgct cttgcgggtg cgtaatctct cagcctttct gtgtctcctt tctcgcgct 60
cagtttgggtg cgggtcgggg gaatggctga ggagatggag tcgtcgctcg aggcaagctt 120
ttcgtccagc ggggcagtgat caggggcctc aggggttttg cctcctgccc gctcccgcct 180
cttcaagata atcgtgatcg gcgactccaa tgtgggcaag acatgcctga cctaccgctt 240
ctgcgctggc cgcttccccg accgcaccga ggccacgata ggggtggatt tccgagaacg 300
agcgggtggag attgatgggg agcgcacaa gatccagcta tgggacacag caggacaaga 360
acgattcaga aagagcatgg ttcagacta ctacagaaat gtacatgctg ttgtcttcgt 420
gtatgatatg accaaccatg ctagttttca tagcctacca tcttggatag aagaatgcaa 480
acaacatttg ctagccaatg atataccacg gattcttggt ggaaataaat gtgacttgag 540
aagtgcata caggtaccca cagacttggc acaaaaattt gctgacacac acagtatgcc 600
tttgtttgaa acgtctgcta aaaaccccaa tgataatgac catgtggaag ctatatattat 660
gaccttggct cataagctta agtgccacaa accattaatg cttagtcagc cccctgataa 720
tggaattatc ctgaagcctg aaccaaagcc tgcaatgacg tgctgggtgt aaataacagt 780
ctttattata ttatctaatt ttgactaaag aaatactttt gaagtatgac agtattaagt 840
cataagattt aatctcaact ataattgggtc atcttgacac tttgctgttt gtcattgtca 900
cgcttttgta ttttgatct acttaagttt gtcactgtga caacacagga aaagtgtggt 960
ttcagggtgag attgaaaatg aagcaaagat aggatgaatc tgaacatctc tccatctaga 1020
gccaatgaa ggaagcttca aatgagaaca tgatggaatc agtaaccatt caatcttttg 1080
tcctaggatt ggaaaaaat gttaaagggt taggacacac ctaatagtat gtcctttgaa 1140
tggaagattt tcttaatagg ataaaaactg gtatttcctt ctccccagag tacttttttg 1200
ttttttccat agagacgggg tcttgctatg ttgtccaggc tggccttgag ctcttggtgt 1260
caag 1264

```

<210> 91

<211> 2640

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 035379CB1

<400> 91

```

cggccgaggg ggcacatga agcgggctgg cggcgctgctg tccccggcgc gcgcgggcgg 60
gaggtgcttc ccaaggaccg tagatgcctc tctagagcat gagctcaggc aagagtgtcc 120
gctacaaccg cttctccggg gggcccagca atcttccac cccagacgtc accacaggga 180
ccagaatgga aacgacctc ggacccgcct ttccagcgt caccaccatc acaaaaagctg 240
acgggaccag cactacaag cagcactgca ggacacctc ctctccagc acccttgctt 300
actccccgcg ggacgaggag gacagcatgc ccccatcag cactccccgc cgctccgact 360

```

```

ccgccatctc tgtccgctcc ctgcactcag agtccagcat gtctctgcgc tccacattct 420
cactgcccga ggaggaggag gagccggagc cactggtggt tgcgggagcag ccctcgggtga 480
agctgtgctg tcagctctgc tgcagcgtct tcaaagaccc cgtgatcacc acgtgtgggc 540
acacgttctg taggagatgc gccttgaagt cagagaagtg tcccgtggac aacgtcaaac 600
tgaccgtggt ggtgaacaac atcgcggtgg ccgagcagat cggggagctc ttcattccact 660
gccggcacgg ctgccgggta gccgggcagcg ggaagcccc catctttgag gtggaccccc 720
gagggtgccc cttcaccatc aagctcagcg cccggaagga ccacgagggc agctgtgact 780
acaggcctgt gcggtgtccc aacaacccca gctgcccccc gctgctcagg atgaacctgg 840
agggccacct caaggagtgc gagcacatca aatgccccca ctccaagtac gggtgacgtg 900
tcacggggaa ccaggacact tacgagacct acctggagac ttgccgcttc gagggcctga 960
aggagtcttc gcagcagacg gatgaccgct tccacgagat gcacgtgggt ctggcccaga 1020
aggaccagga gatgccttc ctgcgctcca tgctgggaaa gctctcggag aagatcgacc 1080
agctagagaa gagcctggag ctcaagtttg acgtcctgga cgaaccagag agcaagctca 1140
gcgaggacct catggagttc cggcgggacg catccatggt aaatgacgag ctgtcccaca 1200
tcaacgcgcg gctgaacatg ggcacctcag gctcctacga ccctcagcag atcttcaagt 1260
gcaaagggac ctttggtggc caccaggggc ctgtgtggtg tctctgcgtc tactccatgg 1320
gtgacctgct cttcagtggc tcctctgaca agaccatcaa ggtgtgggac acatgtacca 1380
cctacaagtg tcagaagaca ctggagggcc atgatggcat cgtgctgggt ctctgcatcc 1440
aggggtgcaa actctacagc ggctctgcag actgcaccat cattgtgtgg gacatccaga 1500
acctgcagaa ggtgaacacc atccggggcc atgacaaccc ggtgtgcacg ctggtctcct 1560
cacacaacgt gctcttcagc ggctccctga aggccatcaa ggtctgggac atcgtgggca 1620
ctgagctgaa gttgaagaag gagctcacag gccccaacca ctgggtgcgg gccctggtgg 1680
ctgcccagag ctacctgtac agcggctcct accagacaat caagatctgg gacatccgaa 1740
cccttgactg catccacgtc ctgcagacgt ctggtggcag cgtctactcc attgctgtga 1800
caaatcacca cattgtctgt ggcacctacg agaacctcat ccacgtgtgg gacattgagt 1860
ccaaggagca ggtgcggacc ctacggggcc acgtgggcac cgtgtatgcc ctggcggcca 1920
tctcgacgcc agaccagacc aaagtcttca gtgcaccta cgaccggtcc ctcagggtct 1980
ggagtatgga caacatgatc tgacgcaga ccctgctgcg tcaccagagc agtgtcaccg 2040
cgctggctgt gtcccggggc cgactcttct caggggctgt ggatagcact gtgaagggtt 2100
ggacttgcta acaggatcca ggccaggctg tgggtttccc tgaaccagcc ctggaccttt 2160
ctgagccagg ctggccacat ggggtggtct cgggggtttct gctgccccg tgggcatagg 2220
tggacaggct ctggcagccc ggcagtggcc tcccgtccc atgctcggcg agcctccc 2280
tactcggcac tgtccttgtc gccagcccc tctctgggtg ccaggtacga cgcttgcccc 2340
ggcccaccct ccacccccc cctccatccc caccctagat ggagcgaggg cctttttact 2400
caccttttct accgttttta gactgtatgt agattggtta cctcctgggt gaaataaatg 2460
ctccacagac tgtggctgtg agtggggaca gctcctcggg acaagggggc tgtgtgtggc 2520
cttgaggttg gtgtgcacag gcactggctg ctgtgagtgg gggggcatgg ggcagtttcc 2580
tttgggtggc cccaggactt cggcccactc cggggcctcc cctcctgctc aggaggtaac 2640

```

<210> 92

<211> 2071

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 275354CB1

<400> 92

```

gtgggaggaa ctctagcgg acacctcgtg gagtccggcc ggaagagcaa ccgagatgaa 60
ggtgaagatg ctgagccgga atccggacaa ttatgtccgc gaaaccaagt tggacttaca 120
gagagttcca agaaactatg atcctgcttt acatcctttt gaggtcccac gagaatagt 180
aagagcttta aatgctacca aactggaacg agtatttgca aaaccattcc ttgctctcgt 240
ggatggtcac cgtgatggag tcaattgctt ggcaaagcat ccagagaagc tggctactgt 300
cctttctggg gcgtgtgatg gagagggttag aatttggaat ctaactcagc ggaattgtat 360
ccgtacaata caagcacatg aaggctttgt acgaggaata tgtactcgtc tttgtgggac 420
ttcttttttc actgttggtg atgacaaaac tgtgaagcag tggaaaatgg atgggccagg 480
ctatggagac gaggaagagc cattacatac aatattagga aagacagtgt atactgggat 540
tgatcatcac tggaaaagaag ctgtttttgc cacatgtgga cagcaagtag acatttggga 600
tgaacaaaga actaatccta tatgttcaat gacctgggga tttgacagta taagtagtgt 660
taaatttaac ccaattgaga catttctctt ggggaagttgt gcatctgaca ggaatatagt 720
actgtacgat atgaggcaag ctactccttt gaaaaagggt atcttagata tgagaacaaa 780
tacaatctgt tggaaacctc tggaaagctt catttttaca gcagcaaatg aagattataa 840

```

```

cttatatact tttgatatgc gtgcactgga cactcctgta atgggtccata tggatcatgt 900
atctgcagtg cttgatgtgg attactctcc cactgggaag gagtttgtgt ctgctagttt 960
cgataaatct attcgaatct ttctgttaga caaaagtcga agcagggagg tatatcatat 1020
aaagagaatg caacatgtta tctgtgtaaa atggacttct gacagcaagt atattatgtg 1080
tggatctgat gaaatgaaca ttctgctgtg gaaagctaag gcttctgaaa aattgggtgt 1140
gcttacatca cgagaaaaag cagccaaggga ttataaccag aaattgaagg agaaatttca 1200
gcattatcct catataaaac gtatagctcg tcatcgacat ctaccaaagt ctatctatag 1260
ccagattcag gaacagcgca tcatgaaaga agctcgctga cgaaaggaag tgaatcgtat 1320
taaacacagc aagcctggat ctgtgccact tgtgtcagag aagaagaaac acgtagtggc 1380
agttgtaaaa taattgggtat tcctaacaat cctgatgtat aattatttgt tacttttgat 1440
ttgagaactc tacaataaaa agtgctggga ctagattaat tgcaaacatt ttagtatat 1500
gtgtagagct ttattgttac tctttttagc taccctgaaa aatgatcctt aaagggtggc 1560
tagttggtaa gactgtttta tcttaatct gcattcttct ttcatgtag aatacagtat 1620
ttgcaactca ttttttcttg tttttattac agatatactt actttctctt tgatctatta 1680
ttgtagacac tatacattca aattgacatt taagaccaa catctcttat gttatcttta 1740
atattacttt gaataatgat tgcaatgatg tttcttcttg tgattccaca taacatttag 1800
aataatgatg tcaatttttt acaactggaat ttatttctag tgctttactt atattgggt 1860
ttttgactct tttaaaacaa tcagcctgca tttatataac ttttataaat aataatataa 1920
tttgggtcaa gttaagatat taaaagttcc tttcagcatt gaaactttgg cctatttttg 1980
gtaaataatt ttcaatctca ctaaactcta aatagctctg tgtaacatag gtttttcttt 2040
ttttaatcat aaacttaata aactttgtgg a 2071

```

<210> 93

<211> 2149

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 311658CB1

<400> 93

```

cattattttt aaaaatatta cccactcttg atagtgtatc tgcactgaga cacgtactgg 60
aagctatata ttgtttgaca tccaatcta aaacaactca tctttcttac ttatgactag 120
agttcctcct cttcatttat attcttttct tgggtgaacat cagtgtctac caatttctaa 180
atgcaaagga gaaagataca attttaagcg aaatgggtgg gatatgcaca acttgcagaa 240
ggttacataa aacttggggt ttccagagatg attttttctc ttcttttttag gatatgttca 300
aggaatgagt gatttacttt cccctctttt atatgtgatg gaaaaatgaag tggatgcctt 360
ttggtgcttt gctctttaca tggaccaaat gcatacagaat ttggaagaac aaattgcaagg 420
catgaagacc cagctaattc agctgagtac cttacttcga ttgttagaca gtggattttg 480
cagttactta gaatctcagg actctggata cttttatttt tgcttcaggt ggcttttaat 540
cagattcaaa aggggaattta gttttctaga tattcttcga ttatgggagg taatgtggac 600
cgaactacca tgtacaaatt tccatcttct tctctgttgt gctattctgg aatcagaaaa 660
gcagcaaata atggaaaagc attatggctt caatgaaata cttaagcata tcaatgaatt 720
gtccatgaaa attgatgtgg aagatatact ctgcaaggca gaagcaattt ctctacagat 780
ggtaaaatgc aaggaattgc cacaagcagt ctgtgagatc cttgggcttc aaggcagtga 840
agttacaaca ccagattcag acgttgggtg agacgaaaat gttgtcatga ctcttgttcc 900
tacatctgca tttcaaagta atgccttgcc tacactctct gccagtggag ccagaaatga 960
cagcccaaca cagataccag tgcctcaga tgtctgcaga ttaacacctg catgatcact 1020
gttcttgctt ttttgggaag agacactttg ttgcaaccct ttttcaagta cttgaaagtt 1080
gaaaatttga aatcttggtt ttgatcatgc ttttaaggtt atgtaaagaa agtgtactga 1140
tgttcttaca ttaaagcttt acaaagattt aaactaatta tttttgtagt tacttctacc 1200
aaatagcctt tctttttcga taacattcct cagtattttt atagccaagt acattttatt 1260
ttcttgctga tgaactggaa ttggataaat attgcaagtg gatgagttgg aaattatgca 1320
ctttgaaaaa cattcacttt gtttaagctt attggtttc agatttgatt aaattaaatg 1380
ttggaggctt ctatagcatt ctaagctgag aagtagattg ttaccagta atgaaataaa 1440
aaataaaaat aaaaggattt ttttctctat tgtttacgac agtactcagc ttaaataatt 1500
atgctggtca aatgtgattt aaattggaca ttttcatcaa tgcagtctaa tgtgtagata 1560
aatatttcaa ccataataag tggattggca gtatattttt tacattgaac ttttcttcac 1620
ttgtatataa agattatata taagtactta ttatagata taagaaaggt taggcataat 1680
ttcattaaat gaataaacga cttgatttat ataacctggg ttatcaaaat ttaacatggc 1740
ttcagtatga gatctttttc aaaactattt tcttaaacat ttatttcatg agattatgtt 1800
caacctgta cctggtgtaa ttttaaaatt aattgcttgt aacctcactt tactaataat 1860

```



```

gtttattatc tttcctaata atgcattaac tgattaatca ggtgtttaaa tttttataaa 1920
atactcttgc aaaaagttaa tttgaaaaat ttctagatgg tctcatgagt ttcaaaaataa 1980
taatttttgt gtatgaacaa agctgttggt tttacatgac agtattgcat gatttttaagt 2040
tatgtggaat taacataact gattttgttt taattgtaag ttgttaactc ctgtatatat 2100
cattaaaata aatctgaagt tgaagtagtg tttttagtta aattatact 2149

```

<210> 94

<211> 2332

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1251632CB1

<400> 94

```

gccaccccag aactgggcag cagcctcaag aagaagaagc ggctctccca gtcagatgag 60
gatgtcatta ggctaataagg acagcacttg aatggccttag ggctcaacca gactgttgat 120
ctcctcatgc aagagtcagg atgtcgttta gaacatcctt ctgctaccaaa attccgaaat 180
catgtcatgg aaggagactg ggataaggca gaaaatgacc tgaatgaact aaagccttta 240
gtgcattctc ctcatgctat tgtgaggatg aagtttttgc tgctgcagca gaagtaccta 300
gaatacctgg aggatggcaa ggtcctggag gcacttcaag ttctacgctg tgaattgacg 360
ccgctgaaat acaatacaga gcgcattcat gttcttagtg ggtatctgat gtgtagccat 420
gcagaagacc tacgtgcaaa agcagaatgg gaaggcaaag ggacagcttc ccgatctaaa 480
ctattggata aacttcagac ctattttacca ccatcagtga tgcttcccc acggcggttta 540
cagactctcc tgcggcaggc ggtggaacta caaagggatc ggtgcctata tcacaatacc 600
aaacttgata ataacttaga ttctgtgtct ctgcttatag accatgtttg tagtaggagg 660
cagttcccat gttatacgca gcagatactt acggagcatt gtaatgaagt gtggttctgt 720
aaattctcta atgatggcac taaactagca acaggatcaa aagatacaac agttatcata 780
tggcaagttg atccggatac acacctgcta aaactgctta aaacattaga aggacatgct 840
tatggcgttt cttatatattg atggagtcca gatgacaact atcttggttg tttgtggcca 900
gatgactgct ctgagctttg gctttggaat gtacaaacag gagaactaag gacaaaaatg 960
agccagtctc atgaagacag tttgacaagt gtggcttggg atccagatgg gaagcgcttt 1020
gtgactggag gtcagcgtgg gcagttctat cagtgtgact tagatggtaa tctccttgac 1080
tcctgggaag gggtaagagt gcaatgcctt ttggtgcttg gtgatggaaa gactgttctg 1140
gcatcagata cacaccagcg aattcggggc tataacttcg aggaccttac agataggaac 1200
atagtacaag aagatcatcc tattatgtct ttactatatt caaaaaatgg ccgattagct 1260
ttgttaaatg tagcaactca gggagttcat ttatgggact tgcaagacag agtttttagta 1320
agaaagtatc aaggtgttac acaagggttt tatacaattc attcatgttt tggaggccat 1380
aatgaagact tcatcgctag tggcagtga gatcacaagg ttacatctg gcacaaacgt 1440
agtgaactgc caattgcgga gctgacaggg cacacacgta cagtaaaactg tgtgagctgg 1500
aaccacacaga ttccatccat gatggccagc gcctcagatg atggcactgt tagaatatgg 1560
ggaccagcac cttttataga ccaccagaat attgaagagg aatgcagtag catggatagt 1620
tgatggtgaa tttggagcag acgacttctg tttaacttaa aattagtcgt attttaattg 1680
cttgggattt ggtgcaaaaca aacatgattg atagctggac agacatgctc gtcatgaaaa 1740
aagaaccatt tctgaagccc gattggggcc aaacatttac accttgcttc atagtaacca 1800
gttgagatga agcacgtcgt tagaacgttg ttggacacca tgttgaatta tcccccatc 1860
ggttgtgaag aactgtgcta cattcaggct taccatttga actcagtata tatatttttt 1920
ttccttctctg tcttttctct ggcaggatac cattcttctg gctcttctgt gtaatgaagt 1980
ttaaagtctt gtttggaataa ctttatttaa cagtttagaa ggcttgatag aaagagtgca 2040
ttagtctgaa gagtatacat tggataggaa agaatttctt tcttttgttt ctccaaatct 2100
ttccgcctta tttagcttga gatcttttga gcttggttca tggattctag ccttgcccgt 2160
tgcgagctat atactgatcc agatgataaa ccagtgaact atgtcaaaag cactctcaat 2220
attacatttg acaaaaagtt ttgtactttt cacatagctt gttgccccgt aaaagggtta 2280
acagcacaat tttttaaaaa taaattaaga agtattttata ggaaaaaaa aa 2332

```

<210> 95

<211> 1751

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1331955CB1

<400> 95

```

gccccgaatcg actccggaga caacgccggg cgacgccacc tgcgcaggtc cccggaggccg 60
ctgggtgtctg tgtacagggc gtgctgtctg tggaaacgcg agggcacact agcactttcc 120
tggaaggacc ccagaccac caagccactc agtccctgga cgagtttcca ctcaccccca 180
ctgcctctgt caccgggtcc ctccaccctt gtctcctgtg cggccagcgt cagagccatg 240
gcgacggagg agaagaagcc cgagaccgag gccgccagag cacagccaac cccttcgtca 300
tccgccactc agagcaagcc tacacctgtg aagccaaact atgctctaaa gttcacccctt 360
gctggccaca ccaaagcagt gtcctccgtg aaattcagcc cgaatggaga gtggctggca 420
agttcatctg ctgataaact tattaataat tggggcgctg atgatgggaa atttgagaaa 480
accatatctg gtcacaagct gggaatatcc gatgtagcct ggctcgtcaga ttctaacctt 540
cttgtttctg cctcagatga caaaccttg aagatatggg acgtgagctc gggcaagtgt 600
ctgaaaaccc tgaagggaca cagtaattat gtcttttgcg gcaacttcaa tccccagtc 660
aaccttattg tctcaggatc ctttgacgaa agcgtgagga tatgggatgt gaaaacaggg 720
aagtgcctca agactttgcc agctcactcg gatccagtct cggccgttca ttttaactcg 780
gatggtacct tgatagtttc aagtagctat gatggtctct gtcgcatctg ggacaccgcc 840
tcaggccagt gcctgaagac gctcatcgat gacgacaacc ccccggtgtc ttttgtgaag 900
ttctccccga acggcaaata catcctggcc gccacgctgg acaacactct gaagctctgg 960
gactacagca aggggaagtg cctgaagacg tacactggcc acaagaatga gaaatactgc 1020
atatttgcca atttctctgt tactggtggg aagtggattg tgtctggctc agaggataac 1080
cttgtttaca tctggaacct tcagacgaaa gagattgtac agaaactaca aggccacaca 1140
gatgtcgtga tctcaacagc ttgtcaccca acagaaaaca tcatcgcttc tgctgcgcta 1200
gaaaatgaca aaacaattaa actgtggaag agtgactgct aagtcccttt gctcctgcc 1260
gcgagagact gtcgggaagt tgacccggat tggcaagaaa cagggtgtct tggagggtgt 1320
ccccagatc tgcgcctggg ggtcaggaca gggcctgatt tgagcctcct ctctgaagat 1380
gatttgcccg agcgggaagt gtggaccacc ggaaagtctt taaaagtgtc tggtagactt 1440
tcttgccaat tctaactctg tctagggaa agttcctagt ctattgtgtt caaacagagt 1500
caacaaaagt ttttaatttt ttattacaga aggggtgaagt tcaatttaac atgcgttgtg 1560
ttttttcagt aaacgttctg tatctttttg atattccatg acccagtgca cgtgtggcc 1620
tgtcaccgcc accgtggccc cgccagctgg cctccctttt ggcccacgcc ggccgcccc 1680
attctctgct gcgtagatgc cctggcccag ggccctgactc tccattcccc ccagtagggg 1740
taccgagctc g

```

<210> 96

<211> 1285

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1412614CB1

<400> 96

```

cggagaaaaa gctgacctaa tgaaactgtg gcaacgtcag cgcttgaggc ttgaagaggg 60
agacaagcta aaagaggata tccagttgtt tcatgatggc atttgacact ccaaaaaaca 120
cagatggtcc caaaatgcag acaaagatga gcacctggac acccctaacc catcagctat 180
tgaatgaccg ggtatttgaa gaaagaagag ccctgcttgg caaatggttt gacaaatgga 240
cagactctca aagaagaaga atcctcacag gcctgttggg gcgctgctcg ctgtcccagc 300
aaaagtctct ctgtcgaaaag cttcaagaga aaattccagc agaagccctg gactttacaa 360
ccaagcttcc aagggtgtta tctttataca tcttttcttt cctggaccct cggagccttt 420
gtcgttgtgc acaggtgtgc tggcattgga agaaccttgc tgagctggac cagctctgga 480
tgctgaaatg tttacggttt aactggtaca tcaatttctc tccaactccc tttgagcagg 540
ggatctggaa gaagcactat attcaaatgg tgaaagaact tcatattacc aagcctaaga 600
caccoccaaa ggatggattt gtaatcgctg acgttcaact agttacaagc aattctccag 660
aggaaaaaca gtccccttta tcagcttttc ggctctcttc ctctttaaga aagaagaata 720
actcagggga gaaagcactt ccaccctggc gatcttctga taagcaccca acagatatca 780
ttcgttttaa ttacctagac aaccgtgacc ccatggagac tgtccagcaa ggaagaagaa 840
aaagaaacca aataacccca gacttcagcc gacagtcaca tgataagaaa aataaattgc 900
aggacagaac taggctaaga aaagcacaat caatgatgtc gaggagaaat cccttcccac 960
tatgtccccta agtgccagct ctcccctaaa agttccagct catctcgctt ggccctcccc 1020
tgagtcagtg ggactcccag ccactgccac cacagctgaa attctcatgc agcatcctca 1080
caggcaccct gggccccaag catgactcat ccaggttcca gagccaaagt ggactgaaca 1140

```

tggaagact tttattatag aaatgacaag atgctttgca cagtggagag ctgaatttac 1200
 ttggctccca ttagaaactc tttcagctta agtacttatt gtggtagtga gtcctacggt 1260
 atttcagtaa aaaggaattc atggc 1285

<210> 97

<211> 3260

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1750781CB1

<400> 97

ccggaagacc gtccccgatg gcctcgggga ctgccagtgt gtggaggtga gctccgggat 60
 tgccggcatt cccgcttctg ctgggttctt catgctgcag gctgcggccg tcagccctcg 120
 ctgcgattgg tggcgctgag gtgccggggc agcaagtgc atgtcgtcgg gcctccgcgc 180
 cgctgacttc ccccgctgga agcgccacat ctcgagcaa ctgaggcgcc gggaccggct 240
 gcagagacag gcgttcgagg agatcatcct gcagtataac aaattgctgg aaaagtcaga 300
 tcttcattca gtgttggccc agaaactaca ggctgaaaag catgacgtac caaacaggca 360
 cgagataagt cccggacatg atggcacatg gaatgacaat cagctacaag aaatggccca 420
 actgaggatt aagcaccaag aggaactgac tgaattacac aagaaacgtg gggagtttagc 480
 tcaactgggtg attgacctga ataaccacaaat gcagcggaag gacagggaga tgcagatgaa 540
 tgaagcaaaa attgcagaat gtttgacagac tatctctgac ctggagacgg agtgcctaga 600
 cctgcgcact aagctttgtg accttgaaaag agccaaccag accctgaagg atgaatatga 660
 tgccctgcag atcactttta ctgccttgga gggaaaactg agggaaaacta cggaagagaa 720
 ccaggagctg gtcaccagat ggatggctga gaaagcccag gaagccaatc ggcttaatgc 780
 agagaatgaa aaagactcca ggaggcgga agcccggctg cagaaagagc ttgcagaagc 840
 agcaaggaa cctctaccag tcgaacagga tgatgacatt gaggtcattg tggatgaaac 900
 ttctgatcac acagaagaga cctctcctgt gcgagccatc agcagagcag ccacgagacg 960
 ctctgtctct tccttcccag tccccagga caatgtggat actcatcctg gttctggtaa 1020
 agaagtgagg gtaccagcta ctgccttggt tgtcttcgat gcacatgatg gggaggtcaa 1080
 cgctgtgcag ttcagtccag gttcccgggt actggccact ggaggcatgg accgcagggt 1140
 taagctttgg gaagtatttg gagaaaaatg tgagttcaag gggtccctat ctggcagtaa 1200
 tgagggaatt acaagcattg aatttgatag tgctggatct tacctcttag cagcttcaaa 1260
 tgattttgca agccgaatct ggactgtgga tgattatcga ttacggcaca cactcacggg 1320
 acacagtggg aaagtgtgtg ctgctaagtt cctgctggac aatgcgcgga ttgtctcagg 1380
 aagtcacgac cggactctca aactctggga tctacgcagc aaagtctgca taaagacagt 1440
 gtttgagga tccagtgcga atgatattgt ctgcacagag caatgtgtaa tgagtggaca 1500
 ttttgacaag aaaattcgtt tctgggacat tcgatcagag agcatagtcc gagagatgga 1560
 gctgttgagg aagattactg ccctggactt aaaccagaa aggactgagc tcctgagctg 1620
 ctcccgatg gacttgctaa aagttattga tctccgaaca aatgctatca agcagacatt 1680
 cagtgcacct gggttcaagt gcggctctga ctggaccaga gttgtcttca gccctgatgg 1740
 cagttacgtg gcggcaggct ctgctgagg atctctgtat atctggagtg tgtcacagg 1800
 gaaagtggaa aaggttcttt caaagcagca cagctcatcc atcaatgcgg tggcgtgggtc 1860
 gccctctggc tcgcacgttg tcagtgtgga caaaggatgc aaagctgtgc tgtgggcaca 1920
 gtactgacgg ggtctcagg gctgggagga cccagtgcc ctccctcagaa gaagcacatg 1980
 ggctcctgca gccctgtcct ggcaggatgat gtgctgggta tagcatggac ctcccagaga 2040
 agctcaagct atgtggcact gtagctttgc cgtgaatggg atttctgaag atttgactga 2100
 ggtctctctt ggcctggaag aataacactg aaaaaacctg acgctgagggt cacttagcag 2160
 aggtcagggt tcttgccctg ggaaacacta ctagctctga ccttccatac ctacttggg 2220
 ggagcacagg gcccgctgg gcctcctcac caacggcagt gccaaaatca gccccacat 2280
 caaggtgggtg ttctctgtgc tttctctcgt ccttccaaag tcggttctgg cctaacgcgt 2340
 gtcccaacac cttgggttca tttggccggg gaactcactt taagcattgg attaacggaa 2400
 actcccgaac tacagacccc tccctgggtg gttgcatgaa tgtgtctcat tactgctgaa 2460
 atgtcctcac atctcttcca ctgttcttca gagctttctg gctctcttcc cccacaaaat 2520
 tcgacacatt taaaaatctc cgtgtggcct taaaaaatgg tttttgttt ttttgtttt 2580
 ttgaggtggg agaggatgtg tgaaaatctt ttccagggaa atgggttcgc tgcagaggta 2640
 aggatgtgtt cctgtatcga tctgcagaca cccagaaggt ggggtgcacac tgcagtcttg 2700
 ggggtgcca gggattcgag acctccaaca tacttctctg aagggtggtg tctctggccat 2760
 ggccctctg ccaagcctgt gtgcgatgcc cttgggtgct tagtgcaaga agcctaggct 2820
 cagaagcaca gcagcgccat ctttccgttt caggggttgt gatgaaggcc aaggaaaaac 2880
 atttatcttt actattttac ctacgtataa agttttagtt cattgggtgt gcgaaacacc 2940

```

ctttttatca ctttttaaatt tgcactttat tttttttctt ccatgcttgt tctctggaca 3000
tttggggatg tgagtgttag agctgggtgag agaggagtca ggcggccttc ccaccgatgg 3060
tcctggcctc cacctgccct ctcttccctg cctgatcacc gctttccaat ttgcccttca 3120
gagaacttaa gtcaaggaga gttgaaattc acaggccagg gcacatcttt tatttatctt 3180
attatgttgg ccaacagaac ttgattgtaa ataataataa agaaatctgt tatatacttt 3240
tcaaaaaaaa aaaaaaaaaa

```

<210> 98
 <211> 1276
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1821658CB1

```

<400> 98
gcggcaccac caaggaagac cagcctgcct ctggctcggtt cctggcgctc tgcgtttcgt 60
gaccttgtcc agtagaaggc tatttaattt tcacaactgc ttgaattttg acatacaaga 120
tgaagcaaga tgcctcaaga aatgctgcct acactgtgga ttgtgaagat tatgtgcatg 180
tggtagaatt taatcccttt gagaatgggg attcaggaaa cctaattgca tatggtggca 240
ataattatgt ggtcattggc acgtgtacgt ttcaggaaga agaagcagac gttgaaggca 300
ttcagtataa aacacttcga acatttcacc atggagtcag ggttgatggc atagcttggg 360
gcccagagac tagacttgat tcattgcctc cagtaatcaa attttgtact tcagctgctg 420
atatgaaaat tagattattt acttcagatc ttcaggataa aaatgaatat aaggttttag 480
agggccatac cgatttcatt aatggtttgg tgtttgatcc caaagaaggc caagaaattg 540
caagtgtgag tgacgatcac acctgcagga tttggaactt ggaaggagtg caaacagctc 600
atattgttct tcattctcct ggcatgagtg tgtgctggca tcctgaggag acttttaagc 660
taatggttgc agagaagaat ggaacaatcc ggttttatga tcttttggcc caacaggcta 720
ttttatctct tgaatcagaa caagtgccat taatgtcagc aactggtgct ttaaaaaaca 780
ccttcaaaatg tggagccgtt gcaggaaatg attggttaat ttgggatatt actcgggtcca 840
gttatcctca aaataagaga cctgttcaca tggatcgagc ctgcttattc aggtgggtcca 900
caattagtga aaactctggtt gcaaccactg gttatcctgg caaaatggca agccagtctc 960
aaattcatca tttaggacac cctcagccca tcctcatggg ttctgtagcc gttggatctg 1020
gactgtcctg gcacgaact ctccctctgt gtgtaattgg aggagaccac aagctgttgt 1080
tttgggtgac tgaagtataa agtgttttct gtaccttaga ttcacaaact ttgtattttt 1140
agtacatatt ttgaagaatt tctatagtac atattttgaa gaatttttat atcaaatata 1200
ccgtatactt tagaaaatgt ctcagttgct tttattaaat aaaatgttga tggtttgaaa 1260
aattaaaaaa aaaaaa

```

<210> 99
 <211> 3608
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1872574CB1

```

<400> 99
gttttgggtc tagccgctcg ccgtccttgc aggcctctgcc gtcggaaagc cgctcattct 60
cgcttccctt tccctttccc ggctcaagtc cttcctctct ctttcccttc tttccgccta 120
tcctttttct gctgccgctc cgggtccggg ccattttccg ggccgggcgc actaagggtc 180
gcgcccccgg ggcccagtat atgaccgcc gcctctgtat ccttcgcttc ccccgcccca 240
tgtggctgcg gggcccgccg gcgctgccc actatggccc ggaaagtagt tagcaggaa 300
cggaagcgcc ccgctcgcc gggagctggg agcgagctc agggcccgca gtttggctgg 360
gatcactcgc ttcacaaaag gaaaagactt cctcctgtga agagatcctt agtatactac 420
ttgaagaacc gggaagtcag gctacagaat gaaaccagct actctcgagt gttgcatggt 480
tatgcagcac agcaacttcc cagtctcctg aaggagagag agtttcacct tgggaccctt 540
aataaagtgt ttgcatctca gtggttgaat cataggcaag tgggtgtgtg cacaaaatgc 600
aacacgctat ttgtcgtaga tgtccagaca agccagatca ccaagatccc cattctgaaa 660
gaccgggagc ctggaggtgt gaccagcag ggctgtggta tccatgccat cgagctgaat 720
ccttctagaa cactgctagc cactggagga gacaacccca acagtcttgc catctatcga 780

```

```

ctacctacgc tggatcctgt gtgtgtagga gatgatggac acaaggactg gatcttttcc 840
atcgcatgga tcagcgacac tatggcagtg tctggctcac gtgatggttc tatgggactc 900
tgggaggtga cagatgatgt tttgacaaa agtgatgcga gacacaatgt gtcacgggtc 960
cctgtgtatg cacacatcac tcacaaggcc ttaaaggaca tcccaaaaga agacacaaac 1020
cctgacaact gcaagggttcg ggctctggcc ttcaacaaca agaacaagga actgggagca 1080
gtgtctctgg atggctactt tcactctctg aaggctgaaa atacactatc taagctcctc 1140
tgccataattg ccgtgagaat gtgtgtctgg cttatggtag tgaatggtca 1200
gtttatgcag tgggctccca agctcatgtc tccttcttgg atccacggca gccatcatac 1260
aacgtcaagt ctgtctgttc cagggagcga ggcagtggaa tccggtcagt gagtttctac 1320
gagcacatca tcaactgtggg aacagggcag ggctccctgc tgttctatga catccgagct 1380
cagagatttc tggaagagag gctctcagct tgttatgggt ccaagcccag actagcaggg 1440
gagaatctga aactaaccac tggcaaaggc tggctgaatc atgatgaaac ctggaggaa 1500
tacttttcag acattgactt cttccccaat gctgtttaca cccactgcta cgactcgtct 1560
ggaacgaaac tctttgtggc aggaggtccc ctcccttcag ggctccatgg aaactatgct 1620
gggctctgga gttaatgaca actcccaaaa tgcagagatt tacactaact tccattctca 1680
gtttccttgt tttttttgat ttttttttct ctaattgtgt gaggctcttg tgttttagtg 1740
ggaacaccaa agtttgccca tagtttaggc aactaatagg aagaagctct gtacagaaat 1800
ctgaaagtgt ttttgctttt tgttttcccc tttggtaatc aaaattttac tatcttttat 1860
tatttctggc ttttcaacca aacattgttg ctaatcccta tttttcttta agtgacacac 1920
attctcctgt ctctggcttc ttcaggctga aatgacatag tctttctcac ccttacttca 1980
ctcttgagag gttagggctcc tttataatta catggttgct ctcagacttt ctgtgaaagt 2040
ttgggagctg tgtgtgtctg tgtgtgtgtg agagagagat cttgtctgcg tgtgtgtgtg 2100
tgatcttgtg tgcctgtagg tactgtgtgt cactgaaatt acctggagtg aggttactt 2160
gtaattaaaa tattataaaa agaaacaact ttattcacag agtccagctt tgggactagt 2220
ctgtatcttg ttttttaagt ctaacaacac tgataatagg aagtaaaaac agaaaggaaa 2280
agaaattacc actgggaaaa tctttttagt tagattgtag gcttcctggg gcctcccatg 2340
ccaggactgc aaagtgatcc agccctacct gtcttccccc ctgtgtgtcc cccgtgtggg 2400
aagttggtgt cacttcccc tcccaccctc acactctgct agccagtagc cacacccta 2460
aaacatcaga ctacccatcc aggtgcagct ccagaggcta caaaaggctt catgggactt 2520
gaatcccatc cctagcttct ctctccttcc cctcaagacc tgatctggtt ttaaggggcc 2580
tggagctggg agtctcaagt ctgctaagat tcacatccat agcccccggt gctttgagga 2640
gaatcctctc tgccattctt ccaatctccc cagtgggttt tgctattatt ttctaaattg 2700
ggttaagtct aagaagggtg ggggtgagcag ggggtttatc tgtgtgtagt gagtgttca 2760
tgtgtggaat attcatttct ttactgcagt gggacttggg gttgaagcca cccctcctac 2820
tctgttggct tagccctgag atgggtgacag gctggcctgc agtcagcatc attgtgcatg 2880
tgacagcatc aatgtgatta gtaatttgtc tgttccctcc ttgaactgtc tgtttagtct 2940
gaggttttta aacttgacag cagctgactg tgatgtccac ttgttccctg atttttacac 3000
atcatgtcaa agataacagc tgttcccacc caccagttcc tctaagcaca tactctgctt 3060
ttctgtcaac atcccatttt ggggaaaagg ttattcctgc accccagttt 3120
tttaacttgt tctcccagtt gtccccctct tctctgggtg taagaaggga aattggaaaa 3180
aaaattatat atatatctc cttttaatgg tggggggcta ctggagagga gagacagcaa 3240
gtccacccta acttgttaca cagcacatac cacaggttct ggaattctca tcttcgaacc 3300
tagagaaata ggtgctataa acagggaatt aagcaaaatg ctggatgcta tagatctttt 3360
aattgtctta atttttttt tattattaaa ctacaggctg tagatttctt agttctcaca 3420
gaacttctat catttttaac tgacttgtat atttaaaaaa aaaatcttca gtaggatgtt 3480
ttgtactatt gctagaccct cttctgtaat gggtaatgct tttgattgtt tgagattttc 3540
tgttttttaa aatgtagcac ttgacttttt gccaaaggaa aaaataaaaa ttattccagt 3600
gcaaaaaa 3608

```

<210> 100

<211> 1311

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2590967CB1

<400> 100

```

ggcaggatga acgctgcttt ccaagatggc gacggagggg ggagggaagg agatgaacga 60
gattaagacc caattcacca cccgggaagg tctgtacaag ctgctgccgc actcggagta 120
cagccgggcc aaccgggtgc ccttcaactc gcagggatcc aacctgtcc gcgtctcctt 180
cgtaaacctc aacgaccagt ctggcaacgg cgaccgcctc tgcttcaatg tgggccggga 240

```

```

gctgtacttc tatactctaca aggggggtccg caaggctgct gacttgagta aaccaataga 300
taaaaggata tacaaggaa cacagcctac ttgtcatgac ttcaaccacc taacagccac 360
agcagaaagt gtctctctcc tagtgggctt ttccgcaggc caagtccagc ttatagacc 420
aatcaaaaaa gaaactagca aactttttta tgaggaaggc tcattgtcat cccaagcca 480
ggccagttct ccaggtggaa ctgtagtgtg gcgacctcac tgctgcgcgc acagtctccc 540
gggacttgga ctcgaggag tgacgaggag gagctccgag ctgcgcctga gccgtgccag 600
ccggcgacc cttaggtgtg gacgtcggtg atagccgtgt ggacgggtgac cggctcactc 660
tgccggcgccg tgctcccgtc gctcacccaa agaagttgtt tccattttta accggtcttt 720
tggggctgca gtaaaaaata agaaatggag ttttcttgct ttttactcta aaattcaatg 780
taattaaatt tcatatatat ataatatata catatatata tagtgtaaaa taaaatgttt 840
cttggaacaag aaatcccctg aaattcagct gttatagtgc ttcactgttt ttgactgat 900
ttttctatac cttaggtgtg cagaagacaa ccttgaatgc actcatagag aaaactgtta 960
ctttctgacg taatgtaatt caggaagaca gacgtgcaa tcacagattt taaaaaattg 1020
tttgacttta aaaatagttg aatgctggtg gaaagtact ttgcagatgg gtgtaaggac 1080
tcatggccct ctgaggtgag gcgtgaagat gcccttttta cccgttgacg tttattttac 1140
gtaaaaaata ctgttgtttc caatgcaatc aactctgtat tatatgtata aatattgtaa 1200
ttctgcaatt ggggaaaaata gttacttcac tagtaatttt catcatttaa gagtgatatt 1260
tctaattcac aaaagttaat attaaaacta tcttgaatat aaaaaaaaaa a 1311

```

<210> 101

<211> 2839

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2824491CB1

<400> 101

```

ggcctgcggg aagccaagat ggcgcatagg ggttctccag gctgcagttg gcgccttatac 60
agtatctaag cggagtgttt tggaaggagt taaggggctg tggcaaacgc cctctccgcc 120
gtcatggccc ggcatcgga tggtcgaggc tataactacg atgaagattt tgaagatgat 180
gatctctacg gccagtctgt agaggatgat tattgtattt cgccgtcaac agctgctcag 240
tttatttatt cacggcgtga caaaccttcc gttgagcctg tggaagaata tgattatgaa 300
gatctgaaag aatcttccaa ttctgtttca aaccatcagc tcagtggatt tgatcaagct 360
cgtctttatt catgccttga tcacatgaga gaggtacttg gagatgctgt gccagatgaa 420
atattaattg aagcagttct gaagaacaag tttgatgtgc agaaggcttt gtcaggggtt 480
ctggaacaag atagagtgca gagtttgaag gacaagaatg aggcaacagt atctacagga 540
aagatagcaa aaggaaaacc agtagattcc cagacatcgc gaagtgaatc tgaattgtg 600
ccaaaagtgt ctaaaatgac tgtatctgga aagaagcaaa ctatgggatt tgaagtgcct 660
ggagtatctt ctgaagaaaa tggtcatagt ttccacacac ctcaaaaagg accgcccatt 720
gaagatgcca ttgcttcttc cgatgttctt gagactgctt ctaaatctgc taatccacc 780
cacacgattc aagcatcaga agagcagagt tcaacccag caccgggtgaa aaagtctggc 840
aagctgaggg agcaaataga tgtgaaggcg gaactggaga agcggaagg agggaaagcag 900
ctactcaact tagtggtcat tggcatgtt gatgctggga aaagtactct gatgggccat 960
atgctttatc ttctgggtaa tataaacaag agaactatgc ataagtatga acaggagtct 1020
aaaaaggctg gcaaagcttc gtttgcatat gcatgggtct tggatgaaac tggcgaagaa 1080
agggaaaggg gagtaaccat ggatgttggt atgacaaagt ttgaaaccac aaccaagtt 1140
attacattaa tggatgctcc aggccataag gacttcattc caaatatgat tacaggagca 1200
gcccaggcgg atgtagctgt tttagttgta gatgccagca ggggagagtt tgaagtggga 1260
tttgagactg gaggacaaac acgagagcat ggactcttgg tccgttctct gggagtgcag 1320
cagcttgacg ttgcagttaa taaatggat caggttaatt ggcaacaaga aaggtttcaa 1380
gagattactg gaaaacttgg gcactttctt aagcaagcag gttttaagga gagtgatgta 1440
ggttttatc ctacaagtgg tctcagtggt gaaaatctaa tcacaagatc tcagtcaagt 1500
gaactcaca aatggtataa aggactatgt ttattagaac aaattgattc ctttaagcct 1560
ccccagcat ctattgacaa acctttttaga ttatgtgtgt ccgatgttt caaagatcaa 1620
ggatctggat ttgacataac tggtaaaata gaagctgggt atatccaaac tggtagaccga 1680
ctactggcaa tgctcctaa tgaaacttgt accgtgaaag gaatcactct gcatgatgaa 1740
cctgtcgact gggcggcagc aggcgatcat gtagtcttta ctttggttgg gatggatatc 1800
atcaaaatca atgttggctg catattttgt ggcccaaaag taccattaa agcttgact 1860
cgtttcagag ccgaatcct catctttaat attgaaattc ctatcactaa aggatttcc 1920
gtgtgtttac actacaaac tgtcagttaa cccgcgttta ttaaacgatt gattagtgtc 1980
ttaaacaaaa gcacgggtga agtcacaaag aaaaagccta agtttttgac taaaggccag 2040

```

```

aatgcattgg tagagctaca gacacaaaga ccaatagctc ttgagctata taaagacttt 2100
aaagagctgg ggaggttcat gctacgttac ggtggttcta caatagctgc tgggtgtgtc 2160
actgagataa aagaatgatg ggtcagaatt tctaccacgt ttctggatac agtgaaatag 2220
ctaacctctg tttcaagaat gcagttatta agtcaaagga acaatgtgca attgatatgt 2280
ttttagatga gagagaaaaa ttaaagctaa aattagctgc aaagaagtat taataatcac 2340
ctctgcaaaa attctaagtt gccaaactggc aaagaaagtc taatgttaaa aacaactttg 2400
cctttgaaac gtttaataat ggatttactt tgctaagatt tatggcaagt gtcaaaaaata 2460
gtatctgaag atactgaatc atcatgaaat gaactctact tctggccaaa gcacaatgta 2520
tttgagttt tctcttttga ttcaattata ctgcacatgt ttttaaggaaa agtaacttaa 2580
ttgggttttt caggcagttg atatttgacc taagcttttt tttttttttt tttttttttt 2640
tccagttaat gctaagaaaa gatattgggga aggttataat aaaagtattt tgtggtgacc 2700
ataagaatgt cctcccccac acaagtaaac ttgtgaaagt ttaatttggg attagtgga 2760
gctgttcctt tgaaagccaa gatattttt aagttgtaaa gccagctaata aaaatgcctt 2820
agtttgagca taaaaaaaaa 2839

```

<210> 102

<211> 1676

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2825460CB1

<400> 102

```

gggaggcgga ggttgagggtg agaggagatc gcgccattgc actccagcct gggcaacaag 60
ggcgaagtgc tctcaaaaga aaaaaaaaaa tcgtcggttt ctttttccca tctttctttc 120
gtgacttata ttccagaacg aagccccaca catcattaat gatttgaatc gtttctaag 180
tgtttcttaa atcgtttctt aaatcgtttg ttgtttcttg tctaacagtc cagaacacat 240
attacataat ggagccggga gacagactag ggctggcttg atccggccac gcagtccagg 300
aaaggtgctt ttcaccccca agtgcaaaat gatcaatgta ttcttccgat ctacataaac 360
aagcacctcc tggtttcatt ttcgtaaaagc aaaacaagca tggaagcttt actgtttcgg 420
ctcttcaaac ttccagcaac tacactgcgc tgcacgcgac tcgacgcccg ctggtgacgc 480
acacgctgcg ccggaagtgt gaactgtctg cctccaggct ttgtcatggc ggctgtgct 540
gcacgctgga accatgtgtg ggtcggcacc gagactggga tcttgaaagg ggtaaatctt 600
cagcgaanaa aggcggcgaa cttcacggcc ggaggacagc cgcggcgcgga ggaggcagtg 660
agcgcctgtg gttggggcac cggcgcgag acccagatgc tgggtgggctg cgcggacagg 720
acggtgaagc acttcagcac cgaggatggc atattccagg gtcagagaca ctgcccgggc 780
ggggaggggc tgttccgtgg cctcggccag gccgacggca cctcatcac atgtgtggat 840
tctgggattc tcagagtctg gcatgacaag gacaaggaca catcctctga cccactcctg 900
gaactgagag tgggccctgg ggtgtgtagg atgcgccaaag acccagcaca ccccatgtg 960
gttgccacag gtgggaaaga gaatgctttg aagatatggg acctgcaggg ctctgaggaa 1020
cctgtgttca gggccaagaa cgtgcggaat gactggctgg acttgcggtt tcccatctgg 1080
gaccaggaca tacagtttct cccaggatca cagaagcttg tcacctgcac aggttaccac 1140
caggtccgtg tttatgatcc agcatcccc cagcgccggc cagtccatga gaccacat 1200
ggagagtacc cactaacagc catgaccctc actccgggag gcaactcagt gattgtggga 1260
aacactcatg ggcagctggc agaaattgac cttcggcaag ggcgtctact gggctgtctg 1320
aaggggctgg caggcagtg gctggtgtg cagtgccacc cttcaaagcc tctactagcc 1380
tcctgtggct tggacagagt cttgaggata cacaggatcc agaatccacg gggctctggag 1440
cataaggatg agccccaaga gcctcaagaa cccaacaagg tgcccctaga agacacagag 1500
acagatgaac tttggcatc cttggaggca gctgccaaag ggaagctctc ggggttggag 1560
cagccccaag gagctctcca aacgagacgg agaaagaaga agcggcctgg gtccaccagc 1620
ccctgacgcc cctgtgcca ctttgtaaat aaactgctga acacccaaaa aaaaaa 1676

```

<210> 103

<211> 3206

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2871116CB1

<400> 103

```
ccagagcgtg cgttcggtgg cccatagggg aagatggcgg ctgctccttt ggaggagcgg 60
gattgagagg atcgggggtg ggagaccaa caagagagac atttctggct ctgaaggcga 120
acgcttcgct ggccatttag gagctctgct caaagccaga cgtatcctag aaggaaaaca 180
tcaccatggc tacagaaatt ggttctcttc ctcgtttttt ccatacgcca aggttccagc 240
accaggcacc tcgacagctg ttttataagc gacctgattt tgcacaacag caagcaatgc 300
aacagcttac ttttgatgga aaacgaatga gaaaagctgt gaaccgaaaa accatagact 360
acaatccatc tgtaattaag tatttgga acagaatat gcaaagagac cagagagata 420
tgcgggcaat tcagcctgat gcaggttatt acaatgatct ggtcccacct ataggaatgt 480
tgaataatcc tatgaatgca gtaacaacaa aatttgttcg gacatcaaca aataaagtaa 540
agtgtcctgt atttggtgtt aggtctgcagg aagagtttga aagcctcagt gtccttaa 600
cgtggactcc agaaggaaga cgcttggtca ctggagcttc tagtggggag tttacctgt 660
ggaatggact cactttcaat tttgaaacaa tattacaggc tcacgacagc ccagtggagg 720
ccatgacgtg gtcacataat gacatgtgga tgttgacagc agaccacgga ggatatgtga 780
aatattggca gtcgaacatg aacaacgtca agatgttcca ggcacataag gaggcgatta 840
gagaggccag gtttatacac aatataccat tttctgtagt ccctattgtc atggttaaa 900
tattctctaa gtgtattctg ggtgcagaga ttgcatgggt ctgtcagttt ctgggaaact 960
ttctgcacc atataaacaca atatttttct ttgttttcac acattcacca tttgtctggc 1020
acctttctga agtagtgttg tcccgggtatc agcctttgca atatgttaga gatgtactgt 1080
ctgccgcatt ttgcactggg tttctctttt catttatgat taataatgtg tatacgttat 1140
tcctttttat tatctactgt gtaagacaag aatatttcat tccaaataaa gaattcagtc 1200
tttaattatg caactgaata aaatctaaag cctacagaaa acaacttcag aattcacaca 1260
aagtggaaaa aggtttaagt gaagacctgg ttggcttggt tatgccacga cttccaaagg 1320
aaagtatagg actaaaaccc tcacagataa ctggatgtgg caaacattaa cggagtaatg 1380
aatgggttct tcaagctttg cagctgtaag cagatcattg tcaagaagac tctaggactt 1440
ttcttctgat tcaactgttg taacatcact tatgcaaatg tatacaataa gtggagttaa 1500
aaatattttc agtgagttgt atatttttac acatcagtga ggtatgtata gtaaaactgg 1560
gggaaaaagt tccaaatata agcctgaaga attgctgcag cctcagaata aagctaaagc 1620
gcattcttta aggttggtgc acccatgtgt gggaggaggt tgacatcttt atggaaacat 1680
catccactgt agtcatttgt tcatactttc agaactctaa cagaaattgt tggatgaaca 1740
tgcttctgct ttgtagattt tgccttagtg tcatgcccac acattgagtt tacacagctg 1800
gtccttcata ggattccaaa gttcaaggga gtttttagag ttagttgaga aacttgatga 1860
tctttcactg ctgggaaaaa ctgactcctt ctgacgagc attctttggc tttcacaca 1920
agtctgaatg tcttattttt aaagttttcc tcaaagggtg aacattcatg gaatagcttg 1980
ccaggaagat gtgaaacttt tctacagacc tttgaaatgg atgagaaaca ttgtatgtag 2040
ggatgttttag caatcagctt tttaatagac agcccacatt gtttcagctt atttcatgaa 2100
gtgtctgagg cagaagctga tgataatttt gggagcagta ttcgtgtgtg atttaaaaga 2160
ctgcaggaat actgcaaaaa tagaatccat ttattttcac cacttaaggc agcttcatgt 2220
gatttcctcg tatcatagaa aatagagaag gaacatggat agcattagca ctaataatag 2280
acatttgaag ttctcagaat actgatgatt gaaaactcaa acaactgctc tgttgaagtc 2340
ttcttttgat gagatgcta tgttagctga cgacattcac ttttaagggt tcttactgg 2400
attcttccct ctctgtttta taatgcagca cagtgttttt atttttccct gtctgagaag 2460
cacagattat ctgttaaatg ctgacttctt tcccctgctg tgtgtcttca tgtaacagtt 2520
tctcaccacc ggataataaa tttgctacat gctctgatga cggcactgtt agaactctgg 2580
actttcttcg ttgccatgag gaaagaattc tccgaggtag gtgtactaac agtactgatt 2640
ggaatatatta aatagggaag acatttgtgg ttaaatcatt acaaaaccac aatactggct 2700
tacacctcca ttcaattttt tttacatata cacaccgtct caggctcttc aaaaaaccc 2760
agcactttct ctgactcaca gtcattttgt aggtttttac taccagtgtt atctttgaat 2820
ttttcagctg taaattaaat acaagagtgc ctccccctta ctgtcttatc tgtatgcac 2880
ttttagggtc gtattccttt tcttctcttg tagccagggt acttgttccc aacatattga 2940
cactgtgggt tgatttagat agccgtcatt ctctgtggag tctttttaca atatgaatta 3000
accgacaaga tagaggatc aaagctacac ttcttagtgt tactattttt gaaagcagtt 3060
ggtttttcag tacaccacat ttgtactaca tggcgggtt gttactaagt tcgggtggca 3120
ttgtgtcttg tttacttttg ttgattttat aattaataaa cctctatgaa attacttcat 3180
tccgtaactg aaaaaaaaa aaaaaa 3200
```

<210> 104

<211> 921

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2942212CB1

<400> 104

```
ggtgctgatg ctgctgccat ttcacacact ttgcgagcgc acatccatcc ctccgctctc 60
ccggcgccctg ggccctacca gcttcggggt cccaggccag cgatgcgctc gcggctgagc 120
tagatcctgc cgagccgcgc tctctgaggc gtcggcgggg cgccccctcc cgccgtcccc 180
ggtccggggc aaggagacct gcagagccgc ggccatggag gccatctggc tgtaccagtt 240
ccggctcatt gtcacggggg attccacagt gggcaagtcc tgcctgatcc gccgcttcac 300
cgagggtcgc tttgcccagg tttctgaccc caccgtgggg gtggattttt tctcccgtt 360
ggtggagatc gagccaggaa aacgcataca gctccagatc tgggataacc cgggtcaaga 420
gaggttcaga tccatcactc gcgcctacta caggaaactca gtaggtggtc ttctcttatt 480
tgccattacc aaccgcaggc ccttccagaa tgtccatgag tgggttagaag agaccaaagt 540
acacgttcag ccctaccaa ttgtatttgt tctggtgggt cacaagtgtg acctggatac 600
acagaggcaa gtgactcgcc acgaggccga gaaactggct gctgcatacg gcataaga 660
cattgaaacg tcagcccgag atgccattaa tgtggagaaa gccttcacag acctgacaag 720
agacatatat gagctggtta aaagggggga gattacaatc caggaggggt gggaaggggt 780
gaagagtggg tttgtaccaa atgtggttca ctcttcagaa gaggttgtca aatcagagag 840
gagatgtttg tgctagtcat ttcttttatt tccaaaacat gctctctac ttgaactgaa 900
aagtaagaga aataaataga a                                     921
```

<210> 105

<211> 1367

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3685151CB1

<400> 105

```
aagaggcacg tgcgctgctg aatggagctg tgcgctgggt gctacgagca ggtcctcttt 60
gggttcgctg tacaccggga gcccagggtt tgcggcgacc acgagcagca atggactctt 120
gtggctgact tcaactacca tgctcacact gcctccttgt cagcagtagc tgtaaatagt 180
cgttttgtgg tcaactggag caaagatgaa acaattcaca tttatgacat gaaaaaagaa 240
attgagcatg gggctctagt gcatcacagt ggtacaataa cttgcctgac attctatggc 300
aacaggcatt taatcagtgg agcgggaagat ggactcatct gtatctggga tgcaaaagaaa 360
tggaatccc tgacgtcaat taaagctcac aaaggacagg tgaccttctt ttctattcac 420
ccatctggca agttggccct gtcggttggg acagataaaa cttaagaac gtggaatctt 480
gtgaaggaa gatcagcatt cataaaaaat ataaaacaaa atgctcacat agtagaatgg 540
tccccaagag gagagcagta tgtagttatc atacagaata aaatagacat ctatcagctt 600
gacactgcat ccattagtgg caccatcaca aatgaaaaga gaatttcctc tgtaaatatt 660
ctttcagagt ctgtccttgc agtggctgga gatgaagaag ttataagggt ttttgactgt 720
gattcactag tgtgcctctg cgaatttaaa gctcatgaaa acagggtaaa ggacatgttc 780
agttttgaaa ttccagagca tcatgttatt gtttcagcat cgagtgatgg tttcatcaaa 840
atgtggaagc ttaagcagga taagaaagt ccccatctt tactctgtga aataaacact 900
aatgccaggc tgacgtgtct tggagtgtgg ctagacaaag tggcagacat gaaagaaagc 960
cttctccag ctgcagagcc ttctcctgta agtaagaac agtccaaaat tggcaaaaag 1020
gagcctgggt acacagtgca caaagaagaa aaagcggtaaa aacctaacac aaagaaacgc 1080
ggtttaacag gtgacagtaa gaaagcaaca aaagaaagt gcctgatac aaccaagaag 1140
aggaaaatgg tagaaatgtt ggaaaagaag aggaaaaga agaaaataaa aacaatgcag 1200
tgaatcacag atgtctcctg aaagaactct tttagatgaa atcattctac tcaaatgtac 1260
cttaattttt tttttttccc tgagtaaaag caagaaattt cttcctttgg aaaaaatata 1320
tatattaaaa aaccactttt agatggtttt ttttaaaaa aaaaaaa 1367
```

<210> 106

<211> 1560

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4881515CB1

<400> 106

```

aggcggactg gggagggcggc ggccctggctc ggccctggcct ggccctgtcag ggcgcggggcg 60
gcgggcggtc cagcaccatg tccctgcagt acggggcgga ggagacgccc ctgcgccggca 120
gttacggcgc ggcggattcg ttccaaagg acttcggcta cggcgtggag gaggaggaag 180
aggagggcggc ggcggcggggc ggagggggtg gggcaggggc aggcgtggc tgtgggtccg 240
ggggcgctga cagctccaag ccgaggattc tgctcatggg actccggcgc agcggcaagt 300
cctccatcca gaaggtggg tttcataaga tgtcacccaa cgagaccctc tttttggaaa 360
gtaccaacaa gatattataag gatgacattt ccaatagctc ctttgtgaat ttccagatat 420
gggattttcc tgggcaaagt gacttttttg acccaacctt tgactatgag atgatcttca 480
ggggaacagg agcattgata tacgtcattg acgcacagga tgactacatg gaggctttaa 540
caagacttca cactactgtt tctaaagcct acaaagttaa ccagacatg aattttgagg 600
tttttattca caaagttgat ggtctgtctg atgatacaaa aatagaaaaca cagagggaca 660
ttcatcaaaag ggccaatgat gaccttgacg atgctgggct agaaaaactc catcttagct 720
tttatctgac tagtatctat gaccattcaa tatttgaagc ctttagtaag gtgggtgcaga 780
aactcattcc acaactgccg accttggaac acctattaaa tatctttata tcaaattcag 840
gtattgaaaa agcttttctc tttgatgttg tcagcaaaat ctacattgca acagacagtt 900
cccctgtgga tatgcaatct tatgaacttt gctgtgacat gatcgatgtt gtaattgatg 960
tgtcttgat atatgggtta aagggaagat gaagtgggag tgcttatgac aaagaatcta 1020
tggaattat caagctgaat aatacaactg tcctttattt aaaggagggt actaaatttt 1080
tggcactggc ctgcattcta agggaagaaa gctttgaaag aaaagggtta atagactaca 1140
acttccactg ttccgaaaa gctattcatg aggtttttga ggtgggtgtg acttctcaca 1200
ggagctgtgg tcaccagact agtgccctca gctgaaagc gctgacacac aatggcacgc 1260
cacgaaacgc catctagtct gaatcccagc gtcggggctc tgtgccagct tactcttcac 1320
tccagggtcg gatgccacgt gctacaggac atgggagctg ctgcttgtgg gaatctgggtg 1380
cctgttccac tagagacaag gggtagagtt tctcatttgg atgaaaacc cttcaactgg 1440
tggtgtacaa ctgaagctac tatatctttt ttgaaaatgg caaaaaaaaa aaaaaaaat 1500
tctggagacc acagaactca agtgtgtgtt tctcctcttt tgggtccctt ttaagtagtt 1560

```

<210> 107

<211> 1495

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5324681CB1

<400> 107

```

gaagaggctc tgggctggca catgtgtatg gcgggtgaggc gggcgggtac atggcggggt 60
ctgtgggact ggcggtgtgc gggcagacgt tgggtgggtgc gggcggcagc cgattccttg 120
ccacctccat agcaagcagt gatgatgaca gcctcttcat ctatgactgc agtgcgtcag 180
aaaagaagtc acaagaaaat aaaggggagg acgcgccctt ggaccagggg agcgggtgcga 240
ttctggcgtc caccttctcc aagtctggca gctattttgc tttaaccgat gacagtaagc 300
gtctgattct tttccgtaca aaacctggc aatgtctgag tgtcaggacc gtggcaagga 360
ggtgtacagc cctgacttcc atagcctcgg aggagaaggt cttgggtggc gacaagtctg 420
gagacgtcta ctcttttct gtgctggagc cacacgggtg tggcgtctta gagctggggc 480
acctgtctat gctgttagat gtggctgtga gtcctgatga ccgcttcac ctactgccg 540
accgggacga gaagatccga gtcagctggg ccgcggcgcc ccatagcacc gactccttct 600
gcttgggggc cacagagttt gtgagccgta tctccgtggg gccaaactcag cccgggctgc 660
ttctgtcttc ctctggggac ggcaccctga ggctctggga gtacaggagc ggccgccagc 720
tgactgtctg tcacctggcc agtctgcagg agctgggtga cccccaggcc ccccgagaag 780
ttgccgcgtc caggattgca ttctgggtgc aggagaactg cgtggcgctc ctgtgcgacg 840
gactcctgt ggtctacatc ttccagctgg acgcccgcag acagcagttg gtgtacaggc 900
agcagctggc gttccagcac caagtgtggg acgtggcttt cgaggagacc caggggctgt 960
gggtgtctca ggactgccag gaagccccc tgggtgtctc caggcctgtg ggcgaccagt 1020
ggcagtcgtg tctgtagagc accgtgttaa agaaagtctc tgggtgttct cgtgggaact 1080
gggccatgct ggaaggctct gccggcgagc acgccagctt cagcagctct tacaaggcca 1140
cgttcgacaa cgtgacctcc tacctgaaga agaaagagga gagactgcag cagcagctag 1200
agaagaagca gcggcgccgg agtccccgcg ctggggccga cgggcatgcc aagaagatga 1260
gaccggggga ggcgacgcta agttgtgtat cgtggcggtc tgtttctgtc gactgtggac 1320
cacttatgtg cgatccgtgg accacttgcg tgcgactgtt cgcccgacga tgagcttgtt 1380
cggatgtagc tccatcgtaa gtcgaggagc atctgtgatt tgtcctctgc ttatgggata 1440
tgtttttccg ctactgagtc tgtgtagtaa atttttgact agggaaaaaa aaaaaa 1495

```

<210> 108
 <211> 1919
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5387651CB1

<400> 108
 cgccctgcat gcgagttggg ccgcgggcgg ggttggagcc tactcggggc gactgcgatg 60
 gacgccttag aaggagagag ctttgcgctg tctttctcct ccgcctctga tgcagaattt 120
 gatgctgtgg ttggatattt agaggacatt atcatggatg acgagttcca gttattacag 180
 agaaatttca tggacaagta ctacctggag tttgaagaca cagaagagaa taaactcatc 240
 tacacacctt tttttaatga atacatttct ttggtagaaa aatacattga agaacagctg 300
 ctgcagcggg ttcttgagtt caacatggca gccttcacca caacattaca gcaccataag 360
 gatgaagtgg ctggtgacat attcgacatg ctgctcacct tcacagattt tctggctttt 420
 aaagaaatgt ttttggacta cagagcagaa aaagaaggcc gaggactgga ctttaagcagt 480
 ggcttagtgg tgacttcatt gtgcaaatca tcttctctgc cagcttcca gaacaatctg 540
 cggcactagg tcctacctcc agccaatgaa tgggatcatt ctggatgtca ccagcccaat 600
 aggctcagct catgatgaca gaacacatct tggaaagact gactctgtta tgtaactctt 660
 cattttatgtt aagtattaat aggtcaaaac caaaatgacc taaccctcct ggacctattt 720
 atcctgaaac accttcttgt attcattaac catagtactc ctccccacct caagtagaca 780
 cctctctcag gagcttctga gtcagacgcc tctggagcga gccctatgtc aggcactcca 840
 cctggggggc ccttccccag catacctgct ggtgtgtaag tgtggactaa cccgccgcca 900
 ccaccctctg ttccagcagg ctctgcatga atctttgtgc acttgcacct ctttttcaca 960
 tggggcacag tttcagtact tcagcctcag tggggttcct gatgtttatc taggggtgta 1020
 ctcaagccca gtttgagatt ttggagtctc ctgtgatcac atcttgtctc ggctgtagga 1080
 atcaacagaa ggagacgtcc tctacataaa agctccatgt gaaaagctac tcctagtctt 1140
 aacatttgca gtccttgtgt cactgtcttc tggctcctgat gtagtccac tgtttctaga 1200
 agtctctttt aagcattatt tttgaaaaaa aaaatatatt tatagatgaa tactcaggct 1260
 aacctagtgg atgtgatctt ggaacttcca tgattatcca cttaaagatc aaagtattat 1320
 atgctgtgtg ctttttaggt gtttgttagt actgtgaagg caaaaatgct ttctacattg 1380
 acattcattc ctattttact gggcacctat gaatgtatgc tgtgtgctag aaatagacta 1440
 aaacatattc ctatagcatg ttagtgtgtt tgcattgttg ctgaaaatcc tttgtgtata 1500
 aaccagtttg taagggtctc tgggttaggt agggactctg cagtttcttc ctgtcaaaat 1560
 ctctcctacc aagatgggtg tccactgtcc agcccagcat gagtagcagg tagagcacag 1620
 ctttactggc tgtttgtatg ctttggttta gtgcaatgtg tggtagatta cttatcagaa 1680
 aacatatatg tcatctctag aacgaagaaa aagcatagta gttcaattcc cagtgtgtcc 1740
 ctttgatttt ttttttttaa tagtaaaaat aagaatctgt actgactttt cacttggcca 1800
 ttctgggttt aaaggacaag ctacaagctc tgtgtttctg tactgatgtg tcacttatta 1860
 aatacttttg taccatgagt aaaacttcag gtgtttcgca agaaccacca ttctcaaaa 1919

<210> 109
 <211> 2941
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 5595679CB1

<400> 109
 attaggctaa taggacagca cttgaatggc ttagggctca accagactgt tgatctcctc 60
 atgcaagagt caggatgtcg tttagaacat ccttctgcta ccaaattccg aaatcatgtc 120
 atggaaggag actgggataa ggcagaaaat gacctgaatg aactaaagcc tttagtgcac 180
 tctcctcatg ctatttgtgt aagaggcgca cttgaaatct ctcaaacgtt gttgggaata 240
 attgtgagga tgaagttttt gctgctgcag cagaagtacc tagaatacct ggaggatggc 300
 aagggtcctg aggcacttca agttctacgc tgtgaattga cgccgctgaa atacaatata 360
 gagcgcattc atgttcttag tgggtatctg atgtgtagcc atgcagaaga cctacgtgca 420
 aaagcagaa gggaaaggcaa agggacagct tcccgatcta aactattgga taaacttcag 480
 acctattttac caccatcagt gatgcttccc ccacggcggt tacagactct cctgcccag 540
 gcggtggaac tacaaaaggga tcggtgccta tatcacaata ccaaacttga taataatcta 600

```

gattctgtgt ctctgcttat agaccatggt ttagtagtagga ggcagttccc atgtttatacg 660
cagcagatac ttacggagca ttgtaatgaa gtgtggttct gtaaattctc taatgatggc 720
actaaactag caacaggatc aaaagataca acagttatca tatggcaagt tgatccggat 780
acacacctgc taaaactgct taaaacatta gaaggacatg cttatggcgt ttctttatatt 840
gcattggagtc cagatgacaa ctatcttggt gcttgtggcc cagatgactg ctctgagctt 900
tggtctttgga atgtacaaac aggagaacta aggacaaaaa tgagccagtc tcatgaagac 960
agtttgacaa gtgtggcttg gaatccagat gggaagcgct ttgtgactgg aggtcagcgt 1020
gggcagttct atcagtggtga cttagatggg aatctccttg actcctggga aggggtaaga 1080
gtgcaatgcc tttggtgctt gagtgtatgga aagactgttc tggcatcaga tacacaccag 1140
cgaattcggg gctataactt cgaggacctt acagatagga acatagtaca agaagatcat 1200
cctattatgt cttttactat ttcaaaaaat ggccgattag ctttgttaaa thtagcaact 1260
cagggagttc atttatggga cttgcaagac agagtttttag taagaaagta tcaaggtgtt 1320
acacaagggt tttatacaat tcattcatgt tttggaggcc ataatagaaga cttcatcgct 1380
agtggcagtg aagatcacaa ggtttacatc tggcacaaac gtagtgaact gccaatgtcg 1440
gagctgacag ggcacacacg tacagtaaac tgtgtgagct ggaaccaca gattccatcc 1500
atgatggcca gcgcctcaga tgatggcact gttagaatat ggggaccagc acctttata 1560
gaccaccaga atattgaaga ggaatgcagt agcatggata gttgatggtg aatttggagc 1620
agacgacttc tgtttaactt aaaattagtc gtattttaat ggcttgggat ttggtgcaaa 1680
caaacatgat tgatagctgg acagacatgc tcgtcatgaa aaaagaacca tttctgaagc 1740
ccgattgggg ccaaacattt acaccttgct tcatagtaac cagttgagat gaagcacgctc 1800
gttagaacgt tgttgacac catgttgaat tattcccca tcggttgtga agaactgtgc 1860
tacattcagg cttaccattt gaactcagta tatatatattt tttccttcct gtctttgtc 1920
tggcaggata ccattcttgt tgctctctg tgtaatgaag tttaaatgct tgtttgaaa 1980
actttattta acagtttaga aggcttgata gaaagagtgc attagtctga agagtataca 2040
ttggatagga aagaatttcc ttcttttggt tctccaaatc tttccgcctt atttagcttg 2100
agatctttgc agcttggttc atggattcta gccttgcccg ttgcgagta tatactgatc 2160
cagatgataa accagtgaac tatgtcaaaa gcactctcaa tattacattt gacaaaaagt 2220
tttgactttt tcacatagct tgttgccccg taaaagggtt aacagcacia ttttttaaaa 2280
ataaattaag aagtatttat aggattaaag tgacttcatt tgtatacatt tgggaatctaa 2340
accagcttaa aaacagtttc ctcaatgact tagatacaca gtataactga tgctcttctg 2400
gaataccaca tgagacatgg tcagaaacag tgcttggaag gacattacac aagaaattca 2460
gagtaatgct ttgaagattt cccccctttt gttttattcc tgaaggaaca tcagatcccg 2520
atcttgaaga aattcaagat tcaaaaagaa ttttaaatat accaacatga gacatcagta 2580
gtcagttggt tttcagtaaa gcttggtcca agttgttctc aacttaggaa gtaatttttg 2640
tgtgatctag caaaagagta ggaatcagcg atacaaccac tttggaagtt tatagtataa 2700
ttgaaattat tagaagaatt cagcagggtta cagacatact taaactggga ttaaaacctc 2760
atagtcattt ttcttaattg cccttaatat tttgacatat agggatacat aaatttaag 2820
aatatttttt tcagttttt tcagatattg ccatactgaa cctcattcta aactggtgct 2880
gtggatagtc tttccctctc ccctcctgtt ttagtttaag gaaagggttc cttcatggaa 2940
a 2941

```

<210> 110

<211> 710

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5782457CB1

<400> 110

```

ctcgcgggtcg cctggccggt gtcattgtcc ctccgctgtc accttttcaa gcccagggt 60
ggctgcttca gaagccctcg acccatgga ggagtgggac gtgccacaga tgaagaaaga 120
ggtggagagc ctcaagtacc agctggcctt ccagcgggag atggcggtcca agaccatccc 180
cgagctgctg aagtggatcg aggacgggat ccccaaggac cccttctga accccgacct 240
gatgaagaac aacccatggg tggaaaaggg caaatgcacc atcctgtgag ccccgacccc 300
ggccctctc acaccatcct gtgagaccac gcccgcccc actcccacca tcttgtaaga 360
ctgtgcccag ccccatcac tccatcctgt gagtcccat cccagcccca ctcccacct 420
cctgtgagcc catgcccggc cccactcaca ccaacctgtg agccccactc ccggccccc 480
tcacaacac ttgtaagact gtgccggcc cacttactc catcctgtga gaccacgcc 540
ggccccactc actctatcct gtgagaccac gcctggcccc actcccacca tctgtgagc 600
cccactcctg gccccactca caccatccta tgagccacg cccggcccca ctcccacct 660
cctgtgaacc ccactccact cgcacgtgat tacagtctgt aaagggtgta 710

```

<210> 111
 <211> 1351
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 760677CB1

```
<400> 111
ccaggcctag tggatagaca ggggtccaaaa tgtgaccctt ctaggctggt atcaccatgg 60
gggctcatg ggctgaggat tctgcagata ggacatcacc acggcagaga tggacagcct 120
gagacaggag agaggtgtca gtctaggatg gccaggctgg gtccccccac cccttactca 180
agagtcactt gttctgtagg gcaagtctca catgaagcta ctcatcattt gcttcgtgtc 240
ctccgagctc cgagagtttg caaagctgat gaaggagcag tagacagcga cccaagcaca 300
ccacttcagc tagggaaaga ccgatttaag gctgcaagga aggagtcctg ggagcatggc 360
tttccctgag ccaaagccgc ggcctccaga gctgccgcag aaacgggttg agacgctgga 420
ctgctgggag ggggagctgc gagccgtacg atttaattgt gatggcaatt actgcctgac 480
gtgctggcag gacaagacgc tgaagctgtg gaaccgcgtt cgggggacgc tgcctgggac 540
gtacagcggc cacggctacg aggtgctgga tgcggccggc tcctttgaca acagtagtct 600
ctgctccggc ggcgggggaca agggcggtggg tctgtggaat gtggcatcag ggcaggtcgt 660
gcgcaaatc cggggccacg caggggaagg gaacacgggt cagttagtg aagaggccac 720
agttatcttg tccggctcta ttgattccag tatccgctgt tgggattgcc gctcacggag 780
gcctgagcca gtgcagacgc tggatgaggc cagagatggc gtgtccagt tgaagggtc 840
agaccacgag atcctggcag gctccgtgga tggccgcgtg agacgctatg acctaaggat 900
ggggcagctc ttctcagact acgtgggcag ccccatcacc tgcacctgct tcagccggga 960
tgggcagtg accctggtgt ccagcctgga tccacattg cggctcctg acaaagacac 1020
aggggagctg ctgggcgagt acaagggcc aagaaccag gaatacaagc tggactgtg 1080
cctgagcgag cgtgacacac atgtggtcag ctgttctgag gacgggaagg tgttctctg 1140
ggacctggtg gagggtgctg tggctctggc cctgcctgtg ggttccgggt tgggtgcagt 1200
gctggactac caccaacag agccctgcct gctgaccgcc atgggaggca gcgtccagt 1260
ctggcgagag gaggcctatg aggcagagga tggagcaggc tgaagccagg ggaccacca 1320
acaggaccaa ggaccgagac acagacatgg c 1351
```

<210> 112
 <211> 1783
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1348567CB1

```
<400> 112
cccacgcgtc cggggacgcg tgggctgaag gctgtggcgc ggggctgtcc ccattccac 60
gtgaagcgct acgctagcat cgctcggctg ggcgtccca gctcgcgcg gagcagtcct 120
ggcagcagcg ggggaccgga agtggtctgc ggaggctcag aagctagtcc cggagcccg 180
cgtgtggcgc ctccgagcgc ggtgacggcg ccatgtccct aatctgctcc atctctaag 240
aagtgcggga gcacccatgt gtatcccctg tctctaatac tgtttatgag cggcggtca 300
tcgagaagta cattgcggag aatgggtaccg acccatcaa caaccagcct ctctccgag 360
agcagctcat cgacatcaaa gttgctcacc caatccggcc caagcctccc tcagccacca 420
gcatcccggc cattctgaaa gctttgcagg atgagtggga tgcagtcagt ccgcacagct 480
tactctgctg ccagcagctg cagacaaccc gccaaagagt gtcacacgct ctgtaccagc 540
acgatgccgc ctgccgtgtc attgcccgtc tcaccaagga agtcactgct gcccgagaag 600
ctctggctac cctgaaacca caggctggcc tcattgtgcc ccaggctgtg ccaagttccc 660
aaccaagtgt tgtgggtgct ggtgagccaa tggatttggg tgagctggtg ggaatgacct 720
cagagattat tcagaagctt caagacaaag ccactgtgct aaccacggag cgcaagaaga 780
gaggggaagac tgtgcctgag gagctggtga agccagaaga gctcagcaaa taccggcagg 840
tggcatccca cgtgggggtg cacagtgcc gcattcctgg gatcctggcc ctggacctct 900
gcccgctcca caccaacaag atcctcactg tggggcgga taaaaatgtc gttgtgtttg 960
acaaaagttc ctggctaccc ctggaaggcc taccagaag gtcaccagcg 1020
tgggtgtttc cccttcccag gacctggtgt tttctgtctt ccccgatgcc actatcagga 1080
tttggctcgg ccccaatgcc tcttgtgtac aggtggttcg ggcccatgag agtgctgtga 1140
```

```

caggcctcag ccttcacgcc actggcgact atctcctgag ctccctccgat gatcagtact 1200
gggctttctc tgacatccag acagggcgctg tgctcaccaa ggtgacagat gagacctccg 1260
gctgctctct cactgtgca cagttccacc ctgacggact catcttttga acaggaacca 1320
tggactctca gatcaagatc tgggacttga aggaacgtac taatgtggcc aacttccctg 1380
gccactcggg ccccatcact agcatcgctt tctctgagaa tggttactac ctggctacag 1440
cggtgatga ctctctgtc aagctctggg atctgcgcaa gcttaagaac ttttaagactt 1500
tgcagctgga taacaacttt gaggtaaagt cactgatctt tgaccagagt ggtacctacc 1560
tggtctctgg gggcacggat gtccagatct acatctgcaa acaatggacg gagattcttc 1620
actttacaga gcatagcggc ctgaccacag ggggtggcctt cgggcatcac gccaaagtta 1680
tcgttcaaac aggcattggac agaagcctca agttctacag cctgtagggc ctggcccttc 1740
tgatggaagc tgggcctcat ctcatgtagg gggtagaatt agg 1783

```

<210> 113

<211> 3453

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1751354CB1

<400> 113

```

ggcttgcgca ctacgtcccc agccagaggg tcctaccggg tcgggggactt ccggaacgcc 60
gggggtgtgt tccgggtcgt gtgcggctcg gggtaatagg gctgctgctc ggccggccgg 120
cggcgccgag cagcaggggc atgagggcta acccggaag cggcagctga gcgggccggg 180
aggagcgccg gtccccgtgg atccccgagag tgcagagctc ggggcagggg ccgggaggcg 240
tgggggagcc gggccctccc ctccaggaacg tgtcccgggg ccgaccgggc ccgtagtggtg 300
gaagcagctt caggtaggtg agctcgtgaa acaatatgaa gaggagaaaa tagcctttta 360
aggaaattgg cccacagaaa ggatggcctt cttggacaat ccaactatca ttctagctca 420
tattcgacag tcacatgtga ccagtgtga cacgggaatg tgtgagatgg ttctcattga 480
tcatgatgtt gacctagaga agattcatcc tccttcaatg cctggagaca gtgggtcaga 540
aattcaggga agcaatgggt agactcaggg ctatgtatat gccagtcag tcgatattac 600
ctcaagtggg gactttggta ttagaagacg ctcaaacaca gctcaaagat tagaacgact 660
ccgaaaagag agacaaaacc agatcaaatg caaaaatatt cagtggaaag aaagaaattc 720
taagcaatca gcccaggagt taaagtcact gtttgaaaaa aaatctctca aagagaagcc 780
tccaatttct gggaagcagt cgatattatc tgtacgccta gaacagtgcc ctctgcagct 840
gaataaccct tttaacgagt attccaaatt tgatggcaag ggtcatgtag gtacaacagc 900
aaccaagaag atcgatgtct acctccctct gcactcgagc caggacagac tgcgtccaat 960
gaccgtgggt acaatggcca gcgccagggt caggagcctg atcgggctca tctgtggcca 1020
gtatacaagc gaaggacggg agccgaagct caatgacaat gtcagtgcct actgcctgca 1080
tattgctgag gatgatgggg aggtggacac cgatttcccc ccgctggatt ccaatgagcc 1140
cattcataag tttggcttca gtactttggc cctggttgaa aagtactcat ctctgtgtct 1200
gacatccaaa gagtcactct ttgttcgaat aaatgctgct catggattct cccttattca 1260
gggtgacaac acaaaggtta ccatgaagga aatcttactg aaggcagtga agcgaagaaa 1320
aggatcccag aaagtttcag gccctcagta ccgcctggag aagcagagcg agcccaatgt 1380
cgccgttgac ctggacagca ctttggagag ccagagcgca tgggagttct gcctggtccg 1440
cgagaacagt tcaagggcag acgggggttt tgaggaggat tcgcaaatg acatagccac 1500
agtacaggat atgcttagca gccaccatta caagtcattc aaagtcagca tgatccacag 1560
actgcgattc acaaccgacg tacagctagg tatctctgga gacaaagtag agatagacc 1620
tgttacgaat cagaaagcca gcactaagtt ttggattaag cagaaaacca tctcaatcga 1680
ttccgacctg ctctgtgctt gtgaccttgc tgaagagaaa agccccagtc acgcaatatt 1740
taaactcacg tatctaagca atcacgacta taaacacctc tactttgaat cggacgctgc 1800
taccgtcaat gaaattgtgc tcaagggtta ctacatcctg gaatcgcgag ctagcactgc 1860
ccgggctgac tactttgtct aaaaacaaag aaaactgaac agacgtacga gcttcagctt 1920
ccagaaggag aagaaatccg ggcagcagtg acactggcct ccagcctcaa tctgttccgt 1980
agctcagagc ctgcctgcca gggccaagtg ccctagagcc caccgggtgt cctgaagtc 2040
tcgggggggag gccagccctt ggctcactgg cacagggcag gtgggctctc ggggaagggtg 2100
tcggggggccc cctaggaggg agcgctgggg acattgccat gggacggaag tctgcttggc 2160
agtggctttg ataagcgatg cttgggggtc agaccacccc ctagaggagc cacgtgccgc 2220
ccagccacct tcaatgcctg ccacctgtcc cgaggatgta cagagccgtg ccacacatt 2280
tccttgcaac ttgatcaaat ttcttaaagc aatgtacatt tctgttttct 2340
cttttaataa acaggtgtac tctttatcat ggttggtatg atggaccatt ctttggggcg 2400
gaggattgat tatgttactc tctttaaaat ctgttcccat attgaacagg cagattggaa 2460

```

```

aagctatggt tgcatttctc agaagaaatg ttttaggtctt agtcaatagt ttttaactatg 2520
ccatttgttt aaatgagtg c atttgcttcg agggtagtgt cttactaaaa gttaggaaca 2580
gagacctagt ggtgtgtcca aggcctgtgc actttcccct tcagcacacc ccagcttctg 2640
acctcagagc ccaggagctg cgtggacagt gtgggggtgcc aggaggagg gcggtggctg 2700
gtcctcaggc acgctgcact cccagccaga catgggtctt cgtttctta agtagcaagt 2760
gtaggtttca gctggcagtt ccacctgcat gttctctgct tcgctgcctt ggaaggggcc 2820
acattcccca ttcctcttct ccttacagcg cctgcctcct ttttcaagca ggcggaaagc 2880
tgctgtttct cacgtttcag ggagaggggt gagcggagg agacctgtgt ccgtgccgtc 2940
cggctccctg ggtgggaaca ggcaagggat cagatgcccc tgacaccacg cctctggcca 3000
caccagatgc ctctgcagtc ctcgacagcc tcttcagtgt ccctcctgcg gtgatgtcct 3060
tactgtcccc agccagggcc ggggaccggg gtttactga ggacctgcat tagaaacatt 3120
ttttaaattg ttgtacagga agagatgtgt ctaaaacagc atcttaaagc tgagtgtatt 3180
tctttgcaca aggggtcatg ctgatgaatt cttctttcat tctgatcttt gttcagccaa 3240
caggagcgtc cttttctaatt gtcttccatt cctaccccc acccaaaaac aaaagaaata 3300
ttttagctt gctatctgta tttgaatttt tagcaatttt atatttagat actttgaaaa 3360
atgtaaata ctaatttggt cattaatct tgtgacatat tcgatattaa aatgatatta 3420
aaataaaagt catataaata cacaaaaaaa aaa 3453

```

<210> 114

<211> 2663

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1976780CB1

<400> 114

```

gaaaaagggt cgaaagaact ggttgtcttc ttgggcgggtg ttgcagggtt catctttact 60
ttttaccaa actcaaggaa gtagcacaag ttggtttggc agtaatcagt ccaaaccaga 120
gttcacagtg gacctcaagg gggcaacaat tgagatggct tcaaaggata aatccagcaa 180
aaagaatgta tttgagctga aaactcgtca aggaacagaa ctgctaattc agtctgacaa 240
tgacactggt ataatgatt ggtttaagt tcttagtagt acaatcaata atcaggcagt 300
agaaactgat gaaggaattg aagaggagat accggattca ccaggaatag aaaagcatga 360
taaagaaaag gaacaaaagg atcccaaaaa gcttcgttcc tttaaagtat ctagcataga 420
ttcttcagaa cagaaaaaaa ccaagaaaaa cttaaagaag tttcttacac gacgccccac 480
tttgcaagct gttcgtgaaa aaggttatat taaagatcag gtatttggat ccaatctcgc 540
taatctgtgt gagagagaga atggcacagt accaaagttt gtgaagttat gtattgaaca 600
tgttgaagaa catggtttgg atattgatgg gatatacaga gtaagtggca acctcgagt 660
gatccagaaa ctaaggtttg cagtcaatca tgatgagaaa ttggacttga atgacagtaa 720
atgggaagat attcatgtca ttactggagc cctcaaaatg ttttttcgag aattaccaga 780
acctcttttt acatttaatc attttaatga tttgttaat gcaattaagc aagaaccaag 840
acagcgagtc gctgctgtta aggacctaat gagacagttg ccaaagccaa accaagacac 900
aatgcagatt ctcttcgac atctcagaag agttatagaa aatggagaga aaaatcgaat 960
gacctatcag agtatagcaa ttgtttttgg tccactcta ttaaaaccag aaaaagagac 1020
tggtaatata gcagttcata ctgtgtacca gaatcagatt gtagaattaa ttcttctgga 1080
actgagttcc atcttcggac gttgattctt actgaagaca acctgtggaa tagaagctgg 1140
attccatcag atttcaaatg tttatacaca atgtatttta ttttttggac caagcagtga 1200
ctctttgatt ttgcactttt tttttgagg atcagaaggg aaggggagag tcgagatgtg 1260
tgttaggccc tcatatttgc tgctttgttg caagttgata taactgcgtg taattatgaa 1320
ttcattttat cctgaatgtt tgcatttcat actctgaatt tcagtaaaaa tcaaaactta 1380
aaattctaac cagtcatata cactggataa tttggtaaga aaactgtatt ttttttccct 1440
gaaattggat aatgtacttt cttctcaaga ttcagtactt gatagaacaa tactttcagt 1500
tatgttgcaa aggctcttgg gcatttttaa caaatgaag tatatccatt ttgaaacctg 1560
tgtatttctt tttcggggtt tctgcatgca gtggcagtc taagtgccaa aattcattat 1620
aacccccaaa taacccttg atgaaggctt gctgtctttt actgtgttac acagcatcct 1680
tactggatat cttagttgct tgtttgggca gcacactaat attacttaaa acactgtgat 1740
atactggagt ttagtttagc ggaagtcagt tcagggcatt ttagggctgt cttgctatac 1800
tgaattgtag ctaacaatcc taattatata tagtaccata ctgagttatt ggtatgacct 1860
tgtggaaaca cacattattt tatgtaataa taggctaaag acttaatgtc ctttagcttg 1920
tgtatataat tgtgtgtgat agtctcagag tacattctaa ccctacattt ctaatcattg 1980
ttattggtaa tcttttctgt gaattatagg tttcctccag aaatgggtccg ttatttggga 2040
aagttaactg tgtgcacttt tagatattaa ctacatttac aggcaaatca ctgtaatgag 2100

```

```

aatggtactg gaaaaatact gaatagactt gctaaatggc acatgcacta caagaggaac 2160
cttttgggtt atttaatatg tacagaaaac attagaaaaa atttattaca gaattctaatt 2220
tccagtatga atagtggaaa cccatctgta aattagatgg atgttggatg gaaaatgaca 2280
ttgctaaatt tgagaatttc tttttacctt ctaatgtaga ttgctttgta taataaaaaca 2340
cagggttttg aaggttttgg tacagggagc atggctctgt gaagattttt aaaatgtatt 2400
tttctagatt aacttctgta catgaaatgt ctaataaaaac tataagaggt ttagagattt 2460
ttccattgga aatgtgcatt ttggtttcta attttttggg tttttcattt actggcatac 2520
tggtatacct cttttttaa aatcaactga atccaatatt tcctgtggca aataacactt 2580
tcctcatttc ataccttttc tcctctcttc catgccaaaca tttctccacc cacaacgtac 2640
actgtttatt tctcatcaat att                                     2663

```

<210> 115

<211> 1218

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2048234CB1

<400> 115

```

gcctgttgca gccatggtgc attgcagttg cgtgtgtgtc agaaagtatg gaaatttcat 60
cgataagcta agactcttca ccaggggagg atccggtgga atgggttatc ctggtttagg 120
tgagaagggt ggaaaagggt gtgatgtctg ggtttagacc cagaacagaa tgactttaaa 180
acaacttaaa gacaggatc ctcggaacg gtttgtggct ggagtaggag caaacagcaa 240
aattagtgca ctgaaaggct ccaaaggaaa agactgggaa atccctgtgc ctgtgggtat 300
ttcagtaact gatgaaaatg gtaaaattat aggagaactc agtaaagaaa atgacagaat 360
tttggtagct caaggagggtc ttggtggttaa attacttaca aatttcttac cattgaaagg 420
ccagaaacga ataattcacc ttgatctaaa acttatagct gatgtaggcc tagtaggatt 480
cccaaatgct ggaaaatcct ctttgctaag ttgtgtttct catgcaaaac ctgcaattgc 540
agattacgca ttacaacat taaagctgaa gctcggaaag ataatgtaca gtgatttcaa 600
acagatatca gtagctgatc ttccgggttt aatagaagga gcacatatga acaaaggaat 660
gggccacaaa ttcctcaagc atatagaaag aactagacaa ctactttttg ttgttgatat 720
ttctggattt cagctttctt ctcacactca atacaggaca gcttttgaaa ccataatact 780
gcttacaaaa gagttggaat tgtacaaaaga ggaacttcag acaaacctg cactcttggc 840
agttaataaa atggacttgc cagatgccca agataagtcc catgaattga tgagccagct 900
ccagaatcct aaagattttc tgcatttatt tgaaaaaaac atgattccag agaggactgt 960
agagttccaa catatcatcc ccatactgac agttactgga gaaggaatcg aagaattaaa 1020
gaattgtata agaaagtcac tggatgaaca ggccaaccag gaaaatgatg cacttcataa 1080
gaaacagttg cttaatttgg ggatttctga tacaatgtct tctactgagc caccatcaaa 1140
gcatgctgtt actacttcca aaatggatat aatttaaata tattaataat ggtattgatg 1200
gaacagtaaa aaaaaaaaaa                                     1218

```

<210> 116

<211> 1286

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2111754CB1

<400> 116

```

ccgccttga acttctggac tagccctcgc attgtttag atgccaagcg gacctcgcg 60
cgctctgcgt tgggccagcc cctcacagct gggttcttac cacgtattgc gcaacggaat 120
ctatgcctgt taccacact ccctgcgccc ccgcaccccg ctctgtgctg caagtccgaa 180
tataaaaccg cggaggagtg agctcttggg gtgtccagtt ggttgccgcg gcagtctctc 240
cgagcagcgc atttgtcttc taggtctgct gggtcgtgcc tccgagaaaag gggctctcctg 300
ctgccagcta agtgtgggag aacttgtgca cgtatctccc ctccgaatcc caacgatggg 360
taacgccagc tttggctcca aggaacagaa gctgctgaag cggttgcggc ttctgcccgc 420
cctgcttata ctccgcgcct tcaagcccca caggaagatc agagattacc gcgtcgtggg 480
agtcggcacc gctggtgtgg ggaaaagtac gctgctgcac aagtgggcga gcggcaactt 540
ccgtcatgag tacctgccga ccattgaaaa tacctactgc cagttgctgg gctgcagcca 600

```



```

cgggtgtgctt tccctgcaca tcaccgacag caagagtggc gacggcaacc gcgctctgca 660
gcgccacgtt atagcccggg gccacgcctt cgtcctggtc tactcagtca ccaagaagga 720
aaccctggaa gagctgaagg ccttctatga gctgatctgc aagatcaaag gtaacaacct 780
gcataagttc cccatcgtgc tgggtgggcaa taaaagtgat gacaccacc gggagggtggc 840
cctgaatgat ggtgccacct gtgcatggga gtggaattgc gccttcattg agatttcagc 900
caagaccgat gtgaatgtgc aggagctgtt ccacatgctg ctgaattaca agaaaaagcc 960
caccaccggc ctccaggagc ccgagaagaa atcccagatg cccaacacca ctgagaagct 1020
gcttgacaag tgcataatca tgtgagccct gggccttaag agccagctct tcctatcctg 1080
tagcgtgtag aaaacgtgga ctcatctcac tatgttacat gtacatggtt gattttgtgc 1140
tgttgtttgg actgtaacat ccatgttgtc aatacgtata ccttgtaagt ggataacttt 1200
tctttttccc aggccagaga attcaaattg ttaaaacatt ggcatttgaa gaggagaaca 1260
aaatgtagca tgatgtattt aaagta 1286

```

<210> 117

<211> 3057

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2123286CB1

<400> 117

```

caaggctccg gcctgcgagg agtcacatta actttgctct agaagacaac tttacaagga 60
tctaaaagga acaggattaa agatgactga atactgggtt ccagaaatctt aaaacaatca 120
gcttagcaaa tcatatatctt ttctgtggag ctgagaattg atgtccgctc ttccccgtga 180
tttggaaact tccaatccca gagaaaagtt gacaaaggga ctgcccagga ctgagtcctat 240
atggaagaag aaacttcctct tttctctgga gacagtggca agccagtaca ggctactctg 300
tcatctttga agatgttaga tgtgggaaag tggccaattt tttccctttg ttctgaagaa 360
gaactacagt taattcgtca ggcttgtgtc tttggcagtg ctggcaatga agttttatac 420
actacagtaa atgatgagat ttttgtgctt ggcacaaaact gctgtggctg tttgggggta 480
ggtgacgtcc agagcaccat tgaacctcgg agactggatt ctttaaatgg caaaaaaata 540
gcctgcctca gctatgggag tggtcacat attgtccttg caacaacaga aggagaagtc 600
tttacctggg gtcataatgc ttatagccag ctgggcaatg ggacaactaa tcatggttta 660
gtgcctgtc atactctctac taatctgtca aacaaacaag tcattgaagt tgccctgtggg 720
tcttaccatt ctttgggtgt aacatctgat ggagaggtat ttgcctgggg ttataataac 780
tctgggcagg taggatctgg atcaacagtt aatcagccaa tccctcgaag agtcaactggc 840
tgcctacaaa ataaagtagt tgtgaccata gcatgtgggc agatgtgctg catggcagtc 900
gtagacacgg gtaggtcta tgtctgggtt tacaacggaa acgggcagct tggactcggc 960
aacagtggca accagccaac cccttcgaga gtggcagctt tgcaaggcat ccgtgtccag 1020
agggtgcct gtggctacgc acacacatta gtattaacag atgaaggcca agtgatgct 1080
tggggcgcca attcttatgg gcagttgggc actggcaata aaagcaacca gtccatctct 1140
actcctgtca ctgtggaaaa ggacaggatt atcgagattg cagcctgtca ctccacacac 1200
acgtctgccc ccaagacgca ggggtggcac gtgtacatgt gggggcagtg ccggggcagc 1260
tccgtgatcc tcccgcacct caccacttc tccgtgactg acgacgtgtt tgccctgctt 1320
gccacgcccg ccgtcacgtg gcgcctcttc tccgtggaac ctgatgacca cctcacagtg 1380
gctgagtcac tgaagaggga atttgacaac ccggacactg cagacctgaa gtttctagtt 1440
gatggaaaagt acatttatgc acataaagtc cttctcaaga ttcatgtga gcattttcgt 1500
tcgtcattgg aagataacga ggatgatatt gtagaaatga gtgaattttc atatcctgtt 1560
taccgggccc tcctggaata cctatacaca gacagcatca gcctttctcc tgaggaggca 1620
gtaggactgc tagacttggc tacattttat agagaaaatc gtttgaaaaa gctctgccaa 1680
caaaactatca agcaaggcat ctgagaggag aatgccatcg ctctgctctc ggtgcgggtg 1740
aagtatgatg cacaggattt agaagaattc tgcttcaggt tttgcataaa ccatctgact 1800
gtagtaacac aaacatcagg ttttgcagaa atggaccatg atctcctgaa gaactttatc 1860
agcaaagcaa gcagagttgg agcctttaaa aattgatccc atctgcagga aagtttttga 1920
gcctttccat ttcccctgca aaagccagag atgaatcact tctctttaat taatagtatg 1980
tatgatgagc tatgtttggc tgagtacttg taactgtcag aagaaggatg gtggtgagtg 2040
gtctttgtct gcctaaaccc agagtttatg tagaaagcat tgaatgttct gatcagatgt 2100
gactaaggtc aaggaaaaaa aattgaaata tcttattttac catttctctt ttttgagtca 2160
cttaaatggg acacctttgg taccctggtc tcagtatatg ctattctggc ccaaatgttc 2220
cattattcag ctggctgata ccacatagat agcttgacaa ggagtgctgt ctgtccttac 2280
cacattttca gcactcagca cagtgccttg tgtataatag gcactcaatt tattataaat 2340
cttcagtatg tcctgagaac agcttttagtc atggaatact gggagaagga ataactttca 2400

```

```

caaaataaac ttaaaacagc ctgtaattat tgaggttcat attcttctgg tatatcattc 2460
tgagaaattg tggctaattt agaacattgt ttagaattga caaaaggccc tggcaattaa 2520
attgtcaagg cccaagggct aatttttaatt ttctttttac ttggagtcac tcattaattt 2580
ctcacatggg attatggagt atgaagtatt atctttgaat gaaattcctg ggctgatctg 2640
ccttacataa tcacataagg tccttttgctt ttcttttggt taagaggggac ttgcctctgt 2700
aaatgaaaat gacaatgtgc ttttcttgta gttgactttc atgtcactca ctataaaaata 2760
gggtctcttaa cctggcacca gtataactat aaagcactag ctgagaagga actgatactt 2820
acatttcatg gacagcatta acaagaatga gataaatttg tacttttttag atcaaaaaca 2880
attacctaatt tgcaaaagag aaactgaaat ggaacatagt ctcagattct tctaattgtg 2940
atctcacaat gtcattgtaat gtaaaggaaa cccttttgga attagaattc ttgttctgat 3000
gctgaactat ttggtaataa agtgcttatt tgcagataac agaaaaaaaa aaaaaaa 3057

```

<210> 118

<211> 1803

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2477507CB1

<400> 118

```

ggtcgcgccc ttcacggggt cctcgccgct cctgagtcac aaatcccaag ctggagccgt 60
tcagctcccc tccaccgctt agagatttgg ggggctctgg ccccgctcct gcggaccatt 120
ccgagggggag tccagaggtg aggccgagga acctccctga ctttgcgggg cgcgccgctc 180
ctgcgctctcc tgccagtctc ccttccttct ttccggtcaa caattgaaaa caaaacgagg 240
aacagcagag gagctactgt ataccgagcc ctcagcattg ttcgtaattc ccgcctgcta 300
acagccttgt gaagaagggt ctattcttct caacacttta cagatgagga cacttgagggt 360
tcggagacgt ggagcctctt gcacagctgc ttaagtgggt gtagagccga gatttgaacc 420
ctcctaacca ttcttttctg ccgcctactg cagctcccag cagagatgat tgaactgttg 480
ctcggggtgag ggccccagag tgtcagtaat taacactgtg gatacctccc atgaggacat 540
gattcacgac gccagatgg actactatgg caccgcctg gcaacctgct catcagacag 600
gtccgtcaaaa atctttgatg tgcgcaatgg agggcagatc cttatcgccg acctcagggg 660
tcatgaggggt cctgtgtggc aagtggcctg ggctcacccc atgtacggca acatcctggc 720
atcgtgctcc tatgaccgga aagtcattat ctggagagag gaaaacggca cctggggagaa 780
gagccacgag catgcgggac acgactcctc agtgaactcg gtgtgctggg ccccccatga 840
ctacggcctg atcctggcct gtgggagctc ggatggggcc atctccctgc tgacttacac 900
cggggaaggc caatgggaag taaagaagat caacaacgct cacaccattg gctgcaatgc 960
cgtcagctgg gccctgctg ttgtacctgg aagcctcata gaccacccat cggggcagaa 1020
acccaattac atcaagaggt ttgcatcagg tggctgtgac aacctcatca agctgtggaa 1080
ggaggaggag gacggccagt ggaaggagga gcagaagcta gaagcgcaca gtgactgggt 1140
tcgagatgtg gcttgggccc cctccatcgg cctgcccacc agcaccatcg ccagctgctc 1200
ccaggatggg cgtgtgttca tttggacctg tgatgatgcc tcaagcaata cgtgggtccc 1260
taaatgtgtg cacaagttca acgatgtggt gtggcatgtg agctgggtcca tcacagccaa 1320
catcctgggt gtctctgggt gagacaataa ggtgaccctg tggaaggagt cagttgatgg 1380
gcagtgggtg tgcatcagtg atgtcaacaa gggccagggc tccgtatcag catcagtgac 1440
agagggccag cagaacgagc agtgacaaga caggtggggc ctgggtcccc acccgccagc 1500
tccaggactg ccccttctcg ggccaactaa ccagacaact gggaagagcc cccaactcca 1560
acaggattat tttcccagga ggagttacag atgcagccac agattgatca tctgccttaa 1620
cgtgatcgga gatgctttgt aatctactgt ccagctgaaa gcactcatgt tacgaaggaag 1680
aaactacaag tgatgttcaa atctattttg ggatcatttt atgtacctt ggggttcaggc 1740
attatttggg gggttttgtt tccaaaggaa ctaaataaag tcatattgct tataaaaaaa 1800
aaa 1803

```

<210> 119

<211> 4407

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2759119CB1

<220>
 <221> unsure
 <222> 4373, 4379
 <223> a, t, c, g, or other

<400> 119
 ggtcgtcatt ggacaaccgc cgcgggggccc tggctctctgc tacctgtagc tgaggggtgct 60
 gttgatgggc agcgcgggcg gctgggaagg ctcggtctctcg cgagagttca gctcccttct 120
 ataccctggt ctgcctcagc acctcgagga tcgacatgga cgctctcgag gactacgttt 180
 ggccgcgggc aacctcgag cttatactcc tcccagtgac gggctctggag tgcgtggggg 240
 accggctgtt ggcggtgag ggtcccgatg tcctgggtgta cagcttgga tttgggtggc 300
 atctgcggat gataaagcga gtgcagaacc tgcttgacca ctatcttacc catggcttcc 360
 gggtagcgcc agagcctaag ggagaccttg acttgagggc catgggtggc gtgtttggaa 420
 gcaagggact ccgagttgtg aaaattagct ggggacaggg ccacttctgg gagctttggc 480
 gctctggcct gtggaacatg tctgactgga tttgggatgc acgctggctt gagggaata 540
 tagccttggc cctggggccac aactcagtg tgctatatga ccctgtagta ggggtgcatcc 600
 tgcaagaggt gccctgcaca gacaggtgca ccctctcttc agcctgcctg attggagacg 660
 cctggaagga gctgaccata gtggcaggtg ctgtttccaa ccagctcttg gtctggtacc 720
 cagcaactgc cttagcagac aacaaacctg tagacctga ccgacgaatc agtgggcatg 780
 tgggcatcat ctccagcatg tcatacctgg aaagcaaggg attgctggct acagcttcag 840
 aagaccgaag cgcttcgtatc tgggaaggtg gcgacctgcg agtgccctgg ggtcgggtgc 900
 agaattattg gcaactgttt ggccacagcg cccgtgtgtg gcaggtcaag cttctagaga 960
 attaccttat cagtgcagga gaggattgtg tctgcttggg gtggagccat gaagggtgaga 1020
 tcttcaggc ctttcgggga caccagggac gtgggatccg ggccatagct gcccatgaga 1080
 ggcaggcctg ggtgatcact ggggtgtgat actcaggcat tcggctgtgg cacttggtag 1140
 ggcgtgggta ccggggattg ggggtctcgg ctctctgctt caagtcctcg agtaggccag 1200
 gtacactcaa ggctgtgact ctggctggct ctggcgact gctggcagtg actgatacag 1260
 gggccctgta tctctatgac gtcgaggtca agtgctggga gcagctgcta gaggataaac 1320
 atttcagtc ctactgcctg ctggaggcag ctctggtcc cgagggcttc ggattgtgtg 1380
 ctatggccaa tggggaaggt cgtgtcaagg ttgtcccat caacactcca actgctgctg 1440
 tggaccagac cctgtttcct ggggaaggtg acagcttgag ctgggacctg cgtggttatg 1500
 aggagctcct gttgctggca tcggggcctg gcgggtagt agcttgccca gagatctcag 1560
 ccgacacctg tggcaaggcc atctttgtca aggaacgttg tcggtacctg ctgcccccaa 1620
 gcaagcagag atggcacaca tgcagtgcct tctaccccc aggtgacttc ctggtgtgtg 1680
 gtgaccgccg gggctctgtg ctgctattcc cctccagacc aggtctgctc aaggacctg 1740
 ggggtgggag caaggctcgg gctggtgctg gggcacctgt agtgggtagt ggtagtagtg 1800
 ggggtgggaa tgctttcact ggggttgggc cagtgtctac cctgccccct ctgcacggga 1860
 agcaggggtg gacctcagtc acatgccatg gtggctatgt gtataccata gggcgtgatg 1920
 gagcctacta ccagctgttt gtacgagacg gccagctcca gccagtccta aggcagaagt 1980
 cctgtcgagg catgaactgg ctgactgggc tccgtatagt gccgatggg agcatgggta 2040
 tcctgggttt ccattgccaa tagtttgtgg tgtggaaccc tcggtcacac gagaagctgc 2100
 acatcgtcaa ctgtgggtgga gggcacctgt cgtgggcatt ctctgatact gaggcggcca 2160
 tggcctttgc ttacctcaag gatggggatg tcatgctgta cagggctctg ggtgctgca 2220
 cccggccaca cgtgattctc cgggagggtc tgcatggcgg tgagatcact tgtgtaaacg 2280
 gtgtgggcac cattaccctg gggcctgaat atggagtgcc cagcttcatg cagcctgatg 2340
 acctggagcc tggcagtgag gggcccgact tgactgacat tgtgatcaca tgtagttagg 2400
 acactactgt ctgtgtccta gcaactccca caaccacagg ctacgccac gcactcacag 2460
 ctgtttgtaa ccatatctcc tcggtacgtg ctgtggctgt gtggggcatt ggcaccccag 2520
 gtggccctca ggatcctcag ccaggcctga ctgcccctgt ggtgtctgcy gggggcgagg 2580
 ctgagatgca ctgcttcagc atcatggtta ctccggaccc cagcacccca agccgcctcg 2640
 cctgccatgt catgcacct tcgtcccacc ggctagatga gtattgggac cggcaacgca 2700
 atcgggcatc gatggttaag gttagaccag agaccaggta catgtccctt gctgtgtgtg 2760
 aacttgacca gcccgccctt gggcccttgg tggtgcagc ctgtagtgat ggggcccgtaa 2820
 gctctttctt ttgcaggatt ctggcggtat ctgagctc cttgctgaaa ccttcacca 2880
 taagcgatgt gtcctcaagg tccactcctt tacacacgag gcacccaacc agaggcgagg 2940
 gctcctcctg tgcagcgcag ctactgatgg cagcctggct ttctgggatc tcaccacat 3000
 gctagaccat gactccactg tcctggagcc tccagtggt cctgggcttc cctaccggt 3060
 tggcaccccc tccctgactc tccaggccca cagctgtggt atcaacagcc tgcacacctt 3120
 gcccaaccgt gagggccacc atctcgtggc cagtggcagt gaagatggat cctccatgt 3180
 ctctgtgctt gctgtggaga tgctacagct agaagaggct gtgggagagg ctggctggt 3240
 accccagctg cgtgtgctag aggaatactc tgtccctgt gcacatgctg cccatgtgac 3300
 aggcctcaag atcctaagcc caagcatcat ggtctcagcc tccattgatc aacggctgac 3360
 cttctggcgt ctggggcatg gtgaacccac cttcatgaat agcactgtgt tccatgtgcc 3420

```

tgatgtggct gacatggact gctggcctgt gagccctgag tttggccacc gttgtgccct 3480
tgggggtcag gggcttgagg tttacaactg gtatgactga ggtatcctgc ggtggctggc 3540
gtgctgggca tggggcctgc tcacagacag catggagcag ggaagggtcg tctgtgcccc 3600
tgctcagcat gccttgaggg gaggaggtgg tggccgtggg ttcttgatgt cgggtgcagga 3660
gctgaaggtg agtggagtg tccaagaat atgccgact ccccatgaca agacagaact 3720
ttgtaacaaa cagtaccaat ttattttggc cgtgggtttt tgcttttttt ccagttgatg 3780
actttgtgaa cattcccagg tattggagcc tctgtggcct taaatgtggc tcagtgaggg 3840
gagacccagc atagccaggc cagtatggag cacctcacgc acagctctca gaagctgcag 3900
gcggaacgaac atctgaccaa agaggtgtgg tcgaggctcc tgaaagagaa agggcctgct 3960
gggtctcatgc tctgcttctc ttgcctttac cctatacctc tctgcacgtc ccaccccgtt 4020
ttgctgtgtg ctcaccccca ggtgtgtgac ccggtttag taggagctga aatccatgct 4080
gagctgtacc aggaacttgc atatctagag acagagactg agtcaactgg ccactctctt 4140
gctcttgtgc ccaggccag aataaagaat agagtgtaga gtgtcctggg tgtctatgcc 4200
tcaccatctc tgtgcgtaca gcaatgtgga ccccggggct gtgcagtcca gcaactgctg 4260
ccggctcagc agatccggaa agggaggata ctgttgaaga gcaacaacca ctcacctgt 4320
ttggggagaa aagtgttgg aagggaatc caggctcctt gtgccagtaa cangagggnc 4380
aatcactcat catgtagcag tgagaag 4407

```

<210> 120

<211> 959

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2823818CB1

<400> 120

```

ccccacgcgc cgccccacgc tccgggagcg tggagcgccg ggactgtgca cgcttgaccg 60
gaagcccaga ccagtgcggg cctagccaga gagaaaggac atttgccaac aatgagacac 120
gaagcgccca tgcagatggc ctctgcccaa gatgccaggt acggccagaa agactcctct 180
gatcagaact ttgactacat gttcaaatta ctcacatcg gcaatagcag tgtggggaaa 240
acatcttttc tattccgtta tgcagatgac tcctttacat ctgcattcgt cagcacagt 300
gggatcgatt tcaaagtaaa aactgtattc aaaaatgtaa agagaatcaa gcttcagatt 360
tgggacacag caggccagga aagatacagg actatcacca cagcctatta tcgtggagcc 420
atgggcttta ttttaatgta tgacattaca aatgaagaat ccttcaatgc agtacaagat 480
tgggtcaactc aaatcaaaac atactcttgg gacaatgccc aagttattct ggttgggaac 540
aagtgtgaca tggaagacga gcgggtcatc tcaactgagc gaggtcaaca tttaggagaa 600
cagcttgggt ttgagttttt tgaaacaagt gccaaaggca acattaatgt caagcagaca 660
tttgagcgcc ttgtggatat catctgcgac aaaatgtcag agagtttgga gactgatcct 720
gccatcactg ctgcaaagca gaacacgaga ctcaaggaaa ctctcctcc accgcagccc 780
aactgtgcct gctagtgtcc ccgtgcacac aggcagctcc agggggctct ggttgccaac 840
aaacagcatt tgtaaatggg ctattagcct tcatttatac tgctaataaa ttatttgaag 900
gaataaaattg atgtcaatgg ctcgtaaaaa aaaaaaaaaa aagtaaaaaa aaaaaaaaaa 959

```

<210> 121

<211> 1809

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2859730CB1

<400> 121

```

ggcagcggtt ggaggcttcg cccggctttg cagcggggac ttcggcgggc ggcctcagg 60
cacctcgccc cggacacgat gaggcgagtg gtacgacaga gcaagtttcg gcatgtattt 120
gggcaagcgg tgaaaaatga ccagtgtat gatgacatcc ggggtttctcg tgtgacctgg 180
gatagtctct ttgtgtgtgt caatcccaga ttgtttgcca taatcataga ggcaagtggg 240
ggaggagcgt tcctgttctt ccctctgcgc aagactgggt gaattgacaa atcttaccct 300
acagtatgtg gccacacagg accagtgtgt gacatagact ggtgcccaca taacgatcag 360
gtcattgcca gcggttcaga ggactgcacg gtcattgtat ggcagatccc agaaaatgga 420
ctcacccctt ccctgactga acctgtgggt attttggaag gccactcaaa gagagtgcgg 480

```

```

atcgtggctt ggcattcaac ggcccgcaat gtgcttctta gtgcaggctg tgataatgcc 540
attatcatct ggaatgtggg aacaggggaa gcccttataa acttggacga tatgcattca 600
gacatgattt acaatgtgag ctggaaccgg aatggcagtc tgatctgcac agcttccaaa 660
gacaagaaag tgagagtcac tgatcccagg aaacaagaga ttgttgctga gaaggagaaa 720
gcacatgaag gagcaagacc catgagagcc atcttctctg ccgatggcaa tgtcttcacc 780
actgggttca gccgcatgag cgagcggcag ctggctctct ggaatccgaa aaatatgcag 840
gaaccaattg ctcttcatga gatggacact agcaatgggg tggttgctgc tttctatgac 900
cctgacacca gcatcattta cttatgtgga aagggtgaca gcagtattcg ctatttttag 960
atcacggatg aatccccgta cgtccactac ctcaacacat tcagcagcaa ggagcctcag 1020
agagggatgg gttacatgcc caagagggga cttgatgtta acaaatgtga gattgccaga 1080
ttcttcaaac ttcatgagag aaagtgtgaa cctattatta tgactgttcc caggaagtct 1140
gaccttttcc aagatgacct gtatcctgac acagcggggc cagaggccgc gctggaggca 1200
gaagagtggg tcgaaggcaa gaatgcagac ccaatcctca tctccttgaa gcacgggtac 1260
attccaggga aaaacaggga tctcaagggt gtcaagaaga acattctgga tagcaagccc 1320
actgcaaaca agaagtgcga cctgatcagc atccccaaga aaaccacaga cacggccagt 1380
gtgcaaaaag aagccaagtt ggatgagatt ttaaaagaga tcaaatctat aaaagacaca 1440
atctgcaatc aagatgagcg tatttccaag ttagaacagc agatggcaaa gatagcagcc 1500
tgaaggtccc acccccaccc ctacagaaaa aatgggagca agaacttgtg cttgggagct 1560
ggttattggg gtggtcctag ggagggcgga aaggagggca ctgccatttg gagacattcc 1620
atttcagatt tgtcaaccag cgataggcca cattccagta agaactcaat ttgtctccca 1680
aatttgcaga aacaaaacgt gatttaaaag ctgagctttt tatcagaaag cttttttgat 1740
gttttaagtg ttatgtgact tgttgaactt tttaaaaagt gctactttta aaatcccaga 1800
tactctgaa 1809

```

<210> 122

<211> 2028

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2861155CB1

<220>

<221> unsure

<222> 1943, 2003

<223> a, t, c, g, or other

<400> 122

```

tggcgggttc cgtgggtcgc ccgcgaaatc tgatccggga tgcggcggcc caatcggaag 60
gtggaccgaa atcccgcgac agcaagaggc ccgtagcgac ccgcgggtgct aaggaacaca 120
gtgctttcaa aagaattggc gtccgctgtt cgctctcct cccgggagtc ttctgcctac 180
tcccagaaga ggagggaagc acaggtgggt ttcttttagct ctgcgtcgga tccctgagaa 240
cttcgaagcc atcctggctg aggtcaatct ccgctgtgct tctctgcag tatgaagact 300
ttggagactc aaccgttagc tccggactgc tgtccttcag accaggaccc agctccagcc 360
catccttctc cccacgcttc cccgatgaat aaaaatgcgg actctgaact gatgccaccg 420
cctcccgaiaa ggggggatcc gcccgggttg tcccagatc ctgtggctgg ctacagctgtg 480
tcccaggagc tacgggaggg ggaccagtt tctctctcca ctcccctgga aacagagttt 540
ggttccccta gtgagttgag tctcgaatc gaggagcaag aactttctga aaatacaagc 600
cttctctcag aagaagcaaa cgggagcctt tctgaagaag aagcgaacgg gccagagttg 660
gggtctggaa aagccatgga agatacctct ggggaacccg ctgcagagga cgaggagac 720
accgcttgga actacagctt ctcccagctg cctcgatttc tcagtgggtc ctggctcagag 780
ttcagcaccc aacctgagaa cttcttgaaa ggctgtaagt gggctcctga cgggtcctgc 840
atcttgacca atagtgtgta taacatcttg cgaatttata acctgcccc agagctgtac 900
catgaggggg agcaggtgga atatgcagaa atggctccctg tcttcgaat ggtggaaggt 960
gataccatct atgattactg ctggtattct ctgatgtcct cagcccagcc agacacctcc 1020
tacgtggcca gcagcagccg ggagaacccg attcatatct gggacgcatt cactggagag 1080
ctccgggctt ctttctcgcc ctacaaccac ctggatgagc tgacggcagc ccattcgctc 1140
tgccttctcc cggatggctc ccagctcttc tgtggcttca accggactgt gcgtgttttt 1200
tccacggccc ggcctggccg agactcgag gtccgagcca catttgcaaa aaagcagggc 1260
cagagcggga tcatctcctg catagccttc agcccagccc agcccctcta tgctgtggc 1320
tctacggcc gtcctctggg tctgtatgcc tgggatgat gctcccctct cgccttgctg 1380
ggagggcacc aagggggcat caccacctc tgccttcatc ccgatggcaa ccgcttcttc 1440

```

```

tcaggagccc gcaaggatgc tgagctcctg tgctgggagc tccggcagtc tgggtaccca 1500
ctgtgggtccc tgggtcgaga ggtgaccacc aatcagcgca tctacttcga tctggaccgg 1560
accgggagcgt tcctagttagg tggcagcacg agcggggctg tctctgtgtg ggacacggac 1620
gggcctggca atgatgggaa gccggagccc gtgttgagtt ttctgcccc aagggactgc 1680
accaatggcg tgagcctgca ccctagcctg cctctcctgg ccactgcctc cggtcagcgt 1740
gtgtttcctg agcccacaga gagtggggag gaaggagagg agctgggcct tcccttgctc 1800
tccacgcgcc acgtccacct tgaatgtcgg cttcagctct ggtggtgtgg gggggggcca 1860
gactccagca tccctgatga tcaccagggc gagaaagggc agggaggaac agggaggagg 1920
tcgtgggggg cgtgatataa aanggtgttt gagtggctgt gactccttcc tacacagggc 1980
cctgataagc ctaggaatgc canagcccag ctgtagggtc ccagtccc 2028

```

<210> 123

<211> 2223

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3002667CB1

<400> 123

```

gcgcgcacgt ggggccgggg cggagagagg cgagcaccgg gaaggggagc gtggggccgc 60
tggaatgggt gaatttaagg tccatcgagt acgtttcttt aattatgttc catcaggaat 120
ccgctgtgtg gcttacaata accagtcaaa cagattgggt gtttcacgaa cagatggcac 180
tgtggaaatt tataacttgt cagcaaaacta ctttcaggag aaatttttcc cagggtcatga 240
gtctcgggct acagaagctt tgtgctgggc agaaggacag cgactcttta gtgctgggct 300
caatggcgag attatggagt atgatttaca ggcgttaaac atcaagtatg ctatggatgc 360
ctttggagga cctatttgga gcatggctgc cagccccagt ggctctcaac ttttgggtgg 420
ttgtgaagat ggatctgtga aactatttca aattacccca gacaaaatcc agtttgaaag 480
aaattttgat cggcagaaaa gtgcgacctt gagtctcagc tggcatccct ctggtaccca 540
cattgcagct ggttccatag actacattag tgtgtttgat gtcaaatacag gcagcgctgt 600
tcataagatg attgtggaca ggcagtatat gggcgtgtct aagcgggaag gcacgtgtg 660
gggtgtcgcc ttctgtccg atggcactat cataagtgtg gactctgctg ggaagggtgca 720
gttctgggac tcagccactg ggacgcttgt gaagagccat ctcatcgcta atgctgacgt 780
gcagtcatt gctgtagctg accaagaaga cagtttcgtg gtgggcacag ccgaggggaa 840
agtcttccat tttcagctgg tccctgtgac atctaacagc agtgagaagc agtgggtgcg 900
gacaaaaccg ttccagcatc acactcatga cgtgcgcact gtggcccaca gcccaacagc 960
gctgatattt ggaggcactg acaccactt agtcttctgt cctctcatgg agaagggtgga 1020
agtaaagaat tacgatgccg ctctccgaaa aatcaccttt cccacccgat gtctcatctc 1080
ctgttctaaa aagaggcagc ttctcctctt ccagtttgc tcatcacttag aactttggcg 1140
actgggatcc acagttgcaa caggcaagaa tggggatact cttccactct ctaaaaatgc 1200
agatcattta ctgcacctaa agacaaaggg tcctgagaac attatctgta gctgtatctc 1260
cccatgtgga agttggatag cctattctac agtttctcgg tttttctct atcggctgaa 1320
ttatgaacat gacaacataa gcctcaaaaag ggtttccaaa atgccagcat tccttcgctc 1380
tgcccttcag attttgtttt ctgaagattc aacaaagctc tttgtagcat caaatcaagg 1440
agctctgcat attgttcagc tgtcaggagg aagcttcaag cacctgcatg ctttccagcc 1500
tcagtcagga acagtggagg ccatgtgtct tttggcagtc agtccagatg ggaattggct 1560
agctgcatca ggtaccagtg ctggagtcca tgtctacaac gtaaaacagc taaagcttca 1620
ctgcacggtg cctgcttaca atttcccagt gactgctatg gctattgcc ccaataccaa 1680
caaccctgtc atcgctcatt cggaccagca ggtatttgag tacagcatcc cagacaaaca 1740
gtatacagat tggagccgga ctgtccagaa gcagggtctt caccaccttt ggctccaaag 1800
ggatactcct atcacacaca tcagttttca tccaagaga ccgatgcaca tccttctcca 1860
tgatgcctac atgttctgca tcattgacaa gtcattgccc cttccaaatg acaaaacctt 1920
actctacaat ccatttctct ccacgaatga atcagatgtc atccggaggc gcacagctca 1980
tgctttttaa atttctaaga tatataagcc tctactcttc atggatcttt tggatgaaag 2040
aacactcgtg gcagtagaac ggctcttgga tgacatcatt gctcagctcc caccacccat 2100
taaaaagaag aaatttgga cctaaaacag ggcactgtct gtgtccttcc ttgaactgtc 2160
taccctgttg cttttcacia atcatggtaa taaaacaagt tattcttgag gaaaaaaaaa 2220
aaa 2223

```

<210> 124

<211> 728

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3043734CB1

<400> 124

```
gcgggcgtttc tgggtggccag gcatccccggt cctcgcgcgt ggcgagctc ccatcgccgg 60
accgacccat gtcgcgcccg cattgggtcc cgggaccccg gcgggagtgc cgcgtccgtc 120
ctttccagtc gccgggagtc tgagtgcggt gccacgcggg agtggcggtg gagagccgc 180
cggtcgttat gaggacggat ctaaaatgac cagcaaacgg aaaccttgcc aaacgcagct 240
caggagatcc atcagtgagc agttgcggga ctccacggcc agagcctggg atctgctgtg 300
gaagaacgtc cgggagaggc ggctggcaga aattgaggca aaagaagcat gtgactggct 360
ccgtgctgcc ggggtccccg aatacgtcca gttatatgag gattcacaat ttcccatcaa 420
cattgtggct gtcaagaatg atcatgattt tcttgaaaag gaccttgtag aacctctttg 480
caggtaaac atgtgaagta tttttgtttc tttccactgt tcagtctgca acaggcatca 540
ctatactgaa gggcgagctc agctattcgg caagtattca ctgagtgcct accatgtgcc 600
tgacccaggt gcaggttcta aatgtactac tgtaaatgag catgatcagt ttgtgttttc 660
atggagctta aatcctagca ggggcctttg gacactagat taggaaaatg acagagaaag 720
aagagaga 728
```

<210> 125

<211> 2161

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3294893CB1

<400> 125

```
gagggcggaag agcttctcgg ctctaggtc tggagtcccg ggagcagtga ggggccaccc 60
ggggcacagg aaagggccgc taggggaggg cgggtgcac tcggggtgtc tgggccgagg 120
gtctgagggg tgaggagggg ccatggccag cgacggggcc aggaagcaat tctggaagcg 180
cacaacagca agctcccggg cagcatccag cagctgtatg gtgcccagca ccccccttt 240
gatccactgt tacatggcac tttgctcagg tccacggcca agatgccgac cacaccagt 300
aaggccaaga ggtcagcac cttccaggag tttgagagca ataccagcga tgcctgggac 360
gctggggagg acgacgatga gctcctggcc atggcgccgg agagcctgaa ctccgaggtg 420
gtcatggaga cggccaaccg tgtgctgcgt aaccacagcc agcggcaggg gcggcccacg 480
ctgcaggagg ggccagggct tcagcagaag cccaggcccg aggcagagcc gccctcacc 540
cccagcggcg acctccggct ggtgaagtgc gtcagtgaag gccacacgtc ctgtcctgca 600
gaaagtgcc gcgatgcgc cctctgcag aggtcccagt ctctccaca ctcggccacc 660
gtcacgtgg gtggcacatc tgaccccagc actctcagca gctcagcgt gagcgaaaga 720
gagggcctcc ggctcgacaa gttcaagcag ctgcttgccg gcccacacac ggaccttgag 780
gaattacgga ggttgagctg gtccggaatc cctaagccag tgcgtccaat gacgtggaag 840
ctcctctcag gttaccttc cgccaatgta gaccggagac cagccactct ccagagaaaa 900
caaaaagaat attttgcat tattgagcac tattacgatt ctaggaacga cgaagttcac 960
caggacacat acaggcagat ccacatagac atccctcgca tgagccctga agcgttgatc 1020
ctgcagccca aggtgacgga gatttttgaa aggatcttgt tcatatgggc gatccgccac 1080
ccagccagtg gatacgttca gggataaat gatctcgtca ctcttttctt tgtggtcttc 1140
atgtgtgaat acatagaggc agaggagggt gacacggtgg acgtctccgg cgtgcccgca 1200
gaggtgctgt gcaacatcga ggccgacacc tactggtgca tgagcaagct gctggatggc 1260
attcaggaca actacacctt tgcccaacct gggattcaaa tgaaagtga aatgttagaa 1320
gaactcgtga gccggattga tgagcaagtg caccggcacc tggaccaaca cgaagtga 1380
tacctgcagt ttgccttcg ctggatgaac aacctgctga tgaggagggt gcccctgcgt 1440
tgtaccatcc gcctgtggga cacctaccag tctgaaccgg acggcttttc tcatctccac 1500
ttgtacgtgt gcgtgcttt tctcgtgaga tggaggagg aaatactaga agaaaaagat 1560
tttcaagagc tgctgctctt cctccagaac ctgcccacag cccactggga tgataggac 1620
atcagcctgt tgctggccga ggccctaccg ctcaagtgtg cttttgccga cgccccaat 1680
cactacaaga atgagccca ggcccaccg cagctggcct cactgtcccg ggtggcgcg 1740
cccacctgcc tggctggtgg tagggccctg tgagctggtc ccgggctgct aaaaggcctt 1800
gtgaggtggc cccaccctcc aggggagctg gtgaagatgg gccacagacc tgggtctagg 1860
ctgacaaaga cagggacagc ctttgttttc tgagatacca aagagagcca ggggagggcc 1920
```

```

ccgggttcgg cggccagagg caggtcaggg gtccccctctc cctctccctg caatgtcctt 1980
gccaaatgac tgcctcctgc tgccccctagt ccgggggcagc ctaggaggcc caccctcttt 2040
ggagtcctgc tgtctgggtg ccagggccgg aacgaggtag tggccatctc atacctactc 2100
tgaaatgcaa aacttctatt ctgttgagtg aaaaaataaa atgtagacaa aaaaaaaaaa 2160
c                                                    2161

```

<210> 126

<211> 2782

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3349052CB1

<400> 126

```

attagctgcc ggcgtgactt tgaccgcttc ccggtgcggt accggcagct gaaccacccc 60
ggcgtcacgg gactttgacg cgtgctctgc gcttgccatg agactcctgg gagccgcagc 120
cgctcgcggt ctggggcgcg gaagggcccc cgctcccta ggctggcaga ggaagcagg 180
taattggaag gcctgccgat ggtcttcac aggggtgatt cctaataaaa aaatacga 240
tattggaatc tcagctcaca ttgattctgg gaaaactaca ttaacagaac gagtccttta 300
ctacactggc agaattgcaa agatgcatga ggtgaaagg aaagatggag ttggtgctgt 360
catggattcc atggaaactag agagacaaa aggaatcact attcagtcag cagccactta 420
caccatgtgg aaagatgtca atattaacat tatagatact cctgggcatg tggacttcac 480
aatagaagt gaaagggccc tgagagtgtt gtaggtgca gtccttggtc tctgtgctgt 540
tgagggggta cagtgccaga ccatgactgt caatcgctcag atgaagcgct acaacgttcc 600
gtttctaact tttattaaca aattggaccg aatgggctcc aaccagcca gggccctgca 660
gcaaattgagg tctaaactaa atcataatgc agcgtttatg cagataccca tgggtttgga 720
gggtaatttt aaaggtatta tagatcttat tgaggaacga gccatctatt ttgatggaga 780
ctttggtcag attgttcgat atggtgagat tccagctgaa ttaagggcgg cggccactga 840
ccaccggcag gagctaattg aatgtgttgc caattcagat gaacagcttg gtgagatgtt 900
tctggaagaa aaaatcccc cgttttctga tttaaagcta gcaattcgaa gagctactct 960
gaaaagatca tttactcctg tatttttggg aagcgcttg aagaacaaag gagttcagcc 1020
tcttttagat gctgttttag aatacctccc aaatccatct gaagtccaga actatgctat 1080
tctcaataaa gaggatgact caaaagagaa aaccaaatac ctaatgaact ccagtagaga 1140
caattcccac ccatgtgtag gcctggcttt taaactggag gtaggtcgat ttggacaatt 1200
aacttatgtt cgcagttatc agggagagct aaagaagggt gacaccatct ataacacaag 1260
gacaagaaag aaagtacggg tgcaacggct ggctcgcatg catgccgaca tgatggagga 1320
tgttgaggaa gtatatgccg gagacatctg tgcattgttt ggcattgact gtgctagtgg 1380
agacacattc acagacaaag ccaacagcgg cctttctatg gagtcaattc atgttcctga 1440
tctgtcatt tcaatagcaa tgaagccttc taacaagaac gatctggaaa aattttcaaa 1500
aggtattggc aggtttacaa gagaagatcc cacatttaaa gtatactttg acactgagaa 1560
caaagagaca gttatatctg gaatgggaga attacacctg gaaatctatg ctcagaggct 1620
ggaaagagag tatggctgtc cttgtatcac aggaaagcca aaagttgcct ttcgagagac 1680
cattactgcc cctgtcccgt ttgactttac acataaaaaa caatcagggtg gtgcaggcca 1740
gtatggaaaa gtaataggtg tcctggagcc tctggacca gaggactaca cttaaattgga 1800
attttcagat gaaacattcg gatcaaatat tccaaagcag tttgtgcctg ctgtagaaaa 1860
ggggttttta gatgcctgcg agaagggccc tctttctggt cacaagctct ctgggctccg 1920
gtttgtcctg caagatggag cacaccacat ggttgattct aatgaaatct ctttcatccg 1980
agcaggagaa ggtgctctta aacaagcctt ggcaaatgca acattatgta ttcttgaacc 2040
tattatggct gtggaagttg tagctccaaa tgaatttcag ggacaagtaa ttgcaggaat 2100
taaccgacgc catggggtaa tctactgggca agatggagtt gaggactatt ttacactgta 2160
tgcagatgtc cctctaaatg atatgtttgg ttattccact gaacttaggt catgcacaga 2220
gggaaaggga gaatacaca tgaggtatag caggtatcag ccatgtttac catccacaca 2280
agaagacgtc attaataagt atttggaagc tacagggtcaa cttcctgtta aaaaaggaaa 2340
agccaagaac taactttgtt tactgtgagt tgactgactc taattgaatc tgcgtgggtt 2400
tgatactttg atggattcca gtggaataaa ttcaggctgc tgaaacaaga aattctgagc 2460
ccaggaagcg ggtcttctt tcttcaaaag aagcccttct tgttcatatt caggagcttc 2520
tgttatattc aaaggtaatt ctatgtctat ctcaactcta ttgattgggt ttatagttta 2580
ttgaaaatcc tcaataaaaa tataattatt actgaaatat gtttaattatt taaggggaaa 2640
agagactaat ttcagttata cttttaagct tagaatgtat gttcatttcc aaattttgta 2700
tcataagagt tttcaacata gagaaaagct gaaaaaatgc aaagaataac cacatacttt 2760
ccatctacct tcctttggtg ac                                                    2782

```


<210> 127
<211> 3019
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3357264CB1

<220>
<221> unsure
<222> 985
<223> a, t, c, g, or other

<400> 127
tggctgggtc cgcgggcggg ggaaggtgtc cttagcgggcc gagcctgcgc tccggattct 60
caggccccatc ctgtggtagg ccgtcccagg caggagttgc ctcgagggat ttggcagcca 120
cgacatccca tcctagcccc gcgatgtgcg gggctgtaat ccccttgcac aaaccggccg 180
gacgtaaatt gcagaatcaa agagctgctt tgaatcagca gatcctgaaa gccgtgcgga 240
tgaggaccgg agcgaaaaac cttctgaaag tggccacaaa ctcaaaggtg cgggagcaag 300
tgcggtgga gctgagcttc gtcaactcag acctgcagat gctcaaggaa gagctggagg 360
ggctgaacat ctcggtgggc gtctatcaga acacagagga ggcatttacg attcccctga 420
ttctcttgg cctgaaggaa acgaaagacg tcgactttgc agtcgtcttc aaggatttta 480
tcctggaaca ttacagtga gatggctatt tatatgaaga tgaaattgca gatcttatgg 540
atctgagaca agcttgtcgg acgcctagcc gggatgaggg cggggtggaa ctgctgatga 600
catacttcat ccagctgggc tttgtcgaga gtgcattctt cccgcccaca cggcagatgg 660
gactcctgtt cacctgggat gactctctca ccgggggttc ggtcagccag cagaacctgc 720
tgctggagaa ggccagtgtc ctgttcaaca ctggggccct ctacaccag attgggacct 780
ggtgtgatcg gcagacgcag gctgggctgg agagtgccat agatgccttt cagagagccg 840
caggggtttt aaattacctg aaagacacat ttaccatac tccaagttac gacatgagcc 900
ctgccatgct cagcgtgtc gtcaaaatga tgcttgacac agcccaagaa agcgtgtttg 960
agaaaatcag ccttctctggg atccngaag aattcttcat gctggtgaag gtggctcagg 1020
aggctgctaa ggtgggagag gtctaccaac agctacacgc agccatgagc caggcgccgg 1080
tgaaagagaa catcccctac tcctgggcca gcttagcctg cgtgaaggcc caccactacg 1140
cggccctggc ccactacttc actgccatcc tcctcatcga ccaccagggtg aagccaggca 1200
cggatctgga ccaccaggag aagtgcctgt ccagctcta cgaccacatg ccagagggggc 1260
tgacaccctt ggccacactg aagaatgatc agcagcgccg acagctgggg aagtcctact 1320
tgcgagagc catggctcat cacgaggagt cgggtgcggga ggcgagcctc tgcaagaagc 1380
tgcgagcgt tgaggtgcta cagaaggtgc tgtgtgccc acaggaacgc tcccggctca 1440
cgtacgcccc gcaccaggag gaggatgacc tgctgaacct gatcgacgcc cccagtgttg 1500
ttgctaaaac tgagcaagag gttgacatta tattgcccc gttctccaag ctgacagtca 1560
cggacttctt ccagaagctg ggccccttat ctgtgttttc ggctaacaag cggtggaagc 1620
ctctcgaag catccgcttc actgcagaag aaggggactt ggggttcacc ttgagaggga 1680
acgccccgt tcagggtcac ttctggatc ctactgtctc tgcctcgggtg gcaggagccc 1740
gggaaggaga ttatatgttc tccattcagc ttgtggattg taagtggctg acgctgagtg 1800
aggttatgaa gctgctgaag agctttggcg aggacgagat cgagatgaaa gtcgtgagcc 1860
tcctggactc cacatcatcc atgcataata agagtgccac atactccgtg ggaatgcaga 1920
aaacgtactc catgatctgc ttagccattg atgatgacga caaaactgat aaaaccaaga 1980
aaatctccaa gaagctttcc ttctgagtt ggggcaccaa caagaacaga cagaagtcag 2040
ccagcacctt gtgcctccca tcggctcgggg ctgcacggcc tcaggtcaag aagaagctgc 2100
cctccccttt cagccttctc aactcagaca gttcttggtg ctaatgtgag gaaacaaaca 2160
tgttcaggcc ccgaacattt ccgggtgctga ctccggcctta aacgtttgtg ccataatgga 2220
aaatatctat ctatctgttc tcaaatectg tttttctcat agtgtaaact cacatttgat 2280
gtgtttttat gaaggaaaagt aaccaagaaa cctctaggaa ttagtgaaaa aagaactttt 2340
ttgaggtgtg ttactatact gctgtaagtt atttattata taaagtattg taaatagaat 2400
agtgttgaag atatgaaata tggctatttt taatggtgac aattatgact ttttagtact 2460
attaaattgg ggttacctat atcagtacaa ttgtagttg tttccagggt tggctaataa 2520
tcattccctt acctagaatt cagatgatcc tggaattaag gcaggtcaga ggactgtaat 2580
gatagaatta aattagtgtc actaaaaact gtcccaaagt gctgcttctc aataggaatt 2640
cattaaccta aaacaagatg ttactattat atcgatagac tatgaatgct atttctagaa 2700
aaagtctagt gccaaatttg tcttattaaa taaaaacaat gtaggagcag cttttcttct 2760
agtttgatgt catttaagaa ttactaacac agtggcagtg ttagatgaag atgctgtcta 2820
caaggtagat aatatactgt ttgatactca aaacattttt cattttgttt aaagtagaag 2880

ttacataatt ctatatattta agtcttgggt aaaaaagtag ttttacattt tataaagtaa 2940
agatgtaa at gattcagctt taaagctcta tttgacttcc ttcttttgtc tgagatagcg 3000
tccagactgc gaaaagcga 3019

<210> 128

<211> 2312

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3576329CB1

<400> 128

gccggcgcg ggtggggcat ggcggttctg cggggtgagg ggcgcacggc ggcgccgagc 60
gtgcgggcgg agaagcggcg gtctgagccc gaactggagc ctgagcccga gccggagccc 120
cccctcctct gcacctctcc tctcagccac agcaccggca gcgattctgg cgtctccgac 180
agcgaggaga gtgtgttctc aggcctggaa gattccggca gtgacagcag tgaggatgat 240
gacgaaggcg acgaggagg agaggacgga gcccttgatg acgagggcca cagtgggatt 300
aaaaagacca ctgaggagca ggtgcaggcc agcactcctt gcccaggagc agagatggcg 360
agcgcccggg ttggggatga gtatgaggag gacagctctg atgaggagga catccggaac 420
acggtgggca acgtgccctt ggagtggtag gatgacttcc cccacgtggg ctacgacctg 480
gatggcaggc gcatctacaa gccctgagg acccgggatg agctggacca gttcctggac 540
aagatggacg atcctgacta ctggcgacc gtgcaggacc cgatgacagg gcgggacctg 600
agactgacgg atgagcaggt ggccctgggt cggcggtgac agagtggcca gtttggggat 660
gtgggcttca acccctatga gccggtgtgc gacttcttca gcggggacgt catgatccac 720
ccggtgacca accgcccggc cgacaagcgc agcttcatcc cctccctggt ggagaaggag 780
aaggtctctc gcatgggtga cgccatcaag atgggctgga tccagcctcg ccggccccga 840
gacccacccc ccagcttcta tgacctgtgg gccagaggag accccaacgc cgtgctcggg 900
cgccacaaga tgcacgtacc tgctcccaag ctggccctgc caggccacgc cgagtcgtac 960
aaccaccccc ctgaatacct gctcagcgag gaggagcgct tggcggtggga acagcaggag 1020
ccaggcgaga ggaagctggg ctttttgcca cgcaagttcc cgagcctgag gcccggtgct 1080
gcctacggac gcttcatcca ggaacgcttc gacgctgcc ttgacctgta cctgtgcccc 1140
cggcagcgca agatgagggt gaatgtagac cctgaggacc tcatcccaaa gctgcctcgg 1200
ccgagggacc tgcagccctt cccacgtgc caggccctgg tctacagggg ccacagtac 1260
cttgtccggt gcctcagtggt ctctcctggg ggccagtggc tgggtttcagg ctctgacgac 1320
ggctccctgc ggctctggga ggtggccact gcccgctgtg tgaggactgt tcccgtgggg 1380
ggcggtggta agagtgtggc ctggaacccc agcccgtg tctgcctggt ggctgcagcc 1440
gtggaggact cgggtgctgct gctgaaccca gctctggggg accggctggt ggcgggcagc 1500
acagatcagc tgttgagcgc cttcgtcccg cctgaggagc ccccttgca gccggcccgc 1560
tggttgagg cctcagagga ggagcgccaa gtgggctgac ggctgcgcat ctgccacggg 1620
aagccagtga cgcaggtgac ctggcacggg cgtggggact acctggccgt ggtgctggcc 1680
acccaaggcc acacccaggt gctgattcac cagctgagcc gtcgccgag ccagagtccg 1740
ttcgcgcgca gccacggaca ggtgcagcga gtggccttcc accctgcccg gcccttctct 1800
ttggtggcgt cccagcgagc cgtccgcctc taccacctgc tgcgccagga gctcaccaag 1860
aagctgatgc ccaactgcaa gtgggtgtcc agcctggcgg tgcacctgc aggtgacaac 1920
gtcatctgtg ggagctacga tagcaagctg gtgtggtttg acctggatct ttccaccaag 1980
ccatacagga tgctgagaca ccacaagaag gctctgcggg ctgtggcctt ccaccgcgg 2040
taccactct ttgcgtcagg ctgcgacgac ggcagtgtca tcgtctgcca tggcatggtg 2100
tacaatgacc ttctgcagaa ccccttgctg gtgcccgtca aggtgctgaa gggacacgtg 2160
ctgacccgag atctgggagt gctggacgtc atcttccacc ccaccagcc gtgggtcttc 2220
tctcggggg cagacgggac tgtccgcctc ttcacctagc tgttctgcct gcctggggct 2280
ggggtggctg tgctgaagtc aacagagcct tc 2312

<210> 129

<211> 921

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3805550CB1

<400> 129

```
aggcggagtc gggcggtgt gctgaggtgg gcctgagggc ggagtcgagg tcgggctgaa 60
ggcgggagtcg gggagggctg aggtgggcct gaaggcagag tcgaggccat ggcagggccg 120
ggcccaggcc cgggggaccc ggacgagcag tacgatttcc tgttcaagct ggtgctggtg 180
ggcgacgcaa gcgtgggcaa gacgtgctg gtgcagcgt tcaagaccg cgccttctcg 240
gagcgccagg gaagcaccat cggcgtcgac ttcacatga agacgctgga gatccagggc 300
aagcgggtca agctgcagat ctgggacacg gccggccagg agcggttccg caccatcacc 360
cagagctact accgcagtgc caatggggcc atccttgctt acgacatcac caagaggagc 420
tccttcctgt cggtgccctca ctggattgag gatgtgagga agtatgctgg ctccaacatt 480
gtgcagctgc tgatcgggaa caagtcagac ctacgcgagc ttcgggaggt ctcttggtc 540
gaggcacaga gcctggctga gcactatgac atcctgtgtg ccattgagac gtctgccaa 600
gactcgagca acgtggagga ggccttctct aggggtggcca cggagctcat catgcccac 660
gggggccccct tgttcagcga gaagagcccc gaccacatcc agctgaacag caaggacatc 720
ggagaaggct ggggctgctg gtgctgacca ggggccgggc cggcagactg ggggttcccc 780
acctccttgc tctccccagc ctgccaagcc cagccctcca gagccagccc tcctgggtac 840
cggcaactac agcagccggg tgaagctctg gagctctgca tcctgtggcc tggctgctgg 900
atggaggctc tccttgagga a 921
```

<210> 130

<211> 1291

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4546403CB1

<400> 130

```
ctcgagcgaa tcggctcgag agatggctcc ttggcggcat gtgcattttc tcctaattgga 60
agcttctttg tcaactggcacc ttcatgtggt gattttaacag tgtgggatga tcaaatgagg 120
tgtctgcata gtgaaaaagc acatgatctt ggaattacct gctgcgattt ttcttcacag 180
ccagtttctg atggagaaca aggtcttcag ttttttcgac tggcatcatg tggtcaggat 240
tgccaagtca aaatttggat tgtttctttt acccatatct taggttttga attaaaatat 300
aaaagtacac tgagtgggca ctgtgctcct gttctggctt gtgctttttc ccatgatggg 360
cagatgctag tctcagggtc agtggataag tctgtcatag tatatgatac taatactgag 420
aatatacttc acacattgac tcagcacacc aggtatgtca caacttgtgc ttttgcacct 480
aatacccttt tacttgctac tggttcaatg gacaaaacag tgaacatctg gcaatttgac 540
ctggcaaacac tttgccaagc aaggagcaca gaacatcagc tgaagcaatt taccgaagat 600
tggtcagagg aggatgtctc aacatggctt tgtgcacaag atttaaaaga tcttggtggt 660
attttcaaga tgaataacat tgatggaaaa gaactgttga atcttcaaaa agaaagtctg 720
gctgatgatt tgaaaattga atctctagga ctgcgtagta aagtgtctgag gaaaattgaa 780
gagctcagga ccaaggttaa atccctttct tcaggaattc ctgatgaatt tatatgtcca 840
ataactagag aacttatgaa agatccggtc atcgcatcag atggctattc atatgaaaag 900
gaagcaatgg aaaattggat cagcaaaaag aaacgtacaa gtcccatgac aaatcttggt 960
cttccttcag cggtaacttac accaaatagg actctgaaaa tggccatcaa tagatggctg 1020
gagacacacc aaaagtaaaa ttgttgatat tgtattatct atattttcag tgatctcatt 1080
tgaatgattt ataggtaaat actaatcaga cattattaaa agcaaaacag gaaaaaggta 1140
aacttcttaa atttagttac ctataaaaaa tgtcaatttt cattctttaa aaacacatgg 1200
acttactata aaagcctttt tgtactagt tgaagaatct tcagctatat agaaaataag 1260
ttatacttta aattgcaaaa aaaaaaaaaa a 1291
```

<210> 131

<211> 1836

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4767318CB1

<400> 131

```
ttttagaagg ttagtggtgg ttcttttatt cgattaaaca ggaatacaca tatgtctacc 60
aaagaatagg taaggagaa ataagaacac taaaaaaact cggaatcgtt aagtgtgaag 120
```

```

catattttgga gttaaaagaa ccaaatatta ctaagtaagc agacgcgggc acgcgctgca 180
taccgggatt tgtagtcctt tccggggcgg ggtacagcgc gcctgcgcag aggggcccgc 240
gctcttccgg gcgcatgctt gcggcagcgg cgccaggact gactgcgcgg tggaggctgc 300
tgcagtgttg tgagttggaa gctggggagc tcggcatggc ggtccccgct gcagccatgg 360
ggccctcggc gttgggcccag agcggccccc gctcgatggc cccgtgggtc tcagtgcgca 420
gcggcccgtc gcgctacgtg cttgggatgc aggaagctgt ccggggccac agcaagacgc 480
gcgagtctct ggccgacagc gccaaaggtg actcgggtgg ctggagtgtg gacgggctgc 540
gcctagcctc ggggtccttc gacaagacgg ccagcgtctt cttgctggag aaggaccggt 600
tggtcaaaga aaacaattat cggggacatg gggatagttg ggaccagctt tgttggcatc 660
caagtaatcc tgacctattt gttacggcgt ctggagataa aaccattcgc atctgggatg 720
tgaggactac aaaatgcatt gccactgtga acactaaagg ggagaacatt aatatctgct 780
ggagtccctg tgggcagacc attgctgtag gcaacaagga tgatgtggtg acctttattg 840
atgccaagac acaccgttcc aaagcagaag agcagttcaa gttcgaggtc aacgaaatct 900
cctggaacaa tgacaataat atgttcttcc tgacaaatgg caatggttgt atcaacatcc 960
tcagctaccc agaactgaag cctgtgcagt ccatcaacgc ccaccttcc aactgcattc 1020
gtatcaagtt tgaccccatg gggaaagtact ttgccacagg aagtgcggat gctttgggtc 1080
gcctctggga tttggatgag tttagtgtgtg ttccgggtgt ttccaggctg gattggcctg 1140
taagaaccct cagtttcagc catgatggga aaatgctggc gtcagcatcg gaagatcatt 1200
ttattgacat tgctgaagtg gagacagggg acaaaactat ggaggtacag tgtgagtctc 1260
cgaccttcac agtggcgtgg caccctctgt ggctctgct ggcatttgcc tgtgatgaca 1320
aagacggcaa atatgacagc agccgggaag ccggaactgt gaagctgttt gggcttctta 1380
atgattcttg agaggaggt gtagggagag gagggccggc cagaggtctt ccttcattgt 1440
gttagtttgg tctgttctct cggagttggt gggcacccta aatatttgta agttggtata 1500
aattgtaaac gtctctggtc aggtcgcgca ttctgttctt ttgctttgtc tgtgtattag 1560
ctctttccat tctttgcccc cagcatgagt taactcgcgt ggactctgca gtgcgagtag 1620
tgacccagc atacctgtc ctctggacct cctgtcttct ctgcttctgg gtgcagtgta 1680
gactttgtgg ctttgatac aacttgaca atacctagt tggaggagg ggaatggaag 1740
ggcatggaag tttttttaa taattaaaa tatatacata taattttgag aattgagcat 1800
ttaataaact gacttttgtt attatggaaa aaaaaa 1836

```

<210> 132

<211> 2136

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4834527CB1

<400> 132

```

ggcgcgcccgg gagccggcag acatgccaca gacgctgagt gcctccgaca tggtcacccc 60
aggcagcctc agccaccccc ccaccgagcc cacagatggc gaacaggctg ggcagccctt 120
cctggatgga gcgccatcct cagcctccct ggaaacactg atccagcacc tgggtgccac 180
agccgactac tacccgaga aagcctacat cttcaccttc ctgctgagct ctgcctctt 240
catcgagccc cgggagctcc tggcccgggt ctgccacctg tgcacgagc agcagcagct 300
ggacaagccg gtgctggaca agggccgggt ccggaagttc ggcccaaac tgctgcagct 360
gttggccgag tggaccgaga ccttcccaag ggacttccag gaagagtcca ctatcgggca 420
ccttaaggac gtcgtgggccc gcatcgcccc ctgtgacgag gcataccgga agaggatgca 480
tcagctccta caggctctgc accagaagct ggcggctctg cgccaggggc cagaaggtct 540
ggtgggtgcc gacaagccca tctcctacag gaccaagcca ccagcctcca tccacagga 600
gctccttggg gtctgcagcg acccctacac actggcccag cagctgaccc acgtggaact 660
ggagcggctg cggcacatcg ggctgagga gttgttccag gcctttgtga acaaggacct 720
tctggccagc acaaagccct gcttcagtga caagaccagc aacctggagg cttatgtgaa 780
atggttcaac aggtgtgtct acctggtggc aactgagatc tgcattgccag ccaagaagaa 840
gcagagggcc caggtgattg agttcttcat cgacgtggcc cgcgagtgtc tcaacatcgg 900
caacttcaac tccctcatgg ccatcatctc cggcatgaac atgagccctg tctccaggct 960
gaagaagacc tgggcaaaag tgaggacggc caagtttttc atcctcgagc accagatgga 1020
cccaacgggg aatttctgca actacaggac agccctgcgc ggggcgggccc accgctccct 1080
gacggccccc agcagccgag agaagattgt cattccttct ttcagcctgc tcatcaaaga 1140
catctacttc ctgaatgagg gctgcgcccc ccgccttccc aatggacacg tcaactttga 1200
gaaattcctg gagctgggga agcaggtggg cgaagttcatc acctggaaac aagtggagt 1260
tcccttcgag caagacgcca gcatcaccca ctacctgtac accgccccca tcttcagtga 1320
ggatgggtctt tatttggctt cttatgaaag tgagagccca gagaaccaa cagaaaaaga 1380

```

aagatggaaa	gctctaagat	cttctatfff	ggggaagaca	tgaaagcgct	gagctgaggg	1440
acgaggaaga	gctggagccc	gcagaagccg	tcacagccc	tgccctcagt	gcccagtg	1500
cagaggccag	ggagtgcctc	actatfff	aaatgccgac	cctgtggcct	gctgcccgc	1560
ccccgcccc	cacagtggcc	atacgggcac	aggagacctt	ttatgggact	ttggccctgg	1620
caggacccag	ggcctccaga	cgtgcggg	gcacatgcct	tggggacatc	ctgccttcag	1680
gaccgtggg	cctggtcagt	ctgtccatcc	tcggcaagga	cacaacactg	ccccagaggg	1740
tgggaccact	gcaagctcga	gaccttgctt	ggtgacatgt	gccactttgg	ccaccaccca	1800
cagtctgtca	ccacgtggct	tggaacttc	tgagaccaca	gcaggcatca	cgtgcgacg	1860
tgagatgcct	gcgccagccc	cgagcccact	ggcagccact	gccattccac	ccatgggtccc	1920
tcaccctgcc	ctgccgacga	gcttgtctct	gcagcccag	gtacccctt	cctggatgct	1980
gctggcccca	ggagatagct	ttccggtgac	agctgtggaa	cgcgtcagca	ggacaaaactg	2040
gacacatgga	gttacagtgt	gtacacggca	gtcccgccac	ccagccccct	tgtaaactct	2100
agtcactata	aacacaccg	tacgcctaaa	aaaaaa			2136